Customer Support Information Plunkett's Biotech & Genetics Industry Almanac 2003-2004 Please register your book immediately… if you did not purchase it directly from Plunkett Research, Ltd. This will enable us to fulfill your replacement request if you have a damaged product, or your requests for assistance. Also it will enable us to notify you of future editions, so that you may purchase them from the source of your choice.
If you are an actual purchaser but did not receive a FREE CD-ROM version with your book… you may request it by returning this form. ____ YES, please register me as a purchaser of the book. I did not buy it directly from Plunkett Research, Ltd. ____ YES, please send me a free CD-ROM version of the book. I am an actual purchaser, but I did not receive one with my book. (Proof of purchase may be required.) Customer Name ____________________________________________________ Title ______________________________________________________________ Organization _______________________________________________________ Address ___________________________________________________________ City_______________________________State________Zip_________________ Country (if other than USA) ___________________________________________ Phone_________________________Fax ________________________________ E-mail ____________________________________________________________
Mail or Fax to:
Plunkett Research, Ltd.
Attn: FREE CD-ROM and/or Registration P.O. Drawer 541737, Houston, TX 77254-1737 USA 713.932.0000 Fax 713.932.7080 www.plunkettresearch.com
PLUNKETT’S BIOTECH & GENETICS INDUSTRY ALMANAC 2003-2004 The Only Comprehensive Guide to Biotech Companies and Trends
Jack W. Plunkett Published by: Plunkett Research, Ltd., Houston, Texas www.plunkettresearch.com
PLUNKETT’S BIOTECH & GENETICS INDUSTRY ALMANAC 2003-2004 Editor and Publisher: Jack W. Plunkett Executive Editor and Database Manager: Martha Burgher Plunkett
Web Page Design: Darren Smith
Senior Editors and Researchers: Elisa Gabbert Ghazal Siddiqi
Cover Design: Kim Paxson, Just Graphics Junction, TX
Editors, Researchers and Assistants: Christie Manck Ray Marumahoko Mariya Paterwic Suzanne Zarosky
Special Thanks to: Burrill & Company San Francisco, CA Food and Drug Administration U.S. Dept. of Health and Human Services National Human Genome Research Institute U.S. National Institutes of Health Patent and Trademark Office U.S. Department of Commerce Pharmaceutical Research and Manufacturers of America Washington, D.C.
Information Technology Director: Alex Preskovsky E-Commerce Manager: Robert Daniel
Plunkett Research, Ltd. P. O. Drawer 541737, Houston, Texas 77254 USA Phone: 713.932.0000 Fax: 713.932.7080 www.plunkettresearch.com
Copyright 2003 by Plunkett Research, Ltd. All rights reserved. No part of this book may be reproduced or transmitted in any form by any means, electronic or mechanical, including by photocopying or by any information storage or retrieval system, without the written permission of the publisher.
Published by: Plunkett Research, Ltd. P. O. Drawer 541737 Houston, Texas 77254-1737 USA Phone: 713.932.0000 Fax: 713.932.7080 Internet: www.plunkettresearch.com ISBN # 1-891775-98-7 Disclaimer of liability for use and results of use: The editors and publishers assume no responsibility for your own success in making an investment or business decision, in seeking or keeping any job, in succeeding at any firm or in obtaining any amount or type of benefits or wages. Your own results and the job stability or financial stability of any company depend on influences outside of our control. All risks are assumed by the reader. Investigate any potential employer or business relationship carefully and carefully verify past and present finances, present business conditions and the level of compensation and benefits currently paid. Each company's details are taken from sources deemed reliable; however, their accuracy is not guaranteed. The editors and publishers assume no liability, beyond the actual payment received from a reader, for any direct, indirect, incidental or consequential, special or exemplary damages, and they do not guarantee, warrant nor make any representation regarding the use of this material. Trademarks or tradenames are used without symbols and only in a descriptive sense, and this use is not authorized by, associated with or sponsored by the trademarks’ owners. Ranks and ratings are presented as an introductory and general glance at corporations, based on our research and our knowledge of businesses and the industries in which they operate. The reader should use caution.
PLUNKETT'S BIOTECH & GENETICS INDUSTRY ALMANAC 2003-2004 CONTENTS A Short Biotech & Genetics Glossary Introduction How To Use This Book Chapter 1: Major Trends & Technologies Affecting the Biotech & Genetics Industry Chapter 2: Biotech & Genetics Industry Statistics Chapter 3: Biotech & Genetics Industry Contacts Addresses, Telephone Numbers and World Wide Web Sites Chapter 4: THE BIOTECH & GENETICS 400: Who They Are and How They Were Chosen Industry List, With Codes Index of Rankings Within Industry Groups (The Biotech & Genetics 400 grouped by industry and ranked for sales and profits) Alphabetical Index Index of Headquarters Location by State Index of Headquarters Location by Country Index by Regions Where the Biotech & Genetics 400 Have Locations Index by Firms With International Operations Individual Profiles on each of THE BIOTECH & GENETICS 400 Appendix: Biotech Research Techniques & Genetic Illustrations Additional Indexes Index of Hot Spots for Advancement for Women/Minorities Index of Subsidiaries, Brand Names and Selected Affiliations List of Major Tables and Charts Biotechnology Industry Profile, 2001: U.S., Europe and Canada Total R&D Investments by Research-Based Pharmaceutical Companies: 1970-2001 Domestic R&D as a Percentage of Sales, U.S. Research-Based Pharmaceutical Companies: 1970-2001 Annual Percent Change in U.S. Research & Development by Research-Based Pharmaceutical Companies: 1980-2001 U.S. Biotech Industry Financing, 2001 U.S. Biotech Industry Fundraising, 1996-Third Quarter 2002 Top 20 Global Biotech and Pharmaceutical Companies, 2001 Major Biotechnology Company Consolidations, 1st through 3rd Quarter 2002 The U.S. Drug Discovery, Development and Approval Process Total U.S. Biotechnology Patents Granted Per Year, 1985-2000 Continued on Next Page
i 1 3 7 25 41 53 54 55 64 67 71 72 78 81 477 498 500
26 27 28 29 30 31 32 33 34 35
Continued from Previous Page New U.S. Biotech Drug and Vaccine and Indication Approvals, 1982-2001 U.S. Drug Development Times U.S. FDA Approval Times for New Drugs, 1987-2001 Average Salaries in the U.S. Pharmaceutical and Biotechnology Industries: 2002 Global Agricultural Biotech At A Glance, 2001 List of Illustrations Andenovirus Amino Acid Antibody Base Pair Blastocyst Chromosome Cytogenetic Map DNA DNA Replication Enzyme Gene Microarray Technology Nucleotide Protein RNA
36 37 38 39 40
481 482 482 483 484 485 486 487 488 489 489 490 491 493 494
Plunkett Research, Ltd.
www,plunkettresearch.com
A Short Biotech & Genetics Industry Glossary 510 K: The application filed with the FDA for a new medical device to show that the apparatus is “substantially equivalent” to one that is already marketed. ADME: Absorption, Distribution, Metabolism and Excretion. In clinical trials, the bodily processes studied to determine the extent and duration of systemic exposure to a drug. AE (Adverse Event): In clinical trials, a condition not observed at baseline or worsened if present at baseline. Sometimes called Treatment Emergent Signs and Symptoms (TESS). Amino Acid: Any of a class of 20 molecules that combine to form proteins. ANDA (Abbreviated New Drug Application): An application filed with the FDA for a drug showing that the substance is the same as an existing, previously approved drug (i.e., a generic version). Angiogenesis: Blood vessel formation, typically in the growth of malignant tissue. Antibody: A protein produced by white blood cells in response to a foreign substance (see “Antigen”). Each antibody can bind only to one specific antigen. Antigen: A foreign substance that causes the immune system to create an antibody (see “Antibody”). Antisense Technology: The use of RNA-like oligonucleotides that bind to RNA and inhibit the expression of a gene. Apoptosis : A normal cellular process leading to the termination of a cell’s life. Applied Research: The application of compounds, processes, materials or other items discovered during “basic research” to practical uses. The goal is to move discoveries along to the final development phase. Array: An orderly arrangement, such as a rectangular matrix of data. In some laboratory
systems, such as microarrays, multiple detectors (probes) are positioned in an array in order to best do research. See “Microarray” below. Assay: A laboratory test to identify and/or measure the amount of a particular substance in a sample. Types of assays include: endpoint assay, in which a single measurement is made at a fixed time; kinetic assay, in which increasing amounts of a product are formed with time and are monitored at multiple points; microbiological assay, which is a measurement of the concentration of antimicrobials in biological material; and immunological assay, in which an analysis or measurement is based on antigen-antibody reactions. Baseline : A set of data used in clinical studies for control or comparison. Basic Research: Attempts to discover compounds, materials, processes or other items that may be largely or entirely new and/or unique. Basic research may start with a theoretical concept that has yet to be proven. The goal is to create discoveries that can be moved along to “applied research.” Basic research is sometimes referred to as “blue sky” research. Bioavailability: In pharmaceuticals, the rate and extent to which a drug is absorbed or is otherwise available to the treatment site in the body. Bioequivalence: In pharmaceuticals, the demonstration that a drug’s rate and extent of absorption are not significantly different from those of an existing drug that is already approved by the FDA. Bioinformatics: Computer-simulated generation and testing of new chemical compounds for possible drug use. This method is much faster and more costeffective than manual methods. Biologic: Any virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic or analogous product or arsphenamine or one of its derivatives (or any other trivalent organic arsenic compound) applicable to the prevention, treatment or cure of disease or injury. Biopharmaceuticals : That portion of the pharmaceutical industry focused on the use of biotechnology to create new drugs.
Copyright@2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Biotechnology: A set of powerful tools that employ living organisms (or parts of organisms) to make or modify products, improve plants or animals (including humans) or develop microorganisms for specific uses. Early uses of biotechnology included traditional animal and plant breeding techniques and the use of yeast in making bread, beer, wine and cheese. Today, biotechnology is most commonly thought of to include the development of human medical therapies and processes using recombinant DNA, cell fusion, other genetic techniques and bioremediation. Blastocyst - A fertilized embryo, aged four to eleven days, which consists of multiplying cells both outside and inside a cavity. It is the blastocyst that embeds itself in the uterine wall and ultimately develops into a fetus. Blastocysts are utilized outside the womb during the process of stem cell cultivation. CANDA (Computer-Assisted New Drug Application): An electronic submission of a new drug application (NDA) to the FDA. CAPLA (Computer-Assisted Product License Application): An electronic submission of a biological product license application (PLA) to the FDA. CBER (Center for Biologics Evaluation and Research): The branch of the FDA responsible for the regulation of biological products, including blood, vaccines, therapeutics and related drugs and devices, to ensure purity, potency, safety, availability and effectiveness. www.fda.gov/cber CDER (Center for Drug Evaluation and Research): The branch of the FDA responsible for the regulation of drug products. www.fda.gov/cder CDRH (Center for Devices and Radiological Health): The branch of the FDA responsible for the regulation of medical devices. www.fda.gov/cdrh Chromosome : A structure that contains genes and is found in the nucleus of a cell. Chromosomes are found in pairs. Class I Device: An FDA classification of medical devices. General controls are sufficient to ensure safety and efficacy.
Class II Device : An FDA classification of medical devices. Performance standards and special controls are sufficient to ensure safety and efficacy. Class III Device: An FDA classification of medical devices. Pre-market approval is required to ensure safety and efficacy, unless the device is substantially equivalent to a currently marketed device. (See “510 K” above.) Clone : A group of identical genes, cells or organisms derived from one ancestor; an identical copy. “Dolly” the sheep is a famous case of cloning a replica of an animal. (Also see "Cloning-Reproductive" and "Cloning-Therapeutic.") Cloning-Reproductive: A method of reproducing an exact copy of an animal, or potentially an exact copy of a human being. A scientist removes the nucleus from a donor's unfertilized egg, inserts a nucleus from the animal to be copied and then stimulates the nucleus to begin dividing to form an embryo. In the case of a mammal, such as a human, the embryo would then be implanted in the uterus of a host female. Also see "Cloning-Therapeutic." Cloning-Therapeutic : A method of reproducing exact copies of cells needed for research or for the development of replacement tissue or organs. A scientist removes the nucleus from a donor's unfertilized egg, inserts a nucleus from the animal, or human, whose cells are to be copied and then stimulates the nucleus to begin dividing to form an embryo. However, the embryo is never allowed to grow to any significant stage of development. Instead, it is allowed to grow for a few hours or days and stem cells are then removed from it for use in regenerating tissue. Also see "CloningReproductive." Combinatorial Chemistry: After researchers determine which protein is involved in a specific disease, they use combinatorial chemistry to find the molecule that controls the protein. This advanced computer technique enables scientists to use automatic fluid handlers to mix chemicals under specific test condit ions at extremely high speed. Combinatorial chemistry can generate thousands of chemical compound variations in a few hours. Previously, traditional chemistry methods could have required several weeks to do the same work.
Copyright@2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Complementary-DNA: cDNA, also called “copy DNA,” is a sequence acquired by copying a messenger RNA (mRNA) molecule back into DNA. In contrast to the original DNA, mRNA codes for an expressed protein without non-coding DNA sequences (“introns”). Therefore, a cDNA probe can also be used to find the specific gene in a complex DNA sample from another organism with different non-coding sequences. Coordinator: In clinical trials, the person at an investigative site who handles the administrative responsibilities of a clinical trial acts as a liaison between the investigative site and the sponsor and reviews data and records during a monitoring visit. CPMP (Committee on Proprietary Medicinal Products): A committee, composed of two people from each EU member state (see “EU” below) that is responsible for the scientific evaluation and assessment of marketing applications for medicinal products in the EU. The CPMP is the major body involved in the harmonization of pharmaceutical regulations within the EU and receives administrative support from the European Medicines Evaluation Agency. (See “EMEA” below.) CRA (Clinical Research Associate): An individual responsible for monitoring clinical trial data to ensure compliance with study protocol and FDA GCP regulations. CRF (Case Report Form): In clinic al trials, a standard document used by clinicians to record and report subject data pertinent to the study protocol. CRO (Contract Research Organization): An independent organization that contracts with a sponsor of a clinical investigation to conduct part of the work on a clinical study. Drug makers and medical device makers frequently outsource work to CROs. CRT (Case Report Tabulation): In clinical trials, a tabular listing of all data collected on study case report forms. Development: The phase of research and development in which researchers attempt to create new products from the results of discoveries and applications created during basic and applied research.
Device: In medical product development, according to the FDA, an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent or other similar or related article, including any component, part or accessory, that 1) is recognized in the official National Formulary or United States Pharmacopoeia or any supplement to them, 2) is intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment or prevention of disease, in man or animals or 3) is intended to affect the structure of the body of man or animals and does not achieve any of its principal intended purposes through chemical action within or on the body of man or animals and is not dependent upon being metabolized for the achievement of any of its principal intended purposes. Diagnostic Radioisotope Facility: In medicine, the use of radioactive isotopes (radiopharmaceuticals) as tracers or indicators to detect an abnormal condition or disease in the body. Distributor: Distributors do not manufacture but may be involved in sales, marketing, warehousing or shipping of drugs and/or medical devices. In medicine, distributors are subject to medical device incident reporting, record keeping, tracking and registration and certification requirements under the Safe Medical Devices Act (see “SMDA” below). DMB (Data Monitoring Board): A committee that monitors the progress of a clinical trial and carefully observes the safety data. DNA: (Deoxyribonucleic Acid): The carrier of the genetic information that cells need to replicate and to produce proteins. DNA Chip: The DNA microchip is a revolutionary tool used to identify mutations in genes like BRCA1 and BRCA2. The chip, which consists of a small glass plate encased in plastic, is manufactured using a process similar to the one used to make computer microchips. On the surface, each chip conta ins synthetic single stranded DNA sequences identical to a normal gene. Drug Utilization Review: A quantitative assessment of patient drug use and physicians’ patterns of prescribing drugs in an effort to determine the usefulness of drug therapy.
Copyright@2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
DSMB (Data and Safety Monitoring Board): See “DMB” above.
FD&C Act (Food, Drug and Cosmetic Act): The federal body of law that governs the manufacture, sale and distribution of food, drugs and cosmetics.
EC (European Community): See “EU” below. EFGCP (European Forum for Good Clinical Practices): The organization dedicated to finding common ground in Europe on the implementation of Good Clinical Practices. (See “GCP” below.) www.efgcp.org ELA (Establishment License Application): An ELA is required for the approval of a biologic (see “Biologic” above). It permits a specific facility to manufacture a biological product for commercial purposes. (Compare to “PLA” below.) EMEA (European Medicines Evaluation Agency): The European agency responsible for supervising and coordinating applications for marketing medicinal products in the European Union (see “EU” below and “CPMP” above). The EMEA is headquartered in the U.K. www.eudraportal.eudra.org Endpoint: A clinical or laboratory measurement used to assess safety, efficacy or other trial objectives of a test article in a clinical trial. Enzyme : A protein that acts as a catalyst, affecting the chemical reactions in cells. EST (Expressed Sequence Tags): Small pieces of DNA sequence (usually 200 to 500 nucleotides long) that are generated by sequencing either one or both ends of an expressed gene. The idea is to sequence bits of DNA that represent genes expressed in certain cells, tissues or organs from different organisms and use these tags to fish a gene out of a portion of chromosomal DNA by matching base pairs. (See "Gene Expression" below.)
FDA (Food and Drug Administration): The U.S. government agency responsible for the enforcement of the FD&C Act (see above), ensuring industry compliance with laws regulating products in commerce. The FDA’s mission is to protect the public from harm and encourage technological advances that hold the promise of benefiting society. www.fda.gov Follow-On: Refers to the offering of additional stock shares as a form of financing; typically occurs after a company has had an initial public offering (IPO). Functional Genomics: The process of attempting to convert the molecular information represented by DNA into an understanding of gene functions and effects. To address gene function and expression specifically, the recovery and identification of mutant and over-expressed phenotypes can be employed. Functional genomics also entails research on the protein function (“proteomics”) or, even more broadly, the whole metabolism (“metabolomics”) of an organism. Functional Proteomics: The study of the function of all of the proteins encoded by an organism's entire genome. GCP (Good Clinical Practices): FDA regulations and guidelines that define the responsibilities of the key figures involved in a clinical trial, including the sponsor, the investigator, the monitor and the Institutional Review Board. (See “IRB” below.) Gene: A working subunit of DNA; the carrier of inheritable traits.
Etiology: The study of diseases.
Gene Chips : See “DNA Chip” above.
EU (European Union): Previously known as the European Community (EC), the EU is a consolidation of different European countries (Member States) functioning as one body to facilitate trade. There are currently 15 member states: Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, The Netherlands, Portugal, Spain, Sweden and the United Kingdom. http://erupa.eu.int
Gene Expression: The term used to describe the transcription of the information contained within the DNA (the repository of genetic information) into messenger RNA (mRNA) molecules that are then translated into the proteins that perform most of the critical functions of cells. Scientists study the kinds and amounts of mRNA produced by a cell to learn which genes are expressed, which in turn provides insights into how the cell responds to its changing needs.
Copyright@2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Gene Knock-Out: The inhibition of gene expression through various scientific methods. Gene Therapy: Treatment based on the alteration of existing genes. (Also see “High Throughput Screening” below.) Genetic Code : The sequence of nucleotides, determining the sequence of amino acids in protein synthesis. Genetically Modified (GM): Bioengineered food that is designed to resist herbicides and pests, and has higher nutritional value than non-engineered food and/or lasts longer on the shelf. An example of GM food is a soybean that has been specially modified to be impervious to the application of a specific pesticide. Genetics : The study of the process of heredity. Genome : The genetic material (composed of DNA) in the chromosomes of a living organism. Genomics : The study of genes, their role in diseases and our ability to manipulate them. Genotype : The genetic constitution of an organism. GLP (Good Laboratory Practices): A collection of regulations and guidelines to be used in laboratories where research is conducted on drugs, biologics or devices that are intended for submission to the FDA. GMP (Good Manufacturing Practices): A collection of regulations and guidelines to be used in manufacturing drugs, biologics and medical devices. High Throughput Screening (HTP): HTP screening makes use of techniques that allow for a fast and simple test on the presence or absence of a desirable structure, such as a specific DNA sequence. HTP screening often uses DNA chips or microarrays and automated data processing for the large-scale screening, for instance to identify new targets for drug development. IDE (Investigational New Device Exemption): An IDE must be filed with the FDA prior to initiating clinical trials of medical devices considered to pose a significant risk to human subjects.
Imaging: In medicine, the viewing of the body’s organs through external, high-tech means. This reduces the need for broad, exploratory surgery. These advances, along with new types of surgical instruments, have made minimally invasive surgery possible. Imaging includes: MRI (Magnetic Resonance Imaging), CT (Computed Tomography or “CAT scan”) and MEG (magnetoencephalography), improved x-ray technology, mammography, ultrasound and angiography. Immunoassay: Types of immunological assays include agglutination, complement fixation, precipitation, immunodiffusion, and electrophoretic assays. Each type of assay utilizes either a particular type of antibody or a specific support medium (such as a gel) to determine the amount of antigen present. In Vitro: Laboratory experiments conducted in the test tube, or otherwise, without using live animals and/or humans. In Vivo: Laboratory experiments conducted with live animals and/or humans. IND (Investigational New Drug Exemption): An IND must be filed with the FDA prior to initiating clinical trials of drugs or biologics. Indication: Refers to a specific disease, illness or condition for which a drug is approved as a treatment. Typically, a new drug is first approved for one indication. Then, an application to the FDA is later made for approval of additional indications. Informatics: See "Bioinformatics" above. Informed Consent: Must be obtained in writing from people who agree to be clinical trial subjects prior to their enrollment in the study. The document must explain the risks associated with the study and treatment and describe alternative therapy available to the patient. A copy of the document must also be provided to the patient. Insertion Mutants : Mutants of genes that are obtained by inserting DNA, for instance through mobile DNA sequences. Furthermore, in plant research, the capacity of the bacterium Agrpbacterium to introduce DNA into the plant genome is employed to induce mutants. In both cases, mutations lead to lacking or changing gene functions that are revealed by aberrant phenotypes.
Copyright@2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Insertion mutant isolation, and subsequent identification and analysis are employed in model plants such as Arabiopsis and in crop plants such as maize and rice. Interferon: A type of biological response modifier (a substance that can improve the body’s natural response to disease). Investigator: In clinical trials, clinicians who agree to supervise the use of an investigational drug, device or biologic in humans. Responsibilities of the investigator include administering the drug, observing and testing the patient, collecting data and the care and welfare of the patient. Responsibilities of the investigator are defined in FDA regulations. IRB (Institutional Review Board): This group of individuals is found in most medical institutions. The main function of the IRB is to review protocols for ethical consideration (to ensure the rights of the patients). Secondly, the IRB evaluates the benefit-torisk ratio of a new drug to see that the risk is acceptable for patient exposure. Responsibilities of the IRB are defined in FDA regulations. ISO 9000, 9001, 9002: Standards set by the International Organization for Standardization for quality procedures. ISO 9000, 9001 and 9002 are the quality certifications for manufacturing. Ligand: Any atom or molecule attached to a central atom in a complex compound. Mass Spectrometry: Usage of analytical devices that can determine the mass (or molecular weight) of proteins and nucleic acids, the sequence of protein molecules, the chemical organization of almost all substances and the identification of gram-negative and gram-positive microorganisms. Medical Device : See “Device” above. Metabolomics : The study of low molecular weight materials produced during genomic expression within a cell. Such studies can lead to a better understanding of how changes within genes and proteins affect the function of cells. Microarray: A Microarray analyzes fragments of genes called Expressed Sequence Tags (ESTs). Minuscule amounts of hundreds or thousands of these ESTs are sprayed onto a single microscope slide by a
robotic process within the microarray. Next the genetic messenger molecules, which signal the production of proteins, from a particular cell are labeled with fluorescent tags and allowed to hybridize, or bind, to the ESTs on the slide whose sequences are complementary to the those of the messengers. After a scanner measures the fluorescence of each sample on the slide, scientists can determine how active the genes represented by the ESTs are in the cell. Strong fluorescence indicates that many of the cell's messengers hybridized to the EST and, therefore, that the gene is very active in the cell. Conversely, no fluorescence indicates that none of the messenger molecules hybridized to the EST and that the gene is inactive in the cell. The results of microarrays lead to knowledge about the genetic makeup of a patient's tissues. For example, they can be used to analyze the genetic nature of a tumor. Monoclonal Antibodies: Substances that can locate and bind to cancer cells wherever they are in the body. Nanotechnology: The science of designing, building or utilizing unique structures that are smaller than 100 nanometers. (A nanometer is one billionth of a meter.) Nanotechnology involves microscopic structures that might be no larger than the width of some cell membranes. NDA (New Drug Application): An application requesting FDA approval, after completion of Phase III studies, to market a new drug for human use in interstate commerce. Clinical trial results generally account for approximately 80% of the NDA. NIH (National Institutes of He alth): A branch of the U.S. Public Health Service that conducts experimental research. www.nih.gov Nonclinical Studies: In vitro (laboratory) or in vivo (animal) pharmacology, toxicology and pharmacokinetic studies that support the testing of a product in humans. Usually at least two or more species are evaluated prior to Phase I clinical trials. Nonclinical studies continue throughout all phases of research to evaluate long-term safety issues. Nucleic Acid: A large molecule composed of nucleotides. Nutraceutical: Nutrient + pharmaceutical – a food or part of a food that has been isolated and sold in a
Copyright@2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
medicinal form and claims to offer benefits such as the treatment or prevention of disease. Nutrigenomics : The study of how food interacts with genes. Oncogene : A unit of DNA that normally directs cell growth, but which can also promote or allow the uncontrolled growth of cancer. Orphan Drug: A drug, biologic or antibiotic designated by the FDA as providing therapeutic benefit for an indication (disease or condition) affecting less than 200,000 people in the U.S. Companies that market orphan drugs are granted a period of market exclusivity in return for the limited commercial potential of the drug. OTC: (Over-the-Counter) Over-the-counter drug products are FDA-regulated products that do not require a physician’s prescription. Some examples include aspirin, sunscreen, nasal spray and sunglasses. Pharmacodynamics: The study of reactions between drugs and living systems. It can be thought of as the study of what a drug does to the body. Pharmacoeconomics : The study of the costs and benefits associated with various treatments. Pharmacogenetics : The investigation of the different reactions of human beings to drugs and the underlying genetic predispositions. The differences in reaction are mainly caused by mutations in certain enzymes responsible for drug metabolization. As a result, the degradation of the active substance can lead to harmful by-products, or the drug might have no effect at all. Pharmacogenomics: The use of the knowledge of the DNA sequences for the development of new drugs. Pharmacokinetics (PK): The study of the processes of bodily absorption, distribution, metabolism and excretion of compounds and medicines. It can be thought of as the study of what the body does to a drug. (See “ADME” above.) Phase I Clinical Trials: Studies in this phase include initial introduction of the investigational drug into humans. These studies are closely monitored and are usually conducted in healthy volunteers. Phase I trials
are conducted after the completion of extensive nonclinical or pre-clinical trials not involving humans. Phase I studies include the determination of clinical pharmacology, bioavailability, drug interactions and side effects associated with increasing doses of the drug. Phase II Clinical Trials: Phase II studies include randomized, masked, controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication(s). During Phase II trials, the minimum effective dose and dosing intervals should be determined. Phase III Clinical Trials : These studies consist of controlled and uncontrolled trials that are performed after preliminary evidence of effectiveness of the drug has been established. They are conducted to document the safety and efficacy of the drug, as well as to determine adequate directions (labeling) for use by the physician. A specific patient population needs to be clearly identified from the results of these studies. Trials during Phase III are conducted in a large number of patients to determine the frequency of adverse events and to obtain data regarding intolerance. Phase IV Clinical Trials : These studies are conducted after approval of the drug has been obtained to gather data supporting new or revised labeling, marketing or advertising claims. Phenomics : The study of how an organism's structure responds to such things as toxins or drugs. Phenotype : Observable characteristics of an organism produced by the organism’s genotype interacting with the environment. Phylogenetic Systematics : The field of biology that deals with identifying and understanding the evolutionary relationships among the many different kinds of life on earth, both living (extant) and dead (extinct). PIPE: Private Investment, Public Equity. A type of financing whereby a private investor or mutual fund buys common stock for a company at a discount to the current market value per share. Pivotal Studies: In clinical trials, a Phase III trial that is designed specifically to support approval of a product. These studies are well controlled (usually by
Copyright@2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
placebo) and are generally designed with input from the FDA so that they will provide data that is adequate to support approval of the product. Two pivotal studies are required for drug product approval, but usually only one study is required for biologics.
For example, a sheet of paper can stop an alpha particle, a beta particle can penetrate tissues in the body and a gamma ray can penetrate concrete. The varying penetration capabilities allow radioisotopes to be used in different ways. (Also called radioactive isotope or radionuclide.)
PLA (Product License Agreement): Required for the approval of a biologic, a PLA permits a manufacturer to produce a biological product for commercial purposes. (Compare to “ELA” above).
Receptor: Proteins in or on a cell that selectively bind a specific substance called a ligand. (See “Ligand” above.)
Platform or Technology Platform Companies: Firms hoping to profit by providing information systems, software, databases and related support to biopharmaceutical companies. PMA (Pre -Market Approval): PMA is required for the approval of a new medical device or a device that is to be used for life-sustaining or life-supporting purposes, is implanted in the human body or presents potential risk of illness or injury. Positional Cloning : The identification and cloning of a specific gene, with chromosomal location as the only source of information about the gene. Post-Marketing Surveillance : The FDA’s ongoing safety monitoring of marketed drugs. Preclinical Studies: See “Nonclinical Studies” above. Protein: A large, complex molecule made up of amino acids. Proteome : The genetic material (composed of amino acids) in the chromosomes of a living organism. Proteomics : The study of gene expression at the protein level, by the identification and characterization of proteins present in a biological sample. QOL (Quality of Life): In medicine, an endpoint of therapeutic assessment used to adjust measures of effectiveness for clinical decision-making. Typically, QOL endpoints measure the improvement of a patient’s day-to-day living as a result of specific therapy. Radioisotope : Radioisotopes have varying properties that allow them to penetrate objects at different rates.
Recombination: The natural process of breaking and rejoining DNA strands to produce new combinations of genes. Reporter Gene : A gene that is inserted into DNA by researchers in order to indicate when a linked gene is successfully expressed or when signal transduction has taken place in a cell. RNA (ribonucleic acid): A macromolecule found in the nucleus and cytoplasm of cells; vital in protein synthesis. Single Nucleotide Polymorphisms: (SNPs) The most common type of genetic variation. SNPs are stable mutations consisting of a change at a single base in a DNA molecule. SNPs can be detected by HTP analyses, for instance with gene chips, and they are then mapped by DNA sequencing. SMDA (Safe Medical Devices Act): This Act became law in 1990 and amends the Food, Drug and Cosmetic Act to impose additional regulations on medical devices. SNP: See “Single -Nucleotide Polymorphism” above. Sponsor: The individual or company that assumes responsibility for the investigation of a new drug, including compliance with the FD&C Act and regulations. The sponsor may be an individual, partnership, corporation or governmental agency and may be a manufacturer, scientific institution or investigator regularly and lawfully engaged in the investigation of new drugs. The sponsor assumes most of the legal and financial responsibility of the clinical trial. Stem Cells: Found in human bone marrow, the blood stream and the umbilical cord, stem cells can be replicated indefinitely and can turn into any type of mature blood cell, including platelets, white blood
Copyright@2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
cells or red blood cells. Also referred to as pluripotent cells. Study Coordinator: See “Coordinator” above. Summary Plan Description: A description of an employee's entire benefit package as required by selffunded plans. Systems Biology: The use of combinations of advanced computer hardware, software and database technologies to take a systemic approach to biological research. Advanced technologies will enable scientists to view genetic predisposition by integrating information about entire biological systems, from DNA to proteins to cells to tissues. T Cell: White blood cell that carries out immune system responses. Target: The proteins involved in a specific disease. Drug compounds stick to specific targets in order to have the greatest positive effect and cut down on the incidence of side effects. Taste Masking: The creation of a barrier between a drug molecule and taste receptors so the drug is easier to take. It masks bitter or unpleasant tastes. TESS: See “AE” above. Toxicogenomics: The study of the relationship between responses to toxic substances and the resulting genetic changes. Trial Coordinator: See “Coordinator” above. Validation of Data: The procedure carried out to ensure that the data contained in a final clinical trial report match the original observations. WHO (World Health Organization): Assists governments in strengthening health services, furnishing technical assistance and aid in emergencies, working on the prevention and control of epidemics and promoting cooperation among different countries to improve nutrition, housing, sanitation, recreation and other aspects of environmental hygiene. Any country that is a member of the United Nations may become a member of the WHO by accepting its constitution. The WHO currently has 191 member states. www.who.int Copyright@2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
INTRODUCTION
PLUNKETT'S BIOTECH & GENETICS INDUSTRY ALMANAC 2003-2004, the second edition of our guide to the biotech and genetics field, is designed as a general source for researchers of all types. The data and areas of interest covered are intentionally broad, ranging from the costs and effectiveness of biotech and genetics engineering and research, to emerging technology, to an in-depth look at the 400 major firms (which we call “THE BIOTECH & GENETICS 400”) within the many sectors that make up the biotech and genetics industry. This reference book is designed to be a general source for researchers. It is especially intended to assist with market research, strategic planning, employment searches, contact or prospect list creation (be sure to see the export capabilities of the accompanying CD-ROM that is available to book and eBook buyers) and financial research, and as a data resource for executives and students of all types. PLUNKETT'S BIOTECH & GENETICS INDUSTRY ALMANAC takes a more rounded approach for the general reader. This book presents a complete overview of the biotech and genetics field (see “How To Use This Book”). For example, stem cells and tissue engineering are discussed, as well as the recent overall drop in biotech financing, the
outlook for manufacturers of related drugs and medical products within the scope of the industry. THE BIOTECH & GENETICS 400 is our unique grouping of the biggest, most successful corporations in all segments of the biotech and genetics industry. Tens of thousands of pieces of information, gathered from a wide variety of sources, have been researched and are presented in a unique form that can be easily understood. This section includes thorough indexes to THE BIOTECH & GENETICS 400, by geography, industry, sales, brand names, subsidiary names and many other topics. (See Chapter 4.) Especially helpful is the way in which PLUNKETT’S BIOTECH & GENETICS INDUSTRY ALMANAC enables readers who have no business background to readily compare the financial records and growth plans of biotech and genetics companies and major industry groups. You’ll see the mid-term financial record of each firm, along with the impact of earnings, sale s and strategic plans on each company’s potential to fuel growth, to create new technologies and to provide lucrative and lasting investment and employment opportunities. No other source provides this book’s easy-tounderstand discussions of growth, expenditures, technologies, corporations, research and many other items of great importance. The information within is crucial to people of all types who may be studying
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
this, one of the newest, most dynamic and most exciting industries in the world today.
•
This volume is intended to be a general guide to a quickly growing industry. That means that researchers should look to this book for an overview and, when conducting in-depth research, should contact the specific corporations or industry associations in question for the very latest changes and data. Where possible, we have listed contact names, toll-free telephone numbers and World Wide Web site addresses for the companies, government agencies and industry associations involved so that the reader may get further details without unnecessary delay.
•
Tables of industry data and statistics used in this book include the latest numbers available at the time of printing, generally through the end of 2001 or 2002.
•
We have used exhaustive efforts to locate and fairly present accurate and complete data. However, when using this book or any other source for business and industry information, the reader should use caution and diligence by conducting further research where it seems appropriate. We wish you success in your endeavors, and we trust that your experience with this book will be both satisfactory and productive.
By scanning the data groups and the unique indexes, you can find the best information to fit your personal research needs. The best major growth companies in biotech and genetics are profiled and then ranked using several different groups of specific criteria . Which firms are the biggest employers? Which biotech and genetics companies earn the most profits? These things and much more are easy to find. In addition to individual company profiles, an overview of biotech and genetic technology and its trends is provided. This book’s job is to help you sort through easy-to-understand summaries of today’s technologies, pharmaceuticals and trends in a quick and effective manner. Whatever your purpose for researching the biotech and genetics field, you’ll find this book to be a valuable guide. Nonetheless, as is true with all resources, this volume has limitations that the reader should be aware of: •
Financial data and other corporate information can change quickly. A book of this type can be no more current than the data that was available as of the time of editing. Consequently, the financial picture, management and ownership of the firm(s) you are studying may have changed since the date of this book. For example, this almanac includes the most up-to-date sales figures and profits available to the editors as of late 2002. That means that we have typically used corporate financial data as of mid-2002.
•
Corporate mergers, acquisitions and downsizing are occurring at a very rapid rate. Such events may have created significant change, subsequent to the publishing of this book, within a company you are studying.
•
Some of the companies in THE BIOTECH & GENETICS 400 are so large in scope and in variety of business endeavors conducted within a parent organization that we have been unable to completely list all subsidiaries, affiliations, divisions and activities within a firm’s corporate structure.
Jack W. Plunkett Houston, Texas January 2003
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
HOW TO USE THIS BOOK
The two primary sections of this book are devoted first to the biotech and genetics industry as a whole and then to the “Individual Data Listings” for THE BIOTECH & GENETICS 400. If time permits, you should begin your research in the front chapters of this book. Also, you will find lengthy indexes in Chapter 4 and in the back of the book. THE BIOTECH & GENETICS INDUSTRY Glossary: A short list of biotech and genetic industry terms. Chapter 1: Major Trends and Technologies Affecting the Biotech & Genetics Industry. This chapter presents an encapsulated view of the major trends that are creating rapid changes in the biotech and genetics industry today. These trends include the use by bioinformatics experts of vast genetics databases, systems biology, stem cell controversies and new developments at the FDA.
Chapter 2: Biotech & Genetics Statistics. This chapter contains charts and tables tracking the industry’s statistics. Chapter 3: Important Biotech & Genetics Industry Contacts – Addresses, Telephone Numbers and World Wide Web Sites. This chapter covers contacts for important government agencies and industry associations. Included are numerous web site addresses. Appendix: Biotech Research Techniques & Genetic Illustrations. This chapter in the back of this book presents in-depth information on the groundbreaking research performed over the past several years, including the different methods of studying DNA. This chapter also contains simple, easily understood illustrations of the complex biotech and genetic models currently under study. These models include human chromosomes, DNA chains, amino acids and RNA, to name a few.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
THE BIOTECH & GENETICS 400 Chapter 4: THE BIOTECH & GENETICS 400: Who They Are and How They Were Chosen. The companies compared in this book were carefully selected from the biotech and genetics industry, primarily in the United States with 48 major foreign firms also included. For a complete description, see THE BIOTECH & GENETICS 400 indexes in this chapter. Individual Data Listings: Look at one of the companies in THE BIOTECH & GENETICS 400’s Individual Data Listings. You’ll find the following information fields: Company Name: The company profiles are in alphabetical order by company name. If you don’t find the company you are looking for, it may be a subsidiary or division of one of the firms covered in this book. Try looking it up in the Index by Subsidiaries, Brand Names and Selected Affiliations in the back of the book. Ranks: Industry Group Code: An NAIC code used to group companies within like segments. (See Chapter 4 for a list of codes.) Ranks Within This Company’s Industry Group: Ranks, within this firm’s segment only, for annual sales and annual profits, with 1 being the highest rank. Business Activities: A grid arranged into five major industry categories and several sub-categories. A “Y” indicates that the firm operates within that sub-category. A complete Index by Industry is included in the beginning of Chapter 4. Types of Business: A listing of the primary types of business specialties conducted by the firm. Brands/Divisions/Affiliations: Major brand names, operating divisions or subsidiaries of the firm, as well as major corporate affiliations—such as another firm that owns a significant portion of the stock. A complete Index of Subsidiaries, Brand Names and Selected Affiliations is in the back of the book. Contacts: The names and titles up to 27 top officers of the company are listed, including human resources contacts.
Address: The firm’s full headquarters address and telephone number, plus toll-free and fax numbers where available. Also provided are web site addresses. Financials: Annual Sales (2002 or the latest fiscal year available to the editors, plus up to four previous years): These are stated in thousands of dollars (add three zeros if you want the full number). This figure represents consolidated worldwide sales from all operations. 2002 figures may be estimates or may be for only part of the year—partial year figures will be appropriately footnoted. Annual Profits (2002 or the latest fiscal year available to the editors, plus up to four previous years): These are stated in thousands of dollars (add three zeros if you want the full number). This figure represents consolidated, after-tax net profit from all operations. 2002 figures may be estimates or may be for only part of the year—partial year figures will be appropriately footnoted. Total Number of Employees: The approximate total number of employees, worldwide, as of 2002 (or the latest data available to the editors). Apparent Salaries/Benefits: A “Y” in appropriate fields indicates “Yes.” Due to wide variations in the manner in which corporations report benefits to the U.S. Government’s regulatory bodies, not all plans will have been uncovered during our effort to research this data. Also, the availability of such plans to employees will vary according to the qualifications that employees must meet to become eligible. For example, some benefit plans may be available only to salaried workers—others only to employees who work more than 1,000 hours yearly. Benefits that are available to employees of the main or parent company may not be available to employees of the subsidiaries. NOTE: Generally, employees covered by wealthbuilding benefit plans do not fully own (“vest in”) funds contributed on their behalf by the employer until as many as five years of service with that employer have passed. Pension Plan: The firm offers a pension plan to qualified employees. The type and generosity of these plans vary widely from firm to firm. Caution: Some employers refer to plans as “pension” or “retirement” plans when they are actually 401(k) savings plans that require a contribution by the employee. True pension plans are rarely offered. ESOP Stock Plan (Employees’ Stock Ownership Plan): This type of plan is in wide use. Typically, the
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
plan borrows money from a bank and uses those funds to purchase a large block of the corporation’s stock. The corporation makes contributions to the plan over a period of time, and the stock purchase loan is eventually paid off. The value of the plan grows significantly as long as the market price of the stock holds up. Qualified employees are allocated a share of the plan based on their length of service and their level of salary. Savings Plan, 401(k): Under this type of plan, employees make a tax-deferred deposit into an account. In the best plans, the company makes annual matching donations to the employees’ accounts, typically in some proportion to deposits made by the employees themselves. A good plan will match onehalf of employee deposits of up to 6% of wages. For example, an employee earning $30,000 yearly might deposit $1,800 (6%) into the plan. The company will match one-half of the employee’s deposit, or $900. The plan grows on a tax-deferred basis, similar to an IRA. A very generous plan will match 100% of employee deposits. However, some plans do not call for the employer to make a matching deposit at all. Other plans call for a matching contribution to be made at the discretion of the firm’s board of directors. Actual terms of these plans vary widely from firm to firm. Generally, these savings plans allow employees to deposit as much as 15% of salary into the plan on a tax-deferred basis. However, the portion that the company uses to calculate its matching deposit is generally limited to a maximum of 6%. Stock Purchase Plan: Qualified employees may purchase the company’s common stock at a price below its market value under a specific plan. Typically, the employee is limited to investing a small percentage of wages in this plan. These pla ns usually offer a 15% discount, but the discount may range from 5 to 15%. Some of these plans allow for deposits to be made through regular monthly payroll deductions. Profit Sharing: Qualified employees are awarded an annual amount equal to some portion of a company’s profits. In a very generous plan, the pool of money awarded to employees would be 15% of profits. Typically, this money is deposited into a long-term retirement account. Caution: Some employers refer to plans as “profit sharing” when they are actually 401(k) savings plans. True profit sharing plans are rarely offered. Highest Executive Salary: The highest executive salary paid, typically a 2001 amount (or the latest
year available to the editors) and typically paid to the Chief Executive Officer. Highest Executive Bonus: The apparent bonus, if any, paid to the above person. Second Highest Executive Salary: The nexthighest executive salary paid, typically a 2001 amount (or the latest year available to the editors) and typically paid to the President or Chief Operating Officer. Second Highest Executive Bonus: The apparent bonus, if any, paid to the above person. Competitive Advantage: A brief statement regarding an outstanding feature that gives the firm an edge in the marketplace. Other Thoughts: Stock Ticker: When available, the unique stock market symbol used to identify this firm’s common stock for trading and tracking purposes. Apparent Women Officers or Directors: It is difficult to obtain this information on an exact basis, and employers generally do not disclose the data in a public way. However, we have indicated what our best efforts reveal to be the apparent number of women who either are in the posts of corporate officers or sit on the board of directors. There is a wide variance from company to company. Hot Spot for Advancement for Women/ Minorities: A “Y” in appropriate fields indicates “Yes.” These are firms that either have posted a far aboveaverage number of women and/or minorities to high posts or that have a good record of going out of their way to recruit, train, promote and retain women or minorities. (See the Index of Hot Spots For Women and Minorities in the back of the book.) Growth Plans/ Special Features: Listed here are observations regarding the firm’s strategy, hiring plans, plans for growth and product development, along with general information regarding a company’s business and prospects. Locations: A “Y” in the appropriate field indicates “Yes.” Primary locations outside of the headquarters, categorized by regions of the United States and by international locations. A complete index by locations is also in the front of this chapter.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Chapter 1 MAJOR TRENDS AND TECHNOLOGIES AFFECTING THE BIOTECH & GENETICS INDUSTRY Trends Affecting the Biotechnology and Genetics Industry: 1) Investors lose patience while financing declines and biotech stocks plummet. 2) Profits are elusive and many startups are out of cash. Meanwhile, mature global drug companies lose market share to generics as blockbuster patents expire. 3) Slow approval processing, new leadership and restructuring at the FDA. 4) Dozens of new drugs that initially seemed promising lead to vast disappointments when they fail in Phase II or III trials. 5) The field of Molecular Diagnostics leaps ahead. 6) A new era of regenerative medicine begins. 7) Biosecurity receives new attention and immense funding. 8) A personalized approach to medicine gains traction.
9) Systems biology will lead to faster, more costeffective drug development. 10) Total cost of patients’ pharmaceuticals soars in the U.S. and leads to calls for price controls and government aid for seniors. 11) Stem cell and cloning controversies abound in the U.S. while research in these fields flourishes overseas. 12) Cloning techniques advance, especially for therapeutic uses. 13) Nanotechnology (the creation of very tiny devices) and information technologies converge with biotechnology. 14) Partnerships and collaboration among biotech startups, major drug manufacturers and the research departments at major universities are at an all-time high. 15) Agricultural biotechnology has scored tremendous breakthroughs, but genetically engineered foods cause great controversy and are snubbed by European nations.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
The State of the Industry in 2003-2004: Despite exponential advances in biopharmaceutical knowledge and technology, companies enduring the task of getting new drugs to market continue to face long timeframes, daunting costs and immense risks. Although the number of new drug applications submitted to the FDA tripled from 1996 through 2001, the number of new drugs receiving final approval remains small. Of every 1,000 experimental drug compounds in some form of preclinical testing, only one actually makes it to clinical trials. Then, only one in five of those drugs makes it to market. The amount of time required to develop a new drug and get it to market has not lessened, and development costs continue to rise rapidly for biopharmaceutical firms. According to the Tufts Center for the Study of Drug Development at Tufts University, the cost of developing a new drug and getting it to market now averages $802 million, up from about $500 million in 1996. (Averaged into these figures are the costs of developing and testing drugs that never reach the market.) The average time elapsed from the synthesis of a new chemical compound to its introduction to the market remains 12 to 14 years—the same timeframe that drug makers have dealt with for the past decade. As a result of these costs and the lengthy time-to-market, young biotech companies face a harsh financial reality: commercial profits take years and years to emerge from promising beginnings in the laboratory. However, advances in systems biology (the use of a combination of state-of-the-art technologies, such as molecular diagnostics, advanced computers and extremely deep, efficient genetic databases) will eventually lead to more efficient, faster drug development at reduced costs. Much of this advance will stem from the use of technology to efficiently target the genetic causes of and develop novel cures for niche diseases. For example, in May 2001 the FDA gave approval for Novartis’ new drug Gleevec (a revolutionary and highly effective treatment for patients suffering from chronic myeloid leukemia) after an astonishingly brief two and one-half months in the approval process had passed (compared to a more typical six years). This fast track approval, which promptly began saving lives, was possible because of two factors in addition to the FDA’s cooperation: 1) Novartis mounted a targeted approach to this niche disease. Its research determined that a specific
genetic malfunction causes the disease, and its drug specifically blocks the protein that causes the genetic malfunction. 2) Thanks to its use of advanced genetic research techniques, Novartis was so convinced of the effectiveness of this drug that it invested heavily and quickly in its development. Internet Research Tip: For extensive commentary and analysis on the true costs of developing new drugs see: Tufts Center for the Study of Drug Development http://csdd.tufts.edu
1) Investors lose patience while financing declines and biotech stocks plummet. In the most recent economic boom, particularly during late 1999 and much of 2000, venture capitalists and investment bankers bet heavily on biotech, which they saw as a promising technologybased alternative to investing in information technologies such as the Internet. A veritable frenzy of new financing poured into biotech startup companies and initial public offerings (IPOs) in 2000, which funded very aggressive research, development and marketing plans. New investments in U.S. biotech firms totaled about $32 billion in 2000—more than had been invested during the previous six years combined. The level of funding dropped quickly thereafter, largely as a result of the infotech industry crash of March 2000. New U.S. biotech capital totaled only $12 billion in 2001, and about $10 to $12 billion in 2002. Future levels of new funding will depend to a large extent on the ability of young biotech firms to get their new drugs successfully through Phase III trials and into the marketplace. Much of the investment burden will be borne by mature, glo bal drug firms that partner with or acquire smaller biotech companies. New drugs and profitable drug companies take a long, long time to develop. Historically, the years of operation required to reach profitability at leading biopharmaceutical firms ranges from, for example, six years at Amgen to 10 years for Chiron and 15 years for Cephalon. These timeframes do not fit the requirements of many investors.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Key Food & Drug Administration (FDA) terms relating to human clinical trials and approval stages: Phase I—Small-scale human trials to determine safety. Typically include 20 to 60 patients and are six months to one year in length. Phase II—Preliminary trials on a drug’s safety/efficacy. Typically include 100 to 500 patients and are one and one-half to two years in length. Phase III—Large-scale controlled trials for efficacy/safety; also the last stage before a request for approval for commercial distribution is made to the FDA. Typically include 1,000 to 7,500 patients and are three to five years in length. Phase IV—Follow-up trials after a drug is released to the public. NDA (New Drug Application)—A document submitted to the FDA that states the results of clinical trials and asks permission to market the drug to the public. PMA (Pre Market Approval)—An application to the FDA seeking permission to sell a medical device (rather than a drug) that is implanted, life-sustaining or life-supporting. Source: Plunkett Research, Ltd.
2) Profits are elusive and many startups are out of cash. Meanwhile, mature global drug companies lose market share to generics as blockbuster patents expire. Restructuring, mergers and bankruptcies will be regular occurrences at smaller firms, as their cash hoards from IPOs or initial rounds of venture capital dry up. Many of these companies are unable to achieve meaningful levels of revenues, and some of them are incurring immense annual losses due to the costs of research, development and regulatory requirements. At the major pharmaceutical firms, such as Bristol-Myers Squibb, Merck & Co., Eli Lilly and Schering-Plough, profits are subdued because many blockbuster drugs have lost their patent protection and face vast competition from generic versions. In the U.S., generic drugs now hold about a 50% market share. This puts pressure on these major, global drug firms to develop new avenues for profits. One such avenue will be partnerships with and investments in young biotech companies, but profits from such
ventures will, in most cases, be slow to appear. At the same time, these giant firms are investing billions inhouse on biotech research and development projects. In 2001, publicly held drug firms in the U.S. invested over $15 billion in research and development—double the amount invested in 1994. Nonetheless, the industry launched only 24 new drugs. Meanwhile, management scandals at ImClone and Elan, along with a heightened emphasis on corporate accountability in general, put pressure on CEOs and dampened the enthusiasm of investors despite the extraordinary long-term promise of the biotech era. 3) Slow approval processing, new leadership and restructuring at the FDA. New drug approval times slowed dramatically during 2001 and 2002, and the agency is in a state of reorganization. The FDA finally has a new chief after 21 months with no one in the top office. At the same time, the FDA has suffered a crisis in its finances that further complicated things. The results were hard on the drug industry. After dropping to as little as 11.7 months during 1998, the average amount of time required for approval of a new drug soared to 18.8 months during 2002. 4) Dozens of new drugs that initially seem promising lead to vast disappointments when they fail in Phase II or III trials. Many drugs seem effective in the small patient populations studie d in Phase I trials, but prove to have dangerous side effects or limited efficacy when tested on hundreds or thousands of patients. Unfortunately, in the first 10 months of 2002 alone, 30 biotech drugs that made it all the way through development and Phase I trials later showed unacceptable results in Phase II or III. 5) The field of Molecular Diagnostics leaps ahead. Diagnosing the individual patient at the genetic level will lead to predictive medicine and ultimately preventative medicine as an individual’s predisposition to be at risk for certain diseases, based on his or her genetic makeup, is revealed. The booming field of molecular diagnostics includes gene-based testing of patients and the use of immunoassays to determine the presence of specific antigens. This field will grow very rapidly as
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
scientists develop hundreds of new gene-based and protein-based assays that will enable physicians to determine how to best treat patients based on their genetic makeup and the presence in their bodies of specific infectious agents. Companies with superior technologies to watch in this area include Diagnostic Products Corporation, Orchid Biosciences and Abbott Laboratories. (See “Backgrounder—The Biotechnology Revolution of the Early 21ST Century” that follows later in this chapter.) 6) We are entering a new era of regenerative medicine. Many firms are conducting product development and research in the areas of skin replacement, vascular tissue replacement, bone graft and regeneration and stem cells, as well as transgenic organs harvested from pigs for use in humans. At its highest and most promising level, regenerative medicine may eventually utilize human stem cells to create virtually any type of replacement organ or tissue. (See “Backgrounder—The Biotechnology Revolution of the Early 21 ST Century” that follows later in this chapter.) 7) Biosecurity receives new attention and immense funding. Both in U.S. domestic and military uses, biosecurity is receiving more emphasis in an effort to thwart bioterrorism and to combat bioweapons on the battlefield. The U.S. Government is investing about $40 billion yearly in this effort, including the purchase of millions of doses of smallpox vaccine. Internet Research Tip: For an excellent “Science Primer” on genetics and basic biotechnology techniques, see: National Center for Biotechnology Information www.ncbi.nlm.nih.gov 8) A personalized approach to medicine gains traction. Perlegen Sciences, Inc. of Mountain View, California has decoded the genomes of about two dozen people. Each person’s genetic makeup took about 10 days and $1.5 million to complete. Meanwhile, a highly successful biologist entrepreneur, J. Craig Ventner, has announced that he
is seeking people who are willing to pay about $500,000 each to have their personal DNA (deoxyribonucleic acid) sequenced. He recognizes that the costs are currently limiting the number of people who can be studied, and he states that the eventual goal is a $1,000 personal genome. Ventner, former head of Celera Genomics, is on the board of a relatively new firm named U.S. Genomics. This new company was founded by researcher Eugene Chan. Chan has developed what he calls the GeneMachine, with the intent to sequence personal genomes in about 45 minutes for about $1,000. A Washington, D.C.-based firm called Alphagenetics plans to offer $1,000 personal profiles that predict how a person will respond to certain foods, based on the study of about 300 specific genes. The point to such a profile is “nutrigenomics,” the study of how food interacts with genes. For example, people with certain genetic makeups face a higher risk of heart disease and should therefore eat fewer foods containing harmful cholesterol. Other firms are already selling at-home DNA testing kits. Meanwhile, organizations ranging from the Mayo Clinic to drug giant GlaxoSmithKline are experimenting with personalized drugs that are designed to provide appropriate therapies based on the patient’s personal genetic makeup. The holy grail in all of this activity is for physicians to be able to receive a genetic model of a patient’s DNA, determine from there whether a particular drug will work effectively without daunting side effects and thus prescribe the drug that is most likely to effect the desired cure. 9) Systems biology will lead to faster, more costeffective drug development. Advanced technologies will enable scientists to view genetic predisposition by integrating information about entire biological systems, from DNA to proteins to cells to tissues. Integrating information from evolving bioinformatics databases into patient therapies and individual care will accelerate the ability to cure and prevent disease. For example, in January 2002 the FDA approved the Visys PathVision HER-2 new Probe, a diagnostic tool developed by Abbott Laboratories. This test helps determine whether a patient has the HER-2 protein, a marker for a certain type of breast cancer. Patients can thus be identified who should be treated
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
with the revolutionary breast cancer drug Herceptin, manufactured by biotech leader Genentech. At the drug development level, benefits of a systems biology approach will include: • Faster selection of the most promising novel protein targets • Better, targeted trial patient selection • Better analysis of trial patient response • Safer drugs with fewer side effects • Faster time to market Commentary: The challenges facing the biopharmaceuticals industry from 2003-2010 • Working with government to develop methods to (safely and effectively) speed approval of new drugs. • Working with the investment community to build confidence and foster patience on the part of investors for the lengthy timeframe required for commercialization of promising new compounds. • Working with civic, government, religious and academic leaders to deal with ethical questions centered on stem cells and other new technologies in a manner that will enable research and development to move forward. • Overcoming, through research, the technical obstacles to therapeutic cloning. • Enhancing sales and distribution channels so that they educate patients, payors and physicians about new drugs in a cost-effective manner. • Emphasizing fair and appropriate pricing models that will enable payors (both private and public) to afford new drugs and diagnostics while providing ample profit incentives to the industry. • Developing appropriate standards that fully realize the potential of systems biology (that is, the use of advanced information technology and the resources of genetic databases) in a manner that will create the synergies necessary to accelerate and lower the total cost of new drug development. • When a large stable of new biopharma drugs becomes available, fostering payor acceptance, diagnostic practices and physician practices that will harness the full potential of genetically-targeted, personalized medicine. Source: Plunkett Research, Ltd.
10) Total cost of patients’ pharmaceuticals soars in the U.S. and leads to calls for price controls and government aid for seniors. Factors leading to soaring drug costs in the American health care system: • Chronic illnesses are increasing as the population ages. • The drug industry is making an intensified sales effort. Direct-to-consumer advertising and legions of sales professionals calling on physicians increase demand for the newest, most expensive drugs. • Convoluted and uncoordinated lists of drug "formularies" (available drugs, their uses and their interactions) require increased administrative work to sort through, thus forcing costs upward. • Physicians continue to prescribe name-brand drugs when a generic equivalent may be available at a fraction of the cost. • Research budgets are escalating rapidly. Breakthroughs in research and development are creating significant new drug therapies, allowing a wide range of popular treatments that were not previously available. An excellent example is the rampant use of antidepressants such as Prozac. Meanwhile, major drug companies face the loss of patent protection on dozens of leading drugs— they are counting on expensive research, partnerships and acquisitions to replace those marquis drugs. • “Lifestyle” drug use is increasing, as shown by the popularity of such drugs as Viagra (for the treatment of sexual dysfunction), Propecia (for the treatment of male baldness) and Botox (for the treatment of facial wrinkles). Overall, the drug industry is one of the world's most profitable industries. Among the Fortune 500 companies in 2001, pharmaceutical firms ranked first in return on revenues at 18.5% (health care ranked 20th at only 3.3%). About 20% of pharmaceutical revenue is redirected toward discovering new medicines, well above the average of 4% reinvested in research and development in most industries. Advanced technology has allowed drug companies to saturate their development programs with smarter, more promising drugs. R&D budgets are staggering. Pfizer invested $4.9 billion in R&D in 2001, and Merck invested $2.6 billion.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Until recently, pharmaceutical research was focused primarily on curing life-threatening or severely debilitating illnesses. But a current generation of drugs, commonly referred to as “lifestyle drugs,” is economically and socially transforming the U.S. pharmaceutical industry. These lifestyle drugs target a variety of medical conditions, ranging from the painful to the inconvenient. Hundreds of millions of dollars are being poured into research for drugs to treat obesity, impotence, memory loss, depression and arthritis. Drug companies also continue to develop new treatments for hair loss and skin wrinkles in an effort to capture their share of the huge anti-aging market aimed at the baby-boomer generation. Thankfully, as the pressure and demand for new and improved treatments intensifies, so does the ability of modern technology. In addition to expediting the process and lowering the costs of drug discovery and development, advanced pharmaceutical technology promises to increase the number of diseases that are treatable with drugs, enhance the effectiveness of those drugs and increase the ability to predict disease, not just the ability to react to it. New technology aided by very fast computers will help control the cost of drug development. For example, development of new chemical compounds for potential drugs was previously a tiresome process that could easily require a full week of a laboratory worker’s effort, at a cost of $5,000 to $10,000 per compound. Now chemists can test thousands of drugs in one day, automatically. (See “combinatorial chemistry” below.) Consumers' voracious appetites for new drugs continue to grow. Insurance companies may raise copayments for drugs, strike deals with drug companies and employ pharmacy benefit management tactics in an effort to fend off rising pharmaceutical costs. Also, as new drugs hit the market, they initially have no generic equivalent, which consequently forces costs upward. In coming years, taming pharmaceutical costs will be one of the biggest challenges facing the health care system. Managed care must be able to determine which promising new drugs can deliver meaningful clinical benefits proportionate to their costs. At the same time, if the FDA can improve its inhouse handling of drug reviews, the incubation period required to develop, test, review and
commercialize a new drug could be substantially reduced. 11) Stem cell and cloning controversies abound in the U.S. while research in these fields flourishes overseas. During the 1980s, a biologist at Stanford University, Irving L. Weissman, was the first to isolate the stem cell that builds human blood (the mammalian hematopoietic cell). Later, Weissman isolated a stem cell in a laboratory mouse and went on to co-found SysTemix, Inc. (now part of drug giant Novartis) and StemCells, Inc. to continue this work in a commercial manner. In November 1998, two different university-based groups of researchers announced that they had accomplished the first isolation and characterization of the human embryonic stem cell (ESC). One group was led by James A. Thomson at the University of Wisconsin at Madison. The second was led by John D. Gearhart at the Johns Hopkins University School of Medicine at Baltimore. The ESC is among the most versatile basic building blocks in the human body. Embryos, when first conceived, begin creating small numbers of ESCs, and these cells eventually differentiate and develop into the 200+ cell types that make up the distinct tissues and organs of the human body, from bones to brains. If scientists can reproduce and then guide the development of these basic ESCs, then they could theoretically grow replacement organs and tissues in the laboratory— even such complicated tissue as brain cells or heart cells. Ethical and regulatory difficulties have arisen from the fact that the only source for human embryonic stem cells is, logically enough, human embryos. A laboratory can obtain these cells in one of three ways: 1) By inserting a patient’s DNA into an egg and thus producing a blastocyst that is a clone of the patient—which is then destroyed after only a few days of development. 2) By harvesting stem cells from aborted fetuses. 3) By harvesting stem cells from embryos that are left over and unused after an in vitro fertilization of a hopeful mother. (Artificial in vitro fertilization requires the creation of a large number of test tube embryos per instance, but only one of these embryos is used in the final process.) A rich source of similar but non-embryonic stem cells is bone marrow. Doctors have been performing bone marrow transplants in humans for years. This procedure essentially harnesses the healing power of
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
stem cells, which proliferate to create healthy new blood cells in the recipient. Several other nonembryonic stem cell sources have great promise—see below. In the fall of 2001, a small biotech company called Advanced Cell Technology announced the first cloning of a human embryo. The announcement set off yet another firestorm of rhetoric and debate on the scientific and ethical questions that cloning and related stem cell technology inspire. While medical researchers laud the seemingly infinite possibilities stem cells promise for fighting disease and the aging process, conservative theologians, policy makers and pro-life groups decry the harvest of cells from aborted fetuses and the possibility of cloning as an ethical and moral abomination. Congress, under the Bush Administration, has banned the use of Federal funding for the creation of new embryonic stem cell lines. This action was taken in spite of impassioned testimony regarding the healing potential of stem cells by physicians, researchers and celebrities, such as actor Michael J. Fox on behalf of research for Parkinson's disease, actor Christopher Reeve for spinal injury study and former first lady Nancy Reagan on behalf of Alzheimer's research. Stem cell research has been underway for years at biotech companies including Stem Cells, Inc., Geron and ViaCell. One company, Osiris Therapeutics, has been at work long enough to have several clinical trial programs in progress. The potential benefits are staggering. Through stem cell therapies, neurological disorders could be reversed with the growth of healthy cells in the brain. Injured cells in the spinal column could be regenerated and function fully again. Damaged organs such as hearts, livers and kidneys could be infused with healthy cells. Stem cell (and cloning) research activity is brisk in certain nations outside the U.S. To begin with, certain institutions around the world have stem cell lines in place, and some make them available for purchase. Groups that own existing lines include the National University of Singapore, Monash University in Australia and Hadassah Medical Centre in Israel. More importantly, several Asian nations, including Singapore, South Korea, Japan and China are investing intensely in biotech research centered on cloning and the development of stem cell therapies. The global lead in the development of stem cell therapies may eventually pass to China, where the Chinese Ministry of Science and Technology readily sees the commercial potential and is
enthusiastically funding research. In addition to funding from the Chinese government, investments in labs and research are being backed by Chinese universities, private companies, venture capitalists and Hong Kong investors. Meanwhile, back in the U.S., in December 2002 Stanford University announced plans to develop a privately funded library of human stem cell lines, which means it will be able to operate outside of the restrictions placed on federally-funded ESC research and development. It is the first U.S. university to take this path. Potential methods of developing “post-embryonic” stem cells without the use of human embryos: • Parthenogenesis—manipulation of unfertilized eggs. • Adult Stem Cells—harvesting of stem cells from bone marrow or brain tissue. • Other Cells—harvesting of stem cells from human placentas or other cells. • De-Differentiation—use of the nucleus of an existing cell, such as a skin cell, that is altered by an egg that has had its own nucleus removed. • Transdifferentiation—making a skin cell dedifferentiate back to its primordial state so that it can then morph into a useable organ cell, such as heart tissue. ESCs (typically harvested from five-day-old human embryos which are destroyed during the process) are used because of their ability to evolve into any cell or tissue in the body. Their versatility is undeniable, yet the implications of the death of the embryo are at the heart of the ethical and moral concerns. Meanwhile, scientists have discovered that there are stem cells in existence in many diverse places in the adult human body, and they are thus succeeding in creating stem cells without embryos, from “postembryonic” cells. Such cells are already showing the ability to differentiate and function in animal and human recipients. Best of all, these types of stem cells are not plagued by problems found in the use of ESCs, such as the tendency to form tumors when ESCs develop into differentiated cells. For scientists, the biggest challenge at present may be to discover the exact process by which stem cells are signaled to differentiate. (Differentiation is the molecular programming that causes stem cells to grow into specific types of tissue such as heart tissue
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
or brain tissue.) Another immense challenge lies in the fact that broad use of therapeutic cloning may require immense numbers of human eggs in which to grow blastocysts. The clearest path to therapeutic cloning may lie in “autologous transplantation.” In this method, a tiny amount of a patient’s muscle or other tissue would be harvested. This sample’s genetic material would then be de-differentiated, that is, it would be reduced to a simple, unprogrammed state. The patient’s DNA sample would then be inserted into an egg to grow a blastocyst. The blastocyst would be manipulated so that its stem cells would differentiate into the desired type of tissue, such as heart tissue. That newly grown tissue would then be transplanted to the patient’s body. Many obstacles must be overcome before such a transplant can become commonplace, but the potential is definitely there to completely revolutionize healing through such regenerative, stem cell-based processes. One type of bone marrow stem cell, recently discovered by scientists at the University of Minnesota, appears to have a wide range of differentiation capability, which means it may become the first cell type that is widely used to grow useful replacement tissue in the laboratory. (See “Cloning” below.) 12) Cloning techniques advance, especially for therapeutic uses. Cloning is a controversial technology, especially in the United States. While, as of mid December 2002, no one has successfully cloned a primate (such as a human being), large domestic animals have in fact been cloned. Reproductive cloning of a human being is illegal in the U.S. Nonetheless, an odd sect called the Raelians claimed, in late December 2002, that they had successfully arranged for the cloning of a human being that had led to a live birth, and that they had several other host mothers carrying human clone fetuses. This claim was unsubstantiated. No doubt, other groups, particularly overseas, will claim to be cloning humans, and eventually it will happen. Unfortunately, the successful birth of a cloned human baby doesn’t necessarily mean that a healthy adult human will result. To date, cloned animals have tended to develop severe health problems. For example, a U.S. firm, Advanced Cell Technology, reports that it has engineered the birth of cloned cows
that appeared healthy at first but developed severe health problems after a few years. Nonetheless, cloning has uses in regenerative medicine that can be vital in treating many types of disease, because cloning can be used to create a source of stem cells. It is instructive to note that there are two distinct types of embryonic cloning: reproductive cloning and therapeutic cloning. While they have similar beginnings, the desired end results are vastly different. Reproductive cloning is a method of reproducing an exact copy of an anima l—or potentially an exact copy of a human being. A scientist would remove the nucleus from a donor's unfertilized egg, insert a nucleus from the animal, or human, to be copied, and then stimulate the nucleus to begin dividing to form an embryo. In the case of a mammal, such as a human, the embryo would then be implanted in the uterus of a host female for gestation and birth. On the other hand, therapeutic cloning is a method of reproducing exact copies of cells needed for research or for the development of replacement tissue. In this case, once again a scientist removes the nucleus from a donor's unfertilized egg, inserts a nucleus from the animal, or human, whose cells are to be copied, and then stimulates the nucleus to begin dividing to form an embryo. However, in therapeutic use, the embryo would never be allowed to grow to any significant stage of development. Instead, it would be allowed to grow for a few hours or days, and stem cells would then be removed from it for use in regenerating tissue. 13) Nanotechnology (the creation of very tiny devices) and information technologies converge with biotechnology. Technologies that have been developed for the biotech market are now leveraging into uses in entirely new areas, such as molecular electronics. For example, tapping the true potential of proteomics will require computing projects that will be among the largest ever attempted by private industry. Biotechnology has become the most demanding commercial use for computer power. In August 2000, computer giant IBM established a specialized division centered on serving the bioinformatics market: IBM Life Sciences, www3.ibm.com/solutions/lifesciences. Eventually, the biotech industry will be one of the largest revenue producers for IBM. NuTec Sciences,
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
www.nutecsciences.com, an Atlanta-based firm, is working with IBM to assemble what it calls the world’s largest privately owned computer cluster: 1,250 IBM pSeries 640 servers linked for parallel processing capable of 7.5 trillion calculations per second. An ancillary result of this computer-based activity will be the development of new, convergent technologies and uses. 14) Partnerships and collaboration among biotech startups, major drug manufacturers and the research departments at major universities are at an all-time high. Small to mid-size biotech firms will continue to look to mature, global pharmaceutical companies for cash, marketing muscle, distribution channels and regulatory expertise. Despite the problems in the ImClone partnership with Bristol-Myers Squibb, major partnerships and acquisitions continue to be signed at a rapid clip. Good examples are the agreement between Millennium Pharmaceuticals and Abbott Laboratories to develop new diagnostics for obesity and diabetes, and the Isis Pharmaceuticals deal to do research into new drugs for inflammatory and metabolic diseases. 15) Agricultural biotechnology has scored tremendous breakthroughs, but genetically engineered foods cause great controversy and are snubbed by European nations. The biotech era technology of “molecular farming” will soon lead to broad commercialization of human drug therapies that are grown via agricultural methods. For example , scientists can manipulate plants into growing certain human proteins (instead of natural plant proteins) by inserting human genes into plants such as corn. The growth in plants of transgenic protein therapies for humans may become widespread. Such drug development methods may prove to be extremely cost-effective. At the same time, hundreds of antibodies produced in farm animals with biotech means, for use in human drug therapies, are currently under development or clinical trials. Meanwhile, genetically modified (GM) foods offer tremendous promise in agriculture—particularly in low-income/high-population-growth nations like China and India. Although scientists have been able to engineer highly desirable traits in GM seeds for crops (such as
disease-resistance and insect-resistance), such modified foods face stiff resistance among many consumers, particularly in Europe. (See Plunkett’s Food Industry Almanac.)
Technologies: HapMap Project. Now that the Human Genome Project has yielded excellent results, public funds are launching a new effort called the HapMap (Haplotype Map) Project. Funded with $100 million from the U.S. National Institutes of Health, similar agencies in China, Canada, Japan and the U.K., as well as corporate and non-profit sponsors, the project is slated to be completed in 2004 or 2005. HapMap will focus on the small percentage of DNA that varies from one individual to another. Blood samples will be collected from four different ethic populations in the nations of China, Nigeria, Japan and the U.S. Haplotypes, the building blocks of single nucleotide polymorphisms, or SNPs (see SNPs later in this chapter), are inherited and may affect diseases such as hypertension and diabetes. These haplotypes will be codified and studied in an effort to identify blocks of DNA that contain common variations in the human genome. The study will show how such variations are shared by many people and is intended to provide a shortcut to identifying which inherited gene sequences are most likely to promote whic h diseases. For additional information, see www.genome.gov/research. Biopharmaceuticals. “Biopharma,” the development and marketing of pharmaceuticals based on biotechnology, is a young, rapidly growing business. In 1982, Genentech received FDA approval to market the first genetically engineered drug for human use, a brand of insulin. Today, approximately 200 new biotech-based drugs and vaccines are on the commercial market, and most of them were approved only within the past five years. The good news is that these drugs are creating highly effective therapies for wide varieties of diseases, and they are having a significant impact on the cure rates and lifestyles of patients. The bad news is that these therapie s can be extremely expensive. Many cost in the range of $10,000 or more per treatment, and the cost can be above $100,000 for a small number of these therapies.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Genomics. The study of genes, as a resource for the commercial development of new drugs, received a significant boost from computer technology in the late 1970s. Frederick Sanger, a chemist, and Walter Gilbert, a biochemist, developed what is known as DNA sequencing technology, receiving a Nobel Prize in 1980 for their effort. In the same way that computer technology enabled the rapid growth of the Internet industry, computerization has been the catalyst for the booming biotech industry. For example, Sanger and Gilbert’s computerized DNA sequencing technology enables scientists to collect massive amounts of data on human genes at high speed, analyzing how certain genes are connected with specific diseases. Using this technology, the gene responsible for Parkinson’s disease was mapped in only nine days—a stark contrast to the nine years required to determine the gene connected with cystic fibrosis. Genomics, the mapping/analysis of genes and their uses, is the basic building block of the biopharma business. Pharmacogenomics is the study of genomics for the purpose of creating new pharmaceuticals. Today there is intense debate as to the actual number of genes in a human being, thought to be from 35,000 to 75,000. Genes are made up of DNA. Genes reside on densely packed fibers called chromosomes. The genetic information encoded in a gene is copied into RNA (ribonucleic acid—closely related to DNA) and then used to assemble proteins. You can think of DNA as a blueprint and RNA as the builder. The human body contains about 75 trillion cells. Each cell contains about 46 chromosomes, arranged in 23 pairs. Each chromosome is a strand of DNA. Each strand of DNA is composed of thousands of segments representing different genes. The sum total of all the DNA contained in all 46 chromosomes is called the human genome . Internet Research Tip: For a superior, easy-to-understand, illustrated resource on genetics and molecular biology, see: http://vector.cshl.org/dnaftb/15/concept/. Gene Tests. As specific disease genes are found, complementary gene tests are developed to screen for the gene in humans who suspect they may be at risk for developing the disease. These tests are usually patented and then licensed by the owners of the disease gene patent. Royalties are due the patent
holders each time the tests are administered, and only licensed entities can conduct the tests. Gene Mapping. This process, including such efforts as the well-known Human Genome Project, uses gene-sequencing computers to analyze genetic samples to determine the exact genetic makeup of the human body. Proteomics. Proteomics is the study of the proteins that a gene produces. Proteins do the work of the cell. A complete set of genetic information is contained in each cell. This information provides a specific set of instructions to the body. The body carries out these instructions via proteins. Genes encode for proteins. All living organisms are composed largely of proteins. They have three main cellular functions: 1) enzymes are proteins, 2) proteins provide cell structure and 3) proteins are involved in cell signaling and cell communication functions. Proteins are important to researchers because they are the link between genes and pharmaceutical development. They indicate which genes are expressed or are being used. They are important for understanding gene function. They also have unique shapes or structures. Understanding these structures and how potential pharmaceuticals will bind to them is a key element in drug design. Proteomic researchers seek to determine the unique role of each of the 500,000 or so proteins in the human body, as well as the relationships that such proteins have with each other and with various diseases. Microarrays enable the high-speed analysis of these proteins and the discovery of SNPs (see below). SNPs (“Snips”). The holy grail of genomics is the search for single nucleotide polymorphisms (SNPs). These are DNA sequence variations that occur when a single nucleotide (A, T, C or G) in the genome sequence is altered. For example an SNP might change the DNA sequence AAGGCTAA to ATGGCTAA (see the Appendix). SNPs occur every 100 to 1,000 bases along the 3 billion-base human genome. SNPs can occur in both coding (gene) and noncoding regions of the genome. Many SNPs have no effect on cell function, but scientists believe others could predispose people to diseases or influence their response to a drug. Variations in DNA sequence can have a major impact on how humans respond to disease; environmental insults such as bacteria, viruses, toxins and chemicals; drugs and other therapies. This makes
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
SNPs of great value for biomedical research and for developing pharmaceutical products or medical diagnostics. Scientists believe SNP maps will help them identify the multiple genes associated with such complex diseases as cancer, diabetes, vascular disease and some forms of mental illness. These associations are difficult to establish with conventional gene-hunting methods because a single altered gene may make only a small contribution to the disease. In April 1999, 10 large pharmaceutical companies and the U.K. Wellcome Trust philanthropy announced the establishment of a non-profit foundation to find and map at least 300,000 common SNPs. Their goal is to generate a widely accepted, high-quality, extensive, publicly available map using SNPs as markers, evenly distributed throughout the human genome. The consortium plans to patent all the SNPs found, but they will not enforce the patents. This will be done only as a measure to prevent others from patenting the same information. Information found by the consortium is being made freely available via the NIH's NCBI public Database of Single Nucleotide Polymorphisms.
a cancer patient’s tumor. That biopsy would be placed into microarray equipment. There, the microarray would arrange hundreds or thousands of microscopic dots of tumor material onto glass laboratory slides. Lasers would scan the slides, and computer software would compare the contents of the slides to vast databases, in order to determine the exact genes in the tumor. Such information may be extremely useful in treating the patient. Initially, genetic information scanned from microarrays has been used to create giant bioinformatics databases. Ideally, such databases could then analyze the genetic blueprint of a patient’s tumor in order to assist a physician in determining the drugs that would best treat the specific genes that have become mutant cancerous material, and thereby have the best opportunity to cure the patient.
Combinatorial Chemistry. After researchers determine which protein is involved in a specific disease, they use combinatorial chemistry to find the molecule that controls the protein. High-throughput screening techniques (see below) enable scientists to use automatic fluid handlers to mix chemicals under specific test conditions at extremely high speed. Combinatorial chemistry can generate thousands of chemical compound variations in a few hours. Previously, traditional chemistry methods could have required several weeks or even months to do the same work. High-throughput screening enables automated, computerized machines to screen as many as 100,000 chemical compounds daily, seeking potential molecules as drug candidates.
Gene Therapies. Generally, biopharma researchers have focused on replacing defective, disease-causing genes with healthy genes that have been engineered in the laboratory. New, healthy genes may be carried into the patient by benign viruses injected into the body or by other advanced delivery methods. (Viruses make effective gene carriers because they are efficie nt at infecting cells.) The healthy genes enable the patient to produce a supply of new, healthy proteins, thereby dissipating the disease at its root. As genomics and proteomics enable scientists to map genes and discover their related proteins, more and more gene therapies will be developed and tested.
DNA Chips. Several semiconductor (chip) platforms have been developed to facilitate molecular biology research. For example, industry leader Affymetrix has developed chips programmed to act like living cells. These chips can run thousands of tests in short order to help scientists determine a specific gene’s expression. Microarrays . In the laboratory, scientists use microarrays to map the DNA of a patient’s tissues. For example, a physician may take a small biopsy of
Bioinformatics. This is the use of specially designed computer software to store, sort and analyze the vast amounts of genetic and molecular data that are produced by computerized research techniques. This is, in many ways, a merger of computer science with biology.
Vaccines. Biopharma companies have developed vaccines that carry specific proteins that can stimulate the human immune system to have a desired response against a specific infectious disease. For example, biotech vaccines that fight hepatitis B have been introduced. Vaccines are under development at various firms for such diseases as herpes and tuberculosis. Additional DNA therapies that are somewhat related to vaccines are being developed to fight specific cancers and such immune system diseases as AIDS.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Agricultural Biotech. This sector became a significant commercial industry during the 1980s. It was fostered both by startups and by large chemical or seed companies. All of these players were focused on developing genetically engineered seeds and plants that had higher yields, better nutritional qualities and/or resistance to diseases or insects. Additional traits of plants that may be genetically modified include resistance to temperature and moisture extremes. At the same time, researchers are modifying the structural makeup of some plants in order to alter leaves, stems, branches, roots or seed structures. The ability to modify the nutritional makeup of plants can have highly desirable effects. For example, Mycogen, an affiliate of Dow AgroSciences, has developed sunflower seeds with higher levels of desirable oleic and linoleic acids. While many areas of biotech are controversial, agricultural biotech is presently the largest target for consumer backlash and government intervention into the marketplace. There are currently dozens of agbio food products on the market. These range from fruits to vegetables to nuts. There is significant potential for rapid development of new products, thanks to the same technologies that are pushing development of human gene therapies. The market for genetically engineered seeds has already reached the $50 billion+ stage, but consumer resistance to food products containing material grown in this manner is suddenly fierce, and the near-term outlook for the market is cloudy at best. In the fall of 2000, a relatively small quantity of taco shells were found to have been manufactured with cornmeal made from genetically engineered corn known as StarLink. Unfortunately, StarLink was intended for hog feed rather than human foods. Consumer interest in agbio regulation soared in the U.S. as a result. In 2000 alone, there were over 30 acts of antibiotech terrorism around the world, including the firebombing of a biotech lab at the University of Michigan. Also in 2000, a U.S. trade representative, Charlene Barshefsky, quietly signed a new section of the Convention on Biological Diversity that may allow member countries of the World Trade Organization to stop the importation of any biological product at any time.
develop a disease in the future, based on his/her genetic makeup today; the potential to harvest replacement organs and tissues from animals or from cloned human genetic material; and the ability to genetically alter the basic foods that we eat are only a handful of the implications of biotech that must be dealt with by socie ty. (Don’t forget the implications of Dolly the cloned sheep, created by Scottish scientists in 1997. Will humans be cloned next?) Watch for intense, impassioned discussion of such issues and a raft of governmental regulation as new technologies and therapies emerge. The biggest single issue may be privacy. Who should have access to your personal genetic records? Where should they be stored? How should they be accessed? Can you be denied employment or insurance coverage due to your genetic makeup? One interesting startup company attempting to deal with some of these issues is GeneSage, www.genesage.com. This San Francisco company was co-founded by Paul Billings, formerly a professor of medicine at Harvard and Stanford. GeneSage’s purpose is to provide genetic information and services online, with the ultimate goal of creating a secure online area where consumers can store their personal genetic information and genetic test results. Internet Research Tip: For official ELSI (Ethical, Legal and Social Issues) information, check out: www.ornl.gov/hgmis/research.elsi.htm.
Ethical Issues. Significant issues of an ethical nature face the biotech industry as it moves forward. The ability to determine an individual’s propensity to Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
BACKGROUNDER— THE BIOTECHNOLOGY REVOLUTION OF THE EARLY 21ST CENTURY A Short History of Biotechnology: The field of biotechnology can trace its true beginnings back to the dawn of civilization, when early man discovered the ability to ferment grains to make alcoholic beverages and learned of the usefulness of cross-pollinating crops in order to create new hybrid strains—the earliest form of genetic engineering. In ancient China, people are thought to have harvested mold from soybean curd to use as an antibiotic as early as 500 B.C. Cells were first described as a concept by Robert Hooke in 1663 A.D., and in the late 1800s Gregor Mendel conducted experiments that became the basis of modern theories about heredity. Alexander Fleming discovered the first commercial antibiotic, penicillin, in 1928. The modern, more common concept of “biotech” could reasonably be said to have its beginnings shortly after World War II. In 1953, scientists James Watson and Frances Crick conceived the “double helix” model of DNA and thus encouraged a rash of scientists to consider the further implications of human DNA. The Watson/Crick three-dimensional model began to unlock the mysteries of heredity and the methods by which replication of genetic material took place within cells. Significant steps toward biotech drugs occurred in the early 1970s. In 1973, Dr. Stanley N. Cohen, a Stanford University genetics professor, and Dr. Herb Boyer, a biochemist, genetic engineer and educator at UC-San Francisco, introduced the concept of genesplicing and created the first form of recombinant DNA. In 1974, Cesar Milstein and Georges Kohler created monoclonal antibodies, cells that clone over and over again to create large quantities of a specific antibody. Many of today’s top biotech drugs are monoclonal antibodies. These two discoveries created the building blocks (recombinant DNA and monoclonal antibodies) of the first modern commercial biotech drugs. Boyer and Cohen’s gene-splicing technique enabled scientists to cut genetic material from the cells of one organism and paste it into another organism. This is important because the genetic material they moved from one place to another tells a cell how to make a particular protein. The organism
on the receiving end of the gene-splicing technique would then be able to make that protein. Over time, scientists perfected the technique of splicing material that enabled cells to create proteins that control such functions as the creation of insulin, the level of blood pressure and many other human functions. Such genetic engineering enabled, for the first time, the creation of massive vats of isolated proteins by growing them in bacteria or in cells harvested from mammals—in quantities large enough for the commercial production of new drugs. (In fact, Boyer and Cohen’s early experiments involved inserting a gene from an African clawed toad into bacterial DNA for duplication.) In 1975 the first human gene was isolated, opening the door to gene therapy and creating the emphasis that led to the beginning of the massive, publicly funded Human Genome Project in 1990. In 1976, Bob Swanson, a venture capitalist at the now-famous Silicon Valley venture capital firm of Kleiner Perkins, formed a new business, Genentech, in conjunction with Herb Boyer (see above). Other early biotech firms followed quickly, generally funded by venture capital firms , angel investors and corporate venture partners (the same triumvirate of funding sources that fueled the recent Internet startup boom). These early biotech startups included many companies that grew into today’s super-successful biopharma corporations: Amgen, Cetus, Chiron, Biogen, Genetics Institute and Genzyme. The creation of these startups, focused on the development of new drugs, was particularly noteworthy because it was the first time in decades that new drug companies had been launched in significant numbers. In fact, most major drug companies in existence at the beginning of the 1970s could trace their histories back to the early 1900s or before. Internet Research Tip: For the latest biotech developments check out www.biospace.com and www.bio.org. Technological Frontiers in Therapies, Treatments and Procedures Stem cells and tissue engineering The potential of the relatively young science of tissue engineering appears to be unlimited. Transgenics (the use of organs and tissues grown in laboratory animals for transplantation to humans) is still considered by many to have great future
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
potential, and improvements in immune system suppression will eventually make it possib le for the human body to tolerate foreign tissue instead of rejecting it. There is also increasing theoretical evidence that one day malfunctioning or defective vital organs such as livers, bladders and kidneys could be replaced with perfectly functioning “neoorgans” (like spare parts) grown in the laboratory from the patient’s own stem cells, with minimal risk of rejection. The extremely versatile human stem cell has the ability to develop into virtually any type of cell or tissue in the body and is a potentially limitless source of cells. The ability of most human tissue to repair itself is due to the activity of these cells. The potential that cultured stem cells have for transplant medicine and basic developmental biology is enormous. Not only might an unlimited amount of human tissues for transplantation be available, but the whole transplant rejection problem could be solved if a tissue could be re-grown from the patient’s own cells, thus eliminating the need for powerful immunosuppressant drugs. The problem of the limited supply of donor organs might finally be solved. On any given day, tens of thousands of patients are waiting for an organ transplant, and many of these patients die as a result of the current shortage of transplantable organs. For example, the American Heart Association reported that in 1999, a mere 14% of the 16,000 Americans aged 55 or younger needing a new heart actually received one. There are 260 transplant centers in the United States, 196 of which perform heart transplants. In 2000, only 2,198 heart transplants were performed in the U.S., fewer than one per center per month. Furthermore, only 20% of the 25,000 healthy Americans who die unexpectedly each year under circumstances conducive to organ use actually donate organs. Neo-organs have the potential to save thousands of lives yearly. For example, expensive dialysis machines would be rendered obsolete if people with damaged kidneys could be given new ones grown from their own stem cells. Each year, approximately 250,000 individuals are admitted to hospitals in the U.S. for diseases associated with liver failure, costing patients and health plans an estimated $10 billion annually. Hospital programs, such as patient monitoring, education and mental health services, requiring several thousand hospital-based professionals, could be reduced significantly. The life of the patient
would also be improved since the fatigue and depression that often accompany dialysis would be avoided. Diabetics who are forced to cope with daily insulin injection treatments could also benefit from engineered tissues. If they could receive a fully functioning replacement pancreas, diabetics might throw away their hypodermic needles once and for all. This could also save the health care system immense sums, since diabetics tend to suffer from many ailments that require hospitalization and intensive treatment, including blindness, organ failure, diabetic coma and circulatory diseases. There are a multitude of additional potential applications for tissue engineering. Tissue engineering could mean less complex and less invasive methods to treat urological disorders, such as bladder reflux and incontinence. Breast cancer patients may eventually have soft tissue alternatives to breast prostheses or implants. Severe bone fractures may no longer require grafts of bone from other parts of the body. Instead, recombinant human bone growth promoters, or stem cells, might be injected into a porous material cut to a specific shape, such as a jaw or limb. While a completely rebuilt heart is many years away, scientists have already been able to grow new blood vessels. Tissue engineering concepts are currently being applied in the area of replacement skin. This is neoskin, actually grown in large quantities by starting in the lab with a small amount of human skin cells. The FDA has approved several replacement skin products, including AlloDerm, Transcyte and Apligraf. Many others are in various stages of development. Over a million people per year suffer from a variety of serious skin disorders, ranging from diabetic ulcers to skin cancer to severe burns. Apligraf, developed by Organogenesis, Inc., closely resembles true skin and consists of both epidermal and dermal skin layers grown from bovine cells and cells from human foreskin. Apligraf is approved to treat certain skin ulcers, such as diabetic ulcers, and is being tested in treatment of other skin conditions, including burns and dermatological surgery. Vitrix, another Organogenesis product, is a replacement connective tissue product that shows promise in healing deep wounds without scarring. Scientists at the LifeCell Corporation have succeeded in regenerating skin tissue from human donors. Purified human tissue from LifeCell is ready for use in the treatment of burn victims, periodontal surgery and plastic and reconstructive surgery.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Incredibly, once in place this tissue is readily accepted by the body and not only restores the tissue that was missing but also restores patients' power to regrow their own tissue. The patients’ own cells slowly replace the acellular tissue as new dermis is formed. LifeCell’s AlloDerm is available in a variety of sheet sizes to fit procedures ranging from repair of large burns to inner ear surgery. The firm also distributes a similar product, called Repliform, for urology and gynecology applications, such as urinary incontinence surgery or pelvic floor replacement, through a partnership with Boston Scientific. Most recently, the company brought to market an injectable form of AlloDerm, called Cymetra, for use in plastic and reconstructive surgical procedures. LifeCell is exploring the use of its cell preservation and regeneration technology in many other areas. For example, it is developing acellular vascular grafts as a potential alternative to autografted (from the patient) blood vessels in coronary bypass procedures. Elsewhere, the harvesting of replacement cartilage, which does not require the growth of new blood vessels, is being used to repair damaged joints and treat urological disorders. Genzyme Corp. recently won FDA approval for its replacement cartilage product Carticel. The Genzyme process involves harvesting the patient’s own cartilageforming cells and, from those cells, re-growing new cartilage in the laboratory. Finally, the physician injects the new cartilage into the damaged area. Full regeneration of the replacement cartilage is expected to take up to 18 months. The Genzyme process can cost up to $30,000, compared to $10,000 for typical cartilage surgery, and many patients who want this new therapy can’t get their health plans to pay for it. Other companies are exploring alternative methods that may be less expensive and therefore more attractive to health plans. LifeCell and Organogenesis are just a few of the many small biotech companies tapping into the potential $80 billion market for engineered tissues. The ultimate success or failure of these companies is directly proportional to the success or failure of their experiments and the ability of their products to make it all the way through clinical trails and the FDA approval process. Advances in human stem cell research may eventually lead to new treatments for brain disorders such as Parkinson’s, Alzheimer’s and disabilities associated with stroke and trauma. Until recently, it was thought that the brain lacked the stem cells
necessary for neuronal regeneration, but we now know that this activity does take place in certain parts of the brain. While these potential applications are several years away, human stem cell research may be more immediately applied to drug development. Pure populations of specific differentiated cells could be tested against hundreds of thousands of chemicals to see if the response to a new drug is effective or not. Researchers are also trying to develop tissues that act as drug delivery vessels. Other potential stem cell applications include injecting heart muscle cells directly into failing heart tissue to shore it up. Human stem cells could be a valuable research tool for studying birth defects, pregnancy loss and cancer biology. Currently, stem cells are being used in a promising treatment for various types of cancer. Autologous stem cell rescue may eventually replace traditional, painful and costly bone marrow transplants. Because chemotherapy will destroy a patient’s bone marrow, doctors use “growth factor” drugs to stimulate stem cell production in the patient’s own blood. Stem cells will regenerate bone marrow function in the patient after high-dose chemotherapy. Also, a vaccine is administered before stem cell collection to stimulate the immune system since the immune system may be suppressed following a stem cell transplant.
Companies to Watch: StemCells, Inc., Palo Alto, CA (www.stemcellsinc.com), is creating a bank of stem cells for transplant. ViaCell, Inc., Boston, MA (www.viacellinc.com), develops therapies using umbilical cord stems.
Genetic Research Begun in 1990, The Human Genome Project is a well-funded, 15-year international effort coordinated by the U.S. Department of Energy and the National Institutes of Health (NIH) to unravel the thousands of genes and determine the sequences of the 3 billion chemical bases that make up human DNA. Genes serve as the blueprint for proteins, which direct cellular activity. Rapid technological advances have put the project ahead of schedule. The Human Genome Project public consortium announced on June 26, 2000 that it had assembled a working draft
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
of the sequence of the human genome – the genetic blueprint for a human being. At the same time Celera Genomics announced that it had completed what it called “the first assembly of the human genome,” which revealed a total of 3.12 billion base pairs in the human genome. Celera Genomics, a for-profit corporation, has been using advanced computer technology in a race to beat the non-profit NIH in mapping the genome. Actually, the two organizations have been using widely different methods. Celera uses two independent approaches to assemble the human genome. First, Celera's Whole Genome Shotgun Assembly (see “Complementary approaches” below) utilizes all of the Celera-generated sequence data from the DNA of five individuals. The results of this assembly process are sequence segments, known as "scaffolds," reconstituting the 24 human chromosomes. Most of the genome is covered by sequence scaffolds of 1 million base pairs or larger. In the case of the NIH’s Human Genome Project consortium, the government-led organization considers its project to have involved two tasks: placing large fragments of DNA in the proper order to cover all of the human chromosomes and determining the DNA sequence of these fragments. The assembly consists of overlapping fragments covering 97% of the human genome, of which the sequence has already been assembled for approximately 85% of the genome. The sequence has been threaded together into a string of A’s, T’s, C’s and G’s arrayed along the length of the human chromosomes. The sequence information from the public project has been continuously, immediately and freely released to the world, with no restrictions on its use or redistribution. The information is scanned daily by scientists in academia and industry, as well as by commercial database companies providing information services to biotechnologists. Already, many tens of thousands of genes have been identified from the genome sequence. Analysis of the current sequence shows 38,000 predicted genes confirmed by experimental evidence. There are many thousands of additional gene predictions to be tested experimentally. (A research group at the University of Ohio recently did an analysis of genomic project results and estimated that we may eventually find that there are 65,000 to 75,000 total human genes. It will be a long time before the actual count is identified.) Large numbers of disease genes have been pinpointed by access to the working draft.
Consortium centers produced far more sequence data than expected (over 22.1 billion bases of raw sequence data, comprising overlapping fragments totaling 3.9 billion bases and providing sevenfold sequence coverage of the human genome). The consortium now expects to complete the finished draft by 2003, under budget and nearly two years ahead of the original projection. The consortium is currently setting new goals for understanding the human genome’s structure, function and roles in health and disease. Meanwhile, Celera is leveraging its technical base to validate drug targets and diagnostic marker candidates. Its research includes small molecule drug development and work on drugs that target asthma and anti-coagulation. It will produce about $80 million in revenues during 2003 from subscriptions and royalties on its genetics databases. Internet Research Tip: For the latest Human Genome Project developments and other government-backed biotech initiatives, check out: the National Human Genome Research Institute at www.genome.gov. Human DNA variation The greater-than-expected sequence production has also yielded a bumper crop of human genetic variations called single nucleotide polymorphisms or SNPs. The Human Genome Project had set a goal of discovering 100,000 SNPs by 2003. Already, with today's assembled sequences and other data accumulated by The SNP Consortium, scientists have now found more than 4 million. These SNPs provide a powerful tool for studies of human disease and human history. Background Sequencing, or determining the exact order of DNA's four chemical bases (commonly abbreviated A, T, C and G), has been expedited in the Human Genome Project by technological advances in deciphering DNA as well as the collaborative nature of the effort, which includes about 1,000 scientists worldwide working together effectively. The Human Genome Sequencing Project aims to determine the sequence of the euchromatic portion of the human genome. The euchromatic portion excludes certain regions consisting of long stretches of highly repetitive DNA that encode little genetic information and that are not recovered in the vector systems used by the genome project. Such regions
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
account for about 10% of the genome and are said to be heterochromatic. (For example, the center of chromosomes, called centromeres, consists of heterochromatic DNA.) The cost of sequencing the human genome is sometimes reported as $3 billion. However, this figure refers to the original estimate of total funding for the Human Genome Project over a 15-year period (1990-2005) for a wide range of scientific activities related to genomics. These include studies of human diseases, experimental organisms (such as bacteria, yeast, worms, flies and mice), development of new technologies for biological and medical research, computational methods to analyze genomes and ethical, legal and social issues related to genetics. Results from the genome mapping efforts Knowledge gained from the NIH and Celera projects assist the biotech industry in its move forward to completely revolutionize medicine, as commercial applications are developed to treat, diagnose and possibly prevent the many thousands of diseases that afflict mankind. Researchers all over the world are already benefiting from the projects. Electronic databases disseminate information from the projects rapidly, thus changing the way biomedical research is conducted. Scientists now believe that almost all diseases have some genetic component. For example, some people have a genetic predisposition to breast cancer or heart disease. In the early years of the 21st Century, newfound understanding of the human genetic system will likely lead to a huge breakthrough in gene therapy for many ailments. Eventually, we will be able to avoid the suffering of hundreds of types of genetic diseases through the genetic manipulation of future generations. Cleveland-based Athersys has developed a technology called RAGE (random activation gene expression) that is a simple, quick way to induce genes to produce proteins. This technology could cut years off biotech drug development timelines, enabling drug discovery companies to rapidly determine the function of genes about which little is currently known. The biggest payoffs from genomic research will come in diagnostics and therapies. Technology currently under development will translate gene information into in vivo and ex vivo therapies. New genetic understanding will enable us to determine who is at the greatest risk of suffering from certain diseases.
Meanwhile, in today’s recombinant DNA therapies, the implantation of selected strands of DNA into bacteria allows large-scale production of hormones, antibodies and other exciting new drugs. (For an example of a company acting in this area, see Genentech.) Recent additions to the medical arsenal developed from this technique include interferons, growth factor hormone, anticoagulants, human insulin (as opposed to the cow and pig insulin that diabetics have used for 60 years) and more effective immunosuppressive drugs. An anticoagulant proven highly effective for some heart attack patients, TPA (see the following section on new drugs) may dramatically reduce heart damage during an attack and cut hospital stays. These new drugs are often expensive, but they may greatly reduce the duration of hospital confinement and the need for any hospitalization at all in some cases. Nevertheless, the high costs associated with recombinant DNA research and production makes it necessary for physicians and hospitals to consider less expensive medicines and treatments and to weigh the costs and benefits involved. Extensive research related to the genetic defects responsible for congenital diseases such as sickle cell anemia is also being conducted. Researchers are experimenting with inserting healthy genetic material directly into cells to replace or repair defective or missing genes. Animal research is beginning to give way to clinical trials. In a recent rodent model, gene therapy was also used to alter a donor liver prior to surgery so that the immune system of the recipient became permanently tolerant of the new organ without the aid of immunosuppressive drugs. A onetime gene therapy treatment could be a source of cost control for the health care industry because immunosuppressive drugs are costly and make the patient vulnerable to infections, cancer and other complications. In addition, gene therapy in animal models is giving researchers a clear understanding of rheumatoid arthritis, which currently afflicts about 2.1 million Americans. Specific applications of gene therapy are already in use for treatment on a limited basis. For example, gene therapy is being used to treat rare immune system disorders. In addition, the Food and Drug Administration has approved gene therapy for use in cancer treatment. As a result, melanoma (a malignant skin cancer for which there is currently no effective cure once the disease has spread to other organs) and cystic fibrosis may be treatable by gene
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
therapy within a few years, which would greatly extend the life span of victims and significantly reduce their rates of hospitalization. Extensive research is underway to identify myriad other possible applications. Polymerase chain reaction (PCR) is a method of replicating genetic material. It creates sufficient amounts of DNA to allow detailed analysis. This may lead to better diagnosis and treatment of diseases such as AIDS, Lyme disease, tuberculosis, viral meningitis, cystic fibrosis, Huntington’s chorea, sickle cell anemia and many others. PCR shows promise of providing cancer susceptibility warnings. Genetic research is rapidly leading to breakthroughs in dozens of other vital areas of medicine. A recent gene discovered by scientists appears to play a major role in widespread forms of the more than 30 different types of congenital heart defects, the most common of all human birth defects. Genes that are used by bacteria to trigger the infection process have also been identified, which could lead to powerful vaccines and antibiotics against life-threatening bacteria such as salmonella. In the area of heart disease, about 300,000 patients yearly undergo heart bypass surgery in an effort to deliver an increased blood flow to and from the heart. Clogged arteries are bypassed with arteries moved from the leg or elsewhere in the patient’s body. Genetic experts have now developed the biobypass. That is, they have determined which genes and human proteins create a condition known as angiogenesis, which is the growth of new blood vessels that can increase blood flow without traumatic bypass surgery. This technique may become widespread in the near future. New Drug Delivery Systems Controlling how drugs are delivered is a huge business. Sales of drugs using new drug delivery systems is expected to balloon to $30 billion by 2007, up from $9.8 billion in 1998. Biotech drugs that can be administered without needles are a major part of
the drug industry’s strategy. Up until the biotech age, drugs were small chemical molecules capable of being absorbed by the stomach and passed into the blood stream. However, many new biotech drugs require injection directly into the bloodstream because they are based on larger molecules that cannot be absorbed by the stomach. Many new drug delivery techniques are already in development. In the near future, there may be an implantable microchip, controlled by a miniature computer, capable of releasing variable doses of multiple potent medications over an extended period, potentially up to one year. The miniscule silicon chips will bear a series of tiny wells, sealed with membranes that dissolve and release the contents when a command is received by the computer. Chips that can receive commands beamed through the skin are also conceptually possible. This technology would help treatment of conditions such as Parkinson’s disease or cancer, where doctors need to vary medications and dosages. This technology must first be tested in animals and then in humans to ensure that the chips are biocompatible. The chips will more likely be used first in external applications such as the staggering of compounds, which may facilitate laboratory testing and drug development. Other potential needle -free drug delivery systems include synthetic molecules attached to a drug, making it tougher for the stomach to render the medicine useless before it reaches the blood. A liquid form of the anticlotting agent Heparin is entering final testing, and an oral osteoporosis drug is under development. High-tech inhalers, which force medicine through the lungs, and biotech drugs that can be imbibed are also in the works. For the patient, this means less pain and the promise of better outcomes. Needle -free systems may also make toxic drugs safer and give older drugs new life. For example, the painkiller Fetanyl was recently converted into a lozenge.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Chapter 2 BIOTECH & GENETICS INDUSTRY STATISTICS Tables and Charts: Biotechnology Industry Profile, 2001: U.S., Europe and Canada Total R&D Investments by Research-Based Pharmaceutical Companies: 1970-2001 Domestic R&D as a Percentage of Sales, U.S. Research-Based Pharmaceutical Companies: 1970-2001 Annual Percent Change in U.S. Research & Development by Research-Based Pharmaceutical Companies: 1980-2001 U.S. Biotech Industry Financing, 2001 U.S. Biotech Industry Fundraising, 1996-Third Quarter 2002 Top 20 Global Biotech and Pharmaceutical Companies, 2001 Major Biotechnology Company Consolidations, 1st through 3rd Quarter 2002 The U.S. Drug Discovery, Development and Approval Process Total U.S. Biotechnology Patents Granted Per Year, 1985-2000 New U.S. Biotech Drug and Vaccine and Indication Approvals, 1982-2001 U.S. Drug Development Times U.S. FDA Approval Times for New Drugs, 1987-2001 Average Salaries in the U.S. Pharmaceutical and Biotechnology Industries: 2002 Global Agricultural Biotech At A Glance, 2001
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
p. 26 p. 27 p. 28 p. 29 p. 30 p. 31 p. 32 p. 33 p. 34 p. 35 p. 36 p. 37 p. 38 p. 39 p. 40
Plunkett Research, Ltd.
www,plunkettresearch.com
Biotechnology Industry Profile, 2001: U.S., Europe and Canada Based on Private and Public Companies US$ Billions
Characteristic
U.S.
Europe
Canada
Sales/Revenue
$39.0
$3.9
$1.5
Annual R&D Spending
$12.3
$2.5
$0.68
Number of Companies
2,000
1,570
339
Number of Employees
157,000
61,104
7,000
356
105
83
Number of Public Companies
Source: Burrill and Company.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Total R&D Investments by Research-Based Pharmaceutical Companies: 1970-2001 Based on Total Expenditures in the U.S. and Abroad US$ Millions Year 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 * Estimate.
Total R&D $618.5 683.8 726.1 825.0 940.8 1,061.5 1,163.7 1,276.1 1,404.0 1,626.8 1,976.7 2,339.5 2,773.7 3,217.6 3,578.8 4,077.6
Year 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001*
Total R&D 4,740.1 5,502.2 6,537.5 7,330.0 8,420.3 9,705.4 11,467.9 12,740.0 13,449.4 15,207.4 16,905.6 18,958.1 20,966.9 22,690.7 26,030.8 30,342.7
PhRMA Annual Membership Survey, 2002.
Total R&D Investments by Research-Based Pharmaceutical Companies: 1970-2001
R&D Expenditures (US$ Millions)
$35,000 $30,000 $25,000 $20,000 $15,000 $10,000 $5,000 $0 1970 1972 1974 1976 1978 1980 1982 1984 1986 1988 1990 1993 1995 1997 1999 2001
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Domestic R&D as a Percentage of Sales, U.S. Research-Based Pharmaceutical Companies: 1970-2001* US$ Millions
Year
Domestic R&D
Domestic Sales
U.S. Exports to Affiliated Firms
R&D as a Percentage of Worldwide Sales
1970
$558.6
$4,552.5
$344.1
11.4%
1975
$894.5
$7,135.7
$753.7
11.3%
1980
$1,554.1
$11,788.6
$1,219.3
11.9%
1985
$3,370.7
$20,742.5
$1,556.9
15.1%
1990
$6,800.1
$38,486.7
$3,420.6
16.2%
1995
$11,833.9
$57,145.5
$3,993.3
19.4%
2000
$21,363.7
$115,881.8
$3,638.3
17.9%
2001*
$23,887.8
$130,673.9
$4,005.8
17.7%
* Preliminary. Source: PhRMA Annual Membership Survey, 2002.
Domestic R&D as a Percentage of Sales, U.S. ResearchBased Pharmaceutical Companies: 1970-2001*
R&D as a Percentage of Sales
25.0%
19.4%
20.0%
17.9%
17.7%
2000
2001*
16.2% 15.1% 15.0% 11.4%
11.3%
1970
1975
11.9%
10.0%
5.0%
0.0% 1980
1985
1990
1995
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Annual Percent Change in U.S. Research & Development by ResearchBased Pharmaceutical Companies, 1980-2001 Year
Percent Change
1980
16.7%
1981 1982
20.7% 21.3%
1983 1984
17.7% 11.6%
1985 1986
13.3% 14.7%
1987 1988
16.2% 16.2%
1989 1990
15.0% 13.0%
1991 1992 1993
16.5% 17.4% 12.5%
1994 1995
6.0% 7.0%
1996 1997
14.8% 13.9%
1998 1999
11.0% 7.4%
2000 2001
8.0% 18.2% Source: PhRMA.
Annual Percent Change in U.S. R&D by Research-Based Companies, 1980-2001 25.0 20.7
21.3 17.7
16.7
16.2 14.7
15.0
16.5
16.2 15.0
13.3
18.2
17.4 14.8 13.9
13.0
12.5
11.6
11.0
10.0 6.0
7.4 8.0
7.0
5.0
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
2001
2000
1999
1998
1997
1996
1995
1994
1993
1992
1991
1990
1989
1988
1987
1986
1985
1984
1983
1982
1981
0.0 1980
Percent Change (%)
20.0
Plunkett Research, Ltd.
www,plunkettresearch.com
U.S. Biotech Industry Financing, 2001
Total Amount (US$ Mil.)
Percent Share
$292.2
2%
Follow-ons 1
$3,510.8
23%
Public/Other
$7,227.0
48%
Venture Funding
$3,763.3
25%
$300.7
2%
$15,094.0
100%
Type of Financing
IPOs
Milestones and Equity2 Total
1 Follow-ons refer to the offering of new shares as a form of additional financing; typically occur after a company has had an initial public offering (IPO). 2 Milestones refer to additional capital invested in a firm when it meets pre-agreed benchmarks in drug development or sales.
Source: BioWorld.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Milestones and Equity2 2%
IPOs 2%
Follow-ons 23%
Venture Funding 25%
1
Public/Other 48%
U.S. Biotech Industry Fundraising, 1996-Third Quarter 2002 US$ Millions
Type
IPO Follow-On1 PIPEs2 Debt Venture Capital Other Total
1996
1997
$1,465 2,414 537 352
$688 1,601 1,283 1,288
$449 103
$569 184
$5,320
$5,613
1998
1999
Public $369 $670 521 5,805 977 1,433 1,262 1,520 Private $800 $1,084 84 184 $4,013
$10,696
2000
2001
2002 Nine Months*
$6,490 12,651 4,061 5,728
$440 2,539 1,741 4,848
$445 779 830 4,734
$2,872 203
$2,397 9
$2,160 128
$32,005
$11,974
$9,096
* Figures through third quarter 2002. 1 Refers to the offering of additional new shares as a form of financing; typically occurs after a company has had an initial public offering (IPO). 2 Private Investment, Public Equity; Occurs when a private investor or mutual fund buys common stock for a company at a discount to the current market value per share. Source: Burrill and Company.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Top 20 Global Biotech and Pharmaceutical Companies, 2001 Based on 2001 Sales US$ Thousands
Rank
Company Name
2001 Sales (US$ 000)
1
Merck & Co., Inc.
$47,716,000
2
Johnson & Johnson
$33,004,000
3
Pfizer, Inc.
$32,259,000
4
Bristol Myers Squibb
$19,423,000
5
Novartis AG
$19,070,000
6
Astrazeneca plc
$16,480,000
7
Abbott Laboratories
$16,285,000
8
Wyeth
$14,128,000
9
Akzo Nobel NV
$12,576,000
10
Eli Lilly & Co.
$11,542,000
11
Schering-Plough Corp.
$9,802,000
12
Baxter International, Inc.
$7,663,000
13
Syngenta AG
$6,323,000
14
Monsanto Co.
$5,462,000
15
Amgen, Inc.
$3,763,000
16
Novo-Nordisk AG
$2,839,000
17
Amersham plc
$2,206,400
18
Genentech, Inc.
$2,081,700
19
Teva Pharmaceutical Industries
$2,077,400
20
Allergan, Inc.
$1,745,500 Source: Plunkett Research, Ltd.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Major Biotechnology and Pharmaceutical Company Consolidations, 1st through 3rd Quarter 2002* Value in US$ Million Rank
Acquirer
Acquired
Value (US$ Mil.)
1
Pfizer
Pharmacia
$49,900
2
Guidant
Cook
3
Alkermes, Inc.
Reliant Pharmaceuticals
$847
4
Cytyc
Digene
$554
5
Johnson & Johnson
Tibotec-Viro NV
$320
6
Berna Biotech
Rhein Biotech
$257
7
Versicor, Inc.
Biosearch Italia S.p.A.
$236
8
Schering AG
Collateral Therapeutics
$140
9
Serono S.A.
Genset S.A.
$104
10
Bio-Technology General Corp.
Rosemont Pharmaceuticals
$100
11
Martek Biosciences
Omega Tech
$90
12
Inwest Investments
Drug Royalty Corp.
$84
13
Bayer AG
Visible Genetics
$61
14
Chiron
Matrix Pharmaceutical
$61
15
Martek Biosciences
Omega Tech
$53
16
deCode
MediChem Life Sciences
$49
17
Endo Pharmaceuticals Holdings
BML Pharmaceuticals
$46
18
Genencor International
Enzyme Bio-Systems
$30
19
Qiagen
GenoVision
$28
20
Harvard Bioscience
Genomic Solutions
$27
21
Deltagen
22
Charles River Laboratories
Biological Laboratories
$23
23
Amersham plc
CodeLink (Motorola)
$20
24
Proteome Sciences
Xzillion Proteomics
$18
25
Lion
NetGenics
$16
26
Argonaut
Jones Chromatography
$16
27
Qiagen
Xeragon
$3,000
Bristol-Myers Squibb Pharma Research Lab
$24
$9
* Mergers and acquisitions reflect available data through third quarter 2002. Plunkett Research, Ltd.; Burrill and Company.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
The U.S. Drug Discovery, Development and Approval Process
Discovery/Preclinical Testing: 6.5 Years ~ Laboratory and animal studies to assess safety, biological activity and formulations 5,000 compounds evaluated
Phase I: 1.5 Years 20-100 Healthy Volunteers ~ Scientists study how the drug works and whether it is safe 5 compounds enter clinical trials
Phase II: 2 Years 100-500 Patient Volunteers ~ Drug is tested to evaluate effectiveness and look for side effects
Phase III: 3.5 Years 1,000-5,000 Patient Volunteers ~ Drug is tested to confirm effectiveness and monitor adverse reactions from long-term use
U.S. FDA Review: 1.5 Years ~ Drug review process and approval ~ NDAs typically run 100,000+ pages 1 compound is approved
Phase IV: Ongoing ~ Additional postmarketing testing required by FDA
Source: Dimasi, Joseph, Risks, Regulation and Rewards in New Drug Development in the United States, Regulatory Toxicology and Pharmacology, Vol. 19, 1994; Boston Consulting Group, January 1996; Tufts Center for the Study of Drug Development; New Medicines in Development Series, PhRMA, 2001.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Total U.S. Biotechnology Patents Granted Per Year, 1985-2000
Source: U.S. Patent and Trademark Office.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
New U.S. Biotech Drug 1 and Vaccine and Indication 2 Approvals, 1982-2001
1
Drugs developed through biotechnology methods. Note the significant number of drugs approved after 1994. 2
Indication refers to a specific disease, illness or condition for which a drug is approved as a treatment. Typically, a new drug is first approved for one indication. Then, application to the FDA is later made for approval of additional indications. Source: Biotechnology Industry Organization.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
U.S. Drug Development Times in Years
Decade
Pre-Clinical
Clinical
Approval
Total Time
1960's
3.2
2.5
2.4
8.1
1970's
5.1
4.4
2.1
11.6
1980's
5.9
5.5
2.8
14.2
1990's
5.6
6.7
1.8
14.1
Source: Burrill and Company.
Drug Development Times, U.S. (in years)
2.8
4.4
5.5
6.7
3.2
5.1
5.9
5.6
1960's
1970's
1980's
1990's
2.4 Years in Development
1.8
2.1
2.5
Pre-Clinical
Clinical
Approval
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
U.S. FDA* Approval Times for New Drugs, 1987-2001 Year
Approval Time (in Months)
1987
32.4
1988
31.3
1989
32.5
1990
27.7
1991
30.3
1992
29.9
1993
26.5
1994
19.7
1995
19.2
1996
17.8
1997
16.2
1998
11.7
1999
12.6
2000
17.6
2001
16.4
* U.S. Food and Drug Administration. Source: FDA.
U.S. FDA* Approval Times for New Drugs, 1987-2001 35
Approval Time in Months
30
32.4
31.3
32.5
30.3 27.7
29.9 26.5
25 19.7 20 15
19.2 17.8
17.6
16.2 11.7
16.4
12.6
10 5 0 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Average Salaries in the U.S. Pharmaceutical and Biotechnology Industries: 2002
Biostatistics MS Entry-Level
$48,000-$60,500
PhD Entry-Level:
$86,000-$96,500 Clinical Research
Junior Laboratory Technician:
$26,500
Senior Laboratory Technician:
$34,000
Associate:
$42,000-$49,000
Senior Associate:
$59,000–$72,000
Manager:
$73,000-$101,000
Clinical Research Physician:
$90,000-$200,000
Product Management Marketing Analyst/Associate Product Manager: Product Manager:
$38,000-$75,000 $60,000-$100,000
Quality Assurance: Specialist:
$36,000-$75,500
Engineer:
$42,000-$86,000 Regulatory Affairs
Associate:
$38,000-$48,000
Senior Associate:
$71,000-$84,000
Source: Salary.com, Wetfeet.com, Stax Research (2002).
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Global Agricultural Biotech At A Glance, 2001 Top Transgenic* Crop Producing Countries, 2001 Rank
Country Name
Amount Grown (in millions of hectares)
Percentage of Global GM Total
1
United States of America
35.7
68%
2
Argentina
11.8
22%
3
Canada
3.2
6%
4
China
1.5
3%
52.2
99%
Total
Note: The U.S.A., Argentina, Canada and China grew 99% of the world's genetically modified crops in 2001. * Also referred to as genetically modified (GM) crops. Source: ISAAA; James, Clive. "Global Review of Commercialized Transgenic Crops: 2001," ISAAA Briefs No. 24: Preview.
Top Genetically Modified (GM) Crops, 2001 Based on Amount of Area Dedicated for Crop Rank
GM Crop Name
Amount of Land used for GM Crop Growth
Percentage of Global GM Area
(in millions of hectares) 1
GM Soybean
33.3
63%
2
GM Corn
9.8
19%
3
GM Cotton
6.8
13%
4
GM Canola
2.7
5%
52.6
100%
Total
Source: ISAAA; James, Clive. "Global Review of Commercialized Transgenic Crops: 2001," ISAAA Briefs No. 24: Preview.
Percent Distribution of Crops that are Genetically Modified (GM), 2001 Based on GM and non-GM crops
GM Crop
Total Area of Crop Grown Amount of Land used for (Based on GM and non-GM GM Crop Growth crops)
Percent of Total Crops that are Genetically Modified
(in millions of hectares) Soybean
72
33.3
46%
Corn
140
9.8
7%
Cotton
34
6.8
20%
Canola
25
2.7
11%
Total
271
52.6
19%
Source: ISAAA; James, Clive. "Global Review of Commercialized Transgenic Crops: 2001," ISAAA Briefs No. 24: Preview.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Chapter 3 IMPORTANT BIOTECH & GENETICS INDUSTRY CONTACTS Addresses, Telephone Numbers and World Wide Web Sites Contents: I. Biotech Associations II. Biotech Careers III. Biotech Investing IV. Biotech Publications V. Biotech Resources VI. Corporate Information VII. Engineering Associations VIII. Health Care Business and Professional Associations IX. Health Care Careers X. Health Care Resources XI. Industry Research/Market Research XII. Laboratories/Research XIII. Libraries XIV. Online Health Data XV. U.S. Government Agencies
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
p. 42 p. 42 p. 43 p. 44 p. 44 p. 46 p. 47 p. 48 p. 49 p. 49 p. 49 p. 50 p. 51 p. 51 p. 51
Plunkett Research, Ltd.
I.
www,plunkettresearch.com
Biotech Associations
BIOCOM/san diego 4510 Executive Dr., Plaza 1 San Diego, CA 92121 Phone: 858-455-0300 Fax: 858-455-0022 Web Address: www.biocom.org BIOCOM/san diego is a trade association for the life science industry.
Fax: 763-765-2329 Web Address: www.biomaterials.org The Society for Biomaterials is a professional society that promotes advances in all phases of materials research and development by encouragement of cooperative educational programs, clinical applications and professional standards in the biomaterials field.
II.
Biotech Careers
BioIndustry Association (The) 14/15 Belgrave Sq. London, England SW1X 8PS Phone: 44-207-565-7190 Fax: 44-207-565-7191 E-mail:
[email protected] Web Address: www.bioindustry.org Promotes bioscience development in the U.K. economy.
Bio Online Career Center 2855 Telegraph Ave. Berkele y, CA 94705 E-mail:
[email protected] Web Address: http://career.bio.com/careercenter/index.jhtml Provided by Bio Online, this site lets the user search an extensive database of jobs in the life sciences field.
Biotechnology Industry Organization 1625 K St. NW, Ste. 1100 Washington, DC 20006 Phone: 202-962-9200 Web Address: www.bio.org The BIO is involved in the research and development of health care, agricultural, industrial and environmental biotechnology products.
Biotechemployment.com 395 South End Ave., Ste. 15-D New York, NY 10280 Phone: 212-912-0175 E-mail:
[email protected] Web Address: www.biotechemployment.com Online resource for job seekers in biotechnology. The site includes resume posting, job search agents and employer profiles.
Environmental Mutagen Society 11250 Roger Bacon Dr., Ste. 8 Reston, VA 20190 Phone: 703-437-4377 Fax: 703-435-4390 E-mail:
[email protected] Web Address: www.ems-us.org Focuses on research on the basics of mutagenesis. Laboratory Robotics Interest Group 1730 W. Circle Dr. Martinsville, NJ 08836-2147 Phone: 732-302-1038 Fax: 508-464-7685 E-mail:
[email protected] Web Address: www.lab-robotics.org Focuses on the application of robotics in the laboratory. Society for Biomate rials 13355 10th Ave. N, Ste. 108 Minneapolis, MN 55441-5510 Phone: 763-543-0908
Chemist Jobs Phone: 44-151-647-0008 Fax: 44-151-647-0047 E-mail:
[email protected] Web Address: www.chemjobs.net Leading Internet site for job seekers in chemistry and related fields. The site is aimed at chemists, biochemists, pharmaceutical scientists and chemical engineers looking for work. Clinical Research Job-Site E-mail:
[email protected] Web Address: www.job-sites.com/cr/crjobs.htm Job listings for jobseekers in the clinical research field. Searchable by geographic location. Direct Links to Jobs at Bio Tech Biopharmaceutical Companies Web Address: www.sackskolken.com/links/USA/jobs/BioPlace.htm l
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
List of biotech employer links. This site links you to the company's employment page as well as the home page or site map.
Monthly newsletter that provides analysis, commentary, news and company developments for biotechnology investors.
Employment Links for the Biomedical Scientist Web Address: www.his.com/~graeme/employ.html Compiled by a fellow scientist, this site offers a list of links for jobseekers using the Internet to locate work in the biomedical field.
BioVenture Consultants Web Address: www.bioventureconsultants.com Provides consulting services, from business plan development to strategic planning, for bioscience companies. Also offers an extensive biotech tutorial.
PlanetJobs Web Address: www.bioplanet.com/planetforums/forumdisplay.php? fid=1 Posts jobs in the bioinformatics field by date.
Burrill & Company One Embarcadero Center, Ste. 2700 San Francisco, CA 94111 Phone: 415-591-5400 Fax: 415-591-5401 E-mail:
[email protected] Web Address: www.burrillandco.com A private merchant bank concentrated on companies in the life sciences industries: biotechnology, pharmaceuticals, medical technologies, agricultural technologies, animal health and nutraceuticals.
Science Jobs Web Address: www.science-jobs.org/index.htm Online site for jobseekers in science. Contains many useful categories of links including employment newsgroups, scientific journals and placement agencies. Sciencejobs.com 275 Washington St. Newton, MA 02458 Phone: 617-558-4904 Fax: 617-558-4933 Web Address: www.sciencejobs.com/bio Produced by the publishers of Cell, BioMednet and New Scientist, this site helps jobseekers and employers in the bioscience fields find each other. Includes a job search engine and a free-of-charge email job alert service. SciWeb Biotechnology Career Center (The) 2934 Beverly Glen Circle PMB 403 Bel Air, CA 90077 E-mail:
[email protected] Web Address: www.biocareer.com Database of biotechnology jobs. Provides access to a job search engine, resume posting, a discussion forum, career articles and career publications.
III.
Biotech Investing
BioTech Sage Report P.O. Box 7274 Beaverton, OR 97007-7274 Phone: 503-649-1355 Fax: 503-649-4490 Web Address: www.biotechnav.com
Medical Technology Stock Letter P.O. Box 40460 Berkeley, CA 94704 Phone: 510-843-1857 Fax: 510-843-0901 E-mail:
[email protected] Web Address: www.bioinvest.com The eight-page newsletter provides financial advice about investing in biotechnology. Distributed by mail and electronically. SmallCaps Online Group LLC 1285 Avenue of the Americas, 35th Fl. New York, NY 10019 E-mail:
[email protected] Web Address: www.smallcapsonline.com Online investment research information on small cap companies in the biotechnology and Internet industries. Techvest LLC 521 5th Ave., 26th Fl. New York, NY 10175 Phone: 212-262-4646 Fax: 212-262-4360 E-mail:
[email protected] Web Address: www.techvestllc.com An investment banking, investment research and consulting firm that specializes in the biotech and health care sectors.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
IV.
www,plunkettresearch.com
Biotech Publications
BioWorld Online 3525 Piedmont Rd. Bldg. 6, Ste. 400 Atlanta, GA 30305 Phone: 404-262-5476 Toll Free: 800-688-2421 E-mail:
[email protected] Web Address: www.bioworld.com Provides daily newspapers for the biotech industry, attainable via fax and online. Genetic Engineering News 2 Madison Ave. Larchmont, NY 10538 Phone: 914-834-3100 Fax: 914-834-3729 E-mail:
[email protected] Web Address: www.genengnews.com The most widely read publication in the field of biotechnology. Offers news on biotechnology, bioregulation, bioprocess, bioresearch and technology transfer. The web site also provides daily biotech news. PJB Publications, Ltd. 18/20 Hill Rise Richmond, Surrey TW10 6UA UK Phone: 44-0-20-8948-3262 Fax: 44-0-20-8332-8993 E-mail:
[email protected] Web Address: www.pjbpubs.com/cms.asp Produces several publications and books for the pharmaceutical industry. Signals Phone: 415-433-1720 E-mail:
[email protected] Web Address: www.signalsmag.com Online magazine of analysis for the biotechnology industry. Provides trends dealing with biotechnology, medical device and pharmaceutical companies involved in the development of medical products. Windhover Information 10 Hoyt St. Norwalk, CT 06851 Phone: 203-838-4401 Fax: 203-838-3214 E-mail:
[email protected] Web Address: www.windhoverinfo.com
Provides analysis and commentary on health care and biotech business strategy.
V.
Biotech Resources
Bio Online 2855 Telegraph Ave., Ste. 210 Berkeley, CA 94705 Phone: 510-548-1171 Fax: 510-548-1173 E-mail:
[email protected] Web Address: www.bio.com This site is an online community of scientists, professionals, businesses and organizations supporting life science for the purpose of an exchange of information. BioAbility P.O. Box 14569 Research Triangle Park, NC 27709-4569 Phone: 919-544-5111 Fax: 919-544-5401 E-mail:
[email protected] Web Address: www.bioability.com Provides strategic business information to the biotechnology, pharmaceutical and life science industries. Bioengineering Industry Links Web Address: www.seas.upenn.edu/be/misc/bmelink/cell.html Provided by the University of Pennsylvania's Department of Bioengineering, this site features links to companies involved in cell and tissue engineering. Biofind Web Address: www.biofind.com This biotechnology portal offers a biotech job search, a biotech chat room, biotech event announcements as well as a place to post biotech innovations for companies to invest in. Biospace.com 245 11th St. San Francisco, CA 94103 Phone: 415-355-6500 Fax: 415-503-1070 Toll Free: 888-246-7722 Web Address: www.biospace.com Biospace.com offers information, breaking news and profiles on biotech companies.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Bio-Tech Info What's New Web Address: www.biotech-info.net/new.html Site discussing news in the biotechnology industry. BioTech Web Address: http://biotech.icmb.utexas.edu This site offers a comprehensive dictionary of biotech terms, plus extensive research data regarding biotechnology. Biotech Law Web Server Links Web Address: www2.ari.net/foley/page2.html Directory of links of biotech and pharmaceutical databases, publications and companies. Biotech Professional Resources Web Address: http://biotech.icmb.utexas.edu/pages/prores.html Contains a brief list of biotechnology links, including links to employment, funding, university programs, research facilities, organizations and biotechnology regulations. Biotech Rumor Mill E-mail:
[email protected] Web Address: www.biofind.com/rumor An open discussion forum that attracts participants from the many biotech disciplines. Biotech Science Resources Web Address: http://biotech.icmb.utexas.edu/pages/scitools.html Links in several areas of biotech including molecular biology, genetics, biochemistry, microbiology and medicine. Biotech Web Links Web Address: www.biotech.ufl.org/BiotechWebLinks.html Broad list of biotech links, including links related to approved biotech drugs, databases, educational resources and biotech legislative information. Biotechnology Hot Links Web Address: http://strategis.ic.gc.ca/SSG/tc00057e.html Canadian site that offers links related to gene therapy, genetic testing and xenotransplantation. Biotechnology Information Directory Section Phone: 919-361-2286 Fax: 919-361-2290 E-mail:
[email protected]
Web Address: www.cato.com/biotech Contains over 1,500 links of companies, research institutes, universities, sources of information and other directories related to biotechnology, pharmaceutical development and similar fields. Focuses on product development. Biotechnology Knowledge Center Web Address: www.biotechknowledge.com Supported by Monsanto, an online resource containing news, technical documents, a discussion board and a glossary. Biotechnology Links and Resource Guide Page Web Address: www.ukabc.org Provides links to life sciences and seeds companies, databases and information resources, publicly funded research bodies and industry associations. Biotechnology Program List of Links E-mail:
[email protected] Web Address: www.biotech.ucdavis.edu Offers an index of links that concerns biotech funding, biotech companies and other assorted biotech topics. Biotechnology Resources on the Internet Web Address: www.sosei.com Assorted biotechnology links including biotech companies, biotech news, biotech vendors, jobs, government resources and pharmaceutical resources. Biotechterms.org Glossary of Biotech Terms Web Address: http://biotechterms.org Online version of Kimball R. Nill's book Glossary of Biotechnology Terms. The user can search the glossary by term for a definition. Business, Regulatory and Biotech Links Web Address: www.intrex.net/agbiotech/busbiot.htm Biotechnology and agriculture-based biotechnology links. Genetic Education Center: Human Genome Project Resources E-mail:
[email protected] Web Address: www.kumc.edu/gec/prof/hgc.html List of links related to the human genome including human genome centers, information sites and news articles. Genetic Engineering for Non-Scientists Web Address: www.dnapatent.com/science
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
A brief primer on genetic engineering in layman's terms. Genetics of Cancer E-mail:
[email protected] Web Address: www.intouchlive.com/cancergenetics An information resource on the genetic basis of cancer. Site contains a bulletin board, a list of case histories on various inherited forms of cancer and a collection of links on the latest concepts and terminology in genetics and cancer. Genomics, Biotech, Drug Discovery and IPR Links Web Address: www.sussex.ac.uk/Users/prpc9/links.htm Links to biotechnology companies, genome centers and pharmaceutical companies. GrantsNet Web Address: www.grantsnet.org Free online service to locate funding for training in the biomedical science industry and undergraduate science education. International Communication Forum in Human Genetics E-mail:
[email protected] Web Address: www.hum-molgen.de One of the leading sources on the Web for the latest information in human molecular genetics. Contains artwork, news articles, a bulletin board and a variety of other services. Kruglick's Forensic DNA Links Web Address: www.kruglaw.com/f_dna.htm Contains a useful list of forensic links. MedWeb: Biomedical Internet Resources Web Address: www.medweb.emory.edu/MedWeb MedWeb lists resources by medical field and allows searches for articles by topic or date. Microbiology Network (The) Web Address: www.microbiol.org A communication starting point for microbiologists. The site incoudes a discussion forum, user's groups and extensive file libraries. Miscellaneous Resources Web Address: www.arabidopsis.com/main/msc/misc.html Diversified biotech links.
Patent Law for Non-Lawyers Web Address: www.dnapatent.com/law/index.html Informative site on how to patent in the industry of biotech and genetic engineering. Assumes a working knowledge of the industry. Also contains a discussion forum. PharmaPortal.com Web Address: www.pharmaportal.com Pharmaceutical portal containing news articles, searchable product database, career services, classified advertisements and various other links. Recombinant Capital 2033 N Main St., Ste. 1050 Walnut Creek, CA 94596-3722 Phone: 925-952-3870 Fax: 925-952-3871 E-mail:
[email protected] Web Address: www.recap.com Contains databases of public information, including press releases, clinical trial references and a library of analyzed collaborations. Tufts Center for the Study of Drug Development 192 South St., Ste. 550 Boston, MA 02111 Phone: 617-636-2187 Web Address: http://csdd.tufts.edu Affiliated with Tufts University, the center provides analyses and commentary on pharmaceutical issues. Its mission is to improve the quality and efficiency of pharmaceutical development, research and utilization. WWW Virtual Library: Microbiology & Virology E-mail:
[email protected] Web Address: www.microbiol.org/vlmicro/vl_assoc.htm Contains lists of organizations and associations in the fields of microbiology, biology and general science. User can also submit new links.
VI.
Corporate Information
Business Wire Web Address: www.businesswire.com Business Wire strives to deliver news in an appropriate and innovative manner. Smart News releases, industry-specific and company-specific news, today's headlines, conference calls, IPOs on the Internet, media services, Tradeshownews.com and
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
BW Connect On-line are all accessible through this informative and continuously updated site. CNNfn Home Page Web Address: http://money.cnn.com Provides the same in-depth financial information online that CNN's cable television financial news unit provides to television viewers. Disclosure Web Address: www.disclosure-investor.com An integrated site offering financial information from Disclosure, Inc., Datastream International, Vestek Systems and I/B/E/S, each Primark subsidiaries and leaders in the financial information field. Edgar Online Web Address: www.edgar-online.com A gateway and search tool for viewing corporate documents, such as annual reports on form 10K, filed with the U.S. Securities Exchange Commission. Hoover’s Online 5800 Airport Blvd. Austin, TX 78752 Phone: 512-374-4500 Fax: 512-374-4505 Toll Free: 800-486-8666 Web Address: www.hoovers.com Hoover's provides thousands of corporate profiles online. This comprehensive site also features links to news, lists, stock quotes and other corporate and business data. PRNewswire 810 7th Ave., 35th Fl. New York, NY 10019 Phone: 212-596-1500 Toll Free: 800-832-5522 E-mail:
[email protected] Web Address: www.prnewswire.com PR Newswire provides comprehensive communications services for public relations and investor relations professionals ranging from information distribution and market intelligence to the creation of online multimedia content and investor relations web sites. Users can also view recent corporate press releases. Silicon Investor InfoSpace, Inc. 601 108th Ave. NE, Ste. 1200 Bellevue, WA 98004
Phone: 425-201-6100 Fax: 425-201-6150 Web Address: www.siliconinvestor.com Silicon Investor is focused on technology companies. The site serves as a financial discussion forum and offers quotes, profiles and charts.
VII.
Engineering Associations
American Society of Agricultural Engineers 2950 Niles Rd. St. Joseph, MI 49085 Phone: 269-429-0300 Fax: 269-429-3852 E-mail:
[email protected] Web Address: www.asae.org Nonprofit professional and technical organization of members interested in engineering knowledge and technology for food and agriculture, associated industries and related resources. Institute of Biological Engineering 3938 West Rd., Ste. 277 Cortland, NY 13045 Phone: 607-753-9227 Fax: 607-753-9227 Toll Free: 877-423-2255 E-mail:
[email protected] Web Address: www.ibeweb.org Professional organization encouraging inquiry and interest in biological engineering. International Society of Pharmaceutical Engineers 3816 W. Linebaugh Ave., Ste. 412 Tampa, FL 33624 Phone: 813-960-2105 Fax: 813-264-2816 Web Address: www.ispe.org Worldwide, nonprofit society of technical professionals who apply their practical knowledge in the regulated health care manufacturing industries. SRI International 333 Ravenswood Ave. Menlo Park, CA 94025-3493 Phone: 650-859-2000 Fax: 650-326-5512 Toll Free: 866-451-5998 E-mail:
[email protected] Web Address: www.sri.com A nonprofit organization offering a wide range of services, including engineering services, information technology, pure and applied physical sciences,
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
product development, pharmaceutical discovery, biopharmaceutical discovery and policy issues.
VIII. Health Care Business and Professional Associations Advanced Medical Technology Association 1200 G St. NW, Ste. 400 Washington, DC 20005-3814 Phone: 202-783-8700 Fax: 202-783-8750 E-mail:
[email protected] Web Address: www.himanet.com AdvaMed strives to be the advocate for a legal, regulatory and economic climate that advances global health care by assuring worldwide patient access to the benefits of medical technology. American Association of Blood Banks 8101 Glenbrook Rd. Bethesda, MD 20814-2749 Phone: 301-907-6977 Fax: 301-907-6895 E-mail:
[email protected] Web Address: www.aabb.org The AABB promotes high standards of care for blood banking and transfusion medicine. American Medical Technologists 710 Higgins Rd. Park Ridge, IL 60068 Phone: 847-823-5169 Fax: 847-823-0458 E-mail:
[email protected] Web Address: www.amt1.com AMT is a nonprofit certification agency and professional membership association representing individuals in allied health care.
E-mail:
[email protected] Web Address: www.ashe.org The ASHE is the advocate and resource for continuous improvement in the health care engineering and facilities management professions. Health Industry Distributors Association 310 Montgomery St. Alexandria , VA 22314 Phone: 703-549-4432 Fax: 703-549-6495 E-mail:
[email protected] Web Address: www.hida.org The HIDA is the international trade association representing medical products distributors. Health Sciences Communication Association 39 Wedgewood Dr., Ste. A Jewett City, CT 06351 Phone: 860-376-5915 Fax: 860-376-6621 E-mail:
[email protected] Web Address: www.hesca.org The HSCA is an association of communications professionals committed to sharing knowledge and resources in the health sciences arena. Independent Medical Distributors Association 5800 Foxridge Dr., Ste. 115 Mission, KS 66202-2740 Phone: 913-262-4513 Fax: 913-262-0174 Toll Free: 800-398-5632 E-mail:
[email protected] Web Address: www.imda.org
American Pharmaceutical Association 2215 Constitution Ave. NW Washington, DC 20037 Phone: 202-628-4410 Fax: 202-783-2351 Web Address: www.aphanet.org APhA is the national professional society of pharmacists.
International Association of Medical Equipment Remarketers & Servicers 9896 E Roadrunner Dr. Scottsdale , AZ 85262 Fax: 480-575-0891 Toll Free: 877-304-2637 E-mail:
[email protected] Web Address: www.iamers.org IAMERS works to improve the quality of pre-owned medical equipment, both domestically and internationally.
American Society for Healthcare Engineering One N Franklin, 27th Fl. Chicago, IL 60606 Phone: 312-422-3800 Fax: 312-422-4571
Medical Device Manufacturers Association 1900 K St. NW, Ste. 300 Washington, DC 20006 Phone: 202-496-7150 Web Address: www.medicaldevices.org
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
The MDMA is a national trade association that represents independent manufacturers of medical devices, diagnostic products and health care information systems. Michigan Medical Device Association P.O. Box 170 Howell, MI 48844 Fax: 517-546-3356 Toll Free: 800-930-5698 E-mail:
[email protected] Web Address: www.mmda.org The MMDA sponsors educational seminars and informational programs, is active in the areas of government relations, networking and business development and acts as a source for the dissemination of matters of interest to its members. Pharmaceutical Research and Manufacturers of America 1100 15th St. NW Washington, DC 20005 Phone: 202-835-3400 Web Address: www.phrma.org Represents the nation's leading research-based pharmaceutical and biotechnology companies.
IX.
Health Care Careers
4Work.com Web Address: www.4work.com This site contains tens of thousands of job openings and offers full search capability. Users can also post resumes. America's Health Care Source -Careers Web Address: www.healthcaresource.com This site offers career-related information for health care professionals.
X.
Health Care Resources
Access Excellence Web Address: www.accessexcellence.org Provides information for high school biology and life science teachers. Produced by the National Health Museum. Bioethics.net 3401 Market St., Ste. 320 Philadelphia , PA 19104-3308 Phone: 215-898-7136
Fax: 215-573-3036 Web Address: www.med.upenn.edu/~bioethic/ The web's first and largest site on bioethics. Discusses ethics dealing with human cloning, genetic engineering and other related scientific advances. CellsAlive.com Web Address: www.cellsalive.com Contains color images of cells and bacteria. Also covers cell biology, microbiology, immunology and microscopy. Aimed at the classroom setting. Citeline.com Web Address: www.citeline.com Allows user to search for information on diseases and therapies. Medical Biochemistry Subject List (The) Web Address: http://web.indstate.edu/thcme/mwking/subjects.html Produced by Indiana State University. A text-based introduction to biochemistry.
XI.
Industry Research/Market Research
Debbie Flanagan’s Industry Information E-mail:
[email protected] Web Address: http://home.sprintmail.com/~debflanagan/industry.ht ml This site provides a wealth of information about where and how to get industry-specific information. The links are useful for job seekers and researchers of all types. Marketresearch.com 11810 Parklawn Dr. Rockville , MD 20852 Phone: 301-468-3650 Fax: 301-468-3651 Web Address: www.marketresearch.com This firm is a leading broker for market research and industry analysis written by professionals. Users can search the company's database of market research publications. Mindbranch 160 Water St. Williamstown, MA 01267 Phone: 413-458-7600 Fax: 413-458-1706 Toll Free: 800-774-4410 Web Address: www.mindbranch.com
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
This firm is a broker for industry research prepared by market research professionals. Users can browse the research organized by different industries. Multex Investor Web Address: www.multexinvestor.com This site is a good source for industry and company reports written by professional stock and business analysts. It also offers news and advice on stocks, funds and personal finance. Plunkett Research, Ltd. P.O. Drawer 541737 Houston, TX 77254-1737 Phone: 713-932-0000 Fax: 713-932-7080 E-mail:
[email protected] Web Address: www.plunkettresearch.com Plunkett Research, Ltd. is a leading provider of market research, industry trends analysis and business statistics. Since 1985, it has served clients worldwide, including corporations, universities, libraries, consultants and government agencies. At the firm's web site, visitors can view product information and pricing, and visitors can access a great deal of basic market information on industries such as financial services, infotech, e-commerce, health care and biotech.
XII.
Laboratories/Research
Alberta Research Council 250 Karl Clark Rd. Edmonton, Alberta T6N 1E4 Canada Phone: 780-450-5111 Fax: 780-450-5333 E-mail:
[email protected] Web Address: www.arc.ab.ca Provides research and development services on a contract basis. Access to resources at facilities in western Canada and to 600 experienced scientists, researchers and business experts. Applied Research Laboratories P.O. Box 8029 Austin, TX 78713 Phone: 512-835-3200 Fax: 512-835-3259 Web Address: www.arlut.utexas.edu Applied Research Laboratories at the University of Texas provides organizational directories and electronic resources.
Battelle Memorial Institute 505 King Ave. Columbus, OH 43201 Phone: 614-424-6424 Toll Free: 800-201-2011 Web Address: www.battelle.org Serves industry and government in developing new technologies and products. Inserts technology into systems and processes for manufacturers; pharmaceutical and agrochemical industries; trade associations and government agencies supporting energy, the environment, health, national security and transportation. The company has annual revenues of approximately $1 billion. Canada's National Research Council National Research Council of Canada, Building M-58 1200 Montreal Rd. Ottawa, Ontario K1A 0R6 Canada Phone: 613-993-9084 Fax: 613-952-7656 Toll Free: 877-672-2672 E-mail:
[email protected] Web Address: www.nrc.ca Sixteen research institutes carry out multidisciplinary research with partners in industries and sectors key to Canada's economic development. Commonwealth Scientific and Industrial Research Organization Bag 10 Clayton South, VIC 3169 Australia Phone: 61-3-9545-2176 Fax: 61-3-9545-2175 E-mail:
[email protected] Web Address: www.csiro.au Performs research and development over a broad range of areas including agriculture, minerals and energy, manufacturing, communications, construction, health and the environment. Computational Neurobiology Laboratory 10010 N. Torrey Pines Rd. La Jolla , CA 92037 Phone: 858-453-4100 Web Address: www.cnl.salk.edu Aimed at understanding the computational resources of the brain from the biophysical to the systems levels Daresbury Laboratory Daresbury, Warrington Cheshire, UK WA4 4AD
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Phone: 44-1925-603000 Fax: 44-1925-603100 E-mail:
[email protected] Web Address: www.dl.ac.uk Operated by the Council of the Central Laboratory of Research Councils, a strong resource in computational science and engineering.
XIII. Libraries Library and Info Systems Web Address: www.cellbio.wustl.edu/library.htm This site provides information on libraries at various higher institutions of learning in the United States. Multimedia Medical Reference Library Web Address: http://med-library.com/medlibrary The MMRL provides a free resource of medical information for both health care consumers and medical professionals. Well Cornell Medical Library E-mail:
[email protected] Web Address: http://lib2.med.cornell.edu WWW Virtual Library: Bioscience – Medicine Oregon Health Sciences University, School of Medecine, Office of the Dean 3181 SW Sam Jackson Park Rd., L102 Portland, OR 97201 Phone: 503-494-8220 Web Address: www.ohsu.edu/cliniweb/wwwvl
XIV.
Online Health Data
MEDMarket 311 Sherman Ave. Coeur d'Alene, ID 83843 Web Address: www.medmarket.com MEDMarket serves as an online guide to the Healthcare Manufacturers Industry, featuring employment listings, an industry index and more. Medscape WebMD Medscape Health Network 224 W 30th St. New York, NY 10001-5399 Web Address: www.medscape.com Medscape, an online resource for better patient care, provides links to several journal articles, health carerelated sites and health care information.
PubMed Web Address: http://www.ncbi.nlm.nih.gov/entrez/query PubMed provides access to over 11 million MEDLINE citations dating back to the mid-1960s and additional life science journals. WEBMD.com 669 River Dr., Ctr. 2 Elmwood Park, NJ 07407 Phone: 201-703-3400 Fax: 201-703-3401 Web Address: www.WEBMD.com WebMD features a broad selection of interrelated health topics, current medical news and its own search engine.
XV.
U.S. Government Agencies
Department of Energy 1000 Independence Ave. SW Washington, DC 20585 Fax: 202-586-4403 Toll Free: 800-342-5363 Web Address: www.energy.gov Food and Drug Administration 5600 Fishers Ln. Rockville , MD 20857 Phone: 301-443-6597 Fax: 301-443-8818 Toll Free: 888-463-6332 Web Address: www.fda.gov The FDA strives to promote and protect public health by helping safe and effective products reach the market in a timely way and monitoring products for continued safety after they are approved for use. National Cancer Institute 6116 Executive Blvd., MSC 8322, Ste. 3036A Bethesda, MD 20892 Phone: 301-435-3848 Toll Free: 800-422-6237 Web Address: www.cancer.gov The NCI is the federal government's principal agency for cancer research and training. National Center for Biotechnology Information National Library of Medicine Bldg. 38 A Bethesda, MD 20894 Phone: 301-496-2475 Web Address: www.ncbi.nlm.nih.gov
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
National Center for Infectious Diseases Office of Health Communication, National Center for Infectious Diseases, CDC Mailstop C-14, 1600 Clifton Rd. Atlanta, GA 30333 Toll Free: 800-311-3435 Web Address: www.cdc.gov/ncidod
Arlington, VA 22230 Phone: 703-292-5111 Toll Free: 800-877-8339 E-mail:
[email protected] Web Address: www.nsf.gov Independent government agency responsible for promoting science and engineering.
National Center for Research Resources 6705 Rockledge Dr., Ste. 5140 Bethesda, MD 20892 Phone: 301-435-0888 Web Address: www.ncrr.nih.gov The NCRR supports primary research to create and develop critical resources, models and technologies.
Oak Ridge National Laboratory P.O. Box 2008 Oak Ridge, TN 37831 Web Address: www.ornl.gov Multiprogram science and technology laboratory managed for the U.S. Department of Energy by U.T.Battelle, LLC. Conducts basic and applied research and development to create scientific knowledge and technological solutions.
National Center for Toxicological Research 3900 NCTR Rd. Jefferson, AR 72079 Phone: 870-543-7130 E-mail:
[email protected] Web Address: www.fda.gov/nctr National Heart, Lung, and Blood Institute (NHLBI) Phone: 301-496-4236 E-mail:
[email protected] Web Address: www.nhlbi.nih.gov The NHLBI provides leadership for a national program in diseases of the heart, blood vessels, lung and blood; blood resources; and sleep disorders.
United States Patent and Trademark Office General Information Services Division, U.S. Patent and Trademark Office Crystal Plaza 3, Room 2C02 Washington, DC 20231 Phone: 703-308-4357 Toll Free: 800-786-9199 Web Address: www.uspto.gov
National Human Genome Research Institute (NHGRI) Communications and Public Liaison Branch, NHGRI Bldg. 31, Room 4B09 31 Center Dr., MSC 2152 9000 Rockville Pike Bethesda, MD 20892-2152 Phone: 301-402-0911 Fax: 301-402-2218 Web Address: www.genome.gov National Institutes of Health Bethesda, MD 20892 Phone: 301-496-4000 E-mail:
[email protected] Web Address: www.nih.gov The NIH is the steward of medical and behavioral research for the nation. National Science Foundation 4201 Wilson Blvd. Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Chapter 4 THE BIOTECH & GENETICS 400: WHO THEY ARE AND HOW THEY WERE CHOSEN Includes Indexes by Company Name, Industry & Location, And a Complete Table of Sales, Profits and Ranks
The companies chosen to be listed in PLUNKETT’S BIOTECH & GENETICS INDUSTRY ALMANAC are not the same as the “Fortune 500” or any other list of corporations. THE BIOTECH & GENETICS 400 (the actual count is 395 companies) were chosen specifically for their dominance in the many facets of biotech and genetics in which they operate. Complete information about each firm can be found in the “Individual Profiles,” beginning later in this chapter. These profiles are in alphabetical order by company name. THE BIOTECH & GENETICS 400 includes companies from all parts of the United States, Canada, Europe and beyond, and from all biotech and related industry segments: manufacturers and distributors of supplies and products; pharmaceuticals manufacturers; drug delivery system manufacturers; labs and testing services; blood and organ banks; nutriceutical manufacturers; related computer software and hardware companies and diagnostics firms. In fact, many fields that have only existed a few years are included, such as micro array makers
and companies dedicated to research and development in genomics and proteomics. Simply stated, the list contains 395 of the largest, most successful, fastest growing firms in biotech and related industries in the world. To be included in our list, the firms had to meet the following criteria: 1) U.S. based, for-profit corporations. (We have also added 48 foreign-based companies in order to better list leading firms in certain industry sectors.) 2) Publicly-held companies where stocks or bonds issued by the firm have been sold to the public (except for a very small number of firms that are privately-held that we have added in order to roundout certain niche sets of companies). 3) Prominence, or a significant presence, in biotech and supporting fields. (See the following Industry Codes section for a complete list of types of businesses that are covered). 4) The companies in THE BIOTECH & GENETICS 400 do not have to be exclusively in the biotech field.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
5) Financial data and vital statistics must have been available to the editors of this book, either directly from the company being written about or from outside sources deemed reliable and accurate by the editors. A small number of companies that we would like to have included are not listed because of a lack of sufficient, objective data. The companies were chosen in this manner for the following reasons: • 395 companies so there is a broad base among which to make comparisons, and from which you can study the major players in this industry. • Non-Government because information about government research agencies can be obtained elsewhere, and so that researchers using PLUNKETT’S BIOTECH & GENETICS INDUSTRY ALMANAC can best study firms in the profit-seeking private sector, where innovative research and development are creating dynamic changes. • Companies with publicly traded stocks because publicly-held firms can be compared fairly, since they are required by law to meet government standards in their methods of reporting, and accounting for, their vital statistics.
INDUSTRY LIST, WITH CODES This book refers to the following list of unique industry codes, based on the NAIC code system (NAIC is used by many analysts as a replacement for older SIC codes because NAIC is more specific to today’s industry sectors): Health Care 325412 325413 325414 339113 325411
621511 621991
Manufacturing 325000
INDEXES TO THE BIOTECH & GENETICS 400, AS FOUND IN THIS CHAPTER AND IN THE BACK OF THE BOOK: Industry List, With Codes Index of Rankings Within Industry Groups Alphabetical Index Geographic Indexes Index of Headquarters Location, by State Index of Headquarters Location, by Country Index by Regions Where THE BIOTECH & GENETICS 400 Have Locations Index by Firms with International Operations Index of Firms Noted as “Hot Spots for Advancement” for Women/Minorities Index by Subsidiaries, Brand Names and Selected Affiliations
p. 54 p. 55 p. 64 p. 67 p. 71
Health Products, Manufacturing Drugs, Manufacturing In Vitro Diagnostic Substance, Manufacturing Biological Products Medical/Dental/Surgical Equipment and Supplies, Manufacturing Medicinal and Botanicals, Manufacturing Health Care-Clinics, Labs and Organizations Laboratories and Diagnostics --Medical Blood and Organ Banks
Chemicals Chemicals, Manufacturing
InfoTech 334413 334515
p. 72
511200
p. 78
514210
Computers & Electronics Manufacturing Chips (Semiconductors)/Integrated Circuits/Components, Manufacturing Test Equipment/Instruments, Manufacturing Software Computer Software Information & Data Processing Services Data Processing Services
p. 498
Services
p. 500
115112
541613 541710
Agriculture Agriculture, Crop Production Support Activities Consulting & Professional Services Consulting--Marketing Research and Development--Physical, Engineering and Life Sciences
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
INDEX OF RANKINGS WITHIN INDUSTRY GROUPS
Company
Industry Code
2001 Sales (Thousands)
2001 Profits
Sales Rank
(Thousands)
Profits Rank
Agriculture, Crop Production Support Activities
EXELIXIS PLANT SCIENCES INC SYNGENTA AG
115112 115112
6,323,000
1
223,000
1
28,900 11,300 9,000 3,900 2,352 4,700 13,700 27,800
1 4 6 8 9 7 3 2
10,300 800
5 10
-28,400 -6,800 -10,300 -4,600 -16,105 -56,500 -16,600 -2,100 -10,174 -30,100 -3,400
9 4 6 3 7 11 8 1 5 10 2
1 2
17,100 -23,400
1 2
2 1 3
598,000 4,339,000 295,000
2 1 3
Biological Products
ADVANCED TISSUE SCIENCES ANIKA THERAPEUTICS INC BIOSPHERE MEDICAL INC DIACRIN INC DONLAR BIOSYNTREX EMISPHERE TECHNOLOGIES GTC BIOTHERAPEUTICS INC LIFECELL CORPORATION NORTHFIELD LABORATORIES ORGANOGENESIS INC STEMCELLS, INC
325414 325414 325414 325414 325414 325414 325414 325414 325414 325414 325414
Blood and Organ Banks
SEROLOGICALS CORP V I TECHNOLOGIES INC
621991 621991
109,800 26,900
Chemicals, Manufacturing
AKZO NOBEL NV E I DU PONT DE NEMOURS & CO MONSANTO CO
325000 325000 325000
12,576,000 24,726,000 5,462,000
Chips (Semiconductors)/Integrated Circuits/Components, Manufacturing
AFFYMETRIX INC CALIPER TECHNOLOGIES CORP CIPHERGEN BIOSYSTEMS INC NANOGEN INC
334413 334413 334413 334413
224,900 26,900 19,000 11,200
1 2 3 4
-33,100 3,800 -25,800 -32,500
4 1 2 3
25,200 10,000 49,100
2 3 1
-21,400 -12,356 5,900
3 2 1
1,332,900
1
185,400
1
28,000
1
-3,800
1
16,285,000 63,606 19,600 200 6,000 42,200 11,805
9 61 95 221 138 71 108
1,550,000 -60,856 -4,500 -6,000 800 -19,600 -57,043 -2,300
9 217 87 96 55 157 213 75
Computer Software
INFORMAX INC LION BIOSCIENCE AG TRIPOS INC
511200 511200 511200 Consulting--Marketing
IMS HEALTH INC
541613
Data Processing Services
ERESEARCH TECHNOLOGY
514210 Drugs, Manufacturing
ABBOTT LABORATORIES ABGENIX INC ABLE LABORATORIES ACCESS PHARMACEUTICALS ADVANCED MAGNETICS INC AKORN INC ALEXION PHARMACEUTICALS ALFACELL CORPORATION
325412 325412 325412 325412 325412 325412 325412 325412
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Company ALIZYME PLC ALLERGAN INC ALLIANCE PHARMACEUTICAL ALLOS THERAPEUTICS INC ALPHARMA INC ALTEON INC ALZA CORP AMARILLO BIOSCIENCES INC AMARIN CORPORATION PLC AMGEN INC AMYLIN PHARMACEUTICALS ANDRX CORP ANGIOTECH PHARMACEUTICALS ANTEX BIOLOGICS INC ANTIGENICS INC APHTON CORP ARENA PHARMACEUTICALS ARIAD PHARMACEUTICALS ASCENT PEDIATRICS INC ASTRAZENECA PLC ATLANTIC TECHNOLOGY VENTURES AUTOIMMUNE INC AVANIR PHARMACEUTICALS AVANT IMMUNOTHERAPEUTICS AVAX TECHNOLOGIES INC AVENTIS SA AVI BIOPHARMA INC AVIGEN INC AXONYX INC BARR LABORATORIES INC BENTLEY PHARMACEUTICALS BIGMAR INC BIO TECHNOLOGY GENERAL BIOCRYST PHARMACEUTICALS BIOGEN INC BIOMARIN PHARMACEUTICAL BIOMIRA INC BIOPURE CORPORATION BIORA AB BIOSPECIF ICS TECHNOLOGIES BIOTECH HOLDINGS LTD BIOTIME INC BIOTRANSPLANT INC BIOVAIL CORPORATION BONE CARE INTERNATIONAL BOSTON LIFE SCIENCES INC BRADLEY PHARMACEUTICALS
Industry Code 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412
2001 Sales (Thousands)
Sales Rank
1,745,500 1,900
17 177
975,000 452
26 213
700 53,800 3,763,000
207 64 13
749,000 700 900 4,600
31 208 198 151
18,100 1,000
97 194
16,480,000 2,700 1,300 12,700 3,300 500 20,447,000 700 1,000
8 169 187 107 164 212 5 209 195
509,700 26,400
34 87
102,000 7,700 1,043,400 11,700 4,600 3,500 10,500 5,500 1,163 200 700 583,300 5,997
52 128 24 109 152 162 116 144 191 222 210 33 139
25,700
89
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
2001 Profits -9,600 224,900 -60,700 -20,100 -37,900 -11,583
Profits Rank 116 17 216 159 199 128
-500 -4,700 1,119,700 -72,000 37,500 -5,300 -6,700 -73,500 -31,300 -6,900 -19,800
64 89 11 224 37 93 99 225 189 100 158
1,097,000 -1,700 800 200 -22,800 -15,100 1,455,000 -26,900 -11,300 -8,144 62,500 1,400
12 69 56 61 166 140 10 178 127 105 32 53
-30,300 -5,000 272,700 -67,600 -24,300 -49,400 -2,400 -1,468 -1,938 -3,700 -42,600 87,400 -9,014 -10,300 3,600
187 90 15 221 171 208 77 67 74 85 201 28 108 122 47
(Thousands)
Plunkett Research, Ltd.
www,plunkettresearch.com
Company BRISTOL MYERS SQUIBB CO BRITISH BIOTECH PLC CAMBREX CORP CARACO PHARMACEUTICAL LABORATORIES CARDIOME PHARMACEUTICAL CARRINGTON LABORATO RIES CELGENE CORP CELL GENESYS INC CELL PATHWAYS INC CELL THERAPEUTICS INC CELLEGY PHARMACEUTICALS CELLTECH GROUP PLC CEL-SCI CORPORATION CEPHALON INC CERUS CORPORATION CHATTEM INC CHIRON CORP CIMA LABS INC COLLAGENEX PHARMACEUTICAL COLLATERAL THERAPEUTICS COLUMBIA LABORATORIES CONNETICS CORPORATION CORIXA CORPORATION CORTECH INC CORTEX PHARMACEUTICALS CORVAS INTERNATIONAL INC CUBIST PHARMACEUTICALS CURIS INC CV THERAPEUTICS INC CYTOGEN CORPORATION CYTRX CORPORATION DEPOMED INC DISCOVERY LABORATORIES DOR BIOPHARMA INC DRAXIS HEALTH INC DSM PHARMACEUTICALS INC DURECT CORP DUSA PHARMACEUTICALS INC DYAX CORP ELAN CORP PLC ELI LILLY & CO ENDO PHARMACEUTICALS HOLDINGS INC ENTREMED INC ENZON INC EPIMMUNE INC
Industry Code 325412 325412 325412
2001 Sales (Thousands)
Sales Rank
19,423,000 2,500 498,900
6 172 35
5,900 402 17,600 114,200 28,300 900 6,200 900 441,400 400 226,100 4,500 198,300 1,140,700 32,000 35,200 5,200 1,800 34,100 58,100
140 214 98 51 86 199 136 200 36 215 44 155 45 23 82 75 146 180 76 63
4,443 300 14,400 1,100 6,800 11,700 4,400 3,700 1,100
157 218 102 192 131 110 158 161 193
325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412
33,000
325412 325412 325412 325412
2001 Profits
Profits Rank 5,245,000 4 -36,253 192 26,600 39
(Thousands)
78
-5,800 -4,557 400 -1,900 -28,700 -31,400 -80,300 -19,500 -80,800 -10,700 -55,500 -49,400 15,300 180,100 15,000 -8,100 -14,600 -15,800 -16,700 148,000 -200 -2,398 -23,400 -69,900 -81,900 -79,700 -12,100 -900 -17,600 -11,100 -14,600 -1,600
94 88 58 72 185 190 231 156 232 124 211 207 42 20 43 104 139 144 149 24 63 76 168 222 233 229 129 66 152 126 137 68
6,500 5,400 33,000 1,512,900 11,542,000
134 145 79 18 11
-44,900 -7,400 -17,200 -887,200 2,780,000
204 102 150 244 6
252,000 1,900 31,587 8,200
40 178 83 127
-36,500 -43,300 11,525 -2,600
193 203 45 78
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Company ESSENTIAL THERAPEUTICS EXEGENICS INC FOREST LABORATORIES INC GELTEX PHARMACEUTICALS GENAERA CORPORATION GENELABS TECHNOLOGIES GENENTECH INC GENEREX BIOTECHNOLOGY GENTA INC GENZYME CORP GENZYME MOLECULAR ONCOLOGY GILEAD SCIENCES INC GLAXOSMITHKLINE PLC GLYCOGENESYS INC GUILFORD PHARMACEUTICALS HEMISPHERX BIOPHARMA INC HESKA CORP HI TECH PHARMACAL CO INC HOLLIS-EDEN PHARMACEUTICALS HUMAN GENOME SCIENCES HYBRIDON INC HYSEQ INC ICN PHARMACEUTICALS INC ICOS CORPORATION ID BIOMEDICAL CORPORATION IDEC PHARMACEUTICALS ILEX ONCOLOGY INC IMCLONE SYSTEMS INC IMMTECH INTERNATIONAL IMMUCELL CORPORATION IMMUNE RESPONSE CORP IMMUNEX CORP IMMUNOGEN INC IMPAX LABORATORIES INC INCARA PHARMACEUTICALS INKINE PHARMACEUTICAL CO INSITE VISION INC INSMED INCORPORATED INSPIRE PHARMACEUTICALS INTERFERON SCIENCES INC INTERMUNE PHARMACEUTICALS INC INTERNATIONAL ISOTOPES INTRABIOTICS PHARMACEUTICALS INTROGEN THERAPEUTICS INC ISIS PHARMACEUTICALS INC IVAX CORPORATION JOHNSON & JOHNSON
Industry Code 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412
2001 Sales
2001 Sales Profits Profits (Thousands) Rank (Thousands) Rank 10,700 115 -27,900 183 1,300 188 -8,800 107 1,205,200 21 215,100 19 900 4,800 2,081,700 1,000 100 1,223,600 6,600 233,800 29,858,600
201 148 15 196 224 19 132 43 4
20,500 400 48,300 29,600
94 216 67 84
12,800 1,600 24,600 858,100 93,400 1,600 272,700 24,600 33,200 1,354 6,400 10,000 986,800 4,479 6,600 100 4,300
106 182 90 29 54 183 38 91 77 186 135 118 25 156 133 225 159
300 7,300 1,500 40,000 2,200
219 130 184 73 175
300 53,300 1,215,400 33,004,000
220 65 20 2
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
-12,900 -13,000 150,300 -27,100 -46,700 -112,100 -29,700 52,300 -158,800 -22,700 -60,300 -9,100 -18,700 2,400 -15,800 -117,200 -5,300 -36,500 64,100 -80,200 -9,200 101,700 -121,000 -102,200 -9,863 400 -16,300 170,000 -15,290 -25,100 -22,200 -15,300 -9,600 -37,200 -23,100 -7,200 -118,200 -2,800 -67,400 -12,300 -73,800 243,200 5,668,000
132 133 22 179 205 236 186 34 241 165 215 109 154 50 143 237 92 194 31 230 112 27 239 235 121 60 147 21 141 174 163 142 117 196 167 101 238 80 220 130 226 16 3
Plunkett Research, Ltd.
www,plunkettresearch.com
Industry Company Code K V PHARMACEUTICAL CO 325412 KING PHARMACEUTICALS INC 325412 KOS PHARMACEUTICALS INC 325412 KOSAN BIOSCIENCES INC 325412 LA JOLLA PHARMACEUTICAL 325412 LABORATORIO CHILE SA 325412 LIGAND PHARMACEUTICALS 325412 LORUS THERAPEUTICS INC 325412 MATRIX PHARMACEUTICAL 325412 MAXIM PHARMACEUTICALS 325412 MEDAREX INC 325412 MEDICIS PHARMACEUTICAL 325412 MEDIMMUNE INC 325412 MEDIMMUNE VACCINES 325412 MERCK & CO INC 325412 MGI PHARMA INC 325412 MICROLOGIX BIOTECH INC 325412 MILLENNIUM PHARMACEUTICALS INC 325412 MIRAVANT MEDICAL TECHNOLOGIES 325412 MOLECULAR BIOSYSTEMS INC 325412 MYLAN LABORATORIES INC 325412 NABI BIOPHARMACEUTICALS 325412 NAPRO BIOTHERAPEUTICS 325412 NASTECH PHARMACEUTICAL 325412 NEORX CORPORATION 325412 NEOSE TECHNOLOGIES INC 325412 NEUROBIOLOGICAL TECHNOLOGIES 325412 INC NEUROCRINE BIOSCIENCES 325412 NEUROGEN CORP 325412 NEXMED INC 325412 NOVARTIS AG 325412 NOVAVAX INC 325412 NOVEN PHARMACEUTICALS 325412 NOVO-NORDISK AS 325412 NPS PHARMACEUTICALS INC 325412 ONYX PHARMACEUTICALS INC 325412 ORAPHARMA INC 325412 ORPHAN MEDICAL INC 325412 OSI PHARMACEUTICALS INC 325412 OXIGENE INC 325412 OXIS INTERNATIONAL INC 325412 PALATIN TECHNOLOGIES INC 325412 PALIGENT INC 325412 PDK LABS INC 325412 PENWEST PHARMACEUTICALS 325412 PEREGRINE PHARMACEUTICALS INC 325412
2001 Sales (Thousands)
182,900 872,300 91,400 5,200
2001 Sales Profits Profits Rank (Thousands) Rank 46 23,600 41 28 218,000 18 55 2,400 49 147 -21,900 162 -24,700 173
76,300
58
-43,000 -9,800
202 120
3,200 42,300 167,800 618,700 14,000 47,716,000 33,000 2,059 246,200 4,700
165 70 47 32 103 1 80 176 41 150
-37,300 -2,700 40,400 149,000 -127,300 7,282,000 -34,800 -7,456 -192,000 -16,400
198 79 35 23 240 2 191 103 242 148
846,700 234,800 15,700 2,600 2,900 1,300
30 42 101 170 168 189
37,100 104,700 -25,800 -9,200 -23,800 -13,300
38 26 177 111 170 134
4,781 41,200 11,500 100 19,070,000 24,100 45,900 2,839,000 10,400 15,800 7,700 11,300 26,000 9,000 3,000 1,788 100
149 72 111 226 7 92 69 14 117 100 129 114 88 121 167 181 227
1,588 -36,900 -25,400 -16,200 4,181,000 -9,700 12,100 461,000 -50,000 -27,600 -25,700 -6,000 -23,700 -4,100 -3,500 -10,599 -1,700
52 195 175 146 5 119 44 13 209 181 176 95 169 86 83 123 71
40,000 979
74 197
-16,000 -9,535
145 115
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Company PFIZER INC PHARMACEUTICAL FORMULATIONS INC PHARMACEUTICAL RESOURCES PHARMACYCLICS INC PHARMOS CORPORATION PHOTOGEN TECHNOLOGIES POLYDEX PHARMACEUTICALS PRAECIS PHARMACEUTICALS PROGENICS PHARMACEUTICALS PROTEIN DESIGN LABS INC PROTEIN POLYMER TECHNOLOGIES QLT INC QUESTCOR PHARMACEUTICALS REGENERON PHARMACEUTICALS INC REPLIGEN CORPORATION RIBOZYME PHARMACEUTICALS SANGSTAT MEDICAL CORP SCHERING-PLOUGH CORP SCICLONE PHARMACEUTICALS SCIOS INC SENETEK PLC SEPRACOR INC SHEFFIELD PHARMACEUTICALS SHIRE PHARMACEUTICALS SHIRE-BIOCHEM INC SICOR INC SIGA TECHNOLOGIES INC SKYEPHARMA PLC SONUS PHARMACEUTICALS SPECTRUM PHARMACEUTICALS SUPERGEN INC SYNAPTIC PHARMACEUTICAL TANOX INC TARGETED GENETICS CORP TARO PHARMACEUTICAL INDUSTRIES TELIK INC TEVA PHARMACEUTICAL INDUSTRIES TEXAS BIOTECHNOLOGY TITAN PHARMACEUTICALS TRANSKARYOTIC THERAPIES TRIANGLE PHARMACEUTICALS TULARIK INC UNIGENE LABORATORIES UNITED THERAPEUTICS CORP UNITED-GUARDIAN INC VALENTIS INC
Industry Code 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412
2001 Sales (Thousands)
2001 Profits
Sales Rank
Profits Rank 7,788,000 1
(Thousands)
32,259,000
3
49,200 271,000 3,121 4,300
66 39 166 160
13,828 9,900 8,900 79,500 800 81,300 5,700 22,000 2,346 8,300 94,500 9,802,000 13,800 47,300 8,900 152,100 900 877,600 369,800 1,200 67,900 8,700 100 11,500 1,400 400 18,900 150,100 1,900 2,077,400 8,900 4,600 6,200 5,800 32,600 900 5,700 9,600 4,600
104 119 122 57 205 56 142 93 173 126 53 12 105 68 123 49 202 27
-14,600 53,900 -30,925 5,000 -9,700 131 -54,600 -1,900 2,600 -3,100 76,700 -8,700 -76,200 -5,278 -59,800 -9,300 1,943,000 -6,200 -62,500 400 -224,000 -9,500 38,800
138 33 188 46 118 62 210 73 48 81 30 106 228 91 214 113 8 97 218 59 243 114 36
37 190 60 125 228 112 185 217 96 50 179 16 124 153 137 141 81 203 143 120 154
79,300 -3,700 -13,900 500 -27,800 -55,600 -21,800 -21,400 -27,200 26,000 -18,600 278,200 -19,100 -17,500 -70,200 -75,900 -48,600 -12,500 -37,300 1,900 -38,200
29 84 136 57 182 212 161 160 180 40 153 14 155 151 223 227 206 131 197 51 200
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Company VAXGEN INC VERTEX PHARMACEUTICALS VICAL INC VION PHARMACEUTICALS INC VIRAGEN INC VIRBAC INC VIROPHARMA INC WARNER CHILCOTT PLC WATSON PHARMACEUTICALS WOMEN FIRST HEALTHCARE WYETH XECHEM INTERNATIONAL XENOVA GROUP PLC XOMA LTD ZILA INC ZONAGEN INCORPORATED
Industry Code 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412 325412
2001 Sales (Thousands)
900 167,500 11,400 700 717 60,600 3,400
2001 Sales Profits Profits Rank (Thousands) Rank 204 -24,400 172 48 -66,300 219 113 -9,200 110 211 -13,800 135 206 -11,010 125 62 1,300 54 163 -83,000 234
1,160,700 28,400 14,128,000 200 2,600 17,300 73,700 2,300
22 85 10 223 171 99 59 174
116,400 -3,400 2,285,000 -1,700 -22,400 -28,000 -6,300 -800
25 82 7 70 164 184 98 65
2,206,400 65,600 35,200 21,800 9,600 113,300 11,000 17,300 31,362 11,229 2,300 45,200 34,900 7,000 27,500 34,100 37,100 18,300
1 3 6 11 16 2 15 13 9 14 18 4 7 17 10 8 5 12
312,800 6,700 700 3,400 -19,200 3,300 -2,200
1 2 7 3 15 4 9
-43,253 -4,750 -8,700 -7,200 3,200 -3,400 400 -36,800 1,400 -26,200
18 12 14 13 5 11 8 17 6 16
500
19
-2,900
10
4 7 5 3 2 1 6 8
5,900 2,229 6,800 -8,400 11,000 37,600 2,500 200
4 6 3 8 2 1 5 7
In Vitro Diagnostic Substance, Manufacturing
AMERSHAM PLC BIOSITE INC BIOSOURCE INTERNATIONAL BOSTON BIOMEDICA INC EPIX MEDICAL INC E-Z-EM INC HEMAGEN DIAGNOSTICS INC HYCOR BIOMEDICAL INC IGEN INTERNATIONAL INC IMMUNOMEDICS INC MATRITECH INC MYRIAD GENETICS INC NEOGEN CORPORATION SPECTRAL DIAGNOSTICS INC SYNBIOTICS CORP THIRD WAVE TECHNOLOGIES TRINITY BIOTECH PLC VIROLOGIC INC VYSIS INC XTRANA INC
325413 325413 325413 325413 325413 325413 325413 325413 325413 325413 325413 325413 325413 325413 325413 325413 325413 325413 325413 325413
Laboratories and Diagnostics--Medical
BIORELIANCE CORP CELSIS INTERNATIONAL PLC ENZO BIOCHEM INC HUNTINGDON LIFE SCIENCES ICON PLC IDEXX LABORATORIES INC MEDTOX SCIENTIFIC INC PACIFIC BIOMETRICS INC
621511 621511 621511 621511 621511 621511 621511 621511
69,700 27,181 58,400 99,200 116,200 386,100 49,100 1,900
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Industry Code
Company
2001 Sales (Thousands)
2001 Profits
Sales Rank
(Thousands)
Profits Rank
Medical/Dental/Surgical Equipment and Supplies, Manufacturing
AASTROM BIOSCIENCES INC ABAXIS INC ACCUMED INTERNATIONAL ACLARA BIOSCIENCES INC ALKERMES INC APPLERA CORPORATION BAUSCH & LOMB INC BAXTER INTERNATIONAL INC BIO RAD LABORATORIES INC BIOCOMPATIBLES INTERNATIONAL PLC BIONX IMPLANTS INC CARDIOTECH INTERNATIONAL CEPHEID CYPRESS BIOSCIENCE INC DIAGNOSTIC PRODUCTS CORP DIGENE CORPORATION EMBREX INC GENZYME BIOSURGERY GLIATECH INC INTEGRA LIFESCIENCES CORP INVITROGEN CORPORATION LIFECORE BIOMEDICAL INC LUMINEX CORPORATION MALLINCKRODT INC MDS INC MOLECULAR DEVICES CORP NEOPROBE CORPORATION NORTH AMERICAN SCIENTIFIC ORASURE TECHNOLOGIES INC QIAGEN NV SYNOVIS LIFE TECHNOLOGIES TECHNE CORP THERAGENICS CORP
339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113 339113
899 29,501
31 20
-5,926 188
20 14
3,200 56,000 1,644,100 1,711,900 7,663,000 817,500
27 14 3 2 1 5
-29,000 -16,900 27,200 21,500 612,000 44,200
28 25 7 9 1 3
100,200 18,900 1,543 11,400 1,600 283,400 34,200 44,700 253,100 3,100 87,700 629,300 34,100 20,900
11 24 30 25 29 7 17 16 9 28 13 6 18 22
-28,600 -2,500 5,705 -15,500 -7,200 39,000 -6,500 8,000 -144,100 -23,700 26,200 -147,700 -3,700 -15,700
27 16 12 23 22 4 21 11 29 26 8 30 17 24
1,031,000 92,200 7,600 19,300 32,600 263,800 28,500 115,400 50,000
4 12 26 23 19 8 21 10 15
46,000 -5,200
2 19
-2,000 -3,700 34,400 1,800 34,000 15,100
15 18 5 13 6 10
4 7 5 1 6 8 3 2
-25,500 -1,067 -2,900 -33,300 -7,876 -12,300 -13,700 1,065
7 2 3 8 4 5 6 1
Medicinals and Botanicals, Manufacturing
ATRIX LABORATORIES INC CYANOTECH CORPORATION FLAMEL TECHNOLOGIES SA HAUSER INC IOMED INC MACROCHEM CORPORATION MARTEK BIOSCIENCES CORP NUTRITION 21 INC
325411 325411 325411 325411 325411 325411 325411 325411
15,800 8,043 13,100 66,700 11,395 800 18,800 23,252
Research and Development--Physical, Engineering and Life Sciences
AAIPHARMA INC ALBANY MOLECULAR RESEARCH
541710 541710
141,100 56,800
9 13
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
5,900 34,400
7 5
Plunkett Research, Ltd.
www,plunkettresearch.com
2001 2001 Industry Sales Sales Profits Profits Company (Thousands) Code Rank (Thousands) Rank APPLIED MOLECULAR EVOLUTION INC 541710 3,600 37 -13,200 16 ARQULE INC 541710 58,400 12 -41,000 29 BIOANALYTICAL SYSTEMS INC 541710 25,300 23 1,800 10 CAMBRIDGE ANTIBODY TECHNOLOGY 541710 10,500 32 -17,300 22 GROUP PLC CELERA GENOMICS GROUP 541710 89,400 11 -186,200 38 CELERIS CORPORATION 541710 9,800 33 -2,700 13 CHARLES RIVER LABORATORIES CORP 541710 465,600 3 35,500 4 CHESAPEAKE BIOLOGICAL LAB 541710 COMMONWEALTH BIOTECHNOLOGIES 541710 4,800 36 -1,700 12 COMPUGEN LTD 541710 11,400 31 -15,100 18 COVALENT GROUP INC 541710 18,400 28 2,000 9 COVANCE INC 541710 855,900 2 47,900 2 CURAGEN CORPORATION 541710 23,500 25 42,900 3 DECODE GENETICS INC 541710 31,600 18 -47,800 33 DIVERSA CORPORATION 541710 36,000 16 -15,700 19 EPOCH BIOSCIENCES 541710 7,500 34 -4,600 14 EXELIXIS INC 541710 41,000 15 -71,200 35 GENE LOGIC INC 541710 43,300 14 -33,200 25 GENENCOR INTERNATIONAL 541710 326,000 6 17,800 6 GENOME THERAPEUTICS 541710 35,700 17 -10,100 15 GENSET SA 541710 17,400 30 -42,000 30 GERON CORPORATION 541710 3,600 38 -42,100 31 INCYTE GENOMICS INC 541710 219,300 7 -183,200 37 KENDLE INTERNATIONAL INC 541710 154,300 8 4,200 8 LARGE SCALE BIOLOGY CORP 541710 17,700 29 -20,700 23 LEXICON GENETICS INC 541710 30,600 21 -35,200 27 LYNX THERAPEUTICS INC 541710 19,300 27 -16,700 21 MAXYGEN INC 541710 30,500 22 -45,000 32 ORCHID BIOSCIENCES INC 541710 31,200 19 -84,700 36 OXFORD GLYCOSCIENCES PLC 541710 19,500 26 -36,900 28 PANVERA LLC 541710 PARADIGM GENETICS INC 541710 24,500 24 -16,000 20 PAREXEL INTERNATIONAL 541710 387,560 5 -825 11 PHARMACEUTICAL PRODUCT DEVELOPMENT INC 541710 431,500 4 49,200 1 PHARMACOPEIA INC 541710 122,300 10 -14,300 17 QUINTILES TRANSNATIONAL 541710 1,619,900 1 -33,900 26 SANGAMO BIOSCIENCES INC 541710 4,900 35 -25,200 24 SEQUENOM INC 541710 30,700 20 -62,600 34 Soap and Cleaning Compound Manufacturing PROCYTE CORPORATION
325610
9,700
1
-900
1
2 1
-24,800 31,200
2 1
Test Equipment/Instruments, Manufacturing
ILLUMINA INC MILLIPORE CORP
334515 334515
2,500 656,900
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
ALPHABETICAL INDEX If you are seeking a company by name and you do not find it on this list, please turn to the back of the book to the Index by Subsidiaries, Brand Names and Selected Affiliations. You may find your target firm there. AAIPHARMA INC AASTROM BIOSCIENCES INC ABAXIS INC ABBOTT LABORATORIES ABGENIX INC ABLE LABORATORIES ACCESS PHARMACEUTICALS ACCUMED INTERNATIONAL ACLARA BIOSCIENCES INC ADVANCED MAGNETICS INC ADVANCED TISSUE SCIENCES AFFYMETRIX INC AKORN INC AKZO NOBEL NV ALBANY MOLECULAR RESEARCH ALEXION PHARMACEUTICALS ALFACELL CORPORATION ALIZYME PLC ALKERMES INC ALLERGAN INC ALLIANCE PHARMACEUTICAL CORP ALLOS THERAPEUTICS INC ALPHARMA INC ALTEON INC ALZA CORP AMARILLO BIOSCIENCES INC AMARIN CORPORATION PLC AMERSHAM PLC AMGEN INC AMYLIN PHARMACEUTICALS INC ANDRX CORP ANGIOTECH PHARMACEUTICALS ANIKA THERAPEUTICS INC ANTEX BIOLOGICS INC ANTIGENICS INC APHTON CORP APPLERA CORPORATION APPLIED MOLECULAR EVOLUTION INC ARENA PHARMACEUTICALS INC ARIAD PHARMACEUTICALS ARQULE INC ASCENT PEDIATRICS INC ASTRAZENECA PLC ATLANTIC TECHNOLOGY VENTURES ATRIX LABORATORIES INC AUTOIMMUNE INC AVANIR PHARMACEUTICALS AVANT IMMUNOTHERAPEUTICS AVAX TECHNOLOGIES INC
AVENTIS SA AVI BIOPHARMA INC AVIGEN INC AXONYX INC BARR LABORATORIES INC BAUSCH & LOMB INC BAXTER INTERNATIONAL INC BENTLEY PHARMACEUTICALS INC BIGMAR INC BIO RAD LABORATORIES INC BIO TECHNOLOGY GENERAL CORP BIOANALYTICAL SYSTEMS INC BIOCOMPATIBLES INTERNATIONAL PLC BIOCRYST PHARMACEUTICALS BIOGEN INC BIOMARIN PHARMACEUTICAL BIOMIRA INC BIONX IMPLANTS INC BIOPURE CORPORATION BIORA AB BIORELIANCE CORP BIOSITE INC BIOSOURCE INTERNATIONAL INC BIOSPECIFICS TECHNOLOGIES CORP BIOSPHERE MEDICAL INC BIOTECH HOLDINGS LTD BIOTIME INC BIOTRANSPLANT INC BIOVAIL CORPORATION BONE CARE INTERNATIONAL BOSTON BIOMEDICA INC BOSTON LIFE SCIENCES INC BRADLEY PHARMACEUTICALS BRISTOL MYERS SQUIBB CO BRITISH BIOTECH PLC CALIPER TECHNOLOGIES CORP CAMBREX CORP CAMBRIDGE ANTIBODY TECHNOLOGY GROUP CARACO PHARMACEUTICAL LABORATORIES CARDIOME PHARMACEUTICAL CORP CARDIOTECH INTERNATIONAL CARRINGTON LABORATORIES INC CELERA GENOMICS GROUP CELERIS CORPORATION CELGENE CORP CELL GENESYS INC CELL PATHWAYS INC CELL THERAPEUTICS INC CELLEGY PHARMACEUTICALS CELLTECH GROUP PLC CEL-SCI CORPORATION CELSIS INTERNATIONAL PLC CEPHALON INC CEPHEID CERUS CORPORATION CHARLES RIVER LABORATORIES CORP CHATTEM INC CHESAPEAKE BIOLOGICAL LAB
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
CHIRON CORP CIMA LABS INC CIPHERGEN BIOSYSTEMS INC COLLAGENEX PHARMACEUTICAL COLLATERAL THERAPEUTICS COLUMBIA LABORATORIES COMMONWEALTH BIOTECHNOLOGIES INC COMPUGEN LTD CONNETICS CORPORATION CORIXA CORPORATION CORTECH INC CORTEX PHARMACEUTICALS CORVAS INTERNATIONAL INC COVALENT GROUP INC COVANCE INC CUBIST PHARMACEUTICALS CURAGEN CORPORATION CURIS INC CV THERAPEUTICS INC CYANOTECH CORPORATION CYPRESS BIOSCIENCE INC CYTOGEN CORPORATION CYTRX CORPORATION DECODE GENETICS INC DEPOMED INC DIACRIN INC DIAGNOSTIC PRODUCTS CORPORATION DIGENE CORPORATION DISCOVERY LABORATORIES DIVERSA CORPORATION DONLAR BIOSYNTREX DOR BIOPHARMA INC DRAXIS HEALTH INC DSM PHARMACEUTICA LS INC DURECT CORP DUSA PHARMACEUTICALS INC DYAX CORP E I DU PONT DE NEMOURS & CO ELAN CORP PLC ELI LILLY & CO EMBREX INC EMISPHERE TECHNOLOGIES ENDO PHARMACEUTICALS HOLDINGS INC ENTREMED INC ENZO BIOCHEM INC ENZON INC EPIMMUNE INC EPIX MEDICAL INC EPOCH BIOSCIENCES ERESEARCH TECHNOLOGY INC ESSENTIAL THERAPEUTICS INC EXEGENICS INC EXELIXIS INC EXELIXIS PLANT SCIENCES INC E-Z-EM INC FLAMEL TECHNOLOGIES SA FOREST LABORATORIES INC GELTEX PHARMACEUTICALS
GENAERA CORPORATION GENE LOGIC INC GENELABS TECHNOLOGIES INC GENENCOR INTERNATIONAL INC GENENTECH INC GENEREX BIOTECHNOLOGY GENOME THERAPEUTICS CORP GENSET SA GENTA INC GENZYME BIOSURGERY GENZYME CORP GENZYME MOLECULAR ONCOLOGY GERON CORPORATION GILEAD SCIENCES INC GLAXOSMITHKLINE PLC GLIATECH INC GLYCOGENESYS INC GTC BIOTHERAPEUTICS INC GUILFORD PHARMACEUTICALS INC HAUSER INC HEMAGEN DIAGNOSTICS INC HEMISPHERX BIOPHARMA INC HESKA CORP HI TECH PHARMACAL CO INC HOLLIS-EDEN PHARMACEUTICALS HUMAN GENOME SCIENCES INC HUNTINGDON LIFE SCIENCES HYBRIDON INC HYCOR BIOMEDICAL INC HYSEQ INC ICN PHARMACEUTICALS INC ICON PLC ICOS CORPORATION ID BIOMEDICAL CORPORATION IDEC PHARMACEUTICALS CORP IDEXX LABORATORIES INC IGEN INTERNATIONAL INC ILEX ONCOLOGY INC ILLUMINA INC IMCLONE SYSTEMS INC IMMTECH INTERNATIONAL IMMUCELL CORPORATION IMMUNE RESPONSE CORP (THE) IMMUNEX CORP IMMUNOGEN INC IMMUNOMEDICS INC IMPAX LABORATORIES INC IMS HEALTH INC INCARA PHARMACEUTICALS INCYTE GENOMICS INC INFORMAX INC INKINE PHARMACEUTICAL CO INSITE VISION INC INSMED INCORPORATED INSPIRE PHARMACEUTICALS INC INTEGRA LIFESCIENCES CORP INTERFERON SCIENCES INC INTERMUNE PHARMACEUTICALS INC
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
INTERNATIONAL ISOTOPES INTRABIOTICS PHARMACEUTICALS INTROGEN THERAPEUTICS INC INVITROGEN CORPORATION IOMED INC ISIS PHARMACEUTICALS INC IVAX CORPORATION JOHNSON & JOHNSON K V PHARMACEUTICAL CO KENDLE INTERNATIONAL INC KING PHARMACEUTICALS INC KOS PHARMACEUTICALS INC KOSAN BIOSCIENCES INC LA JOLLA PHARMACEUTICAL LABORATORIO CHILE SA LARGE SCALE BIOLOGY CORP LEXICON GENETICS INC LIFECELL CORPORATION LIFECORE BIOMEDICAL INC LIGAND PHARMACEUTICALS INC LION BIOSCIENCE AG LORUS THERAPEUTICS INC LUMINEX CORPORATION LYNX THERAPEUTICS INC MACROCHEM CORPORATION MALLINCKRODT INC MARTEK BIOSCIENCES CORP MATRITECH INC MATRIX PHARMACEUTICAL MAXIM PHARMACEUTICALS MAXYGEN INC MDS INC MEDAREX INC MEDICIS PHARMACEUTICAL CORP MEDIMMUNE INC MEDIMMUNE VACCINES MEDTOX SCIENTIFIC INC MERCK & CO INC MGI PHARMA INC MICROLOGIX BIOTECH INC MILLENNIUM PHARMACEUTICALS INC MILLIPORE CORP MIRAVANT MEDICAL TECHNOLOGIES MOLECULAR BIOSYSTEMS INC MOLECULAR DEVICES CORP MONSANTO CO MYLAN LABORATORIES INC MYRIAD GENETICS INC NABI BIOPHARMACEUTICALS NANOGEN INC NAPRO BIOTHERAPEUTICS INC NASTECH PHARMACEUTICAL CO INC NEOGEN CORPORATION NEOPROBE CORPORATION NEORX CORPORATION NEOSE TECHNOLOGIES INC NEUROBIOLOGICAL TECHNOLOGIES INC NEUROCRINE BIOSCIENCES INC
NEUROGEN CORP NEXMED INC NORTH AMERICAN SCIENTIFIC NORTHFIELD LABORATORIES NOVARTIS AG NOVAVAX INC NOVEN PHARMACEUTICALS NOVO-NORDISK AS NPS PHARMACEUTICALS INC NUTRITION 21 INC ONYX PHARMACEUTICALS INC ORAPHARMA INC ORASURE TECHNOLOGIES INC ORCHID BIOSCIENCES INC ORGANOGENESIS INC ORPHAN MEDICAL INC OSI PHARMACEUTICALS INC OXFORD GLYCOSCIENCES PLC OXIGENE INC OXIS INTERNATIONAL INC PACIFIC BIOMETRICS INC PALATIN TECHNOLOGIES INC PALIGENT INC PANVERA LLC PARADIGM GENETICS INC PAREXEL INTERNATIONAL PDK LABS INC PENWEST PHARMACEUTICALS CO PEREGRINE PHARMACEUTICALS INC PFIZER INC PHARMACEUTICAL FORMULATIONS INC PHARMACEUTICAL PRODUCT DEVELOPMENT INC PHARMACEUTICAL RESOURCES INC PHARMACOPEIA INC PHARMACYCLICS INC PHARMOS CORPORATION PHOTOGEN TECHNOLOGIES INC POLYDEX PHARMACEUTICALS PRAECIS PHARMACEUTICALS PROCYTE CORPORATION PROGENICS PHARMACEUTICALS PROTEIN DESIGN LABS INC PROTEIN POLYMER TECHNOLOGIES QIAGEN NV QLT INC QUESTCOR PHARMACEUTICALS QUINTILES TRANSNATIONAL CORP REGENERON PHARMACEUTICALS INC REPLIGEN CORPORATION RIBOZYME PHARMACEUTICALS SANGAMO BIOSCIENCES INC SANGSTAT MEDICAL CORP SCHERING-PLOUGH CORP SCICLONE PHARMACEUTICALS SCIOS INC SENETEK PLC SEPRACOR INC SEQUENOM INC
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
SEROLOGICALS CORP SHEFFIELD PHARMACEUTICALS SHIRE PHARMACEUTICALS PLC SHIRE-BIOCHEM INC SICOR INC SIGA TECHNOLOGIES INC SKYEPHARMA PLC SONUS PHARMACEUTICALS SPECTRAL DIAGNOSTICS INC SPECTRUM PHARMACEUTICALS STEMCELLS, INC SUPERGEN INC SYNAPTIC PHARMACEUTICAL SYNBIOTICS CORP SYNGENTA AG SYNOVIS LIFE TECHNOLOGIES INC TANOX INC TARGETED GENETICS CORP TARO PHARMACEUTICAL INDUSTRIES TECHNE CORP TELIK INC TEVA PHARMACEUTICAL INDUSTRIES TEXAS BIOTECHNOLOGY CORP THERAGENICS CORP THIRD WAVE TECHNOLOGIES INC TITAN PHARMACEUTICALS TRANSKARYOTIC THERAPIES TRIANGLE PHARMACEUTICALS TRINITY BIOTECH PLC TRIPOS INC TULARIK INC UNIGENE LABORATORIES UNITED THERAPEUTICS CORP UNITED-GUARDIAN INC V I TECHNOLOGIES INC VALENTIS INC VAXGEN INC VERTEX PHARMACEUTICALS INC VICAL INC VION PHARMACEUTICALS INC VIRAGEN INC VIRBAC INC VIROLOGIC INC VIROPHARMA INC VYSIS INC WARNER CHILCOTT PLC WATSON PHARMACEUTICALS INC WOMEN FIRST HEALTHCARE WYETH XECHEM INTERNATIONAL XENOVA GROUP PLC XOMA LTD XTRANA INC ZILA INC ZONAGEN INCORPORATED
GEOGRAPHICAL INDEXES 1) Company headquarters locations by state 2) Foreign company headquarters locations by country 3) Offices and subsidiaries by regions of the U.S. 4) Firms with international operations The headquarters locations of each company are on the following indexes to help you locate members of THE BIOTECH & GENETICS 400 within the part of the country, or the world, of interest. However, companies are constantly opening and closing various locations. You should consider contacting companies that particularly interest you, to see whether they have locations in your area.
INDEX OF HEADQUARTERS LOCATION, BY STATE To help you locate members of THE BIOTECH & GENETICS 400 geographically, the city and state of the headquarters of each company are indexed. ALABAMA BIOCRYST PHARMACEUTICALS; Birmingham
ARIZONA MEDICIS PHARMACEUTICAL CORP; Scottsdale ZILA INC; Phoenix
CALIFORNIA ABAXIS INC; Union City ABGENIX INC; Fremont ACLARA BIOSCIENCES INC; Mountain View ADVANCED TISSUE SCIENCES; La Jolla AFFYMETRIX INC; Santa Clara ALLERGAN INC; Irvine ALLIANCE PHARMACEUTICAL CORP; San Diego ALZA CORP; Mountain View AMGEN INC; Thousand Oaks AMYLIN PHARMACEUTICALS INC; San Diego APPLIED MOLECULAR EVOLUTION INC; San Diego ARENA PHARMACEUTICALS INC; San Diego AUTOIMMUNE INC; Pasadena AVANIR PHARMACEUTICALS; San Diego AVIGEN INC; Alameda BIO RAD LABORATORIES INC; Hercules BIOMARIN PHARMACEUTICAL; Novato BIOSITE INC; San Diego BIOSOURCE INTERNATIONAL INC; Camarillo BIOTIME INC; Berkeley CALIPER TECHNOLOGIES CORP; Mountain View CELL GENESYS INC; Foster City
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
CELLEGY PHARMACEUTICALS; South San Francisco CEPHEID; Sunnyvale CERUS CORPORATION; Concord CHIRON CORP; Emeryville CIPHERGEN BIOSYSTEMS INC; Fremont COLLATERAL THERAPEUTICS; San Diego CONNETICS CORPORATION; Palo Alto CORTEX PHARMACEUTICALS; Irvine CORVAS INTERNATIONAL INC; San Diego CV THERAPEUTICS INC; Palo Alto CYPRESS BIOSCIENCE INC; San Diego DEPOMED INC; Menlo Park DIAGNOSTIC PRODUCTS CORPORATION; Los Angeles DIVERSA CORPORATION; San Diego DURECT CORP; Cupertino EPIMMUNE INC; San Diego EXELIXIS INC; South San Francisco GENELABS TECHNOLOGIES INC; Redwood City GENENCOR INTERNATIONAL INC; Palo Alto GENENTECH INC; South San Francisco GERON CORPORATION; Menlo Park GILEAD SCIENCES INC; Foster City HAUSER INC; Long Beach HOLLIS-EDEN PHARMACEUTICALS; San Diego HYCOR BIOMEDICAL INC; Garden Grove HYSEQ INC; Sunnyvale ICN PHARMACEUTICALS INC; Costa Mesa IDEC PHARMACEUTICALS CORP; San Diego ILLUMINA INC; San Diego IMMUNE RESPONSE CORP (THE); Carlsbad IMPAX LABORATORIES INC; Hayward INCYTE GENOMICS INC; Palo Alto INSITE VISION INC; Almeda INTERMUNE PHARMACEUTICALS INC; Brisbane INTRABIOTICS PHARMACEUTICALS; Mountain View INVITROGEN CORPORATION; Carlsbad ISIS PHARMACEUTICALS INC; Carlsbad KOSAN BIOSCIENCES INC; Hayward LA JOLLA PHARMACEUTICAL; San Diego LARGE SCALE BIOLOGY CORP; Vacaville LIGAND PHARMACEUTICALS INC; San Diego LYNX THERAPEUTICS INC; Hayward MATRIX PHARMACEUTICAL; Fremont MAXIM PHARMACEUTICALS; San Diego MAXYGEN INC; Redwood City MEDIMMUNE VACCINES; Mountain View MIRAVANT MEDICAL TECHNOLOGIES; Santa Barbara MOLECULAR BIOSYSTEMS INC; San Diego MOLECULAR DEVICES CORP; Sunnyvale NANOGEN INC; San Diego NEUROBIOLOGICAL TECHNOLOGIES INC; Richmond NEUROCRINE BIOSCIENCES INC; San Diego NORTH AMERICAN SCIENTIFIC; Chatsworth ONYX PHARMACEUTICALS INC; Richmond
PANVERA LLC; San Diego PEREGRINE PHARMACEUTICALS INC; Tustin PHARMACYCLICS INC; Sunnyvale PROTEIN DESIGN LABS INC; Fremont PROTEIN POLYMER TECHNOLOGIES; San Diego QUESTCOR PHARMACEUTICALS; Union City SANGAMO BIOSCIENCES INC; Richmond SANGSTAT MEDICAL CORP; Fremont SCICLO NE PHARMACEUTICALS; San Mateo SCIOS INC; Sunnyvale SENETEK PLC; Napa SEQUENOM INC; San Diego SICOR INC; Irvine SPECTRUM PHARMACEUTICALS; Irvine STEMCELLS, INC; Palo Alto SUPERGEN INC; Dublin SYNBIOTICS CORP; San Diego TELIK INC; South San Francisco TITAN PHARMACEUTICALS; South San Francisco TULARIK INC; South San Francisco VALENTIS INC; Burlingame VAXGEN INC; Brisbane VICAL INC; San Diego VIROLOGIC INC; South San Francisco WATSON PHARMACEUTICALS INC; Corona WOMEN FIRST HEALTHCARE; San Diego XOMA LTD; Berkeley
COLORADO ALLOS THERAPEUTICS INC; Denver ATRIX LABORATORIES INC; Fort Collins HESKA CORP; Fort Collins NAPRO BIOTHERAPEUTICS INC; Boulder RIBOZYME PHARMACEUTICALS; Boulder XTRANA INC; Broomfield
CONNECTICUT ALEXION PHARMACEUTICALS; Cheshire APPLERA CORPORATION; Norwalk CURAGEN CORPORATION; New Haven IMS HEALTH INC; Fairfield NEUROGEN CORP; Branford VION PHARMACEUTICALS INC; New Haven
DELAWARE E I DU PONT DE NEMOURS & CO; Wilmington
FLORIDA ANDRX CORP; Davie APHTON CORP; Miami IVAX CORPORATION; Miami KOS PHARMACEUTICALS INC; Miami NABI BIOPHARMACEUTICALS; Boca Raton NOVEN PHARMACEUTICALS; Miami VIRAGEN INC; Plantation
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
GEORGIA CYTRX CORPORATION; Norcross SEROLOGICALS CORP; Norcross THERAGENICS CORP; Buford
HAWAII CYANOTECH CORPORATION; Kailua-Kona
IDAHO INTERNATIONAL ISOTOPES; Idaho Falls
ILLINOIS ABBOTT LABORATORIES; Abbott Park ACCUMED INTERNATIONAL; Chicago AKORN INC; Buffalo Grove BAXTER INTERNATIONAL INC; Deerfield DONLAR BIOSYNTREX; Bedford Park DOR BIOPHARMA INC; Lake Forest IMMTECH INTERNATIONAL; Vernon Hills NORTHFIELD LABORATORIES; Evanston VYSIS INC; Downers Grove
INDIANA BIOANALYTICAL SYSTEMS INC; West Lafayette ELI LILLY & CO; Indianapolis
KANSAS AVAX TECHNOLOGIES INC; Overland Park
MAINE IDEXX LABORATORIES INC; Westbrook IMMUCELL CORPORATION; Portland
MARYLAND ANTEX BIOLOGICS INC; Gaithersburg BIORELIANCE CORP; Rockville CELERA GENOMICS GROUP; Rockville CHESAPEAKE BIOLOGICAL LAB; Baltimore DIGENE CORPORATION; Gaithersburg ENTREMED INC; Rockville GENE LOGIC INC; Gaithersburg GUILFORD PHARMACEUTICALS INC; Baltimore HEMAGEN DIAGNOSTICS INC; Columbia HUMAN GENOME SCIENCES INC; Rockville IGEN INTERNATIONAL INC; Gaithersburg INFORMAX INC; Bethesda MARTEK BIOSCIENCES CORP; Columbia MEDIMMUNE INC; Gaithersburg NOVAVAX INC; Columbia UNITED THERAPEUTICS CORP; Silver Spring
MASSACHUSETTS ADVANCED MAGNETICS INC; Cambridge ALKERMES INC; Cambridge ANIKA THERAPEUTICS INC; Woburn ARIAD PHARMACEUTICALS; Cambridge ARQULE INC; Woburn
ASCENT PEDIATRICS INC; Wilmington AVANT IMMUNOTHERAPEUTICS; Needham BIOGEN INC; Cambridge BIOPURE CORPORATION; Cambridge BIOSPHERE MEDICAL INC; Rockland BIOTRANSPLANT INC; Charlestown BOSTON BIOMEDICA INC; West Bridgewater BOSTON LIFE SCIENCES INC; Boston CARDIOTECH INTERNATIONAL; Woburn CHARLES RIVER LABORATORIES CORP; Wilmington CUBIST PHARMACEUTICALS; Lexington CURIS INC; Cambridge DIACRIN INC; Charlestown DUSA PHARMACEUTICALS INC; Wilmington DYAX CORP; Cambridge EPIX MEDICAL INC; Cambridge ESSENTIAL THERAPEUTICS INC; Waltham GELTEX PHARMACEUTICALS; Waltham GENOME THERAPEUTICS CORP; Waltham GENZYME BIOSURGERY; Cambridge GENZYME CORP; Cambridge GENZYME MOLECULAR ONCOLOGY; Framingham GLYCOGENESYS INC; Boston GTC BIOTHERAPEUTICS INC; Framingham HYBRIDON INC; Cambridge IMMUNOGEN INC; Cambridge MACROCHEM CORPORATION; Lexington MATRITECH INC; Newton MILLENNIUM PHARMACEUTICALS INC; Cambridge MILLIPORE CORP; Bedford ORGANOGENESIS INC; Canton OXIGENE INC; Watertown PAREXEL INTERNATIONAL; Waltham PRAECIS PHARMACEUTICALS; Waltham REPLIGEN CORPORATION; Waltham SEPRACOR INC; Marlborough TRANSKARYOTIC THERAPIES; Cambridge V I TECHNOLOGIES INC; Watertown VERTEX PHARMACEUTICALS INC; Cambridge
MICHIGAN AASTROM BIOSCIENCES INC; Ann Arbor CARACO PHARMACEUTICAL LABORATORIES; Detroit NEOGEN CORPORATION; Lansing
MINNESOTA CIMA LABS INC; Eden Prairie LIFECORE BIOMEDICAL INC; Chaska MEDTOX SCIENTIFIC INC; St. Paul MGI PHARMA INC; Bloomington ORPHAN MEDICAL INC; Minnetonka SYNOVIS LIFE TECHNOLOGIES INC; St. Paul TECHNE CORP; Minneapolis
MISSOURI K V PHARMACEUTICAL CO; St. Louis
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
MALLINCKRODT INC; Hazelwood MONSANTO CO; St. Louis SHEFFIELD PHARMACEUTICALS; St. Louis TRIPOS INC; St. Louis
NEW HAMPSHIRE BENTLEY PHARMACEUTICALS INC; North Hampton
NEW JERSEY ABLE LABORATORIES; South Plainfield ALFACELL CORPORATION; Bloomfield ALPHARMA INC; Fort Lee ALTEON INC; Ramsey BIO TECHNOLOGY GENERAL CORP; Iselin BRADLEY PHARMACEUTICALS; Fairfield CAMBREX CORP; East Rutherford CELGENE CORP; Warren COLUMBIA LABORATORIES; Livingston CORTECH INC; Bedminster COVANCE INC; Princeton CYTOGEN CORPORATION; Princeton ENZON INC; Bridgewater GENTA INC; Berkeley Heights HUNTINGDON LIFE SCIENCES; Hackensack IMMUNOMEDICS INC; Morris Plains INTEGRA LIFESCIENCES CORP; Plainsboro INTERFERON SCIENCES INC; New Brunswick JOHNSON & JOHNSON; New Brunswick LIFECELL CORPORATION; Branchburg MEDAREX INC; Princeton MERCK & CO INC; Whitehouse Station NEXMED INC; Robbinsville ORCHID BIOSCIENCES INC; Princeton PALATIN TECHNOLOGIES INC; Cranbury PHARMACEUTICAL FORMULATIONS INC; Edison PHARMACOPEIA INC; Princeton PHARMOS CORPORATION; Iselin SCHERING-PLOUGH CORP; Kenilworth SYNAPTIC PHARMACEUTICAL; Paramus UNIGENE LABORATORIES; Fairfield WYETH; Madison XECHEM INTERNATIONAL; New Brunswick
NEW YORK ALBANY MOLECULAR RESEARCH; Albany ANTIGENICS INC; New York ATLANTIC TECHNOLOGY VENTURES; New York AXONYX INC; New York BARR LABORATORIES INC; Pomona BAUSCH & LOMB INC; Rochester BIOSPECIFICS TECHNOLOGIES CORP; Lynbrook BRISTOL MYERS SQUIBB CO; New York EMISPHERE TECHNOLOGIES; Tarrytown ENZO BIOCHEM INC; Farmingdale E-Z-EM INC; Westbury FOREST LABORATORIES INC; New York HI TECH PHARMACAL CO INC; Amityville IMCLONE SYSTEMS INC; New York
NUTRITION 21 INC; Purchase OSI PHARMACEUTICALS INC; Melville PALIGENT INC; New York PDK LABS INC; Hauppauge PENWEST PHARMACEUTICALS CO; Patterson PFIZER INC; New York PHARMACEUTICAL RESOURCES INC; Spring Valley PROGENICS PHARMACEUTICALS; Tarrytown REGENERON PHARMACEUTICALS INC; Tarrytown SIGA TECHNOLOGIES INC; New York UNITED-GUARDIAN INC; Hauppauge
NORTH CAROLINA AAIPHARMA INC; Wilmington DSM PHARMACEUTICALS INC; Greenville EMBREX INC; Durham INCARA PHARMACEUTICALS; Research Triangle Park INSPIRE PHARMACEUTICALS INC; Durham PARADIGM GENETICS INC; Research Triangle Park PHARMACEUTICAL PRODUCT DEVELOPMENT INC; Wilmington QUINTILES TRANSNATIONAL CORP; Durham TRIANGLE PHARMACEUTICALS; Durham
OHIO BIGMAR INC; Johnstown GLIATECH INC; Cleveland KENDLE INTERNATIONAL INC; Cincinnati NEOPROBE CORPORATION; Dublin
OREGON AVI BIOPHARMA INC; Portland EXELIXIS PLANT SCIENCES INC; Portland OXIS INTERNATIONAL INC; Portland
PENNSYLVANIA BIONX IMPLANTS INC; Blue Bell CELL PATHWAYS INC; Horsham CEPHALON INC; West Chester COLLAGENEX PHARMACEUTICAL; Newton COVALENT GROUP INC; Wayne DISCOVERY LABORATORIES; Doylestown ENDO PHARMACEUTICALS HOLDINGS INC; Chadds Ford ERESEARCH TECHNOLOGY INC; Philadelphia GENAERA CORPORATION; Plymouth Meeting HEMISPHERX BIOPHARMA INC; Philadelphia INKINE PHARMACEUTICAL CO; Blue Bell MYLAN LABORATORIES INC; Pittsburgh NEOSE TECHNOLOGIES INC; Horsham ORAPHARMA INC; Warminster ORASURE TECHNOLOGIES INC; Bethlehem PHOTOGEN TECHNOLOGIES INC; New Hope VIROPHARMA INC; Exton
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
TENNESSEE CELERIS CORPORATION; Nashville CHATTEM INC; Chattanooga KING PHARMACEUTICALS INC; Bristol
TEXAS ACCESS PHARMACEUTICALS; Dallas AMARILLO BIOSCIENCES INC; Amarillo CARRINGTON LABORATORIES INC; Irving EXEGENICS INC; Dallas ILEX ONCOLOGY INC; San Antonio INTROGEN THERAPEUTICS INC; Austin LEXICON GENETICS INC; The Woodlands LUMINEX CORPORATION; Austin TANOX INC; Houston TEXAS BIOTECHNOLOGY CORP; Houston VIRBAC INC; Fort Worth ZONAGEN INCORPORATED; The Woodlands
UTAH IOMED INC; Salt Lake City MYRIAD GENETICS INC; Salt Lake City NPS PHARMACEUTICALS INC; Salt Lake City
VIRGINIA CEL-SCI CORPORATION; Vienna COMMONWEALTH BIOTECHNOLOGIES INC; Richmond INSMED INCORPORATED; Glen Allen
INDEX OF HEADQUARTERS LOCATION BY COUNTRY To help you locate members of THE BIOTECH & GENETICS 400 that have non-U.S. headquarters, the city and country of the headquarters of such companies are included in the following index. CANADA ANGIOTECH PHARMACEUTICALS; Vancouver BIOMIRA INC; Edmonton BIOTECH HOLDINGS LTD; Vancouver BIOVAIL CORPORATION; Mississauga CARDIOME PHARMACEUTICAL CORP; Vancouver DRAXIS HEALTH INC; Mississauga GENEREX BIOTECHNOLOGY; Toronto ID BIOMEDICAL CORPORATION; Vancouver LORUS THERAPEUTICS INC; Toronto MDS INC; Toronto MICROLOGIX BIOTECH INC; Vancouver POLYDEX PHARMACEUTICALS; Toronto QLT INC; Vancouver SHIRE-BIOCHEM INC; Laval SPECTRAL DIAGNOSTICS INC; Toronto
CHILE LABORATORIO CHILE SA; Santiago
DENMARK
WASHINGTON CELL THERAPEUTICS INC; Seattle CORIXA CORPORATION; Seattle EPOCH BIOSCIENCES; Bothell ICOS CORPORATION; Bothell IMMUNEX CORP; Seattle NASTECH PHARMACEUTICAL CO INC; Bothell NEORX CORPORATION; Seattle PACIFIC BIOMETRICS INC; Seattle PROCYTE CORPORATION; Redmond SONUS PHARMACEUTICALS; Bothell TARGETED GENETICS CORP; Seattle
NOVO-NORDISK AS; Basgvaerd
FRANCE AVENTIS SA; Schiltingheim FLAMEL TECHNOLOGIES SA; Venissieux Cedex GENSET SA; Paris
GERMANY LION BIOSCIENCE AG; Heidelberg
ICELAND DECODE GENETICS INC; Reykjavik
WISCONSIN BONE CARE INTERNATIONAL; Madison THIRD WAVE TECHNOLOGIES INC; Madison
IRELAND ELAN CORP PLC; Dublin ICON PLC; Dublin TRINITY BIOTECH PLC; Wicklow WARNER CHILCOTT PLC; Dublin
ISRAEL COMPUGEN LTD; Tel Aviv TARO PHARMACEUTICAL INDUSTRIES; Haifa Bay TEVA PHARMACEUTICAL INDUSTRIES; Petach Tikva
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
SWEDEN
INDEX BY U.S. REGIONS WHERE THE BIOTECH & GENETICS 400 FIRMS HAVE LOCATIONS
BIORA AB; Malmo
SWITZERLAND NOVARTIS AG; Basel SYNGENTA AG; Basel
WEST
THE NETHERLANDS AKZO NOBEL NV; Arnhem QIAGEN NV; Venlo
UNITED KINGDOM ALIZYME PLC; Cambridge AMARIN CORPORATION PLC; London AMERSHAM PLC; Little Chalfont ASTRAZENECA PLC; London BIOCOMPATIBLES INTERNATIONAL PLC; Farnham BRITISH BIOTECH PLC; Oxford CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC; Melbourne CELLTECH GROUP PLC; Slough CELSIS INTERNATIONAL PLC; Cambridge GLAXOSMITHKLINE PLC; Brentford OXFORD GLYCOSCIENCES PLC; Abingdon Oxon SHIRE PHARMACEUTICALS PLC; Basingstoke SKYEPHARMA PLC; London XENOVA GROUP PLC; Slough
AAIPHARMA INC ABAXIS INC ABBOTT LABORATORIES ABGENIX INC ACLARA BIOSCIENCES INC ADVANCED TISSUE SCIENCES AFFYMETRIX INC AKORN INC AKZO NOBEL NV ALEXION PHARMACEUTICALS ALLERGAN INC ALLIANCE PHARMACEUTICAL CORP ALLOS THERAPEUTICS INC ALPHARMA INC ALZA CORP AMGEN INC AMYLIN PHARMACEUTICALS INC APPLERA CORPORATION APPLIED MOLECULAR EVOLUTION INC ARENA PHARMACEUTICALS INC ATRIX LABORATORIES INC AUTOIMMUNE INC AVANIR PHARMACEUTICALS AVENTIS SA AVI BIOPHARMA INC AVIGEN INC BAUSCH & LOMB INC BAXTER INTERNATIONAL INC BIO RAD LABORATORIES INC BIOMARIN PHARMACEUTICAL BIOSITE INC BIOSOURCE INTERNATIONAL INC BIOTIME INC BOSTON BIOMEDICA INC BRISTOL MYERS SQUIBB CO CALIPER TECHNOLOGIES CORP CELL GENESYS INC CELL THERAPEUTICS INC CELLEGY PHARMACEUTICALS CELSIS INTERNATIONAL PLC CEPHALON INC CEPHEID CERUS CORPORATION CHARLES RIVER LABORATORIES CORP CHATTEM INC CHIRON CORP CIPHERGEN BIOSYSTEMS INC COLLATERAL THERAPEUTICS COMPUGEN LTD CONNETICS CORPORATION CORIXA CORPORATION CORTEX PHARMACEUTICALS
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
CORVAS INTERNATIONAL INC COVANCE INC CV THERAPEUTICS INC CYANOTECH CORPORATION CYPRESS BIOSCIENCE INC DEPOMED INC DIAGNOSTIC PRODUCTS CORPORATION DIVERSA CORPORATION DURECT CORP E I DU PONT DE NEMOURS & CO ELAN CORP PLC ELI LILLY & CO EPIMMUNE INC EPOCH BIOSCIENCES ESSENTIAL THERAPEUTICS INC EXELIXIS INC EXELIXIS PLANT SCIENCES INC FOREST LABORATORIES INC GENE LOGIC INC GENELABS TECHNOLOGIES INC GENENCOR INTERNATIONAL INC GENENTECH INC GENSET SA GENZYME CORP GERON CORPORATION GILEAD SCIENCES INC GLAXOSMITHKLINE PLC HAUSER INC HEMAGEN DIAGNOSTICS INC HESKA CORP HOLLIS-EDEN PHARMACEUTICALS HYCOR BIOMEDICAL INC HYSEQ INC ICN PHARMACEUTICALS INC ICON PLC ICOS CORPORATION ID BIOMEDICAL CORPORATION IDEC PHARMACEUTICALS CORP IDEXX LABORATORIES INC ILLUMINA INC IMMUNE RESPONSE CORP (THE) IMMUNEX CORP IMPAX LABORATORIES INC INCYTE GENOMICS INC INFORMAX INC INSITE VISION INC INTEGRA LIFESCIENCES CORP INTERMUNE PHARMACEUTICALS INC INTERNATIONAL ISOTOPES INTRABIOTICS PHARMACEUTICALS INVITROGEN CORPORATION IOMED INC ISIS PHARMACEUTICALS INC IVAX CORPORATION JOHNSON & JOHNSON KENDLE INTERNATIONAL INC KOSAN BIOSCIENCES INC LA JOLLA PHARMACEUTICAL
LARGE SCALE BIOLOGY CORP LIGAND PHARMACEUTICALS INC LION BIOSCIENCE AG LYNX THERAPEUTICS INC MALLINCKRODT INC MARTEK BIOSCIENCES CORP MATRIX PHARMACEUTICAL MAXIM PHARMACEUTICALS MAXYGEN INC MDS INC MEDAREX INC MEDIMMUNE VA CCINES MERCK & CO INC MILLENNIUM PHARMACEUTICALS INC MIRAVANT MEDICAL TECHNOLOGIES MOLECULAR BIOSYSTEMS INC MOLECULAR DEVICES CORP MONSANTO CO MYRIAD GENETICS INC NABI BIOPHARMACEUTICALS NANOGEN INC NAPRO BIOTHERAPEUTICS INC NASTECH PHARMACEUTICAL CO INC NEORX CORPORATION NEOSE TECHNOLOGIES INC NEUROBIOLOGICAL TECHNOLOGIES INC NEUROCRINE BIOSCIENCES INC NORTH AMERICAN SCIENTIFIC NOVO-NORDISK AS NPS PHARMACEUTICALS INC ONYX PHARMACEUTICALS INC ORASURE TECHNOLOGIES INC OSI PHARMACEUTICALS INC OXIS INTERNATIONAL INC PACIFIC BIOMETRICS INC PANVERA LLC PAREXEL INTERNATIONAL PEREGRINE PHARMACEUTICALS INC PFIZER INC PHARMACEUTICAL PRODUCT DEVELOPMENT INC PHARMACYCLICS INC PROCYTE CORPORATION PROTEIN DESIGN LABS INC PROTEIN POLYMER TECHNOLOGIES QIAGEN NV QUESTCOR PHARMACEUTICALS QUINTILES TRANSNATIONAL CORP RIBOZYME PHARMACEUTICALS SANGAMO BIOSCIENCES INC SANGSTAT MEDICAL CORP SCHERING-PLOUGH CORP SCICLONE PHARMACEUTICALS SCIOS INC SENETEK PLC SEQUENOM INC SEROLOGICALS CORP SHIRE PHARMACEUTICALS PLC SICOR INC
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
SIGA TECHNOLOGIES INC SKYEPHARMA PLC SONUS PHARMACEUTICALS SPECTRAL DIAGNOSTICS INC SPECTRUM PHARMACEUTICALS STEMCELLS, INC SUPERGEN INC SYNBIOTICS CORP SYNGENTA AG TARGETED GENETICS CORP TELIK INC TITAN PHARMACEUTICALS TRINITY BIOTECH PLC TRIPOS INC TULARIK INC VALENTIS INC VAXGEN INC VERTEX PHARMACEUTICALS INC VICAL INC VIROLOGIC INC WATSON PHARMACEUTICALS INC WOMEN FIRST HEALTHCARE WYETH XOMA LTD XTRANA INC ZILA INC
IMMUNEX CORP INTERNATIONAL ISOTOPES INTROGEN THERAPEUTICS INC IVAX CORPORATION JOHNSON & JOHNSON LEXICON GENETICS INC LUMINEX CORPORATION MALLINCKRODT INC MDS INC MEDICIS PHARMACEUTICAL CORP MERCK & CO INC MONSANTO CO NABI BIOPHARMACEUTICALS NEORX CORPORATION ORCHID BIOSCIENCES INC PAREXEL INTERNATIONA L PFIZER INC QUINTILES TRANSNATIONAL CORP SCHERING-PLOUGH CORP SEROLOGICALS CORP SHIRE PHARMACEUTICALS PLC TANOX INC TEXAS BIOTECHNOLOGY CORP VIRBAC INC WYETH ZILA INC ZONAGEN INCORPORATED
SOUTHWEST ABBOTT LABORATORIES ACCESS PHARMACEUTICALS ACLARA BIOSCIENCES INC AFFYMETRIX INC AKORN INC AKZO NOBEL NV ALLERGAN INC ALPHARMA INC AMYLIN PHARMACEUTICALS INC APHTON CORP APPLERA CORPORATION AVENTIS SA BAUSCH & LOMB INC BAXTER INTERNATIONAL INC BIO RAD LABORATORIES INC BRISTOL MYERS SQUIBB CO CARRINGTON LABORATORIES INC CHIRON CORP CONNETICS CORPORATION E I DU PONT DE NEMOURS & CO ELI LILLY & CO EXEGENICS INC FOREST LABORATORIES INC GENELABS TECHNOLOGIES INC GENENTECH INC GENZYME CORP GLAXOSMITHKLINE PLC IDEXX LABORATORIES INC ILEX ONCOLOGY INC
MIDWEST AAIPHARMA INC AASTROM BIOSCIENCES INC ABBOTT LABORATORIES ACCUMED INTERNATIONAL AFFYMETRIX INC AKORN INC AKZO NOBEL NV ALBANY MOLECULAR RESEARCH ALKERMES INC ALLERGAN INC ALPHARMA INC ALZA CORP AMGEN INC AMYLIN PHARMACEUTICALS INC AVAX TECHNOLOGIES INC AVENTIS SA BAUSCH & LOMB INC BAXTER INTERNATIONAL INC BIGMAR INC BIO RAD LABORATORIES INC BIOANALYTICAL SYSTEMS INC BONE CARE INTERNATIONAL BRISTOL MYERS SQUIBB CO CAMBREX CORP CARACO PHARMACEUTICAL LABORATORIES CELSIS INTERNATIONAL PLC CHIRON CORP CIMA LABS INC
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
COVANCE INC DONLAR BIOSYNTREX DOR BIOPHARMA INC DSM PHARMACEUTICALS INC E I DU PONT DE NEMOURS & CO ELAN CORP PLC ELI LILLY & CO FOREST LABORATORIES INC GENENTECH INC GENZYME CORP GLAXOSMITHKLINE PLC GLIATECH INC HESKA CORP ICN PHARMACEUTICALS INC ICON PLC IDEXX LABORATORIES INC IMMTECH INTERNATIONAL IMMUNEX CORP INCYTE GENOMICS INC IVAX CORPORATION JOHNSON & JOHNSON K V PHARMACEUTICAL CO KENDLE INTERNATIONAL INC KING PHARMACEUTICALS INC LIFECORE BIOMEDICAL INC LION BIOSCIENCE AG MALLINCKRODT INC MDS INC MEDTOX SCIENTIFIC INC MERCK & CO INC MGI PHARMA INC MONSANTO CO MYLAN LABORATORIES INC NABI BIOPHARMACEUTICALS NEOGEN CORPORATION NEOPROBE CORPORATION NORTHFIELD LABORATORIES ORPHAN MEDICAL INC PAREXEL INTERNATIONAL PENWEST PHARMACEUTICALS CO PFIZER INC PHARMACEUTICAL PRODUCT DEVELOPMENT INC PROTEIN DESIGN LA BS INC QUINTILES TRANSNATIONAL CORP SCHERING-PLOUGH CORP SEROLOGICALS CORP SHEFFIELD PHARMACEUTICALS SHIRE PHARMACEUTICALS PLC SPECTRAL DIAGNOSTICS INC SYNBIOTICS CORP SYNGENTA AG SYNOVIS LIFE TECHNOLOGIES INC TECHNE CORP THIRD WAVE TECHNOLOGIES INC TRIPOS INC UNITED THERAPEUTICS CORP VYSIS INC WATSON PHARMACEUTICALS INC
WYETH ZILA INC
SOUTHEAST AAIPHARMA INC ABBOTT LABORATORIES AFFYMETRIX INC AKORN INC AKZO NOBEL NV ALLERGAN INC ALPHARMA INC AMARILLO BIOSCIENCES INC AMYLIN PHARMACEUTICALS INC ANDRX CORP APHTON CORP AVENTIS SA BAUSCH & LOMB INC BAXTER INTERNATIONAL INC BIO RAD LABORATORIES INC BIOANALYTICAL SYSTEMS INC BIOCRYST PHARMACEUTICALS BRISTOL MYERS SQUIBB CO CELERIS CORPORATION CHATTEM INC CHIRON CORP CYTRX CORPORATION DIAGNOSTIC PRODUCTS CORPORATION E I DU PONT DE NEMOURS & CO ELAN CORP PLC ELI LILLY & CO EMBREX INC E-Z-EM INC FOREST LABORATORIES INC GENENTECH INC GENZYME BIOSURGERY GENZYME CORP GLAXOSMITHKLINE PLC HAUSER INC ICON PLC IDEXX LABORATORIES INC IMMUNEX CORP INSPIRE PHARMACEUTICALS INC IVAX CORPORATION JOHNSON & JOHNSON KING PHARMACEUTICALS INC KOS PHARMACEUTICALS INC LARGE SCALE BIOLOGY CORP MARTEK BIOSCIENCES CORP MDS INC MERCK & CO INC MONSANTO CO MYLAN LABORATORIES INC NABI BIOPHARMACEUTICALS NEOGEN CORPORATION NOVEN PHARMACEUTICALS NOVO-NORDISK AS PARADIGM GENETICS INC
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
PAREXEL INTERNATIONAL PFIZER INC POLYDEX PHARMACEUTICALS QUINTILES TRANSNATIONAL CORP SCHERING-PLOUGH CORP SEROLOGICALS CORP SHIRE PHARMACEUTICALS PLC SYNGENTA AG THERAGENICS CORP VIRAGEN INC WATSON PHARMACEUTICALS INC WYETH
NORTHEAST AAIPHARMA INC ABBOTT LABORATORIES ABLE LABORATORIES ADVANCED MAGNETICS INC AFFYMETRIX INC AKORN INC AKZO NOBEL NV ALBANY MOLECULAR RESEARCH ALEXION PHARMACEUTICALS ALFACELL CORPORATION ALKERMES INC ALLERGAN INC ALLIANCE PHARMACEUTICAL CORP ALPHARMA INC ALTEON INC AMARIN CORPORATION PLC AMGEN INC AMYLIN PHARMACEUTICALS INC ANIKA THERAPEUTICS INC ANTEX BIOLOGICS INC ANTIGENICS INC APPLERA CORPORATION ARIAD PHARMACEUTICALS ARQULE INC ASCENT PEDIATRICS INC ASTRAZENECA PLC ATLANTIC TECHNOLOGY VENTURES AVANT IMMUNOTHERAPEUTICS AVENTIS SA AXONYX INC BARR LABORATORIES INC BAUSCH & LOMB INC BAXTER INTERNATIONAL INC BENTLEY PHARMACEUTICALS INC BIO RAD LABORATORIES INC BIO TECHNOLOGY GENERAL CORP BIOANALYTICAL SYSTEMS INC BIOGEN INC BIOMIRA INC BIONX IMPLANTS INC BIOPURE CORPORATION BIORELIANCE CORP BIOSOURCE INTERNATIONAL INC
BIOSPECIFICS TECHNOLOGIES CORP BIOSPHERE MEDICAL INC BIOTRANSPLANT INC BIOVAIL CORPORATION BOSTON BIOMEDICA INC BOSTON LIFE SCIENCES INC BRADLEY PHARMACEUTICALS BRISTOL MYERS SQUIBB CO CAMBREX CORP CARDIOTECH INTERNATIONAL CELERA GENOMICS GROUP CELERIS CORPORATION CELGENE CORP CELL PATHWAYS INC CEL-SCI CORPORATION CELSIS INTERNATIONAL PLC CEPHALON INC CHARLES RIVER LABORATORIES CORP CHESAPEAKE BIOLOGICAL LAB CHIRON CORP COLLAGENEX PHARMACEUTICAL COLUMBIA LABORATORIES COMMONWEALTH BIOTECHNOLOGIES INC COMPUGEN LTD CORTECH INC COVALENT GROUP INC COVANCE INC CUBIST PHARMACEUTICALS CURAGEN CORPORATION CURIS INC CYTOGEN CORPORATION DIACRIN INC DIAGNOSTIC PRODUCTS CORPORATION DIGENE CORPORATION DISCOVERY LABORATORIES DSM PHARMACEUTICALS INC DUSA PHARMACEUTICALS INC DYAX CORP E I DU PONT DE NEMOURS & CO ELAN CORP PLC ELI LILLY & CO EMBREX INC EMISPHERE TECHNOLOGIES ENDO PHARMACEUTICALS HOLDINGS INC ENTREMED INC ENZO BIOCHEM INC ENZON INC EPIX MEDICAL INC ERESEARCH TECHNOLOGY INC ESSENTIAL THERAPEUTICS INC E-Z-EM INC FOREST LABORATORIES INC GELTEX PHARMACEUTICALS GENAERA CORPORATION GENE LOGIC INC GENELABS TECHNOLOGIES INC GENENTECH INC GENOME THERAPEUTICS CORP
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
GENTA INC GENZYME BIOSURGERY GENZYME CORP GENZYME MOLECULAR ONCOLOGY GLAXOSMITHKLINE PLC GLYCOGENESYS INC GTC BIOTHERAPEUTICS INC GUILFORD PHARMACEUTICALS INC HAUSER INC HEMAGEN DIAGNOSTICS INC HEMISPHERX BIOPHARMA INC HESKA CORP HI TECH PHARMACAL CO INC HUMAN GENOME SCIENCES INC HUNTINGDON LIFE SCIENCES HYBRIDON INC ICN PHARMACEUTICALS INC ICON PLC IDEXX LABORATORIES INC IGEN INTERNATIONAL INC ILEX ONCOLOGY INC IMCLONE SYSTEMS INC IMMUCELL CORPORATION IMMUNE RESPONSE CORP (THE) IMMUNEX CORP IMMUNOGEN INC IMMUNOMEDICS INC IMPAX LABORATORIES INC IMS HEALTH INC INCARA PHARMACEUTICALS INCYTE GENOMICS INC INFORMAX INC INKINE PHARMACEUTICAL CO INSMED INCORPORATED INTEGRA LIFESCIENCES CORP INTERFERON SCIENCES INC IVAX CORPORATION JOHNSON & JOHNSON KENDLE INTERNATIONAL INC KOS PHARMACEUTICALS INC LARGE SCALE BIOLOGY CORP LEXICON GENETICS INC LIFECELL CORPORATION LION BIOSCIENCE AG MACROCHEM CORPORATION MARTEK BIOSCIENCES CORP MATRITECH INC MDS INC MEDAREX INC MEDIMMUNE INC MEDTOX SCIENTIFIC INC MERCK & CO INC MILLENNIUM PHARMACEUTICALS INC MILLIPORE CORP MONSANTO CO MYLAN LABORATORIES INC NABI BIOPHARMACEUTICALS NASTECH PHARMACEUTICAL CO INC
NEOGEN CORPORATION NEOSE TECHNOLOGIES INC NEUROGEN CORP NEXMED INC NORTH AMERICAN SCIENTIFIC NOVARTIS AG NOVAVAX INC NOVO-NORDISK AS NUTRITION 21 INC ORAPHA RMA INC ORASURE TECHNOLOGIES INC ORCHID BIOSCIENCES INC ORGANOGENESIS INC OSI PHARMACEUTICALS INC OXIGENE INC PALATIN TECHNOLOGIES INC PALIGENT INC PAREXEL INTERNATIONAL PDK LABS INC PENWEST PHARMACEUTICALS CO PFIZER INC PHARMACEUTICAL FORMULATIONS INC PHA RMACEUTICAL PRODUCT DEVELOPMENT INC PHARMACEUTICAL RESOURCES INC PHARMACOPEIA INC PHARMOS CORPORATION PHOTOGEN TECHNOLOGIES INC PRAECIS PHARMACEUTICALS PROGENICS PHARMACEUTICALS QIAGEN NV QUINTILES TRANSNATIONAL CORP REGENERON PHARMACEUTICALS INC REPLIGEN CORPORATION SANGSTAT MEDICAL CORP SCHERING-PLOUGH CORP SEPRACOR INC SEQUENOM INC SEROLOGICALS CORP SHIRE PHARMACEUTICALS PLC SHIRE-BIOCHEM INC SIGA TECHNOLOGIES INC SPECTRAL DIAGNOSTICS INC SYNAPTIC PHARMACEUTICAL SYNBIOTICS CORP SYNGENTA AG TARO PHARMACEU TICAL INDUSTRIES TEVA PHARMACEUTICAL INDUSTRIES TITAN PHARMACEUTICALS TRANSKARYOTIC THERAPIES TRIANGLE PHARMACEUTICALS TRINITY BIOTECH PLC TRIPOS INC TULARIK INC UNIGENE LABORATORIES UNITED THERAPEUTICS CORP UNITED-GUARDIAN INC V I TECHNOLOGIES INC VERTEX PHARMACEUTICALS INC
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
VICAL INC VION PHARMACEUTICALS INC VIROPHARMA INC WATSON PHARMACEUTICALS INC WYETH XECHEM INTERNATIONAL
INDEX BY FIRMS WITH INTERNATIONAL OPERATIONS AAIPHARMA INC ABBOTT LABORATORIES ACCESS PHARMACEUTICALS AFFYMETRIX INC AKZO NOBEL NV ALIZYME PLC ALKERMES INC ALLERGAN INC ALPHARMA INC AMARIN CORPORATION PLC AMERSHAM PLC AMGEN INC AMYLIN PHARMACEUTICALS INC ANGIOTECH PHARMACEUTICALS APHTON CORP APPLERA CORPORATION ASTRAZENECA PLC AVAX TECHNOLOGIES INC AVENTIS SA AXONYX INC BAUSCH & LOM B INC BAXTER INTERNATIONAL INC BENTLEY PHARMACEUTICALS INC BIGMAR INC BIO RAD LABORATORIES INC BIO TECHNOLOGY GENERAL CORP BIOANALYTICAL SYSTEMS INC BIOCOMPATIBLES INTERNATIONAL PLC BIOGEN INC BIOMIRA INC BIONX IMPLANTS INC BIOPURE CORPORATION BIORA AB BIORELIANCE CORP BIOSOURCE INTERNATIONAL INC BIOSPECIFICS TECHNOLOGIES CORP BIOSPHERE MEDICAL INC BIOTECH HOLDINGS LTD BIOVAIL CORPORATION BRISTOL MYERS SQUIBB CO BRITISH BIOTECH PLC CAMBREX CORP CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC CARACO PHARMACEUTICAL LABORATORIES CARDIOME PHARMACEUTICAL CORP CARDIOTECH INTERNATIONAL CARRINGTON LABORATORIES INC CELLEGY PHARMACEUTICALS CELLTECH GROUP PLC CELSIS INTERNATIONAL PLC CEPHALON INC CEPHEID CHARLES RIVER LABORATORIES CORP CHATTEM INC
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
CHIRON CORP CIPHERGEN BIOSYSTEMS INC COLUMBIA LABORATORIES COMPUGEN LTD CONNETICS CORPORATION COVALENT GROUP INC COVANCE INC CUBIST PHARMACEUTICALS CYANOTECH CORPORATION DECODE GENETICS INC DIAGNOSTIC PRODUCTS CORPORATION DIGENE CORPORATION DRAXIS HEALTH INC DSM PHARMACEUTICALS INC DUSA PHARMACEUTICALS INC DYAX CORP E I DU PONT DE NEMOURS & CO ELAN CORP PLC ELI LILLY & CO EMBREX INC ERESEARCH TECHNOLOGY INC EXELIXIS INC E-Z-EM INC FLAMEL TECHNOLOGIES SA FOREST LABORATORIES INC GELTEX PHARMACEUTICALS GENELABS TECHNOLOGIES INC GENEREX BIOTECHNOLOGY GENSET SA GENTA INC GENZYME BIOSURGERY GENZYME CORP GERON CORPORATION GILEAD SCIENCES INC GLAXOSMITHKLINE PLC HAUSER INC HEMAGEN DIAGNOSTICS INC HESKA CORP HUNTINGDON LIFE SCIENCES HYCOR BIOMEDICAL INC ICN PHARMACEUTICALS INC ICON PLC ID BIOMEDICAL CORPORATION IDEXX LABORATORIES INC IGEN INTERNATIONAL INC ILEX ONCOLOGY INC IMMUNOMEDICS INC IMS HEALTH INC INCYTE GENOMICS INC INFORMAX INC INTEGRA LIFESCIENCES CORP INTROGEN THERAPEUTICS INC INVITROGEN CORPORATION ISIS PHARMACEUTICALS INC IVAX CORPORATION JOHNSON & JOHNSON KENDLE INTERNATIONAL INC LABORATORIO CHILE SA
LIFECORE BIOMEDICAL INC LION BIOSCIENCE AG LORUS THERAPEUTICS INC LYNX THERAPEUTICS INC MALLINCKRODT INC MATRITECH INC MAXYGEN INC MDS INC MEDAREX INC MEDIMMUNE INC MERCK & CO INC MICROLOGIX BIOTECH INC MILLENNIUM PHARMACEUTICALS INC MILLIPORE CORP MOLECULAR DEVICES CORP MONSANTO CO NABI BIOPHARMACEUTICALS NANOGEN INC NAPRO BIOTHERAPEUTICS INC NEOGEN CORPORATION NEUROBIOLOGICAL TECHNOLOGIES INC NEXMED INC NOVARTIS AG NOVO-NORDISK AS NPS PHARMACEUTICALS INC ORASURE TECHNOLOGIES INC ORCHID BIOSCIENCES INC OSI PHARMACEUTICALS INC OXFORD GLYCOSCIENCES PLC PAREXEL INTERNATIONAL PDK LABS INC PENWEST PHARMACEUTICALS CO PFIZER INC PHARMACEUTICAL PRODUCT DEVELOPMENT INC PHARMACEUTICAL RESOURCES INC PHARMACOPEIA INC PHARMOS CORPORATION POLYDEX PHARMACEUTICALS QIAGEN NV QLT INC QUINTILES TRANSNATIONAL CORP SANGAMO BIOSCIENCES INC SANGSTAT MEDICAL CORP SCHERING-PLOUGH CORP SCICLONE PHARMACEUTICALS SEPRACOR INC SEQUENOM INC SEROLOGICALS CORP SHIRE PHARMACEUTICALS PLC SHIRE-BIOCHEM INC SICOR INC SKYEPHARMA PLC SPECTRAL DIAGNOSTICS INC SYNBIOTICS CORP SYNGENTA AG TANOX INC TARO PHARMACEUTICAL INDUSTRIES TECHNE CORP
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
TEVA PHARMACEUTICAL INDUSTRIES TRANSKARYOTIC THERAPIES TRINITY BIOTECH PLC TRIPOS INC TULARIK INC VALENTIS INC VAXGEN INC VERTEX PHARMACEUTICALS INC VIRAGEN INC VIRBAC INC VIROPHARMA INC VYSIS INC WARNER CHILCOTT PLC WATSON PHARMACEUTICALS INC WYETH XECHEM INTERNATIONAL XENOVA GROUP PLC
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
Individual Data Profiles On Each Of THE BIOTECH & GENETICS 400
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Plunkett Research, Ltd.
www,plunkettresearch.com
AAIPHARMA INC
www.aaiintl.com
Industry Group Code: 541710 Ranks within this company's industry group: Sales: 9 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Y
TYPES OF BUSINESS:
Profits: 7
Computers: Hardware: Software: Arrays: Database Management:
Specialty: Specialty Servic es: Consulting: Blood Collection:
Y
GROWTH PLANS/SPECIAL FEATURES:
Research and Development Services Analytical Testing Bioanalytical Testing Clinical Distribution Devices Formulations Development Regulatory Affairs Consulting Drugs Microbiology Testing Services
AaiPharma, Inc., formerly Applied Analytical Industries, Inc. is a specialty pharmaceutical and product development company with comprehensive drug development capabilities in the United States, Europe and Asia. The company partners with pharmaceutical companies on both a fee-for-service and royalty and milestone payment basis, providing the expertise and knowledge to create quality health care products. The firm has earned a reputation for solving complex pharmaceutical challenges utilizing analytical testing and formulations development techniques, as well as validation and regulatory affairs support services. AaiPharma operates in three divisions: NeoSan Pharmaceuticals, aaiResearch and AAI International. NeoSan Pharmaceuticals acquires and commercializes branded pharmaceutical products in targeted therapeutic classes. The firm recently acquired the drugs Aquasol, Brethine, Darvon and Darvocet. aaiResearch provides research and development expertise and maintains a portfolio of drug-delivery technologies and intellectual property rights which the company uses to develop better and cheaper drugs. AAI International offers a comprehensive range of pharmaceutical product development services to international customers.
BRANDS/DIVISIONS/AFFILIATES: NeoSan Pharmaceuticals aaiResearch AAI International Applied Analytical Industries, Inc. Aquasol Brethine Darvon Darvocet
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Frederick D. Sancilio, CEO Philip S. Tabbiner, COO Philip S. Tabbiner, Pres. William L. Ginna, Jr., Exec. VP/CFO Stephen Cottrell, Exec. VP-Mktg. & Sales Bowin Lindgren, Dir.-Human Resources George E. Van Lear, VP-Research Dev. John Hogan, Controller Richard J. Parker, Pres.-Clinical Trials Div. Gregory S. Bentley , Exec. VP/General Counsel David Johnston, Exec. VP-Non-Clinical Oper. J. Spencer Goldsmith, VP-eCommerce Eugene T. Haley, Treas. Eugene T. Haley, Int'l Managing Dir. Joachim Rexhaus, Exec. VP-European Oper. Vijay Aggarwal, Pres., AAI International
Phone: 910-254-7000 Fax: 910-815-2379 Toll-Free: 800-575-4224 Address: 2320 Scientific Park Dr., Wilmington, NC 28405 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $168,200 ( 9 months) 2002 Profits: $10,000 ( 9 months) Stock Ticker: AAII 2001 Sales: $141,100 2001 Profits: $5,900 Employees: 1,200 2000 Sales: $104,245 2000 Profits: $- 402 Fiscal Year Ends: 12/31 1999 Sales: $102,175 1999 Profits: $-7,913 1998 Sales: $98,243 1998 Profits: $6,538
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $400,000 Bonus: $ Stock Purch. Plan: Second Exec. Salary: $285,000 Bonus: $ ADVANTAGE: Offers an extensive portfolio of high quality drug development and support services.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
West: Y
Southwest:
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Northeast: Y
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
AASTROM BIOSCIENCES INC
www.aastrom.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales: 31 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Y
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Y
TYPES OF BUSINESS:
Profits: 21
Computers: Hardware: Software: Arrays: Database Management:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Systems for Cell Reproduction Cell Therapy Kits
Aastrom Biosciences, Inc. is a leader in developing human cell therapy products in automated clinical systems, designed to enable therapeutic procedures using living cells in the treatment of diseases (including cancer) and in the restoration of normal tissues. The company has three product areas in various stages of development: tissue repair cells; therapeutic cells for immunotherapy; and devices for cell production. The AastromReplicell Cell Production System, Aastrom's lead product, is currently in multi-site U.S. clinical trials for the production of either bone marrow or umbilical cord blood cells to mitigate the toxicity of aggressive chemotherapy used to treat cancer and other blood disorders. The AastromReplicell System is designed to place patient-specific cell production capability directly in patient treatment centers and to enable physicians to access cells for therapy just as they do with traditional pharmaceuticals. This system is created as a family of products keyed by a multi-use instrumentation platform that operates single-use, therapyspecific kits tailored for each patient application. In Europe, the firm has begun market launch of the AastromReplicell System, the SC-I Therapy Kit for the production of bone-marrow derived stem cells and the CBI Therapy Kit for the production of umbilical cord blood cells. The AastromReplicell is also available for sale in the U.S. for research and investigational use. Recently, Aastrom was awarded a grant by the Defense Advanced Research Projects Agency to provide research and development of a system to engineer human stem cells into an artificial immune system. In other news, the company entered into an agreement with an Italian cancer treatment center, AUSL Ravenna, for the purchase and use of Aastrom’s bone marrow stem cell therapy product for an experimental clinical approach in the treatment of breast cancer.
BRANDS/DIVISIONS/AFFILIATES: AastromReplicell Zellera SC-I Therapy Kit CB-I Therapy Kit
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. R. Douglas Armstrong, CEO R. Douglas Armstrong, Pres. Michael S. Durski, CFO/VP-Finance and Admin. Steven Wolff, VP-Medical Research Michael S. Durski, Corp. Sec. Alan M. Wright, Sr. VP-Admin. and Financial Services Michael S. Durski, Treas. Robert J. Bard, VP-Quality Systems and Regulatory Affairs Brian S. Hampson, VP-Product Dev. R. Douglas Armstrong, Chmn.
Phone: 734-930-5555 Fax: 734-665-0485 Toll-Free: Address: 24 Frank Lloyd Wright Dr., Ann Arbor, MI 48106 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $ 900 (12 months) 2002 Profits: $-7,900 (12 months) Stock Ticker: ASTM 2001 Sales: $ 899 2001 Profits: $-5,926 Employees: 40 2000 Sales: $1,200 2000 Profits: $-9,400 Fiscal Year Ends: 6/30 1999 Sales: $ 900 1999 Profits: $-11,000 1998 Sales: $ 200 1998 Profits: $-17,200
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $250,000 Stock Purch. Plan: Y Second Exec. Salary: $140,933 ADVANTAGE: Focus on cell reproduction technology.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
West:
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $ Bonus: $
Northeast:
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
ABAXIS INC
www.abaxis.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales: 20 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Y
TYPES OF BUSINESS:
Profits: 14
Computers: Hardware: Software: Arrays: Database Management:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Equipment- Point-of-Care Blood Analyzer Systems Veterinary Products
Abaxis, Inc. develops, manufactures and markets portable blood analysis systems for use in any patient-care setting to provide clinicians with rapid blood constituent measurements. The company’s primary product consists of a compact 6.9-kilogram analyzer and a series of singleuse plastic discs, called reagent discs, containing all the chemicals required to perform a panel of up to 12 tests. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma using either venous or fingerstick samples. The system provides test results in less than 15 minutes with precision and accuracy equivalent to a clinical laboratory analyzer. Abaxis also sells a system that provides a complete blood count including three-part white blood cell differential in less than two minutes, with results for eight selectable species, plus two user-configurable programs. The company currently markets these systems for veterinary use under the names VetScan and VetScan HMT (DXS System) and in the human medical market under the name Piccolo. Abaxis sells its products in the U.S., Europe, Latin America and Asia. The firm's point-ofcare blood chemistry analyzer system has a total of 22 test methods. Nineteen of these tests are marketed for both human and veterinary markets. Abaxis markets its reagent products by configuring these 22 test methods in panels that are designed to meet a variety of clinical diagnostic needs. In recent news, the company announced the release of the VetScan T4-Cholesterol rotor, which will provide screening sensitivity and therapeutic monitoring for canine hypothyroidism, the most common endocrine disease in dogs, and feline hyperthyroidism in cats. Abaxis offers its employees comprehensive medical benefits, as well as a range of mutual funds and a flexible spending account plan.
BRANDS/DIVISIONS/AFFILIATES: Piccolo VetScan
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Clinton H. Severson, CEO Robert B. Milder, COO Clinton H.Severson, Pres. Alberto R. Santa Ines, VP-Finance/CFO Michael Mercer, VP-Domestic Mktg. and Sales Kenneth Aron, VP-Research and Dev. Vladimir E. Ostioch, VP-Eng. Clinton H. Severson, Chmn.
Phone: 510-675-6500 Fax: 510-441-6150 Toll-Free: 800-822-2947 Address: 3240 Whipple Rd., Union City, CA 94587 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $30,600 (12 months) 2002 Profits: $1,300 (12 months) Stock Ticker: ABAX 2001 Sales: $29,501 2001 Profits: $ 188 Employees: 124 2000 Sales: $23,200 2000 Profits: $- 600 Fiscal Year Ends: 3/31 1999 Sales: $13,300 1999 Profits: $-4,200 1998 Sales: $12,200 1998 Profits: $-4,400
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $250,000 Stock Purch. Plan: Second Exec. Salary: $155,000 ADVANTAGE: Sophisticated portable systems that can perform up to 12 different blood tests.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $226,500 Bonus: $143,500
Northeast:
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
ABBOTT LABORATORIES
www.abbott.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 7 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y Y Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Y
TYPES OF BUSINESS:
Profits: 9
Computers: Hardware: Software: Arrays: Database Management:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Antibiotics and Synthetic Hormones Nutritional Products Diagnostic Systems Intravenous and Irrigation Fluid Equipment Electronic Drug Delivery Systems Diagnostic Imaging Products
Abbott Laboratories' principal business is the discovery, development, manufacture and sale of a diversified line of health care products and services. The company operates through five major business segments: pharmaceutical products, diagnostic products, hospital products, Ross products and international. Principal pharmaceutical products include Depakote, which treats epilepsy, migraine, and bipolar disorder; the anti-infective clarithromycin; various forms of erythromycin; and a broad line of cardiovascular products. The diagnostics segment markets systems for blood banks, hospitals, commercial laboratories, alternate-care testing sites and consumers. Hospital products include drugs and drug delivery systems, perioperative and intensive care products, cardiovascular, renal and oncology products. This segment also markets intravenous and irrigation solutions, related manual and electronic administration equipment and diagnostic imaging equipment. Ross products include a broad line of adult and pediatric nutritionals, specialty pharmaceuticals and consumer products. Ross brands include Similac and Isomil infant formulas, Ensure, Pedialyte, Selsun Blue and the Fact Plus line of pregnancy tests. The international segment markets a broad line of hospital, pharmaceutical and adult and pediatric nutritional products outside the United States. The firm also conducts its own research and development. Among Abbott’s developments is Norvir, an AIDS drug that, when taken with another protease inhibitor or other anti-viral drugs, can reduce HIV in the blood to undetectable levels. Through a joint venture with TAP Pharmaceutical Products, Abbott makes the best-selling prostate cancer drug Lupron. The company offers employees adoption assistance, legal assistance, flexible hours, telecommuting, an onsite childcare center, sports programs and wellness programs. It also offers 12-week summer internships to college students in such areas as engineering, research and marketing. Abbott has been recognized as one of the top 50 Best Companies for Minorities in FORTUNE Magazine.
BRANDS/DIVISIONS/AFFILIATES: Depakote Similac Koss Ensure Pedialyte Selsun Blue Norvir Lupron
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Miles D. White, CEO Thomas C. Freyman, Sr. VP-Finance/CFO Thomas M. Wascoe, Sr. VP-Human Resources Jeffrey M. Leiden, Exec. VP/Chief Scientific Officer Karen L. Miller, VP-IT Gary L. Flynn, VP/Controller John C. Landgraf, VP-Corp. Eng. Jose M. de Lasa, Corp. Sec. Jose M. de Lasa, General Counsel William G. Dempsey, Sr. VP-Int'l Oper. Steven J. Weger, Jr., VP-Corp. Planning & Dev. Catherine V. Babington, VP-Public Affairs Catherine V. Babington, VP-Investor Rel. Greg W. Linder, VP/Treas. Richard A. Gonzalez, Pres./CEO, Medical Products Group Joy A. Amundson, Sr. VP-Ross Products Christopher B. Begley, Sr. VP-Hospital Products Jeffrey M. Leiden, Pres./CEO, Pharmaceuticals Group
Phone: 847-937-6100 Fax: 847-937-1511 Toll-Free: Address: 100 Abbott Park Rd., Abbott Park, IL 60064-6400 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $12,845,414 ( 9 months) 2002 Profits: $2,166,596 ( 9 months) Stock Ticker: ABT 2001 Sales: $16,285,000 2001 Profits: $1,550,000 Employees: 71,426 2000 Sales: $13,745,900 2000 Profits: $2,786,000 Fiscal Year Ends: 12/31 1999 Sales: $13,177,600 1999 Profits: $2,445,800 1998 Sales: $12,512,700 1998 Profits: $2,334,400
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $1,455,622 Stock Purch. Plan: Second Exec. Salary: $619,569 ADVANTAGE: Heavily involved in research/Worldwide recognition.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 5 Hot Spot for Advancement for Women/Minorities: Y
West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $2,100,000 Bonus: $700,000
Northeast: Y
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
ABGENIX INC
www.abgenix.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 58 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Y
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 214
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Diversified Antibody Research
Abgenix, a leading biopharmaceutical company, develops and intends to commercialize several products for a variety of diseases. The company specializes in developing treatments for inflammatory and autoimmune disorders and cancer, as well as cardiovascular diseases, transplant-related and infectious diseases. Abgenix has developed a proprietary technology known as XenoMouse to help rapidly generate highly specific, fully human antibody product candidates. Under the XenoMouse model, the antibody gene of a genetically engineered mouse is suppressed and replaced with human antibody gene expression. The rest of the mouse’s immune system is left intact. The firm generates revenues by licensing XenoMouse technology to pharmaceutical and biotechnology companies interested in developing antibody-based products. The company has recently collaborated with such prestigious firms as Millennium Pharmaceuticals, Pfizer, Human Genome Sciences, Johnson and Johnson, Chiron and Amgen. Abgenix's newest collaboration is a drug discovery alliance with Lexicon Genetics, Inc. The firm's partnership with Abbott Laboratories is a recent one as well; the two companies are working jointly to generate fully-human antibodies. The company also owns SLAM technology, which enables the rapid identification of antibodies with desired function and characteristics. Abgenix recently deployed XenoMax, a technology in which SLAM is used to select and isolate antibodies with particular function and characteristics from antibody-producing cells generated by XenoMouse animals. The company provides a comprehensive program of employee compensation and benefits, including medical, dental, vision, EAP, a flexible spending program, a 401(k) plan and stock options.
BRANDS/DIVISIONS/AFFILIATES: XenoMouse Cell Genesys Lexicon Genetics, Inc. Chiron Pfizer Johnson and Johnson SLAM XenoMax
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. R.Scott Greer, CEO Raymond M. Withy, COO Raymond M. Withy, Pres. Kurt W. Leutzinger, CFO John C. Meyer, Dir.-Human Resources C. Geoffery Davis , Chief Scientific Officer H. David Miller, VP-IT Gisela M. Schwab, Chief Medical Officer Patrick M. Murphy, VP-Mfg. Susan L. Thorner, Corp. Sec. Susan L. Thorner, VP/General Counsel Catherine Maynard, VP-Oper. Gayle M. Mills, VP-Bus. Dev. Gregory M. Bell, VP-Clinical Dev., Inflammation Steve M. Chamow , VP-Process Sciences Bruce A. keyt, VP-Preclinical Dev. Gregory M. Landes, VP-Product Discovery
Phone: 510-608-6500 Fax: 510-608-6511 Toll-Free: Address: 6701 Kaiser Dr., Fremont, CA 94555 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $31,595 ( 9 months) 2002 Profits: $-170,015 ( 9 months) Stock Ticker: ABGX 2001 Sales: $63,606 2001 Profits: $-60,856 Employees: 324 2000 Sales: $59,449 2000 Profits: $-8,793 Fiscal Year Ends: 12/31 1999 Sales: $15,330 1999 Profits: $-19,499 1998 Sales: $4,803 1998 Profits: $-16,827
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Y Second Exec. Salary: $ ADVANTAGE: Collaboration with major firms/Proprietary XenoMouse technology.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 4 Hot Spot for Advancement for Women/Minorities: Y
West: Y
Southwest:
Midwest:
Bonus: $ Bonus: $
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Northeast:
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
ABLE LABORATORIES
www.ablelabs.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 92 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 85
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Generic
Able Laboratories, Inc., which recently merged with DynaGen, Inc., develops, manufactures and sells prescription generic medications. These generic drugs are the chemical and therapeutic equivalents of brandname drugs. Its manufacturing facility produces the medications in tablet, capsule and suppository dosage form. Some of these generic drugs deal with the treatment of health issues involving tension headaches, attention disorder, anxiety disorder, obesity and rheumatoid arthritis. The company has received 16 abbreviated new drug application (ANDA) approvals and one new drug application approval from the FDA. There are several drug applications pending. Recently, Able Labs announced that it entered into an ANDA transfer and marketing agreement with IVAX Pharmaceuticals, Inc., a subsidiary of IVAX Corporation, for Able Labs ' Tramadol Hydrochloride Tablets. Able Labs will manufacture and supply Tramadol exclusively to IVAX under their label, and IVAX will exclusively sell Able Labs' manufactured product. In other news, Able Labs received FDA approval for its ANDAs for hydrocodone bitartrate and acetaminophen tablets and its acetaminophen and codeine phosphate tablets.
BRANDS/DIVISIONS/AFFILIATES: Superior Pharmaceutical Co. Able Labs DynaGen, Inc. Tramadol
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Dhananjay G. Wadekar, CEO Dhananjay G. Wadekar, Pres. Dhananjay G. Wadekar, CFO Loken Patel, V P-Mktg. and Sales George H. Sager, Jr., Controller Dhananjay G. Wadekar, Corp. Sec. Kamlesh Haribhakti, Dir.-Product Dev. Dhananjay G. Wadekar, Treas. Shailesh Daftari, Exec. VP Shashikant Shah, VP-Quality/Regulatory Dwight Nix, VP-Nat'l Accounts Iva Klemick, Dir.-Regulatory Affairs Dhananjay G. Wadekar, Chmn.
Phone: 781-449-4926 Fax: 781-890-0118 Toll-Free: Address: 200 Highland Ave., Ste. 301, Needham , MA 02494 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $36,828 ( 9 months) 2002 Profits: $7,057 ( 9 months) Stock Ticker: ABLA 2001 Sales: $19,600 2001 Profits: $-4,500 Employees: 180 2000 Sales: $31,500 2000 Profits: $-8,500 Fiscal Year Ends: 12/31 1999 Sales: $29,100 1999 Profits: $-8,200 1998 Sales: $25,000 1998 Profits: $-12,600
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Merger with DynaGen.
OTHER THOUGHTS:
Top Exec. Salary: $145,000 Second Exec. Salary: $
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $ Bonus: $
Northeast: Y
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
ACCESS PHARMACEUTICALS
www.accesspharma.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 215 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 95
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Drug Delivery Systems Polymer Technology Cancer Treatment Oral Disease Treatment Dermatology Disorder Treatment
Access Pharmaceutical is an emerging pharmaceutical company that develops novel low-development risk product candidates and technologies with long-term product opportunities. The firm is currently focused on developing drug delivery systems and advanced polymer technology for application in cancer treatment, dermatology and oral diseases. The company has seven proprietary technology platforms, including synthetic polymers, vitamin mediated targeted delivery, nanoparticles and nanoparticle networks, bio-erodible hydrogels, Residerm, carbohydrate targeting technology and agents for the prevention and treatment of viral diseases, including HIV. Additionally, the company and one of its partners, GlaxoSmithKline, jointly developed a product for the treatment of canker sores. GlaxoSmithKline is marketing this product under the trade name Aphthasol within the U.S. Another partner, Strakan Limited, received authorization to market this product in the United Kingdom under the trade name Aptheal. Strakan has also used the patented Residerm technology to develop zinc clindamycin for the treatment of acne, which it began marketing in the U.K. under the trade name Zindaclin in 2002. Recently, the newly created subsidiary Access Pharmaceuticals Australia acquired the targeted therapeutic technology business of Biotech Australia. Under the terms of the acquisition agreement, Access Pharmaceuticals Australia acquired the patents to three targeted therapeutics technologies and retained the scientific group that has developed this technology. Several products in development include Amlexanox Cream and Gel, OraRinse and Mucoadhesive Liquid Technology, OraDisc, DACH Platinum and Polymer Platinate. Access provides medical, life and long-term disability insurance to its employees. Additionally, employees are allowed three to four weeks of vacation and holiday time per year.
BRANDS/DIVISIONS/AFFILIATES: Block Drug Company Aphthasol Residerm OraRinse Amlexanox OraDisc Biotech Australia Access Pharmaceuticals Australia
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Kerry P. Gray, CEO Kerry P. Gray, Pres. Stephen B. Thompson, CFO/VP David P. Nowotnik, VP-Research and Dev. Stephen B. Thompson, Treas. Herbert H. McDade, Jr., Chmn.
Phone: 214-905-5100 Fax: 214-905-5101 Toll-Free: Address: 2600 Stemmons Fwy., Ste. 176, Dallas , TX 752077 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 500 ( 9 months) 2002 Profits: $-7,100 ( 9 months) Stock Ticker: AKC 2001 Sales: $ 200 2001 Profits: $-6,000 Employees: 28 2000 Sales: $ 107 2000 Profits: $-5,428 Fiscal Year Ends: 12/31 1999 Sales: $ 15 1999 Profits: $-3,300 1998 Sales: $ 100 1998 Profits: $-3,400
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Novel drug delivery technology.
OTHER THOUGHTS:
Top Exec. Salary: $307,449 Second Exec. Salary: $196,254
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
West:
Southwest: Y
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $105,000 Bonus: $19,960
Northeast:
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
ACCUMED INTERNATIONAL
www.accumed.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales: Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Y Y
TYPES OF BUSINESS:
Profits: Computers: Hardware: Software: Arrays: Database Management:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Equipment-Diagnosis Screening Instruments Clinical Diagnostic Products
AccuMed International, Inc., recently acquired by Ampersand Medical Corporation, is engaged in the marketing and development of screening instruments and systems for clinical diagnostic laboratories, hospitals and other applications. The company’s integrated systems use technology that improves efficiency and achieves significant improvements in disease detection. The firm is currently developing computer-aided image cytometry instruments and systems that support early detection and diagnosis programs for screening high-risk individuals for cellular disease. AccuMed designs, builds and supplies two product lines. The first product line consists of AcCells computer-aided microscopes, which help medical experts to examine and diagnose specimens of human cells. These products include robotic slide-feeding systems, bar-code readers, electro-mechanical scanning stages, automatic physical dotters and data management system software. The second product line consists of AcCell-Savant, which includes all the AcCell components along with electronic imaging system and image analysis software.
BRANDS/DIVISIONS/AFFILIATES: BCAM International Ventana Medical Systems CellMetrix Ampersand Medical Corporation
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Paul F. Lavallee, CEO Norman J. Pressman, Pres. Joseph Plandowski, Sr. VP-Sales & Mktg. Darlene Czaja, Human Resources Admin. Norman J. Pressman, Chief Scientific Officer
Phone: 312-642-9200 Fax: 312-642-8684 Toll-Free: Address: 920 N. Franklin St., Ste. 402, Chicago, IL 60610 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 2000 Sales: $ 477 2000 Profits: $-3,098 Fiscal Year Ends: 12/31 1999 Sales: $ 136 1999 Profits: $1,400 1998 Sales: $ 300 1998 Profits: $-8,200
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVAN TAGE: Innovative technology for disease detection.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
West:
Southwest:
Midwest: Y
Bonus: $ Bonus: $
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Northeast:
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
ACLARA BIOSCIENCES INC
www.aclara.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales: 27 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 29
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Y Y Y
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drug Discovery Microchips Biochemical Analysis and Synthesis Products
Aclara BioSciences, Inc., formerly Soane BioSciences, Inc., provides miniaturized microfluidic tools for biochemical analysis and synthesis. It develops multiple products to address the genomic, proteomic and pharmaceutical drug screening markets. Its proprietary microfluidics technology allows researchers to rapidly perform large numbers of chemical and biological measurements in a multiplexed, automated format. The Aretas HTS assay miniaturization device enables biochemical assays to be performed at nanoliter volumes. The eTag chemistry platform was developed specifically to bring genomics and functional proteomics assays to the drug development process. The eTag assay system enables gene expression, protein expression and protein function analysis concurrently from the same sample. Focusing on pharmaceutical development, Aclara provides high-throughput, multiplexed gene expression and protein expression assays for screening of pharmaceutical drug candidates. Another microfluidic product, the Plurex Multiplexing Card, integrates proprietary chemistry into a microfluidic card that enables a novel approach to multiplexing the polymerase chain reactions (PCR). LabCard, another multiplexing system device, contains 96 channels that support multiple PCR reactions. The advantages of LabCard include high throughput, minimal reagent and sample use, reliability, compatibility, multiple detection platforms and user-defined primers. The company is developing a LabCard-based eTag analysis system that will enable much greater throughput at higher sensitivity through the integration of chemistry and microfluidic components. Recently, Aclara entered into license and supply agreements with Third Wave Technologies Inc., a manufacturer and marketer of genetic analysis products. Under this agreement, Aclara will incorporate Third Wave’s Invader technology and Cleavase enzyme with its own eTag technology to offer the eTag Assay System for multiplexed gene expression applications in the research market.
BRANDS/DIVISIONS/AFFILIATES: Soane BioSciences, Inc. Plurex Multiplexing Card eTag GeneMate System Microsequencer System DNA Sample Preparation System Aretas HTS LabCard
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Joseph M. Limber, CEO Joseph M. Limber, Pres. Alfred G. Merriweather, VP-Finance/CFO Dan G. Morrow , VP-Oper. Dennis W. Harris, Sr. VP-Systems Integration and Bus. Dev. Sharat Singh, Sr. VP-eTag Assay Tech. Stephen C. Macevicz, VP-Intellectual Property Thomas R. Baruch, Chmn.
Phone: 650-210-1200 Fax: 650-210-1210 Toll-Free: Address: 1288 Pear Ave., Mountain View, CA 94043 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,768 ( 9 months) 2002 Profits: $-30,138 ( 9 months) Stock Ticker: ACLA 2001 Sales: $3,200 2001 Profits: $-29,000 Employees: 170 2000 Sales: $3,500 2000 Profits: $-59,200 Fiscal Year Ends: 12/31 1999 Sales: $2,900 1999 Profits: $-8,200 1998 Sales: $1,400 1998 Profits: $-5,500
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $320,000 Stock Purch. Plan: Y Second Exec. Salary: $220,000 ADVANTAGE: Miniaturized, proprietary technology referred to as microfluidics.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
West: Y
Southwest: Y
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $112,000 Bonus: $51,150
Northeast:
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
ADVANCED MAGNETICS INC
www.advancedmagnetics.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 134 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 53
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Diagnostic Contrast Agents Organ-Specific Contrast Agents
Advanced Magnetics, Inc. (AMI) develops and markets therapeutic iron compounds for treating anemia as well as novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Code 7228 is the firm's lead product in development for use as an iron replacement for patients suffering from chronic anemia and for use in magnetic resonance angiography. It is also being evaluated for magnetic resonance imaging applications in oncology. The company’s liver contrast agent, Feridex I.V., has been approved by the FDA and is being marketed in the United States, Europe, Japan, Argentina, South Korea, China and Israel. The firm’s oral contrast agent, GastroMARK, is manufactured for delineating the bowel in MRI procedures and is approved and marketed for sale in the United States and Europe. In addition, AMI received a letter of intent from the FDA for the approval of Combidex, a contrast agent for the diagnosis of lymph node and liver disease. Recently, AMI announced it entered into two clinical trial agreements with the Biomedical Imaging Program and the National Cancer Institute to study the use of Combidex and Code 7228 MRI contrast agents in the detection of metastatic disease in lymph nodes. In other news, the firm announced a recent study showing that Combidex may also be useful for the imaging of brain tumors and may assist in viral vector delivery of therapeutic agents.
BRANDS/DIVISIONS/AFFILIATES: Feridex I.V. GastroMARK Combidex Code 7228
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jerome Goldstein, CEO Leonard M. Baum, COO Leonard M. Baum, Pres. James A. Matheson, VP-Finance Jerome M. Lewis, VP-Scientific Oper. Marlene Kaplan Goldstein, Sec. Paula M. Jacobs, VP-Dev. Jerome Goldstein, Treas. Mark C. Roessel, VP-Regulatory Affairs Dennis R. Lawler, VP-Quality Control Jerome Goldstein, Chmn.
Phone: 617-497-2070 Fax: 617-547-2445 Toll-Free: Address: 61 Mooney St., Cambridge, MA 02138 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $4,686 ( 9 months) 2002 Profits: $ 671 ( 9 months) Stock Ticker: AVM 2001 Sales: $6,000 2001 Profits: $ 800 Employees: 24 2000 Sales: $4,074 2000 Profits: $-11,263 Fiscal Year Ends: 9/30 1999 Sales: $7,430 1999 Profits: $-4,400 1998 Sales: $6,404 1998 Profits: $-6,300
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $272,886 Stock Purch. Plan: Y Second Exec. Salary: $149,769 ADVANTAGE: Expertise in diagnostic contrast agents drug development.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $ Bonus: $
Northeast: Y
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
ADVANCED TISSUE SCIENCES
www.advancedtissue.com
Industry Group Code: 325414 Ranks within this company's industry group: Sales: 1 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Y
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 8
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Skin Replacement Products Tissue Replacement Technology
Advanced Tissue Sciences, a leader in tissue engineering technology, develops products for the repair or replacement of damaged and destroyed tissues. The firm’s efforts are concentrated in four areas: wound care, aesthetic and reconstructive, cardiovascular and orthopedic. The company’s three main products are Transcycle, a temporary wound covering for the treatment of burns; Dermagraft, a treatment for skin ulcers; and NouriCel, a product for skin care and other aesthetic applications. Advanced Tissue holds more than 100 patents, including patents covering the growth of vascularized human tissues or organs on threedimensional scaffolds inside the body, three-dimensional tissue constructs made with genetically modified cells and the growth of three-dimensional tissue-engineered tubular structures. The company is currently developing heart tissue. It joined a 10-year, $10 million collaborative effort led by the University of Washington to develop a fully functional human heart using stem, cardiac and skeletal muscle cells. The firm has also presented data showing Dermagraft’s ability to stimulate blood vessel formation in the heart, a capability critical to the regeneration of damaged cardiac tissue. Advanced Tissue's threedimensional stromal tissue culture is a technology critical to the company’s research on stem cells that could lead to the eventual growth of organs in labs. The company recently announced a major restructuring effort. Separate business units will be established to focus on new commercial opportunities for core technologies. New subsidiary BioNuvia is the first of these units. BioNuvia will develop and market bioengineered products primarily designed for appearance enhancement and body rejuvenation. Current products NouriCel, NouriCel-MD and human-based collagen for aesthetic applications are now part of the BioNuvia line. BioNuvia will explore the option to develop subsidiaries of its own, while Advanced Tissue will continue establishing other business units.
BRANDS/DIVISIONS/AFFILIATES: ATS Orthopedics, Inc. ATS Dermagraft, Inc. Segenix, Inc. DermEquip, LLC Dermagraft LaserDerm TransCyte BioNuvia
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Arthur J. Benvenuto, CEO Joseph R. Kletzel, COO Arthur J. Benvenuto, Pres. Mark J. Gergen, Sr. VP/CFO Robert O. Gaskin, Jr., VP-Human Resources David L. Horwitz, Sr. VP-Tech. Terry E. Gibson, VP-Oper. Mark J. Gergen, Sr. VP/Chief Dev. Officer Mark J. Gergen, VP-Investor Rel. Charles E. Anderson, VP-Quality Kenneth R. Heilbrunn, VP-Clinical Research Anthony Ratcliffe, VP-Research
Phone: 858-713-7300 Fax: 858-713-7400 Toll-Free: Address: 10933 N. Torrey Pines Rd., La Jolla, CA 92037-1005 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $16,000 ( 9 months) 2002 Profits: $-26,100 ( 9 months) Stock Ticker: ATISQ.OB 2001 Sales: $28,900 2001 Profits: $-28,400 Employees: 226 2000 Sales: $25,271 2000 Profits: $-24,571 Fiscal Year Ends: 12/31 1999 Sales: $42,803 1999 Profits: $-21,306 1998 Sales: $20,481 1998 Profits: $-43,285
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $441,000 Stock Purch. Plan: Second Exec. Salary: $330,750 ADVANTAGE: Owns significant patents/A leader in skin replacement technology.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $500,000 Bonus: $200,000
Northeast:
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
AFFYMETRIX INC
www.affymetrix.com
Industry Group Code: 334413 Ranks within this company's industry group: Sales: 1 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Sv cs.: Assays/Diagnostics:
Y
TYPES OF BUSINESS:
Profits: 4
Computers: Hardware: Software: Arrays: Database Management:
Y
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Chips-Genetics Genetic Testing Instruments
Affymetrix develops technology for examining and managing complex genetic information for use in biomedical research, genomics and clinical diagnostics. The cornerstone of the company is its GeneChip technology, used for sequence analysis, genotyping and gene expression monitoring. The firm maintains three primary focuses as part of its business strategy: gene expression monitoring, which identifies gene functions; polymorphism analysis, which examines mutations of gene sequences and disease management, which is aimed at using genetic analysis to develop better health care solutions for various diseases. The company recently launched the NetAffx web site, its first Internet source aimed at giving users a new web-based tool that will streamline public and private information (from various databases) with the data that is produced by Affymetrix's GeneChip arrays. The firm has also extended its product line by introducing the GeneChip CustomExpress array program. The improved technology will offer customers a single system for any gene expression study. Notably, Affymetrix has entered an important agreement with deCODE to develop DNA-based tests for patients that would predict responsiveness to treatments. Such responses would play a key role in the production of more effective medicines. The company has recently expanded into agriculture by entering into a custom supply agreement with Monsanto Co., which will allow Monsanto to use the GeneChip technology to study plant development and disease.
BRANDS/DIVISIONS/AFFILIATES: Genetic MicroSystems, Inc. GeneChip Spotted Array Systems GeneChip CustomExpress GenFlex Tag Array Perlegen Sciences, Inc. Neomorphic NetAffx
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Stephen P. A. Fodor, CEO Susan E. Siegel, Pres. Gregory T. Schiffman, VP/CFO Thane Kreiner, VP-Sales/Mktg. Karen H. Haynes, VP-Human Resources/Admin. Richard P. Rava, Sr. VP/Chief Tech. Officer Barbara A. Caulfield, General Counsel Ronald D. Verdoorn, Exec. VP-Global Oper. Edward Hurwitz, Sr. VP-Corp. Strategy and New Ventures Robert H. Ellis, Exec. VP-Product Dev. and Quality
Phone: 408-731-5000 Fax: 408-481-0422 Toll-Free: Address: 3380 Central Expy., Santa Clara, CA 95051 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $211,575 ( 9 months) 2002 Profits: $554,000 ( 9 months) Stock Ticker: AFFX 2001 Sales: $224,900 2001 Profits: $-33,100 Employees: 905 2000 Sales: $200,830 2000 Profits: $-53,990 Fiscal Year Ends: 12/31 1999 Sales: $109,074 1999 Profits: $-25,504 1998 Sales: $52,413 1998 Profits: $-26,800
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $420,433 Stock Purch. Plan: Second Exec. Salary: $372,933 ADVANTAGE: Owns leading gene analysis technology/Growth through acquisitions.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $175,000 Bonus: $150,000
Northeast: Y
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
AKORN INC
www.akorn.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 68 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Y
TYPES OF BUSINESS:
Profits: 155
Computers: Hardware: Software: Arrays: Database Management:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Ophthalmic and Injectable Surgical Pharmaceutical Products Over-the-Counter Ophthalmic Products Injectable Pharmaceutical Products Sterile Contract Manufacturing Services Surgical Instruments
Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals in specialty areas such as ophthalmology, rheumatology, anesthesia and antidotes. Through its ophthalmics division, the company markets an extensive line of diagnostic and therapeutic ophthalmic pharmaceutical products as well as surgical instruments and related supplies. Diagnostic products, primarily used in the office setting, include mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions and angiography dyes. Therapeutic products, sold primarily to wholesalers and other national account customers, include antibiotics, anti-infectives, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines and anti-edema medications. Surgical products include surgical knives and other surgical instruments, balanced salt solution, post-operative kits, surgical tapes, eye shields, anti-ultraviolet goggles, facial drape supports and other supplies. Non-pharmaceutical products include various artificial tear solutions, preservative-free lubricating ointments, lid cleansers, vitamin supplements and contact lens accessories. Akorn also markets a line of specialty injectable pharmaceutical products, including anesthesia products used in the treatm ent of rheumatoid arthritis and pain management. The company provides its employees with tuition reimbursement and a comprehensive health benefits plan.
BRANDS/DIVISIONS/AFFILIATES: Taylor Pharmaceuticals, Inc. Opthalmic Division Pasadena Research Laboratories, Inc. Sufenta Alfenta Paremyd
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John N. Kapoor, CEO Antonio Pera, COO Antonio Pera, Pres. Ben J. Pothast, VP/CFO Neil Shanahan, Human Resources Abu Alam, VP-Research and Dev. Rita McConville, Corp. Controller Kevin M. Harris, Corp. Sec. Kevin M. Harris, Treas. Shahid Ahmed, VP-Quality Assurance
Phone: 847-279-6100 Fax: 847-943-3694 Toll-Free: 800-535-7155 Address: 2500 Millbrook Dr., Buffalo Grove, IL 60089-4694 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $41,259 ( 9 months) 2002 Profits: $-1,153 ( 9 months) Stock Ticker: AKRN.PK 2001 Sales: $42,200 2001 Profits: $-19,600 Employees: 310 2000 Sales: $66,927 2000 Profits: $2,187 Fiscal Year Ends: 12/31 1999 Sales: $64,632 1999 Profits: $6,670 1998 Sales: $56,667 1998 Pr ofits: $4,647
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Y Second Exec. Salary: $ ADVANTAGE: Merger with Pasadena Research Laboratories, Inc.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
West: Y
Southwest: Y
Midwest: Y
Bonus: $ Bonus: $
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Northeast: Y
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
AKZO NOBEL NV
www.akzonobel.com
Industry Group Code: 325000 Ranks within this company's industry group: Sales: 1 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 1
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Manufacturing-Paint Pharmaceuticals Chemicals
Based in The Netherlands, Akzo Nobel N.V. is leading producer of health care products, coatings and chemicals. The pharmaceuticals division provides products for both the human and animal health care markets, including contraceptives, fertility drugs, antipsychotics, over-thecounter drugs, antidepressants and veterinary medicines. Akzo Nobel manufactures the Sikkens, International, Crown and Interpon coating brands. These coating products were used on London’s Millennium Wheel, La Scala Opera House in Milan, the Oresund Bridge between Denmark and Sweden and Stadium Australia in Sydney. The company is also one of the world’s leading chemicals producers, primarily specializing in chemicals found in cosmetics, plastics, glass and baked goods. Subsidiaries include Advanced BioScience Laboratories, Inc., Colbond Geosynthetics, Akzo Nobel, Inc., DioSynth, Inc., Intervet, Inc., Organon Teknika Corporation and Rosemont Pharmaceutical Corporation. Akzo Nobel has operations in 80 countries. The firm has experienced rapid growth and was labeled Europe’s fastest growing pharmaceutical company. Recently, Akzo Nobel’s polymer chemicals high purity metalorganics unit acquired Mochem GmbH, an active member in the field of metalorganics for semiconductors in opto-electronics. The company is also investing in a non-stick coatings facility in Southern China to be built adjacent to its existing wood coatings plant. This facility will provide coatings for the cookware industry and for specialized industrial applications. In other news, Akzo Nobel's coatings unit announced the purchase of a 50% stake in Industrial de Acabados, a Mexican powder coatings producer. The new joint venture, Akzo Nobel INDA, will manufacture and market powder coatings products under the Interpon brand.
BRANDS/DIVISIONS/AFFILIATES: Advanced BioScience Laboratories, Inc. Colbond Geosynthetics Akzo Nobel, Inc. DioSynth, Inc. Intervet, Inc. Organon Teknika Corporation Rosemont Pharmaceutical Corporation Akzo Nobel INDA
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Cees J.A. van Lede, CEO Fritz W. Frohlich, CFO Olle Werner, VP-Human Resources Bart C.M.I. Beusmans, Corp. Sec. A. Jan A.J. Eijsbouts, General Counsel Dag Strömqvist, Pres.-Chemicals Paul K. Brons, Pres.-Pharma Rudy M.J. van der Meer, Pres.-Coatings Fritz Hensel, Sr. VP-Finance Cees J.A. van Lede, Chmn.
Phone: +31-26-366-4433 Fax: +31-26-366-3250 Toll-Free: Address: Velperweg 76, Arnhem, 6800 SB The Netherlands
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 6 months. 2002 Sales: $6,649,000 ( 6 months) 2002 Profits: $452,000 ( 6 months) Stock Ticker: AKZOY 2001 Sales: $12,576,000 2001 Profits: $598,000 Employees: 66,300 2000 Sales: $12,215,800 2000 Profits: $842,700 Fiscal Year Ends: 12/31 1999 Sales: $12,590,100 1999 Profits: $-547,000 1998 Sales: $23,996,300 1998 Profits: $1,171,600
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: An international giant in chemicals, coatings and health care products.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $ Bonus: $
Northeast: Y
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
ALBANY MOLECULAR RESEARCH
www.albmolecular.com
Industry Group Code: 541710 Ranks within this company's industry group: Sales: 13 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Y
TYPES OF BUSINESS:
Profits: 5
Computers: Hardware: Software: Arrays: Database Management:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Research and Development Services
Albany Molecular Research, Inc. (Albany) is a leading, fully integrated provider of drug discovery and development, chemistry research and manufacturing services to companies in the pharmaceutical, genomic and biotechnology industries. Albany also provides contract chemistry services to customers across the entire product development cycle, from lead discovery to commercial manufacturing. These services include drug discovery, medicinal chemistry, chemical development, analytical chemistry services and small-scale and pilot-plant manufacturing. The company has also expanded its service offerings to include commercial manufacturing through its strategic relationship with Organichem Corporation. Albany’s services permit its customers to reduce overall drug development time and cost and to simultaneously pursue a greater number of drug discovery and development opportunities. Albany’s proprietary research and development activities led to the development, patenting and manufacturing of a substantially pure form of the active ingredient in the nonsedating antihistamine marketed by Aventis as Allegra. The company’s key research facilities include Albany Research Center, Bothell Research Center, Bruno Biotechnology Development Center and Syracuse Research Center. Recently, Albany added drug metabolism assay and metabolite production capabilities to its drug discovery and development technologies, which will provide information concerning the metabolic properties and enzyme interactions of compounds. In other news, the company signed a three-year drug discovery research agreement with Merck & Co., Inc. Under this agreement, Albany will perform chemistry research and lead optimization using computer-assisted chemical design and synthesis technologies. Albany also announced a drug discovery collaboration with Genzyme Corp., in which it will provide libraries of natural product extracts for biological screening.
BRANDS/DIVISIONS/AFFILIATES: Allegra Organichem Corp. Flourous Technologies, Inc. EnzyMed Bothell Research Center Syracuse Research Center Bruno Biotechnology Development Center Albany Research Center
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Thomas E. D'Ambra, CEO Donald E. Kuhla, COO Donald E. Kuhla, Pres. David P. Waldek, CFO Harold Meckler, VP-Science and Tech. David P. Waldek, Corp. Sec. James J. Grates, VP-Oper. Lawrence D. Jones, Sr. VP-Bus. Dev. David P. Waldek, Treas. Barry A. Berkowitz, Corp. VP Michael P. Trova, Sr. VP-Medicinal Chemistry Thomas E. D'Ambra, Chmn.
Phone: 518-464-0279 Fax: 518-464-0289 Toll-Free: Address: 21 Corporate Circle, Albany, NY 12203 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $91,312 ( 9 months) 2002 Profits: $29,538 ( 9 months) Stock Ticker: AMRI 2001 Sales: $56,800 2001 Profits: $34,400 Employees: 532 2000 Sales: $66,603 2000 Profits: $23,593 Fiscal Year Ends: 12/31 1999 Sales: $43,471 1999 Profits: $13,800 1998 Sales: $33,294 1998 Profits: $10,497
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $279,231 Stock Purch. Plan: Second Exec. Salary: $250,000 ADVANTAGE: Highly diversified research and development.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
West:
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $108,750 Bonus: $
Northeast: Y
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
ALEXION PHARMACEUTICALS www.alexionpharmaceuticals.com Industry Group Code: 325412 Ranks within this company's industry group: Sales: 104 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Y
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 210
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Neurological Disease Xenotransplantation Technology
Alexion Pharmaceuticals, Inc. is engaged in drug discovery, research and product and clinical development. The company develops products for the treatment of cardiovascular, autoimmune and hematologic disorders, inflammation and cancer stemming from unwanted effects of the immune system. The firm focuses on technologies that shut down particular components of the human immune system to reduce inflammation while allowing beneficial aspects of the immune system to remain functional. Alexion is currently collaborating with Procter & Gamble to develop Pexelizumab, a treatment for cardiovascular diseases associated with coronary angioplasty. The company is also working to develop 5G1.1, a treatment for rheumatoid arthritis, nephritis, psoriasis, dermatomyositis and lupus. Alexion’s Apogen program targets the autoimmune disease multiple sclerosis. Furthermore, the firm is a major pioneer in the field of xenotransplantation, which is the transplant of organs from animals to humans; the company is currently developing various treatments to prevent human immune systems from rejecting animal organs. Recently, entered into a drug target discovery and validation agreement with CuraGen Corporation, a genomics -based pharmaceutical company. Under this agreement, CuraGen will apply its genomic technologies to identify potential drug targets derived from Alexion's research materials.
BRANDS/DIVISIONS/AFFILIATES: Apogen Program Pexelizumab 5G1.1
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Leonard Bell, CEO David W. Keiser, COO David W. Keiser, Pres. Barry P. Luke, VP-Finance Russell P. Rother, VP-Discovery Research Daniel N. Caron, Sr. Dir.-Eng. and Oper. Samuel S. Chu, VP-Mfg. and Process Sciences Thomas I.H. Dubin, VP/General Counsel Paul W. Finnegan, VP-Oper. Paul W. Finnegan, VP-Dev. Leonard Bell, Treas. Stephen P. Squinto, Exec. VP-Research Nancy Motola, VP-Regulatory Affairs and Quality Assurance Scott A. Rollins, VP-Drug Dev. and Project Mgmt. Katherine S. Bowdish, Sr. VP-Antibody Discovery John H. Fried, Chmn.
Phone: 203-272-2596 Fax: 203-271-8190 Toll-Free: Address: 325 Knotter Dr., Cheshire, CT 06410 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $6,500 (12 months) 2002 Profits: $-56,500 (12 months) Stock Ticker: ALXN 2001 Sales: $11,805 2001 Profits: $-57,043 Employees: 140 2000 Sales: $21,400 2000 Profits: $-20,200 Fiscal Year Ends: 7/31 1999 Sales: $18,800 1999 Profits: $-6,400 1998 Sales: $5,000 1998 Profits: $-8,765
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Focus on immune system diseases.
OTHER THOUGHTS:
Top Exec. Salary: $332,000 Second Exec. Salary: $230,381
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $100,000 Bonus: $50,000
Northeast: Y
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
ALFACELL CORPORATION
www.alfacell.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 73 Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Cancer and AIDS
Alfacell Corporation is a biopharmaceutical company engaged in the discovery and development of new drugs for the treatment of cancer and other pathological conditions. The company is dedicated to finding a new class of anti-cancer and anti-viral drugs from amphibian ribonucleases (RNases). Researchers have learned that eggs and early embryos of leopard frogs contain certain proteins that are a potential aid in cancer research and therapy. The RNases degrade ribonucleic acids, causing an interruption in protein synthesis and resulting in inhibition of cell growth and induction of programmed cell death. The company’s proprietary product is Onconase, which targets solid tumors that have become resistant to other chemotherapeutic drugs. Alfacell is currently engaged in phase III clinical studies of Onconase and its effects on tumor cell death in leukemia and prostate cells and its anti-viral activity at two stages in the HIV-1 lifecycle. The company has partners in Canada, Europe, Japan and Latin America. It also has strategic research collaborations with The National Institute of Health, Harvard University, New York Medical College, Institute of Medicinal Virology at Johann Wolfgang University of Frankfurt, Germany and University Degli Studi G.D. Annunzio in Chieti, Italy. Recently, Alfacell expanded its research partnership with The National Cancer Institute (NCI). NCI will evaluate Alfacell’s Onconase as a radiation enhancer.
BRANDS/DIVISIONS/AFFILIATES: Onconase ONC+ Mab P-32
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Kuslima Shogen, CEO Kuslima Shogen, CFO Stanislaw M. Mikulski, Exec. VP/Medical Dir. Kuslima Shogen, Chmn.
Phone: 973-748-8082 Fax: 973-748-1355 Toll-Free: Address: 225 Belleville Ave., Bloomfield, NJ 07003 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 282 ( 9 months) 2002 Profits: $-19,000 ( 9 months) Stock Ticker: ACEL.OB 2001 Sales: $ 2001 Profits: $-2,300 Employees: 14 2000 Sales: $ 51 2000 Profits: $-1,722 Fiscal Year Ends: 7/31 1999 Sales: $ 168 1999 Profits: $-3,156 1998 Sales: $ 300 1998 Profits: $-6,400
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Unique anti-cancer therapies.
OTHER THOUGHTS:
Top Exec. Salary: $150,000 Second Exec. Salary: $130,000
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $ Bonus: $
Northeast: Y
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
ALIZYME PLC
www.alizyme.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 116 Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Gastrointestinal Colonic Drug Delivery System
Alizyme Therapeutics develops prescription drugs for the treatment of obesity and related diseases as well as gastrointestinal disorders, including irritable bowel syndrome (IBS), inflammatory bowel diseases and mucositis. Alizyme generally takes products from an early stage into clinical development through the proof of efficacy in humans stage, in phase II clinical trials, with the intention of licensing out products for late-stage clinical trials and eventual marketing. The company applies novel COLAL technology, which delivers drugs directly to the colon. Products in phase II trials include Renzapride for treatment of IBS; ATL-962 for treatment of obesity; and ATL-104 for treatment of mucositis. COLAL-PRED used for treatment of inflammatory bowel disease is currently in phase III development. This product incorporates an antiinflammatory steroid with the colonic drug delivery system COLAL and is under development for the management of ulcerative colitis. Recently, Alizyme announced it had been granted permission from the U.K. Medicines Control Agency to undertake a phase IIb clinical trial to evaluate ATL-962 for the treatment of obesity.
BRANDS/DIVISIONS/AFFILIATES: Renzapride ATL-1251 ATL-2502 ATL-962 COLAL COLAL-PRED
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard M.J. Palmer, CEO Timothy P. McCarthy, Dir.-Finance Roger Hickling, Head-Dev. Oper. Brian Richards, Chmn.
Phone: +44-1223-896-000 Fax: +44-1223-896-001 Toll-Free: Address: Granta Park, Great Abington, Cambridge, CB1 6CX UK
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 6 months. 2002 Sales: $17,854 ( 6 months) 2002 Profits: $-7,110 ( 6 months) Stock Ticker: Private 2001 Sales: $ 2001 Profits: $-9,600 Employees: 15 2000 Sales: $ 2000 Profits: $-8,400 Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $-6,700 1998 Sales: $ 1998 Profits: $-7,200
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: COLAL drug delivery system.
OTHER THOUGHTS:
Top Exec. Salary: $ Second Exec. Salary: $
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
West:
Southwest:
Midwest:
Bonus: $ Bonus: $
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Northeast:
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
ALKERMES INC
www.alkermes.com
Industry Group Code: 339113 Ranks within this company's indus try group: Sales: 14 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 26
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Sustained-Release Injection Systems
Alkermes specializes in the development of sophisticated drug delivery technologies. Two of the company's main areas of focus, ProLease and Medisorb technologies, release injectable drugs in controlled amounts over a specified short period of time. Significant concentration is also placed on Alkermes’ Advanced Inhalation Research (AIR) technology, a major innovation among pulmonary delivery systems, which maximizes drug delivery to the lungs. Aside from patenting new products, the company’s expansion is concentrated toward forming partnerships to license its products. Alkermes first product, Nutropin Depot, developed in collaboration with Genetech, Inc., is based on ProLease technology. Risperdal Consta, an anti-psychotic drug developed in collaboration with Janssen Pharmaceutica, is based on Medisorb technology and is expected to be the firm’s second product to reach the U.S. market. Recently, the company announced its partner, Johnson & Johnson Pharmaceutical Research and Development, received approval to market Risperdal Consta in Germany. Alkermes also entered an alliance with Eli Lilly and Company to develop an inhaled form of insulin for the treatment of diabetes based on the Alkermes AIR pulmonary drug delivery system. The company has proprietary projects in development stages including Albuterol for the treatment of asthma and Vivitrex for the treatment of alcohol abuse. Employee benefits at Alkermes include tuition reimbursement, a comprehensive health plan and transportation subsidies. Notably, every employee starts with an allowance of three weeks of vacation time per year.
BRANDS/DIVISIONS/AFFILIATES: ProLease Medisorb Nutropin Depot Albuterol Vivitrex Albulast Risperdal Consta AIR
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard F. Pops, CEO David Broecker, COO David Broecker, Pres. James M. Frates, VP/CFO J. Duncan Higgons, Sr. VP-Mktg. Raymond T. Bartus, Sr. VP-Life Sciences Research and Dev. Elliot W. Ehrich, VP-Medical Affairs Gordon Pugh, VP-Oper. J. Duncan Higgons, Sr. VP-Bus. Dev. James M. Frates, Treas. Michael J. Landine, VP-Corp. Dev. Paul F. Hebert, VP- Process Dev. Stephen E. Zale, VP-Formulations
Phone: 617-494-0171 Fax: 617-494-9263 Toll-Free: Address: 88 Sidney St., Cambridge, MA 02139-4234 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $54,100 (12 months) 2002 Profits: $-61,400 (12 months) Stock Ticker: ALKS 2001 Sales: $56,000 2001 Profits: $-16,900 Employees: 415 2000 Sales: $22,900 2000 Profits: $-68,000 Fiscal Year Ends: 3/31 1999 Sales: $33,900 1999 Profits: $-41,100 1998 Sales: $25,500 1998 Profits: $-12,600
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $406,462 Stock Purch. Plan: Y Second Exec. Salary: $294,685 ADVANTAGE: Focus on new drug delivery technologies.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
West:
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $175,000 Bonus: $100,000
Northeast: Y
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
ALLERGAN INC
www.allergan.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 15 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Y
TYPES OF BUSINESS:
Profits: 16
Computers: Hardware: Software: Arrays: Database Management:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Supplies-Eye Care Niche Pharmaceuticals Skin Care Products Medical Devices
Allergan is a technology-driven, global health care company that develops and commercializes specialty pharmaceutical products for the ophthalmic, neurological, dermatological and other specialty markets, as well as ophthalmic surgical devices and contact lens care solutions. The company focuses on products for the treatment of a wide range of disease areas, including glaucoma and retinal disease, cataracts, dry eye, psoriasis, acne photodamage, movement disorders, metabolic disease and various cancers. The cornerstone of the company’s product line is its Alphagan ophthalmic solution, which is used for the treatment of open-angle glaucoma and ocular hypertension. Other products introduced by Allergan include Array multifocal lens for cataract patients, BOTOX for neuromuscular disorder sufferers, Refresh Tears for dry eyes and M.D. Forte for ultraviolet sunscreen protection. The company’s expansion has been predicated on the release of new products and the revision of its existing product line. The FDA recently granted approval for the use of BOTOX in smoothing wrinkles. This innovative application of the muscle relaxant has become one of the fastest growing cosmetic treatments performed by surgeons in the United States. In other news, the company’s board of directors recently approved a spin-off of its pharmaceutical and optical medical device businesses into two independent companies. Following the completion of the divestiture, Allergan will change its name to Advanced Medical Optics, Inc. and will become a specialty pharmaceutical company with businesses in ophthalmic, dermatological and neuromuscular/neurotoxin pharmaceuticals.
BRANDS/DIVISIONS/AFFILIATES: CrownPharma, Ltd. Pacific Pharma, Inc. Herbert Laboratories AMO Holdings, Inc. BOTOX Alphagan Betagan Advanced Medical Optics, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David E.I. Pyott, CEO David E.I. Pyott, Pres. Eric Brandt, CFO Lester J. Kaplan, VP-Research James M. Hindman, Controller Francis R. Tunney, Jr., Corp. Sec. Francis R. Tunney, Jr., General Counsel Jacqueline J. Schiavo, VP-Oper. George M. Lasezkay , VP-Corp. Dev. Jeffrey L. Edwards , VP-Investor Rel. Jeffrey L. Edwards , Treas. David A. Fellows, VP/Pres.-Asia/Pacific Region Nelson R. A. Marques, VP/Pres-Latin America Region
Phone: 714-246-4500 Fax: 714-246-6987 Toll-Free: 800-347-4500 Address: 2525 Dupont Dr., Irvine, CA 92612-9534 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,006,800 ( 9 months) 2002 Profits: $10,800 ( 9 months) Stock Ticker: AGN 2001 Sales: $1,745,500 2001 Profits: $224,900 Employees: 6,436 2000 Sales: $1,625,500 2000 Profits: $215,100 Fiscal Year Ends: 12/31 1999 Sales: $1,452,400 1999 Profits: $188,200 1998 Sales: $1,296,100 1998 Profits: $-90,200
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Technology-based growth strategy.
OTHER THOUGHTS:
Top Exec. Salary: $870,384 Second Exec. Salary: $367,538
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $875,000 Bonus: $223,000
Northeast: Y
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
ALLIANCE PHARMACEUTICAL CORP Industry Group Code: 325412 Ranks within this company's industry group: Sales: 172 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Y
TYPES OF BUSINESS:
www.allp.com Profits: 213
Computers: Hardware: Software: Arrays: Database Management:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Cardiovascular and Respiratory Reusable Magnetic Resonance Imaging Accessories
Alliance Pharmaceutical Corp. is a pharmaceutical research and development company that focuses on developing scientific discoveries into medical products. Subsequently, these advances are licensed to multinational pharmaceutical companies in exchange for fixed payments and royalty or profit sharing payments. Two of the company's products in late stage development are Oxygent, an intravascular oxygen carrier that reduces the need for donor blood in patients at risk of acute tissue hypoxia (oxygen deficiency); and Imavist (formerly nam ed Imagent), an intravenous contrast agent for enhancement of ultrasound images to assess cardiac structure and function and to detect organ lesions and blood flow abnormalities. Alliance and Baxter Healthcare Corporation have formed a joint venture to further develop and market Oxygent in the U.S., Canada and Europe, and Imavist is licensed on a worldwide basis to Schering AG, Germany. The company's strategy is to identify potential new medical products through its own efforts and scientific collaborations with researchers and clinicians in universities and medical centers, where many of the basic causes of disease and potential targets for new therapies are discovered. The company seeks collaborative relationships for the final stages of product development, including completing late-phase human testing, obtaining worldwide regulatory approvals, building large-scale manufacturing capacities and marketing.
BRANDS/DIVISIONS/AFFILIATES: Oxygent LiquiVent Imavist Astral, Inc. MDV Technologies, Inc. Baxter Healthcare Pulmospheres Schering AG
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Duane J. Roth, CEO Theodore D. Roth, COO Theodore D. Roth, Pres. Tim Hart, CFO Carole McWilson, Dir.-Human Resources David H. Klein, Sr. VP-Pharmaceutical R&D Keith W. Chapman, VP-Oper. Harold W. DeLong, Exec. VP-Bus. Dev. Gwen Roseberg, VP-Corp. Comm. Tim Hart, Treas. Howard C. Dittrich, VP-Regulatory Affairs
Phone: 858-410-5200 Fax: 858-410-5343 Toll-Free: Address: 3040 Science Park Rd., San Diego, CA 92121 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $10,300 (12 months) 2002 Profits: $-34,200 (12 months) Stock Ticker: ALLP.OB 2001 Sales: $1,900 2001 Pr ofits: $-60,700 Employees: 178 2000 Sales: $16,000 2000 Profits: $-46,467 Fiscal Year Ends: 6/30 1999 Sales: $8,251 1999 Profits: $-62,473 1998 Sales: $21,209 1998 Profits: $-33,003
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $454,250 Bonus: $200,000 Stock Purch. Plan: Second Exec. Salary: $337,462 Bonus: $110,000 ADVANTAGE: Has several collaborative relationships with multinational pharmaceutical companies.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Northeast: Y
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
ALLOS THERAPEUTICS INC
www.allos.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 157 Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Cons ulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Diversified Small-Molecule Therapies
Allos Therapeutics focuses its efforts on developing and commercializing innovative small molecule drugs for improving cancer treatments. Small-molecule pharmaceuticals developed by Allos increase the level of oxygen released by red blood cells, therefore alleviating tumor resistance that occurs due to poor oxygenation. The company’s lead compound, RSR13, is a product designed to make solid tumors more receptive to radiation therapy. Allos demonstrated in Phase II clinical trials that RSR13 significantly improves the efficacy of radiation therapy for treating brain metastases, tumors that have spread to the brain, glioblastoma multiforme, a highly aggressive form of primary brain cancer, and non-small cell lung cancer. The firm has recently announced initiation of a Phase I/II clinical trial of RSR13 for patients with locally advanced cancer of the cervix receiving chemoradiation. Beyond its uses for cancer treatment, RSR13 is being tested for applications relating to cardiovascular disease and stroke. Other products for the treatment of acute hypoxia, RSR46 and JP7, are in preclinical stages of the development process. Allos is currently researching pyruvarte kinsase inhibitors for the treatment of chronic hypoxia. Allos offers a wide range of employee benefits with comprehensive protection, individual choice and flexibility.
BRANDS/DIVISIONS/AFFILIATES: RSR13 RSR46 JP7
CONTACTS: Note: Officers with more than one job titl e may be intentionally listed here more than once. Michael E. Hart, CEO Michael E. Hart, Pres. Daniel R. Hudspeth, CFO/VP Barbara E. Baring, VP-Human Resources Jean-Francois Liard, Sr. VP-Clinical Dev. Douglas G. Johnson, Sr. Dir.-Mfg. Michael E. Hart, Corp. Sec. Eric Malek, Dir.-Corp. Dev. Monique Greer, Dir.-Corp. Comm. Markus F. Herzig, Sr. VP-Regulatory Affairs John O. Hackman, Sr. Dir.-Biometrics and Statistics Stephen J. Hoffman, Chmn.
Phone: 303-426-6262 Fax: 303-412-9160 Toll-Free: Address: 7000 N. Broadway, Ste. 400, Denver, CO 80221 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $-18,700 ( months) Stock Ticker: ALTH 2001 Sales: $ 2001 Profits: $-20,100 Employees: 61 2000 Sales: $ 100 2000 Profits: $-23,361 Fiscal Year Ends: 12/31 1999 Sales: $ 100 1999 Profits: $-11,288 1998 Sales: $ 1998 Profits: $-8,574
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $275,000 Stock Purch. Plan: Y Second Exec. Salary: $239,979 ADVANTAGE: Focus on novel pharmaceuticals to treat certain types of cancer.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $32,681 Bonus: $27,191
Northeast:
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
ALPHARMA INC
www.alpharma.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 24 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 196
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Animal Health Proprietary Human Pharmaceutical Products Animal Health Products
Alpharma, Inc. is a multinational pharmaceutical company that develops, manufactures and markets specialty generic and proprietary human pharmaceutical and animal health products. The company is the largest manufacturer of generic liquid and topical pharmaceuticals in the United States and has an established and growing market position in finished pharmaceuticals in Europe and the Far East. Alpharma offers a comprehensive range of over 800 tablet, capsule, liquid and topical generic human phrmaceutical products and over 100 animal health products. It is one of the world's leading producers of important specialty antibiotics. The company is also known as a leading provider of animal feed additives for poultry and livestock and vaccines for farmed fish. Alpharma is continuing to strengthen its international market presence and is accelerating research and development for new products. Alpharma announced that its international pharmaceutical division purchased a 20% ownership of indiemed.com, a new European pharmaceutical e-commerce business. Indiemed.com is the first e-commerce company to market its services toward the whole pharmaceutical supply chain. Alpharma also recently acquired the medicated feed additive business of Roche, which manufactures products for preventing and treating diseases in livestock. The company also recently acquired the oral solid dose pharmaceutical business of F.H. Faulding and Co., Ltd.
BRANDS/DIVISIONS/AFFILIATES: indiemed.com Roche F.H. Faulding and Co., Ltd.
CONTACTS: Note: Officers with more than one job ti tle may be intentionally listed here more than once. Ingrid Wiik, CEO Ingrid Wiik, Pres. Jeffrey E. Smith, CFO/VP-Finance Nancy V. Ryan, VP-Human Resources John S. Towler, VP/Controller Robert F. Wrobel, VP/Chief Legal Officer David R. Jackson, VP/Corp. Comm. David R. Jackson, VP-Investor Rel. Albert N. Marchio II, Treas. Liang Chao, General Mgr.-China Market Stig Jarle Pettersen, VP-Finance, Int'l Pharmaceutical Div. Thomas L. Anderson, VP/Pres., U.S. Pharmaceuticals Div. Bruce I. Andrews, VP/Pres., Animal Health Div.
Phone: 201-947-7774 Fax: 201-947-4879 Toll-Free: 800-645-4216 Address: One Executive Dr., Fort Lee, NJ 07024 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $895,811 ( 9 months) 2002 Profits: $-27,271 ( 9 months) Stock Ticker: ALO 2001 Sales: $975,000 2001 Profits: $-37,900 Employees: 4,900 2000 Sales: $919,523 2000 Profits: $61,143 Fiscal Year Ends: 12/31 1999 Sales: $732,443 1999 Profits: $36,972 1998 Sales: $604,584 1998 Profits: $24,211
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: The largest manufacturer of generic liquid and topical pharmaceuticals in the U.S.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $ Bonus: $
Northeast: Y
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
ALTEON INC
www.alteonpharma.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 207 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 127
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Diabetes Cardiovascular Drugs Glucose Lowering Agents
Alteon, Inc. is a product-based biopharmaceutical company primarily engaged in the discovery and development of oral drugs to reverse or inhibit cardiovascular aging and diabetic complications. Its product candidates represent novel approaches to some of the largest pharmaceutical markets. Two of the firm's compounds are in clinical development, and several others are in early development. These candidates were developed as a result of research on the advanced glycosylation end-product (AGE) pathway, a fundamental process and consequence of aging and diabetes that causes or contributes to many medical disorders. Alteon's current research and drug development activities targeting this pathway take three directions: the breaking of AGE crosslinks between proteins; the prevention or inhibition of AGE formation; and the reduction of the AGE burden through a novel class of anti-hyperglycemic agents, or glucose lowering agents (GLAs). Since its inception, Alteon has created an extensive library of compounds targeting the AGE pathway and has actively pursued patent protection for these discoveries. The company's lead product candidate is ALT-711, an AGE crosslink barrier that offers the first therapeutic approach to breaking these crosslinks, which may reverse tissue damage caused by aging and diabetes , thereby restoring flexibility and function to blood vessels and organs of the body. Results suggest that ALT-711 is a novel potential therapy for systolic hypertension, which occurs as a result of vascular stiffening due to age or diabetes. Other products in development include ALT-744 for skin aging and Pimagedine for diabetic kidney disease. Alteon maintains a number of licensing and collaboration agreements relating to the development and distribution of its AGE technology. In recent news, the company completed several rounds of trials in the development of ALT-711 and expects to release this data during 2003.
BRANDS/DIVISIONS/AFFILIATES: Pimagedine ALT-711 ALT-744
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Kenneth I. Moch, CEO Kenneth I. Moch, Pres. Elizabeth A. O'Dell, VP-Finance Robert C. deGroof, Sr. VP-Scientific Affairs Elizabeth A. O'Dell, Corp. Sec. Elizabeth A. O'Dell, VP-Admin. Judith S. Hedstrom, Sr. VP-Corp. Dev. Susan M. Pietropaolo, Dir.-Corp. Comm. Susan M. Pietropaolo, Dir.-Investor Rel. Elizabeth A. O'Dell, Treas. Henry W. Founds, Exec. Dir.-Non-Clinical Oper.
Phone: 201-934-5000 Fax: 201-934-8880 Toll-Free: Address: 170 Williams Dr., Ramsey, NJ 07446 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 346 ( 9 months) 2002 Profits: $-13,798 ( 9 months) Stock Ticker: ALT 2001 Sales: $ 452 2001 Profits: $-11,583 Employees: 33 2000 Sales: $ 570 2000 Profits: $-9,570 Fiscal Year Ends: 12/31 1999 Sales: $1,435 1999 Profits: $-10,932 1998 Sales: $1,321 1998 Profits: $-26,346
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Significant partnerships.
OTHER THOUGHTS:
Top Exec. Salary: $326,025 Second Exec. Salary: $215,000
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $100,000 Bonus: $50,000
Northeast: Y
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
ALZA CORP
www.alza.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Drug Delivery Technologies Drug Therapies and Systems
ALZA Corporation develops and markets innovative pharmaceutical products using advanced drug delivery technologies to add medical and economic value to drug therapies. The company focuses on several therapeutic areas, including oncology, AIDS, pain management, endocrinology and urology. ALZA's Therapeutic Discovery Corporation selects and develops new human pharmaceutical products, combining the company's proprietary drug delivery systems with various drug compounds, and commercializes such products, usually through licensing arrangements with ALZA. Some of the company’s more commonly known drugs are Ditropan XL for the treatment of urge urinary incontinence, DUROS for the palliative treatment of advanced prostate cancer, OROS for the treatment of attention deficit/hyperactivity disorder, E-TRANS (fentanyl) for chronic pain, E-TRANS (LHRH) for infertility and E-TRANS Macroflux for Type II diabetes. Another drug, Caelyx, treats advanced ovarian cancer. ALZA operates as a wholly owned subsidiary of Johnson and Johnson. ALZA offers employees an extensive benefits package including 85% paid dental coverage, stock options, bonuses, maternity leave, telecommuting and transit. In addition, the company also matches gifts to charities and has a holiday shutdown period and a sabbatical program.
BRANDS/DIVISIONS/AFFILIATES: Caelyx Ditropan XL E-TRANS Therapeutic Discovery Corp. NeuTrexin Crescendo Pharmaceuticals Johnson and Johnson DUROS
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Samuel R. Saks, Company Group Chairman Robert Clark, CFO/VP-Finance Joseph Michalcewicz, VP-Human Resources B. Michael Silber, VP-Research Suzanne C. Martin, VP-Program Mgmt. and IT Janne L. Wissel, Sr. VP-Oper. Erik D. Wilberg, VP-Bus. Dev. Detlef Albrecht, VP-Clinical Dev. Suneel Gupta, VP-Research and Pharmacology Howard B. Rosen, VP-Strategic and New Product Planning
Phone: 650-564-5000 Fax: 650-564-7070 Toll-Free: 800-233-5222 Address: 1900 Charleston Rd., Mountain View, CA 94039 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 2,442 2000 Sales: $988,500 2000 Profits: $223,300 Fiscal Year Ends: 12/31 1999 Sales: $795,900 1999 Profits: $91,000 1998 Sales: $646,900 1998 Profits: $108,300
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Y Second Exec. Salary: $ ADVANTAGE: Advanced drug delivery technologies.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
West: Y
Southwest:
Midwest: Y
Bonus: $ Bonus: $
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Northeast:
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
AMARILLO BIOSCIENCES INC
www.amarbio.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 203 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 62
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Diversified Nutritionals Orally Delivered Drugs
Amarillo Biosciences, Inc., a development-stage company, focuses its development efforts on biologics for the treatment of human and animal diseases. The company is currently channeling its research into human health indications for the use of low-dose orally administered natural interferon alpha, or IFN[alpha], particularly for the treatment of Sjogren's syndrome, fibromyalgia, idiopathic pulmonary fibrosis and asthma. Amarillo Biosciences owns or licenses 20 United States patents relating to lowdose oral natural IFN[alpha]. The company is developing a topical formulation of the drug. It has also obtained licenses for natural human interferon gama (IFNg) and tumor necrosis factor alpha from its Japanese partner, Hayashibara Biochemical Laboratories, Inc. Recently, Amarillo Biosciences executed a license agreement with Atrix Laboratories, Inc. of Fort Collins, Colorado, providing the rights to oral low-dose interferon alpha for the treatment of Behcet's disease and oral papillomavirus warts in HIV-positive patients. In other news, the company signed another license agreement with African Health Solution, LLC, providing the rights to low-dose oral interferon alpha for the treatment of hepatitis B patients in 40 African countries. Amarillo Biosciences also announced the expansion of its existing relationship with Global Damon of Seoul, Korea. Global Damon will distribute Amarillo Biosciences' dietary supplement for dry mouth in Korea. In addition, the company agreed to supply nutraceuticals in territories of China, Taiwan and Pakistan through agreements with STC International and Majsons Corporation.
BRANDS/DIVISIONS/AFFILIATES: Hayashibara Biochemical Laboratories, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Joseph M. Cummins, CEO Kathleen L. Kelleher, COO Joseph M. Cummins, Pres. Joseph M. Cummins, CFO Kathleen L. Kelleher, VP-Bus. Dev. Joseph M. Cummins, Chmn.
Phone: 806-376-1741 Fax: 806-376-9301 Toll-Free: Address: 800 W. 9th Ave., Amarillo, TX 79101 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 100 ( 9 months) 2002 Profits: $- 700 ( 9 months) Stock Ticker: AMAR 2001 Sales: $ 700 2001 Profits: $- 500 Employees: 4 2000 Sales: $ 100 2000 Profits: $-3,400 Fiscal Year Ends: 12/31 1999 Sales: $ 108 1999 Profits: $-6,119 1998 Sales: $ 222 1998 Profits: $-2,333
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Expertise in low dose oral interferons/Owns a large number of patents.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
West:
Southwest:
Midwest:
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $ Bonus: $
Northeast:
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
AMARIN CORPORATION PLC
www.amarincorp.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 61 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Sv cs.: Assays/Diagnostics:
Profits: 87
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Generic Prescription Drugs Over-the-Counter Drugs
Amarin Corporation is an emerging specialty pharmaceutical company engaged in the development and sale of pharmaceutical products worldwide. The company’s strategy is to obtain and acquire licenses for pharmaceutical products that larger companies do not actively market. Its U.S. subsidiary, Amarin Pharmaceuticals, Inc., increases the sales of these products through aggressive promotion activities, including the use of the Internet. The European subsidiary, Amarin Development AB, is responsible for researching and developing drug solutions to enhance new and existing drugs. LAX-101, currently in phase III studies, is being developed to treat Huntington’s disease. The company also has the rights for Moraxen, a drug used to treat severe pain in end-stage cancer. Amarin Development AB has entered into a research collaboration with CellGate, Inc., whereby CellGate’s technology will be used to develop drug transporter conjugates that will aid Amarin’s controlled-release technology. Recently, Amarin acquired the U.S. rights to Permax, a dopamine receptor agonist indicated as adjunctive therapy in the management of Parkinson's disease.
BRANDS/DIVISIONS/AFFILIATES: Amarin Pharmaceuticals, Inc. Amarin Development AB LAX-101 Moraxen Permax
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard A.B. Stewart, CEO Michael Coffee, COO Michael Coffee, Pres. Nigel Bell, CFO Jonathan Lamb, Corp. Sec. Jonathan Lamb, General Counsel Donald R. Joseph, VP-Commercial Dev. Stephan Ohlsson, Managing Dir.-Amarin Development Michael M. Wess, VP-Medical Affairs, Amarin Pharmaceuticals Margie Nemcik-Cruz, VP-Regulatory Affairs, Amarin Pharmaceuticals Thomas G. Lynch, Chmn.
Phone: +44-20-7499-9009 Fax: +44-20-7499-9004 Toll-Free: Address: 7 Curzon St., London, W1J 5HG UK
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $51,500 ( 9 months) 2002 Profits: $5,600 ( 9 months) Stock Ticker: AMRN 2001 Sales: $53,800 2001 Profits: $-4,700 Employees: 84 2000 Sales: $26,200 2000 Profits: $2,400 Fiscal Year Ends: 12/31 1999 Sales: $11,200 1999 Profits: $4,400 1998 Sales: $ 1998 Profits: $
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Aggressive promotion activities/Product line growth through acquisition.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $ Bonus: $
Northeast: Y
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
AMERSHAM PLC
www.nycomed-amersham.com
Industry Group Code: 325413 Ranks within this company's industry group: Sales: 1 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Y
TYPES OF BUSINESS:
Profits: 1
Computers: Hardware: Software: Arrays: Database Management:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Contrasting and Radiotherapy Agents Treatment for Prostate Cancer Radiopharmaceuticals Industrial Separations Technology
Amersham is a leading producer of contrasting agents that enhance the quality of images in procedures such as xrays, magnetic resonance imaging and ultrasounds. It also produces radiopharmaceuticals used in nuclear medicine imaging. The company’s life sciences business division, Amersham Biosciences, offers drug discovery and systems for gene and protein analysis and drug screening. Amersham Biosciences is a market leader in industrial separators, where it provides systems for the purification and production of biopharmaceuticals. This division also provides research products for use in different laboratories. Amersham Health, another division, produces imaging and radiotherapy agents, which help in the diagnosis and treatment of diseases. Its products focus on areas of cardiology, neurology and oncology. Recently, Amersham Health signed an agreement with Link Pharmaceuticals, a U.K. hospital specialty sales and marketing company to promote the therapy product Metastron for the treatment of pain from metastatic prostate cancer. In other news, Amersham Health’s radiopharmaceutical imaging agent, MYOVIEW, was approved for use in breast cancer screening in 12 European countries, including France, Germany, the U.K. and Spain. MYOVIEW was originally used to diagnose heart disease by visualising blood flow to the heart muscle. In addition, Amersham Biosciences recently opened its first Malaysian branch office.
BRANDS/DIVISIONS/AFFILIATES: Amersham Biosciences Amersham Health MYOVIEW Theragenics Corporation TheraSeed OncoSeed Pharmacia
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. William M. Castell, CEO Andrew Carr, Pres. Giles F. B. Kerr, Dir.-Finance George Battersby, Dir.-Group Human Resources Robert Allnutt, Sec./Group Legal Advisor Lynne Gailey, Dir.-Corp. Affairs Alexandra Morris, Mgr.-Investor Rel. John M. Padfield, CEO-Amersham Health
Phone: +44-1494-544000 Fax: +44-1494-542266 Toll-Free: Address: Amersham Place, Little Chalfont, Buckinghamshire HP7 9NA UK
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 6 months. 2002 Sales: $1,140,500 ( 6 months) 2002 Profits: $147,600 ( 6 months) Stock Ticker: AHM 2001 Sales: $2,206,400 2001 Profits: $312,800 Employees: 9,500 2000 Sales: $1,834,000 2000 Profits: $104,000 Fiscal Year Ends: 12/31 1999 Sales: $1,848,000 1999 Profits: $21,000 1998 Sales: $1,893,000 1998 Profits: $-3,000
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Second Exec. Salary: $ Bonus: $ ADVANTAGE: A leading producer of imaging agents, the company has diversified into many additional areas.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Northeast:
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
AMGEN INC
www.amgen.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 11 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 10
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Diversified Advanced Cellular Biology Advanced Molecular Biology
Amgen, Inc. is a global biotechnology company that develops, manufactures and markets human therapeutics based on advanced cellular and molecular biology. Its products are used for the treatment of nephrology, cancer, inflammatory disorders and metabolic and neurodegenerative diseases. Amgen manufactures and markets four human therapeutic products: Neupogen, Epogen, Infergen and Stemgen. Neupogen selectively stimulates the growth of infection-fighting white blood cells (known as neutrophils). Epogen stimulates the production of red blood cells. Infergen stimulates the immune system to fight viral infections and is being marketed for the treatment of Hepatitis C. Stemgen is approved for stem cell therapy in Australia, Canada and New Zealand. Amgen also has promising drugs that are currently in various stages of development. These drugs under development include Aranesp, a version of Epogen that is longer lasting and can be marketed worldwide, and Abarelix, a drug used for prostate cancer. It has research and marketing alliances with companies such as Hoffmann-La Roche, Johnson & Johnson and Kirin. The firm recently announced that it intends to acquire Immunex in a deal valued at $16 billion.
BRANDS/DIVISIONS/AFFILIATES: Neupogen Epogen Infergen Stemgen Immunex Aranesp Abarelix
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Kevin W. Sharer, CEO Kevin W. Sharer, Pres. Richard D. Nanula, CFO George Morrow , Sr. VP-Sales & Mktg. Brian McNamee, VP-Human Resources Roger Perlmutter, Exec. VP-Research & Dev. Hassan Dayem, Sr. VP/CIO Marc M.P. de Garidel, VP/Controller Sarah M. Jensen, VP-Eng. & Oper. Services Edward E. Bjurstrom, VP-Mfg. Steven M. Orde, Sr. VP-Sec. Steven M. Orde, General Counsel Dennis M. Fenton, Exec. VP-Oper. Richard D. Nanula, Exec. VP-Strategy Peter B. Teeley, Sr. VP-Gov't. Affairs & Public John J. Elginer, Treas. Beth C. Seidenberg, Sr. VP-Dev. George Morstyn, Sr. VP-Dev./Chief Medical Officer
Phone: 805-447-1000 Fax: 805-447-1010 Toll-Free: 800-772-6436 Address: 1 Amgen Center Dr., Thousand Oaks , CA 91320-1799 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $3,756,900 ( 9 months) 2002 Profits: $-1,848,300 ( 9 months) Stock Ticker: AMGN 2001 Sales: $3,763,000 2001 Profits: $1,119,700 Employees: 7,700 2000 Sales: $3,629,400 2000 Profits: $1,138,500 Fiscal Year Ends: 12/31 1999 Sales: $3,340,100 1999 Profits: $1,096,400 1998 Sales: $2,718,200 1998 Profits: $863,200
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Top Exec. Salary: $ Bonus: $ Stock Purch. Plan: Y Second Exec. Salary: $ Bonus: $ ADVANTAGE: A global biotechnology company with a specific market niche/One of the best known and fastest growing biotech firms.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
West: Y
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Northeast: Y
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
AMYLIN PHARMACEUTICALS INC
www.amylin.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 221 Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Diabetes Drugs for Metabolic Disorders
Amylin Pharmaceuticals, Inc. develops novel medicines for treating diabetes and related metabolic disorders. The company was founded after the discovery of amylin, a hormone that is missing in persons with type 1 diabetes and deficient in those with type 2 diabetes. Amylin Pharmaceuticals, Inc. is currently developing and testing four products. SYMLIN, a drug intended to treat diabetics who use insulin, is in phase III clinical studies. This drug is a synthetic version of the human hormone (amylin) that demonstrates activity in blood glucose regulation. Marketing authorization applications for SYMLIN have been accepted for filing by the EMEA and Swiss Regulatory Authorities. AC2993 is currently in phase III evaluation for the treatment of type 2 diabetes. It is an amino acid peptide that exhibits several anti-diabetic, or glucose lowering, actions. AC2993 LAR, an injectable long-acting formulation of AC2993, is currently in phase II evaluation also. AC3056, an in-licensed drug from Aventis Pharma, is being evaluated as a treatment to prevent restenosis after vascular repair procedures and for diseases resulting from atherosclerosis. AC3056 is currently in phase I studies. Recently, Amylin signed a global agreement with Eli Lilly to collaborate on the development and commercialization of its AC2993, receiving $325 million from Lilly, which greatly improved Amylin's financial condition..
BRANDS/DIVISIONS/AFFILIATES: Amylin Europe, Ltd. Pramlintide SYMLIN AC2993 LAR AC2993 AC3056
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Joseph C. Cook, Jr., CEO Mark G. Foletta, CFO/VP-Finance Cathy Jackson, Human Resources Admin. Andrew A. Young, VP/Sr. Research Fellow Nancy K. Dahl, VP/Corp. Sec. Nancy K. Dahl, General Counsel Martin R. Brown, Sr. VP-Oper. Michael Step, Sr. VP-Corp. Dev. Alain D. Baron, Sr. VP-Clinical Research Daniel M. Bradbury, Exec. VP Julia R. Brown, Exec. VP Joann L. Data, Sr. VP-Regulatory Affairs and Quality Assurance Joseph C. Cook, Jr., Chmn.
Phone: 858-552-2200 Fax: 858-552-2212 Toll-Free: Address: 9373 Towne Centre Dr., San Diego, CA 92121 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,600 ( 9 months) 2002 Profits: $80,600 ( 9 months) Stock Ticker: AMLN 2001 Sales: $ 2001 Profits: $-72,000 Employees: 215 2000 Sales: $ 100 2000 Profits: $-44,000 Fiscal Year Ends: 12/31 1999 Sales: $ 100 1999 Profits: $-30,600 1998 Sales: $16,200 1998 Profits: $-51,098
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $475,000 Stock Purch. Plan: Second Exec. Salary: $300,000 ADVANTAGE: Has developed a synthetic hormone with excellent potential to treat diabetes.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 4 Hot Spot for Advancement for Women/Minorities: Y
West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $250,000 Bonus: $
Northeast: Y
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
ANDRX CORP
www.andrx.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 29 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 35
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Controlled Release Drug Delivery Technologies
Andrx Corporation formulates and commercializes controlled-release oral pharmaceuticals using proprietary drug delivery technologies. To date, the company has developed 10 different drug delivery technologies that have been patented or for which patent applications have been filed. Andrx believes that its technologies are flexible and can be modified to apply to a variety of pharmaceutical products. Through Andrx Pharmaceuticals and Andrx Laboratories, the company is applying proprietary drug delivery technologies and formulation skills, either directly or through collaborative arrangements, to the development of generic versions of select brand name pharmaceuticals. Andrx also markets and distributes generic drugs manufactured by third parties. Andrx is a 50% partner in ANCIRC Pharmaceuticals, a joint venture with Watson, for the development of up to eight generic controlled-release pharmaceuticals. Andrx Labs develops controlled-release products using the technologies created by Andrx Laboratories. The company also manufactures and sells internally developed products, including Cartia XT, Diltia XT, Ketroprofen Extended Release and Metformin IR, along with the bioequivalent versions of Cardizem CD, Dilacor XR, Oruvail and Glucophage. Anda, a unit of the company, purchases products directly from manufactures and wholesalers and markets them through its telemarketing staff and sales representatives. Andrx uses POL Physicians Online to gain access to physicians through the Internet. In recent news, Andrx received tentative FDA approval for generic Novaldex, generic Clariditin-D24 and generic GlucophageXR. The drug Alcor has been approved by the FDA and generic K-Dur received FDA marketing approval.
BRANDS/DIVISIONS/AFFILIATES: ANCIRC Pharmaceuticals Cartia XT Andrx Laboratories Andrx Pharmaceuticals Diltia XT Metformin IR Anda, Inc. Ketroprofen
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard J. Lane, CEO Elliot F. Hahn, Pres. Angelo C. Malahias, VP/CFO Scott Lodin, Exec. VP/Corp. Sec. Scott Lodin, General Counsel Elliot F. Hahn, Chmn.
Phone: 954-584-0300 Fax: 954-217-4327 Toll-Free: Address: 4955 Orange Dr., Davie, FL 33314 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $553,604 ( 9 months) 2002 Profits: $-59,436 ( 9 months) Stock Ticker: ADRX 2001 Sales: $749,000 2001 Profits: $37,500 Employees: 1,837 2000 Sales: $520,000 2000 Profits: $58,500 Fiscal Year Ends: 12/31 1999 Sales: $476,000 1999 Profits: $94,100 1998 Sales: $247,100 1998 Profits: $8,400
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $348,400 Bonus: $175,000 Stock Purch. Plan: Second Exec. Salary: $323,600 Bonus: $150,000 ADVANTAGE: Applies proprietary drug delivery technologies and formulation skills to the development of generic versions of brand name drugs.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
West:
Southwest:
Midwest:
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Northeast:
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
ANGIOTECH PHARMACEUTICALS
www.angiotech.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 201 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 91
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Inflammatory Disease Medical Device Coatings
Angiotech Pharmaceuticals, Inc. is a Canadian pharmaceutical company dedicated to the development of medical device coatings and treatments for chronic inflammatory diseases. These treatments are bas ed upon the company’s discovery that paclitaxel, one of the most commercially successful and clinically effective anticancer drugs ever produced, also blocks an important cellular pathway involved in inflammation. The firm is currently developing polymeric formulations to deliver paclitaxel as a stent coating for restenosis, an intravenous treatment for secondary progressive multiple sclerosis and rheumatoid arthritis and a topical gel for psoriasis. Other medical device programs include paclitaxel-loaded surgical implants for the treatment of restenosis associated with peripheral vascular surgery. The company has alliances with device manufactures to provide support in these developments. Boston Scientific Corp. and Cook, Inc. develop paclitaxel-coated stents, and C.R. Bard develops vascular wraps. Angiotech also has research collaborations with worldwide institutions to aid in its internal product research efforts. Recently, Angiotech signed a definitive agreement to acquire Cohesion Technologies, Inc., a biomaterials and biosurgical company. Under this agreement, Angiotech will gain Cohesion's product development and research, clinical experience, delivery systems and specialized sales force. Angiotech offers a comprehensive benefits package, along with training and professinal development programs, an employee fitness center and parking and transit passes.
BRANDS/DIVISIONS/AFFILIATES: Cohesion Technologies, Inc. Boston Scientific Alcon C.R. Bard Cook, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. William L. Hunter, CEO William L. Hunter, Pres. David M. Hall, CFO David D. McMasters, General Counsel/VP-Intellectual David Hartnett, Sr. VP-Oper. Jeanne M. Bertonis, VP-Corp. Dev. Rui Avelar, VP-Corp. Comm. Rui Avelar, VP-Investor Rel. David T. Howard, Chmn.
Phone: 604-221-7676 Fax: 604-221-2330 Toll-Free: Address: 6660 NW Marine Dr., Vancouver, BC V6T 1Z4 Canada
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $4,700 ( 9 months) 2002 Profits: $-11,700 ( 9 months) Stock Ticker: ANPI 2001 Sales: $ 700 2001 Profits: $-5,300 Employees: 56 2000 Sales: $2,900 2000 Profits: $-1,200 Fiscal Year Ends: 9/30 1999 Sales: $2,100 1999 Profits: $-6,474 1998 Sales: $ 500 1998 Profits: $-4,407
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Expertise in medical device coatings.
OTHER THOUGHTS:
Top Exec. Salary: $ Second Exec. Salary: $
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
West:
Southwest:
Midwest:
Bonus: $ Bonus: $
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Northeast:
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
ANIKA THERAPEUTICS INC
www.anikatherapeutics.com
Industry Group Code: 325414 Ranks within this company's industry group: Sales: 4 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Y
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 4
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Bone, Cartilage and Soft Tissue Tissue Repair Technology
Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products and devices intended to promote the protection and healing of bone, cartilage and soft tissue. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. Due to its unique biophysical and biochemical properties, HA plays an important role in a number of physiological functions, such as the protection and lubrication of soft tissues and joints, the maintenance of the structural integrity of tissues and the transport of molecules to and within cells. The company's currently marketed products consist of ORTHOVISC, an HA product used in the treatment of some forms of osteoarthritis in humans, and HYVISC, an HA product used in the treatment of equine osteoarthritis. ORTHOVISC is approved for sale and marketed in Canada, Europe, Turkey, Israel and Iceland. The company also manufactures AMVISC and AMVISC Plus, used as viscoelastic supplements in ophthalmic surgery, for Bausch & Lomb Surgical, a subsidiary of Bausch & Lomb. STAARVISC II, an injectable ophthalmic viscoelastic, is produced for STAAR Surgical Company, and ShellGel, also an injectable ophthalmic viscoelastic, is produced for Cytosol Ophthalmics, Inc. Anika is currently developing INCERT, an HA-based product designed for use in the prevention of post-surgical adhesions. Anika holds exclusive rights to manufacture OSSIGEL for Orquest, Inc. Recently, Anika announced a three-year supply agreement with a unit of Allergan, Inc. Allergan will market Anika's CoEase, a product used during opthalamic surgery, including cataract and intraocular lens implantation. In other news, the company signed an exclusive distribution agreement for ORTHOVISC in Canada with Rivex Pharma, Inc. and in the U.K. with Surgicraft, Ltd., a manufacturer and distributor of medical devices.
BRANDS/DIVISIONS/AFFILIATES: ORTHOVISC HYVISC INCERT AMVISC STAARVISC II ShellGel CoEase
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Charles H. Sherwood, CEO Charles H. Sherwood, Pres. William J. Knight, VP-Finance/CFO Bob Tellis, Sr. VP-Sales and Mktg. Scott P. Bruder, VP-Research and Dev. Frank Luppino, Exec. Dir.-Oper. Ed Gaj, Jr., Exec. Dir.-New Bus. Dev. William J. Knight, Treas. Ed Gaj, Jr., Exec. Dir.-Mktg.
Phone: 781-932-6616 Fax: 781-935-4120 Toll-Free: Address: 236 W. Cummings Park, Woburn, MA 01801 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $9,000 ( 9 months) 2002 Profits: $-3,700 ( 9 months) Stock Ticker: ANIK 2001 Sales: $11,300 2001 Profits: $-6,800 Employees: 67 2000 Sales: $16,335 2000 Profits: $ 174 Fiscal Year Ends: 12/31 1999 Sales: $13,500 1999 Profits: $-2,500 1998 Sales: $13,273 1998 Profits: $3,752
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $205,750 Stock Purch. Plan: Second Exec. Salary: $203,696 ADVANTAGE: Focus on unique technologies based on hyaluronic acid.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $54,500 Bonus: $54,500
Northeast: Y
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
ANTEX BIOLOGICS INC
www.antexbiologics.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 193 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev . Svcs.: Assays/Diagnostics:
Profits: 98
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Bacterial Infection Vaccines and Antibiotics
Antex Biologics, Inc. is a biopharmaceutical company committed to developing and marketing products to prevent and treat infections and related diseases. Its AntexPharma subsidiary focuses on developing new antibiotics with broad-spectrum activity as organismspecific antibacterial agents. Antex has developed three platform technologies. Antigen Receptor Technology (ART) and Nutriment Signal Transduction (NST) enhance the company’s ability to discover disease-specific proteins. The company has also developed a Virulence Expression Profiling (VEP) platform, which uses functional genomics to profile and identify disease-specific proteins. The firm’s Antex Proteomics subsidiary identifies vaccine and smallmolecule drug candidates for internal development and commercialization, in addition to establishing collaborations with other biotechnology companies for access to its database. Over the years, Antex has formed strategic alliances with major pharmaceutical companies. The company licensed Hin47 to Aventis Pasteur. It also established a strategic alliance with GlaxoSmithKline to develop and commercialize human bacterial vaccines. In addition, Antex entered into a cooperative research and development agreement with the U.S. Navy whereby the Navy will support and conduct clinical trials of CAMPYVAX, a vaccine to prevent diarrhea. AntexPharma also has a development and license agreement with the University of Maryland, Baltimore, for new peptides intended to treat serious symptoms related to lung disorders. Recently, Antex announced that two Phase II trials for its HELIVAX vaccine against Helicobacter pylori, a bacterial pathogen responsible for peptic ulcers and stomach cancers, are scheduled to begin. In other news, the company was issued three new patents: one from South America for a protein from the Neisseria family, the second from Singapore for a protein from the Moraxella catarrhalis bacteria family and the third from Mexico for the method of producing enhanced antigenic Helicobacter pylori bacteria. These new patents increase the company’s totals to 101 issued patents and 339 pending applications.
BRANDS/DIVISIONS/AFFILIATES: AntexPharma Antex Proteomics HELIVAX Hin47 CAMPYVAX Maryland Industrial Partnerships
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. V.M. Esposito, CEO Stephen N. Keith, COO Stephen N. Keith, Pres. Jeffrey V. Pirone, CFO/Exec. VP James Jackson, VP-Research Alan Liss, VP-Product Dev. Kyle W. Keese, VP-Bus. Dev.
Phone: 301-590-0129 Fax: 301-590-1251 Toll-Free: Address: 300 Professional Dr., Gaithersburg, MD 20879 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 300 ( 9 months) 2002 Profits: $-6,700 ( 9 months) Stock Ticker: ANX 2001 Sales: $ 900 2001 Profits: $-6,700 Employees: 36 2000 Sales: $ 349 2000 Profits: $-6,296 Fiscal Year Ends: 12/31 1999 Sales: $2,600 1999 Profits: $-3,500 1998 Sales: $4,500 1998 Profits: $-2,800
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $400,015 Stock Purch. Plan: Second Exec. Salary: $143,339 ADVANTAGE: Research and development agreement with the U.S. Navy.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $ Bonus: $
Northeast: Y
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
ANTIGENICS INC
www.antigenics.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 146 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 222
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Cancer, Infectious Disease and Autoimmune Disease
Antigenics is focused on therapeutic vaccines and treatments for cancer, infectious diseases and autoimmune disorders. The company’s lead development programs include immunotherapeutics based on a specific class of proteins, known as heat shock proteins, and an immune system adjuvant called QS-21. Oncophage, its lead product, uses proprietary heat shock protein technology to stimulate a powerful T cell-based immune response capable of targeting and killing cancer cells. It is currently in Phase III trials for treatment of renal cell carcinoma and melanoma. In addition, Antigenics is developing Aroplatin and ATRA-IV, unique liposomal formulations of anticancer drugs that are designed to offer improvements over existing cancer drugs. Antigenics is also developing immunotherapeutics to treat infectious diseases such as genital herpes, AIDS and tuberculosis and autoimmune disorders such as diabetes and multiple sclerosis. AG-702 is its heat shock protein-based therapy for genital herpes. The company has seven corporate partners that have licensed the QS-21 adjuvant for a variety of human diseases: GlaxoSmithKline, WyethLederle Vaccines, Aventis Pasteur, Progenics Pharmaceuticals, VaxGen, Elan Corporation and Korea Green Cross. These pharmaceutical and biotechnology companies are using QS-21 in their products developed for the treatment of several chronic and debilitating diseases, including malaria, hepatitis B, melanoma and HIV. Recently, Antigenics announced that the first patient has been enrolled in a Phase II study evaluating Aroplatin as a treatment for metastatic colorectal cancer. The trial will evaluate the effects of Aroplatin monotherapy in patients whose disease is not responsive to standard treatments. Additionally, the company acquired Aronex Pharmaceuticals, Inc., which adds two advanced-stage cancer products to its portfolio of trial programs.
BRANDS/DIVISIONS/AFFILIATES: Oncophage Aroplatin ATRA -IV QS-21 AG-702 Aronex Pharmaceuticals, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Garo Armen, CEO Russell Herndon, COO Russell Herndon, Pres. Jeff Rona, CFO Pramod K. Srivastava, Chief Scientific Officer Jonathan J. Lewis , Chief Medical Officer Neal F. Gordon, Sr. VP-Mfg. Oper. Deanna Petersen, VP-Bus. Dev. Garo Armen, Chmn.
Phone: 212-994-8200 Fax: 212-332-4778 Toll-Free: Address: 630 5th Ave., Ste. 2100, New York, NY 10111 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $2,700 ( 9 months) 2002 Profits: $-39,600 ( 9 months) Stock Ticker: AGEN 2001 Sales: $4,600 2001 Profits: $-73,500 Employees: 208 2000 Sales: $ 443 2000 Profits: $-46,729 Fiscal Year Ends: 12/31 1999 Sales: $ 100 1999 Profits: $-18,100 1998 Sales: $ 1998 Profits: $-8,900
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Focus on immune system therapies.
OTHER THOUGHTS:
Top Exec. Salary: $312,500 Second Exec. Salary: $182,500
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $93,750 Bonus: $30,000
Northeast: Y
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
APHTON CORP
www.aphton.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 186 Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Gastrointestinal and Reproductive-System Disease Anti-Hormone Therapy
Aphton Corporation is a biopharmaceutical company that is developing products using its innovative vaccine-like technology for neutralizing and eliminating hormones that participate in gastrointestinal system and reproductive system diseases. The firm is also developing products for neutralizing hormones in order to prevent pregnancy. The company’s lead products include G-17, GnRH Pharmaccine and immuno-contraception. G-17 is being used to treat advanced pancreatic, stomach, esophagus and colorectal cancers. It is also being tested for the treatment of gastro-intestinal ulcerations and gastroesophageal reflux disease. Aphton has a strategic alliance with Aventis Pasteur for all cancer applications of G-17 immunogen in North America, Mexico and Europe. GnRH Pharmaccine is being developed to treat reproductive system cancers including prostate cancer. The company has a strategic alliance with GlaxoSmithKline for all human applications of GnRH Pharmaccine. Aphton's immuno-contraceptive product, which prevents pregnancy, is in phase II trials, funded by the World Health Organization. Immuno-contraception neutralizes the female hormone known as hCG. Aphton also belongs to an alliance with Schering-Plough, a worldwide pharmaceutical company, for all animal applications of its anti-gastrin immunogen. Recently, Aphton received approval to initiate a clinical trial in Europe for patients suffering from gastroesophageal reflux disease.
BRANDS/DIVISIONS/AFFILIATES: GnRH Pharmaccine G17
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Philip C. Gevas, Co-CEO Philip C. Gevas, Pres. Douglas A. Eayers, CFO Sue A. Russell, Dir.-Human Resources Richard Ascione, VP/Dir.-Laboratory Molecular Medicine Frederick W. Jacobs , Chief Accounting Officer Dov Michaeli, Chief Medical Officer/Dir.-Medical Science Peter Blackburn, VP-Mfg. Theo de Roij, VP-Bus. and Product Dev. Jeannette L. Whitmore, VP-Corp. Comm. Jeannette L. Whitmore, VP-Investor Rel. Frederick W. Jacobs , VP/Treas. William A. Hasler, Co-CEO Paul Broome, VP-Clinical Trials and Regulatory Affairs, Europe Peter Blackburn, VP-Program Dev. Donald Henderson, VP/Managing Dir.-Finance and Admin., Europe Philip C. Gevas, Chmn.
Phone: 305-374-7338 Fax: 305-374-7615 Toll-Free: 877-274-8660 Address: 80 SW 8th St., Ste. 2160, Miami, FL 33130 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $-30,845 ( months) Stock Ticker: APHT 2001 Sales: $ 2001 Profits: $-31,300 Employees: 50 2000 Sales: $ 2000 Profits: $-11,200 Fiscal Year Ends: 1/31 1999 Sales: $ 1999 Profits: $-9,800 1998 Sales: $ 1998 Profits: $-6,600
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $183,333 Stock Purch. Plan: Second Exec. Salary: $165,000 ADVANTAGE: Innovative vaccine-like technology/Significant alliances.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
West:
Southwest: Y
Midwest:
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $183,333 Bonus: $
Northeast:
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
APPLERA CORPORATION
www.applera.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales: 3 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Y Y
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Y
TYPES OF BUSINESS:
Profits: 7
Computers: Hardware: Software: Arrays: Database Management:
Y Y
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Equipment-Life Sciences and Genomics Genetic Database Management Proteomics Medical Software Microbial Populations DNA Sequencing Organic Synthesis High Throughput Screening
Applera Corporation, formerly known as PE Corporation, provides leading technology and information solutions that help life scientists understand and use the power of biology. Two divisions of the company, Applied Biosystems and Celera Genomics integrated to form a separate joint venture, Celera Diagnostics. Applied Biosystems is principally engaged in the development, manufacture, sale and service of instrument systems and associated consumable products for life science research and related applications. Its products are used in applications including the synthesis, amplification, purification, isolation, analysis and sequencing of nucleic acids, proteins and other biological molecules. Celera Genomics is principally engaged in integrating high throughput technologies to create therapeutic discovery and development capabilities for internal use and for its customers and collaborators. Celera Genomics' lines of business are online information and therapeutic discovery. Pharmaceutical, biotechnology and academic customers use this information, along with the firm’s customized information technology solutions, to enhance their capabilities in the fields of life science research and pharmaceutical and diagnostic discovery and development. Celera Genomics intends to leverage its capabilities in genomics, proteomics and bioinformatics, both in internal programs and through collaborations, to identify drug targets and diagnostic markers and to discover and develop novel therapeutic candidates. Celera Diagnostics focuses on the discovery, development and commercialization of novel diagnostic tests in order to pursue new methods for diagnosing and treating disease. The Applera groups recently announced a collaboration with Myriad Proteomics and the Institute for Systems Biology to develop more effective measures of medical research and solutions. Applera offers its employees an educational assistance plan, travel accident insurance, basic and supplemental life insurance and an adoption assistance program.
BRANDS/DIVISIONS/AFFILIATES: PE Corporation Applied Biosystems Celera Genomics Millipore Corporation Diversa Corporation Celera Diagnostics
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Tony L. White, CEO Tony L. White, Pres. Dennis L. Winger, CFO/Sr. VP Barbara J. Kerr, VP-Human Resources Ronald D. Edelstein, CIO Vikram Jog, Corp. Controller William B. Sawch, General Counsel/Sr. VP Kenneth D. Noonan, VP-Corp. Dev. John S. Ostaszewski, Treas. Michael W. Hunkapiller, Pres., Applied Biosystems Group/Sr. VP J. Craig Venter, Pres./Chief Scientific Officer, Celera Genomics Kathy P. Ordonez, Sr. VP/Pres.-Celera Genomics and Celera Diagnostic Elaine J. Heron, VP-PE Biosystems
Phone: 203-840-2000 Fax: 203-762-6000 Toll-Free: 800-761-5381 Address: 301 Merritt 7, Norwalk, CT 06856-5435 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,701,218 (12 months) 2002 Profits: $-40,581 (12 months) Stock Ticker: Private 2001 Sales: $1,644,100 2001 Profits: $27,200 Employees: 5,544 2000 Sales: $1,371,000 2000 Profits: $95,500 Fiscal Year Ends: 6/30 1999 Sales: $1,216,900 1999 Profits: $175,900 1998 Sales: $1,531,200 1998 Profits: $56,400
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: Y ADVANTAGE: Cutting edge genomics technology.
OTHER THOUGHTS:
Top Exec. Salary: $984,615 Second Exec. Salary: $529,307
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
West: Y
Southwest: Y
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $1,150,000 Bonus: $462,977
Northeast: Y
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
APPLIED MOLECULAR EVOLUTION INCwww.amevolution.com Industry Group Code: 541710 Ranks within this company's industry group: Sales: 36 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Y Y
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Y
TYPES OF BUSINESS:
Profits: 16
Computers: Hardware: Software: Arrays: Database Management:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Research and Development-Directed Evolution Biopharmaceuticals Human Biotherapeutics Drugs-Small Molecule
Applied Molecular Evolution, Inc. (AME) is a leader in the application of directed evolution to the development of biotherapeutics. The company uses its proprietary system technology to develop improved versions of currently marketed, FDA-approved biopharmaceuticals as well as novel human biotherapeutics. It does so by adjusting amino acids in individual proteins to create positive characteristics. There are three components to the AMEsystem technology. DirectAME is a gene synthesis process that enables the rapid production of a library of variant genes based on an initial gene. ExpressAME consists of gene expression systems that efficiently produce proteins from the genes generated using DirectAME. SelectAME is a series of tests or screens which facilitate the selection and identification of proteins with the optimal, desired commercial properties from the protein libraries produced using ExpressAME. AME has collaborations with leading developers of biotherapeutics including Centocor, Lilly, Chiron, MedImmune, BristolMyers Squibb, Seattle Genetics, Cell Matrix and Bios ynexus. The company also has academic collaborations with University of Nebraska Medical Center, The Mayo Clinic, Scripps Research Institute and MD Anderson Cancer Center. Recently, AME granted NascaCell GmbH a non-exclusive, worldwide license to its Kauffman patents for directed molecular evolution. NascaCell will use the licensed technology to generate aptamers, antibody-like nucleic acids that specifically bind to and inactivate target molecules. The company also entered into an agreement to engineer an antibody therapeutic for Centocor, Inc. AME will apply its technology to optimize the function of the antibody Centocor provides. AME also recently agreed to optimize another therapeutic antibody candidate for Eli Lilly. Among its flexible, comprehensive benefits, AME offers educational assistance and a private corporate fitness center.
BRANDS/DIVISIONS/AFFILIATES: AME System DirectAME ExpressAME SelectAME
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. William D. Huse, CEO William D. Huse, Pres. Lawrence E. Bloch, CFO Jeffry D. Watkins, Chief Scientific Officer James B. Breitmeyer, Chief Medical Officer Lawrence E. Bloch, Corp. Sec. William L. Respess, VP/General Counsel Keith S. Manchester, VP-Bus. Dev. Chris Erdman, Dir.-Corp. Comm. William D. Huse, Chmn.
Phone: 858-597-4990 Fax: 858-597-4950 Toll-Free: Address: 3520 Dunhill St., San Diego, CA 92121 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $5,652 ( 9 months) 2002 Profits: $-13,463 ( 9 months) Stock Ticker: AMEV 2001 Sales: $3,600 2001 Profits: $-13,200 Employees: 83 2000 Sales: $2,693 2000 Profits: $-13,559 Fiscal Year Ends: 12/31 1999 Sales: $2,600 1999 Profits: $-3,376 1998 Sales: $2,600 1998 Profits: $-1,900
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $285,000 Stock Purch. Plan: Y Second Exec. Salary: $175,000 ADVANTAGE: Leader in directed cell evolution/AME system technology.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $109,725 Bonus: $57,750
Northeast:
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
ARENA PHARMACEUTICALS INC
www.arenapharm.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 94 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Y
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Y
TYPES OF BUSINESS:
Profits: 99
Computers: Hardware: Software: Arrays: Database Management:
Y
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Drug Discovery Database Management Drugs-Receptor Based
Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused principally on discovering and developing drugs that target G protein-coupled receptors, called GPCRs. The company applies its proprietary CART technology in order to discover these receptor-based drugs. Moreover, the company has developed a webbased database that can be used to access relevant information and data generated from its research and development programs. The database allows individual users to obtain information on specific G protein-coupled receptor (GPCR) targets, including gene sequence information, the results of drug screening and the results of animal studies. Arena has entered into drug discovery and development collaborative arrangements with many leading pharmaceutical and biotechnology companies, including Eli Lilly, Taisho Pharmaceutical Co., Ltd., Fujisawa Pharmaceutical Co., Ltd., and TaiGen Biotechnology Co., Ltd. BRL Screening, Inc., a subsidiary of the company, acquired Bunsen Rush Laboratories, Inc., a research-based company that provided screening for the pharmaceutical and biotechnology industries using proprietary and patented Melanophore Technology. Arena has an ongoing program directed towards the development of novel anti-obesity drugs. It has also identified several orphan GPCRs, which are believed to represent therapeutic targets for the treatment of a variety of cancers, including ovarian, colorectal, gastrointestinal and uterine cancer. Other identified orphan GPCRs target cardiovascular disease, diabetes, inflammation and Alzheimer’s disease. Recently, Arena entered into a multiyear research and licensing agreement with Merck & Co., Inc. The company will utilize Arena's CART and Melanophore technologies along with its chemistry group to discover and commercialize compounds with therapeutic capability. Arena offers its employees medical, life and disability insurance and flexible spending accounts.
BRANDS/DIVISIONS/AFFILIATES: CART Technology Melanophore Technology BRL Screening, Inc. Bunsen Rush Laboratories, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Jack Lief, CEO Jack Lief, Pres. Joseph F. Mooney, CFO Dominic P. Behan, VP-Research Steven W. Spector, Corp. Sec./VP Steven W. Spector, General Counsel Louis J. Scotti, VP-Bus. Dev. Joyce H. Williams , VP-Drug Dev. Robert Hoffman, VP-Finance Nigel Beeley, Chief Chemical Officer Derek T. Chalmers, VP-Research
Phone: 858-453-7200 Fax: 858-453-7210 Toll-Free: Address: 6166 Nancy Ridge Dr., San Diego, CA 92121 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $13,057 ( 9 months) 2002 Profits: $-24,051 ( 9 months) Stock Ticker: ARNA 2001 Sales: $18,100 2001 Profits: $-6,900 Employees: 209 2000 Sales: $7,683 2000 Profits: $-6,362 Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $-10,200 1998 Sales: $ 1998 Profits: $-3,400
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $502,083 Stock Purch. Plan: Second Exec. Salary: $262,083 ADVANTAGE: Proprietary CART technology for drug discovery.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $ Bonus: $55,000
Northeast:
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
ARIAD PHARMACEUTICALS
www.ariad.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 189 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 156
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Diversified Small-Molecule Drugs Oncology and Hematology Products Osteoporosis Products
ARIAD Pharmaceuticals, Inc. is engaged in the discovery and development of breakthrough medicines that regulate cell signaling with small molecules. The company has seven lead product candidates, including a drug candidate, AP23573, that controls cell proliferation and nutrient uptake to tumors to treat cancer; a bone-targeted drug candidate, AP23451, to treat the complications of cancer that has spread to bone; a regulated protein therapy product to treat anemia, AP22594; a T cell immunotherapy product in which a nonimmunosuppresant drug, AP1903, may be used to treat graft-vs-host disease; and a dual-action drug candidate, AP23485, that blocks bone resorption and stimulates bone formation to treat osteoporosis. ARIAD's strategy includes developing its current lead products at least through phase 2 clinical trials; establishing the commercial infrastructure to market its portfolio of hematology and oncology products in the U.S.; and pursuing a worldwide partner for its os teoporosis candidate and partners for hematology and oncology products outside the U.S. The firm's RegTech cell-signaling regulation technologies are already being used in over 500 academic investigations and are the subject of more than 120 published papers in the scientific literature. In recent news, the firm announced the discovery of a novel anti-cancer product candidate designed to treat the progression and spread of solid tumors, such as colon cancer. ARIAD also recently announced findings that make possible the use of stem cell therapy to potentially cure genetic blood diseases, such as sickle cell disease, as well as chronic diseases including congestive heart failure and diabetes. Ariad offers its employees benefits including tuition reimbursem ent, stock options and medical, dental and life insurance, as well as free parking or subway passes.
BRANDS/DIVISIONS/AFFILIATES: Ariad Gene Therapeutics RegTech ARGENT Signaling ARGENT Transcription RPD Secretion Technologies AP23573 AP23451 AP22594
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Harvey J. Berger, CEO Harvey J. Berger, Pres. Edward M. Fitzgerald, Sr. VP/CFO Kathy Lawton, Mgr.-Human Resources Timothy P. Clackson, Sr. VP-Science and Tech. Joseph Bratica, Controller Camille Bedrosian, VP/Chief Medical Officer Laurie A. Allen, Sr. VP/Corp. Sec. Laurie A. Allen, Chief Legal Officer Thomas A. Pearson, Sr. VP-Corp. Strategy Thomas A. Pearson, Sr. VP-Corp. Comm. Edward M. Fitzgerald, Treas. John D. Iuliucci, Sr. VP-Drug Dev. Tomi K. Sawyer, VP-Drug Discovery David L. Bernstein, Sr. VP/Chief Patent Officer Fritz Casselman, Sr. VP/Chief Bus. Officer Harvey J. Berger, Chmn.
Phone: 617-494-0400 Fax: 617-494-8144 Toll-Free: Address: 26 Landsdowne St., Cambridge, MA 02139-4234 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 25 ( 9 months) 2002 Profits: $-21,029 ( 9 months) Stock Ticker: ARIA 2001 Sales: $1,000 2001 Profits: $-19,800 Employees: 69 2000 Sales: $2,178 2000 Profits: $-13,832 Fiscal Year Ends: 12/31 1999 Sales: $12,913 1999 Profits: $24,200 1998 Sales: $13,100 1998 Profits: $-26,100
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $395,000 Stock Purch. Plan: Y Second Exec. Salary: $221,000 ADVANTAGE: Extensive list of products in development.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $ Bonus: $60,000
Northeast: Y
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
ARQULE INC
www.arqule.com
Industry Group Code: 541710 Ranks within this company's industry group: Sales: 12 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Y
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Y
TYPES OF BUSINESS:
Profits: 28
Computers: Hardware: Software: Arrays: Database Management:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Research-Drug Discovery High-Throughput Chemical Compound Research
ArQule seeks to bridge the gap between genomics and clinical development by applying its proprietary technology platform and world-class chemistry capabilities to drug discovery. Discovering new compounds to test is a major obstacle to drug companies. Due in part to the lack of early information about lead compounds and the lack of alternative chemotypes, very few lead compounds meet the minimum criteria to become clinical candidates. Additionally, too many approved lead compounds are only marginally acceptable clinical candidates and are therefore more likely to fail during clinical development. In order to solve these problems, ArQule has developed the AMAP Chemistry Operating System, which allows it to perform high-throughput, automated production of new chemical compounds. The AMAP system forms the foundation of the company’s parallel synthesis approach to combinatorial chemistry. AMAP consists of an integrated series of automated workstations that perform tasks such as weighing and dissolution, chemical synthesis, thermally controlled agitation and reaction process development. The AMAP system also incorporates purification, quality control, the ability to reformat libraries and the ability to replicate libraries for multiple customers. ArQule’s proprietary Array Information Management and Process Control Management System (AIMS/PCMS) software controls and monitors the overall production process within the system. The software allows the firm to capture information about every compound in the library, as well as to process this information and to audit test data. The company's clients include Bayer, Johnson & Johnson, Pfizer and Pharmacia Corporation. As part of its strategic growth plan, the firm completed a merger with Camitro Corporation, a predictive modeling company.
BRANDS/DIVISIONS/AFFILIATES: AMAP Chemistry Operating System AIMS/PCMS Camitro Corporation Sankyo Company, Ltd. Compass and Mapping Array Libraries Directed Array
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Stephen A. Hill, CEO Stephen A. Hill, Pres. David C. Hastings, CFO Anthony S. Messina, VP-Human Dev. Philippe Bey, Chief Scientific Officer Alan L. Hillyard, CIO J. David Jacobs, VP-Legal/General Counsel Michael Rivard, VP-Strategic Dev. Jean M. Devine, Director-Investor Rel. David C. Hastings, Treas. Carmen M. Baldino, V P-Chemistry Sheila H. DeWitt, VP- Drug Discovery Philippe Bey, Sr. VP-Research and Dev.
Phone: 781-994-0300 Fax: 781-376-6019 Toll-Free: Address: 19 Presidential Way, Woburn, MA 01801-5140 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $46,658 ( 9 months) 2002 Profits: $-18,700 ( 9 months) Stock Ticker: ARQL 2001 Sales: $58,400 2001 Profits: $-41,000 Employees: 385 2000 Sales: $50,300 2000 Profits: $3,900 Fiscal Year Ends: 12/31 1999 Sales: $18,600 1999 Profits: $-17,400 1998 Sales: $22,200 1998 Profits: $-6,500
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $328,462 Stock Purch. Plan: Y Second Exec. Salary: $245,686 ADVANTAGE: Superior, proprietary technology/Strong client base.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $140,000 Bonus: $84,000
Northeast: Y
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
ASCENT PEDIATRICS INC
www.ascentpediatrics.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Reformulated Pediatric Drugs
Ascent Pedriatics is engaged in the development and marketing of pharmaceuticals for use in the treatment of common pediatric illnesses. Ascent seeks to develop a broad line of products that are based on commonlyprescribed off-patent pharmaceuticals, attempting to improve the products by reducing their dosing frequency, improving their taste, making them easier to administer or developing them as substitutes for products with considerable side effects. Ascent also specializes in taste masking, which involves the removal or masking of an objectionable or unpleasant taste of various common ingredients used in pediatric pharmaceuticals. The company believes that a drug's taste is a critical factor in pediatric patient compliance, particularly when frequent dosing is required. In late 1999, the firm devoted its resources to obtaining regulatory approval of Primsol and Orapred and currently is preparing for the commercial launch of these products. Ascent also entered into a strategic alliance with Alpharma, Inc. in which Ascent will borrow $40 million to finance its growing operations.
BRANDS/DIVISIONS/AFFILIATES: Feverall Alpharma Primsol Orapred
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Alan R. Fox, CEO Alan R. Fox, Pres. Eliot Lurier, VP/CFO Gregory A. Vannatter, VP-Mktg. And Business Diane Worrick, VP-Human Resources Mumtaz Ahmed, VP-Medical Affairs Bobby R. Owen, VP-Oper. William E. Brochu, VP-Regulatory and Quality Affairs Steve Evans, National Sales Dir.
Phone: 978-658-2500 Fax: 978-658-3939 Toll-Free: Address: 187 Ballardvale St., Ste. B125, Wilmington, MA 01887 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: Subsidiary 2001 Sales: $ 2001 Profits: $ Employees: 2000 Sales: $4,464 2000 Profits: $-14,339 Fiscal Year Ends: 12/31 1999 Sales: $7,048 1999 Profits: $-15,653 1998 Sales: $4,476 1998 Profits: $-18,231
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Unique strategy to improve existing drugs for use by children.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
West:
Southwest:
Midwest:
Bonus: $ Bonus: $
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Northeast: Y
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
ASTRAZENECA PLC
www.astrazeneca.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 6 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 11
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Diversified Pharmaceutical Manufacturing Therapeutic Drugs
AstraZeneca is a leading pharmaceutical company that provides innovative, effective products to fight disease in areas of medical necessity. Formed in 1999, the company is the result of the merger of the Zeneca Group with Astra. The company focuses on therapeutic interventions in cardiovascular, central nervous system, gastrointestinal, infection, oncology, pain control and anesthesia and respiratory areas. The firm’s product lines include Accolate, Atacand, Casodex, Diprivan, EMLA, Nolvadex, Prilosec, Rhinocort and Zomig, to name a few. The United Kingdom -based company conducts business in Sweden, the U.K. and the United States. AstraZeneca’s research facilities are the Bioinformatics Centre, the AstraZeneca Transgenic Centre and the AstraZeneca Biotech Laboratory. The company recently announced it received the U.S. patent rights for Nolvadex, a drug developed for the treatment of breas t cancer. Additionally, the company received FDA approval for Faslodex, another treatment for breast cancer, and Atacand HCT, a therapeutic drug for hypertension. The FDA also approved Symbicort Turbuhaler for the treatment of asthma and Pulmicort Respules, a breakthrough in the treatment of asthma in children and infants.
BRANDS/DIVISIONS/AFFILIATES: Bioinformatics Centre Novartis Agribusiness Pulmicort Respules Accolate Faslodex Diprivan Prilosec Zeneca Group
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Tom McKillop, CEO Johnathan Symonds, CFO Michael O'Brien, Exec. VP-Int'l Sales & Mktg. Tony Thorpe, Human Resources Claes Wilhelmsson, Exec. Dir.-Research & Dev. Barrie Thorpe, Exec. VP-Oper. Ake Stavling, Exec. Dir.-Bus. Dev. & Integration David Brennan, VP-North America Bruno Angelici, VP-Europe and Row John Patterson, Exec. VP
Phone: +44-20-77304-500 Fax: +44-20-77304-515 Toll-Free: Address: 15 Stanhope Gate, London, W1 Y6LN UK
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $13,153,000 ( 9 months) 2002 Profits: $2,408,000 ( 9 months) Stock Ticker: AZN 2001 Sales: $16,480,000 2001 Profits: $1,097,000 Employees: 54,600 2000 Sales: $18,103,000 2000 Pr ofits: $865,000 Fiscal Year Ends: 12/31 1999 Sales: $18,445,000 1999 Profits: $-3,539,000 1998 Sales: $15,402,000 1998 Profits: $1,036,000
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Produces Prilosec for treating ulcers.
OTHER THOUGHTS:
Top Exec. Salary: $1,191,000 Second Exec. Salary: $732,000
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $588,000 Bonus: $347,000
Northeast: Y
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
ATLANTIC TECHNOLOGY VENTURES Industry Group Code: 325412 Ranks within this company's industry group: Sales: 164 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
www.atlan.com Profits: 67
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
Y
GROWTH PLANS/SPECIAL FEATURES:
Investments in Biotech Firms Pharmaceutical Development
Atlantic Technology Ventures is a diversified pharmaceutical development company with a variety of goals. The firm seeks to identify early development-stage biomedical, pharmaceutical or medical devices or other technologies and to acquire proprietary rights, fund research and development efforts and bring the resulting products to market. Atlantic focuses its efforts on drugs used for the treatment of cancer, infectious disease, ophthalmic disorders, pain and inflammation. Its scope of operations has recently expanded to include the commercialization of a broad portfolio of patented technologies. The firm’s name, previously Atlantic Pharmaceuticals, changed in accordance with these efforts. Recently, the firm’s majority-owned subsidiary, Optex, sold to Bausch & Lomb substantially all of its assets including those related to the Catarex technology. Aside from ophthalmic efforts, Atlantic Technology Ventures’ pain and inflammation developments are substantial. The firm is currently developing its proprietary compound CT-3 as an alternative to nonsteroidal antiinflammatory drugs such as asprin or ibuprofen. Atlantic is conducting additional preclinical tests to study the analgesic activity of CT-3, particularly with reference to neuropathic pain. The company is also preparing to conduct Phase II clinical trials to evaluate the efficacy of CT-3 in multiple-sclerosis -associated tremors and spasticity. Recently, Atlantic Technology Ventures licensed from its inventors the worldwide rights to ATV-02, an antimicrobial agent for the local treatment of topical infections. The company also recently licensed the exclusive worldwide rights for CT-3 to Indevus Pharmaceuticals. Indevus is now responsible for the clinical development, regulatory activities and commercialization of this compound.
BRANDS/DIVISIONS/AFFILIATES: ATV-02 Optex Atlantic Pharmaceuticals CT-3
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Frederic P. Zotos, CEO Fredrick P. Zotos, Pres. Nicholas J. Rossettos, CFO A. Joseph Rudick, Chief Scientific Officer A. Joseph Rudick, Chief Medical Officer Nicholas J. Rossettos, Corp. Sec. Michael L. Ferrari, VP-Bus. Dev. Nicholas J. Rossettos, Treas.
Phone: 212-267-2503 Fax: 212-267-2159 Toll-Free: Address: 350 5th Ave., Ste. 5507, New York, NY 10118 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 500 ( 9 months) 2002 Profits: $-1,176 ( 9 months) Stock Ticker: ATLC.OB 2001 Sales: $2,700 2001 Profits: $-1,700 Employees: 5 2000 Sales: $5,359 2000 Profits: $-5,802 Fiscal Year Ends: 12/31 1999 Sales: $1,200 1999 Profits: $-2,400 1998 Sales: $3,000 1998 Profits: $-2,800
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $208,750 Stock Purch. Plan: Second Exec. Salary: $125,000 ADVANTAGE: Increased commercialization of its patented technologies.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $50,000 Bonus: $25,000
Northeast: Y
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
ATRIX LABORATORIES INC
www.atrixlabs.com
Industry Group Code: 325411 Ranks within this company's industry group: Sales: 4 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 12
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Equipment-Dental/Periodontol Drug Delivery Systems Oncology Products Pain Management Products Veterinary Products
Atrix Laboratories is engaged in the research, development and commercialization of a broad range of medical, dental and veterinary products based on its proprietary drug delivery systems. Its five patented drug delivery technologies involve proprietary oncology, pain management, growth hormone releasing peptide-1, oral interferon and dermatology products. Atrigel is a release implant for local or systemic delivery of drugs, proteins and peptides from minutes to months. Bema is used in the delivery of drugs from minutes to hours. SMP is a topical gel providing two-stage dermal delivery of water insoluble drugs. MCA is a water-resistant topical gel providing sustained drug delivery. BCP is a non-cytotoxic gel/liquid for topical delivery. Atrix has significant strategic alliances with companies including Pfizer, Inc., SanofiSynthelabo, Inc., MediGene AG, Fujisawa Healthcare, Inc., Elan International Services, Ltd., Geneva Pharmaceuticals, Inc. and CollaGenex Pharmaceuticals, Inc. Atrix executed a non-exclusive comprehensive research and worldwide licensing agreement with Pfizer to provide broad-based access to its proprietary drug delivery systems in the development of new products. Recently, Pfizer submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for a novel bone growth product which uses Atrix's proprietary Atrigel drug delivery technology. Atrix also formed a joint venture with Elan Corporation to develop and commercialize oncology and pain management products. The joint venture will utilize Atrix’s Bema and Atrigel systems to control side effects caused by chemotherapy, radiation therapy, breakthrough cancer pain and tumor-directed cytotoxic agents. In other news, Atrix entered into an exclusive North American marketing agreement with EmerGen, Inc. for a leuprolide product for the treatment of endometriosis . The company also launched Eligard 22.5mg, a new product for the treatment of advanced prostate cancer. Atrix Laboratories provide its employees with health and dental benefits and tuition assistance.
BRANDS/DIVISIONS/AFFILIATES: Atridox Atrisorb Gtr Atrigel Elan Corp. Eligard Bema ViroTex SMP
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David R. Bethune, CEO Brian G. Richmond, CFO Stephen L. Warren, VP-Research and Dev. Michael R. Duncan, VP-Technical Oper. Michael R. Duncan, VP-Mfg. Brian G. Richmond, Corp. Sec. Charles P. Cox, Sr. VP-Corp. Dev. Brian G. Richmond, Treas. Richard L. Dunn, Principle Research Scientist Mark D. Sweeney , VP-Quality Assurance David W. Osborne, VP-Dermatology Div. J. Steven Garrett, VP-Dental Div. David R. Bethune, Chmn.
Phone: 970-482-5868 Fax: 970-482-9735 Toll-Free: Address: 2579 Midpoint Dr., Fort Collins , CO 80525 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $19,135 ( 9 months) 2002 Profits: $-12,807 ( 9 months) Stock Ticker: ATRX 2001 Sales: $15,800 2001 Profits: $-25,500 Employees: 148 2000 Sales: $10,043 2000 Profits: $-47,411 Fiscal Year Ends: 12/31 1999 Sales: $5,600 1999 Profits: $-13,200 1998 Sales: $21,100 1998 Profits: $1,700
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $271,667 Stock Purch. Plan: Y Second Exec. Salary: $260,000 ADVANTAGE: Holds several patents relating to drug delivery technology..
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $ Bonus: $
Northeast:
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
AUTOIMMUNE INC
www.autoimmuneinc.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 182 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Sv cs.: Assays/Diagnostics:
Profits: 54
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs -Immune System and Inflammatory Dis ease
AutoImmune, Inc., a biopharmaceutical company, focuses on the development of a new class of therapeutics for the treatment of autoimmune and other cell -mediated inflammatory diseases and conditions. The firm’s preclinical and clinical data indicates that its proprietary approach to therapy can induce tissue-specific immunosuppression without toxicity or significant side effects. Additional clinical and commercial advantages of the firm's approach include the possibility of administering products orally (the preferred method for treating chronic diseases) and the potential for application to a variety of inflammatory diseases and conditions. The company’s products are based upon the principles of mucosal tolerance. When proteins are administered by a mucosal route (e.g., oral, nasal or by aerosol to the lungs) the body's natural immune system mechanisms suppress the response that would otherwise arise against a foreign substance. This immune suppression can be directed toward a specific tissue through appropriate selection and dosing of the protein in a mucosally delivered product. To date, AutoImmune has completed 10 human clinical trials of Colloral (its principal product) involving over 1,900 patients to investigate its use in treating rheumatoid arthritis. AutoImmune also completed a market analysis for Colloral as a nutraceutical product. The company recently announced the formation of Colloral, LLC, a joint venture with Deseret Laboratories International, for the manufacture, marketing and sale of Colloral. AutoImmune has license agreements with Teva Pharmaceutical Industries, Ltd. and BioMS Medical Corporation. Teva is working on an oral formulation of Copaxone and BioMS Medical Corporation is analyzing results from the phase II trial of AutoImmune's MBP8298 product for the treatment of chronic progressive multiple sclerosis.
BRANDS/DIVISIONS/AFFILIATES: Colloral Colloral, LLC Deseret Laboratories International Copaxone MBP8298
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Robert C. Bishop, CEO Robert C. Bishop, Pres. Heather A. Ellerkamp , Dir.-Finance Heather A. Ellerkamp , Treas. Robert C. Bishop, Chmn.
Phone: 626-792-1235 Fax: 626-792-1236 Toll- Free: Address: 1199 Madia St., Pasadena , CA 91103 US
FINANCIALS:
Sales and profits are in thousands of dollars —add 000 to get the full amount . Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 300 ( 9 months) 2002 Profits: $- 638 ( 9 months) Stock Ticker: AIMM 2001 Sales: $1,300 2001 Profits: $ 800 Employees: 2000 Sales: $4,010 2000 Profits: $3,148 Fiscal Year Ends: 12/31 1999 Sales: $ 1999 Profits: $-10,700 1998 Sales: $ 1998 Profits: $-13,200
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $113,245 Bonus: $ Stock Purch. Plan: Second Exec. Salary: $45,683 Bonus: $ ADVANTAGE: Innovative therapeutics for the treatment of autoimmune and other cell-mediated diseases.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors : 1 Hot Spot for Advancement for Women/Minorities :
West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Northeast:
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
AVANIR PHARMACEUTICALS
www.avanir.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 103 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Y
TYPES OF BUSINESS:
Profits: 59
Computers: Hardware: Software: Arrays: Database Management:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Oral Herpes Human Antibody Technology Research Central Nervous System Research Allergy and Asthma Drugs
Avanir Pharmaceuticals is engaged in research, development, commercialization, licensing and sales of innovative drug products and antibody generation services. Avanir’s subsidiary, Xenerex Biosciences, is engaged in research collaborations with partner companies for developing and commercializing completely human antibody products to target antigens. The company’s lead product, Abreva cream, is a topical treatment for oral-facial herpes (more commonly known as cold sores or fever blisters). Abreva’s performance claims were approved by the FDA, making the drug the first overthe-counter product for cold sore treatment with such approval. GlaxoSmithKline is the marketing partner for the Abreva product in the U.S. and Canada. Beyond cold sore medications, Avanir develops asthma and allergy pharmaceuticals. Using a combination of tissue culture, in vitro assays and in vivo models, the firm has screened and identified several active candidate compounds that appear to be significantly selective and specific in their inhibition of human responses to allergens. Avanir has filed several patent applications for its candidate compounds. Avanir also conducts central nervous system research and human antibody technology development. Neurodex, a medication for the treatment of emotional lability in neurodegenerative diseases, neuropathic pain and chronic cough is currently under trial. Cholesterol-lowering and inflammation drugs and work on genital herpes medications are in development as well. Avanir has agreements with several companies for the promotion of Docosanol 10% cream and Neurodex, including Biopharm Group, CTS Chemical Industries, Ltd., Medison Pharma, Ltd. and Shanghai New Asiatic Pharmaceutical Co., Ltd. In recent news, Xenerex Biosciences was awarded funding from the Center for Commercialization of Advanced Technology (CCAT) to develop a treatment that will reduce the damaging effects of exposure to anthrax toxins. Avanir offers a competitive benefits package, including medical, dental and vision insurance.
BRANDS/DIVISIONS/AFFILIATES: Xenerex Biosciences Abreva Dososanal Neurodex
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Gerald J. Yakatan, CEO Gerald J. Yakatan, Pres. Gregory P. Hansen, VP/CFO James E. Berg, VP-Clinical and Regulatory Affairs Gregory P. Hansen, Corp. Sec. J. David Hansen, Pres./COO, Xenerex Biosciences J. David Hansen, VP-Commercial Dev.
Phone: 858-622-5200 Fax: 858-658-7447 Toll-Free: Address: 11388 Sorrento Valley Rd., Ste. 200, San Diego, CA 92121 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $7,600 ( 9 months) 2002 Profits: $-5,800 ( 9 months) Stock Ticker: AVN 2001 Sales: $12,700 2001 Profits: $ 200 Employees: 44 2000 Sales: $10,687 2000 Profits: $- 582 Fiscal Year Ends: 9/30 1999 Sales: $ 100 1999 Profits: $-8,600 1998 Sales: $ 600 1998 Profits: $-8,200
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $388,462 Stock Purch. Plan: Second Exec. Salary: $213,462 ADVANTAGE: Novel therapeutic products to treat chronic illness.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $100,000 Bonus: $
Northeast:
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
AVANT IMMUNOTHERAPEUTICS
www.avantimmune.com
Industry Group Code: 325412 Ranks w ithin this company's industry group: Sales: 159 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 163
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Cardiovascular, Pulmonary and Autoimmune Disorder
AVANT Immunotherapeutics, Inc., is a biopharmaceutical company that uses novel applications of immunology to prevent and treat illnesses caused by autoimmune diseases, cardiovascular diseases, cancer, inflammation, infectious diseases and organ transplant rejection. AVANT was created from the merger of T Cell Sciences and Virus Research Institute. Using its expertise in immunology, AVANT is building business franchises in three major disease areas: travelers' vaccines, cholesterol management and anti-viral vaccines. Each of AVANT's products addresses large market opportunities for which current therapies are inadequate or non-existent. The company’s products derive from a broad set of technologies with the ability to inhibit the complement system, regulate T and B cell activity and enable the creation and delivery of preventative and therapeutic vaccines. AVANT is using these technologies to develop vaccines and immunotherapeutics that prevent or treat disease caused by infectious organisms, as well as drugs and treatment vaccines that modify undesirable activity by the body's own proteins or cells. All of the firm’s products are in various stages of research and development. Recently, AVANT agreed to acquire the technology and intellectual property portfolio of Universal Preservation Technologies, Inc. (UPT). Through this acquisition, AVANT will gain exclusive rights to UPT's VitriLife process for use in its oral vaccines and certain other non-injectable applications. In other news, DynPort Vaccine Company, a partner of AVANT, initiated a phase I clinical trial of an injectable recombinant anthrax vaccine.
BRANDS/DIVISIONS/AFFILIATES: T Cell Sciences Virus Research Institute Universal Preservation Technologies, Inc. VitriLife
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Una S. Ryan, CEO Una S. Ryan, Pres. Avery W. Catlin, Sr. VP/CFO Henry C. Marsh, VP-Research Alistair W.E. Wheeler, VP-Medical Affairs J. Barrie Ward, Chmn.
Phone: 781-433-0771 Fax: 781-433-0262 Toll-Free: Address: 119 4th Ave., Needham , MA 02494 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $5,900 ( 9 months) 2002 Profits: $-10,400 ( 9 months) Stock Ticker: AVAN 2001 Sales: $3,300 2001 Profits: $-22,800 Employees: 71 2000 Sales: $ 763 2000 Profits: $-21,975 Fiscal Year Ends: 12/31 1999 Sales: $1,500 1999 Profits: $-11,300 1998 Sales: $2,200 1998 Profits: $-51,800
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $315,000 Stock Purch. Plan: Second Exec. Salary: $208,586 ADVANTAGE: Several significant therapies under development.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $37,800 Bonus: $17,285
Northeast: Y
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
AVAX TECHNOLOGIES INC
www.avax-tech.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 206 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 138
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Cancer Melanoma Treatment
AVAX Technologies, Inc. is a development-stage biopharmaceutical company engaged in the development and commercialization of products and technologies for the treatment of cancer and other life-threatening diseases. AVAX recently initiated its own research to supplement that being done through research agreements with several universities. The company is primarily focusing its efforts on the development of immunotherapies for the treatment of cancer. The firm places the majority of its focus on its autologous cell vaccines, called AC Vaccines, which have been developed with the help of Thomas Jefferson University. The vaccines use a patient’s own cancer cells and are designed to stimulate the patient's immune system to recognize, contain and eliminate malignant cells. The company's leading AC Vaccine is M-Vax, which is designed as an immunotherapy for the post-surgical treatment of stage-three melanoma. AVAX believes that M-Vax is the first immunotherapy to show a substantial increase in the survival rate for patients with this type of melanoma. In Phase II clinical trials, over 400 melanoma patients were treated post-surgically on an outpatient basis with M-Vax. Another vaccine, O-Vax, is currently in clinical trials for the treatment of individuals with ovarian cancer. AVAX plans to utilize the technology used to develop M-Vax and O-Vax for the treatment of other cancers, including breast, kidney and lung cancer. In recent news, AVAX signed a distribution agreement with Ferrer Internacional, S.A. for the sales and distribution of the AC Vaccine technology in European, Latin American and Asian territories. AVAX also reached a production agreement with MediGene AG for the processing of clinical samples of MediGene’s vaccine for the treatment of malignant melanoma.
BRANDS/DIVISIONS/AFFILIATES: AC Vaccine M-Vax O-Vax
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Richard P. Rainey, Acting Pres. Richard P. Rainey, VP-Finance Lorne F. Erdile, Dir.-Research Richard P. Rainey, VP-Admin.
Phone: 913-693-8491 Fax: 913-693-8497 Toll-Free: Address: 9200 Indian Creek Pkwy., Ste. 200, Overland Park, KS 66210 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 500 ( 9 months) 2002 Profits: $-6,700 ( 9 months) Stock Ticker: AVXT 2001 Sales: $ 500 2001 Profits: $-15,100 Employees: 43 2000 Sales: $ 112 2000 Profits: $-16,277 Fiscal Year Ends: 12/31 1999 Sales: $1,500 1999 Profits: $-7,868 1998 Sales: $ 100 1998 Profits: $-5,800
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $253,750 Stock Purch. Plan: Second Exec. Salary: $216,666 ADVANTAGE: Innovative immunotherapy for the post-surgical treatment of melanoma.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
West:
Southwest:
Midwest: Y
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $91,000 Bonus: $60,000
Northeast:
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
AVENTIS SA
www.aventis.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 5 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Y
TYPES OF BUSINESS:
Profits: 10
Computers: Hardware: Software: Arrays: Database Management:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Diversified Pharmaceutical Manufacturing Drug Research and Development Animal Health Vaccines and Proteins Skin Care Treatment
Aventis is a global leader in the pharmaceutical industry. The company offers a wide assortment of patented prescription drugs to treat patients with serious diseases through its many subsidiaries, including Aventis Pharma, which accounts for about 85% of revenues. Aventis has leading positions in several therapeutic areas, such as cardiology, oncology, diabetes and respiratory. The firm is also involved in animal health and nutrition through Merial, its joint venture with Merck & Co., Inc.; human vaccines developm ent and research through Aventis Pasteur; and therapeutic proteins through Aventis Behring. Other subsidiaries of the firm include Aventis Pharmaceuticals, Inc., the U.S. branch of Aventis; and Dermick Laboratories, Inc., which makes treatments for skin problems, such as dermatitis, acne and rosacea. Aventis concentrates its marketing efforts on its strategic prescription drug brands, such as Allegra/Telfast, a drug that treats seasonal allergies; Lovenox/Clexane, which treats deep vein thrombosis (DVT) and heart attacks; and Taxotere, a leading drug for the treatment of breast cancer. The firm focuses on advertising to the word’s largest markets, such as the U.S., France, Germany and Japan, through its sales force of over 19,000 people. The U.S. accounts for the majority of sales of Aventis’ strategic brands. In addition, Aventis is continually developing therapeutic innovations, including compounds for the treatment of diabetes, cancer, cardiovascular diseases and respiratory problems. Other research and development efforts include progress in AIDS vaccines, Alzheimer’s treatments and Parkinson’s care. In recent news, Aventis is shifting its focus to purely pharmaceutical businesses, with the divesture of the Aventis CropScience and Aventis Animal Nutrition subsidiaries.
BRANDS/DIVISIONS/AFFILIATES: Aventis Pharma Allegra/Telfast Lovenox/Clexane Merial Aventis Pasteur Aventis Behring Taxotere Dermick Laboratories, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Igor Landau, Chair-Managing Board Patrick Langlois, Exec. VP/CFO Rene Penisson, Group Exec. VP.-Human Resources Dirk Oldenburg, General Counsel/Exec. VP Thierry Soursac , Exec. VP-Commercial Oper. Frank L. Douglas, Exec. VP-Drug Innovation and Approval Arvind K. Sood, Head-Investor Rel. Richard J. Markman, CEO, Aventis Pharma David J. Williams , Pres./CEO, Aventis Pasteur Heinz-Werner Meier, Exec. VP-Human Resources Robert J. Bitterman, Pres., Dermick Laboratories, Inc.
Phone: +33-3-88-99-1100 Fax: +33-3-88-99-1101 Toll-Free: Address: 1, Avenue de l'Europe, Schiltingheim , F-67300 France
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $13,629,000 ( 9 months) 2002 Profits: $2,057,000 ( 9 months) Stock Ticker: AVE 2001 Sales: $20,447,000 2001 Profits: $1,455,000 Employees: 91,729 2000 Sales: $21,006,000 2000 Profits: $-27,000 Fiscal Year Ends: 12/31 1999 Sales: $12,714,000 1999 Profits: $-859,000 1998 Sales: $15,501,900 1998 Profits: $921,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: One of the world's largest pharmaceutical firms.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
West: Y
Southwest: Y
Midwest: Y
Bonus: $ Bonus: $
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Northeast: Y
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
AVI BIOPHARMA INC
www.antivirals.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 202 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 175
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Cancer and Cardiovascular Disease Cancer Immunotherapy Gene Targeted Drugs Drug Delivery Systems
AVI BioPharma, Inc. (formerly Antivirals, Inc.) is a biopharmaceutical company that develops therapeutic products using two distinct platform technologies: cancer immunotherapy and gene-targeted drugs (NeuGene). The company’s focus is on the treatment of life-threatening diseases, with applications in cardiovascular disease, colorectal cancer, pancreatic cancer, polycystic kidney disease, and drug metabolism. The cancer immunology sector is currently developing Avicine and Xactin for the treatment of cancer. Avicine has completed three Phase II trials for colorectal and pancreatic cancer. The NeuGene antisense products include Resten-NG for the treatment of cardiovascular restenosis, Oncomyc-NG for the treatment of cancer and NeuBiotics for the treatment of infectious disease. AVI Biopharma has many collaborative research programs with universities around the world. The company is currently involved in a strategic alliance with SuperGen, Inc. for the shared development and marketing of Avicine. AVI BioPharma and Abgenix, Inc. have an alliance for the development of human monoclonal antibodies for cancer. The company also has a research alliance with XTL Pharmaceuticals for pre-clinical development of hepatitis B and C antisense drugs. Recently, AVI BioPharma announced the initiation of two human clinical trials that will evaluate its AVI-4557 drug in modifying the function of a liver enzyme critical to the metabolism of many drugs.
BRANDS/DIVISIONS/AFFILIATES: Avicine Xactin Resten-NG Oncomyc-NG AVI-4557 XTL Pharmaceuticals Abgenix, Inc. Antivirals, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Denis R. Burger, CEO Alan P. Timmins, COO Alan P. Timmins, Pres. Mark M. Webber, CFO Patrick L. Iversen, Sr. VP-Research and Dev. Mark M. Webber, CIO Dwight D. Weller, Sr. VP-Mfg. and Chemistry David Mason, VP-Regulatory Affairs and Clinical Dev. Denis R. Burger, Chmn.
Phone: 503-227-0554 Fax: 503-227-0751 Toll-Free: Address: One SW Columbia, Ste. 1105, Portland, OR 97258 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 600 ( 9 months) 2002 Profits: $-25,400 ( 9 months) Stock Ticker: AVII 2001 Sales: $ 700 2001 Profits: $-26,900 Employees: 85 2000 Sales: $1,297 2000 Profits: $-9,240 Fiscal Year Ends: 12/31 1999 Sales: $ 17 1999 Profits: $-8,278 1998 Sales: $ 120 1998 Profits: $-26,734
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $280,000 Stock Purch. Plan: Second Exec. Salary: $230,400 ADVANTAGE: Strategic partnerships/Significant research successes.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $100,000 Bonus: $75,000
Northeast:
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
AVIGEN INC
www.avigen.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 190 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 126
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Hemophilia Gene Therapy Products Gene Delivery Technology
Avigen is focused on the development of gene therapy products for the treatment of disease. The firm has developed a proprietary technology based on adenoassociated virus vectors, known as AAV Vectors. This technology is designed to deliver DNA into the cells of patients in order to produce therapeutic results as an alternative to existing pharmaceutical and surgical treatments. Rather than treating the symptoms of a disease, the company's gene-based products target the root cause at the fundamental cellular level, holding great promise for treating a variety of disease that are not adequately addressed by current medical science. AAV vectors can be used to deliver genes that promote therapeutic responses in patients suffering from illnesses including hemophilia, metabolic diseases and non-genetic diseases such as Parkinson's disease, congestive heart failure, anemia and cancer. All of Avigen's products in development are based on this technology, which is designed to take advantage of the natural efficiency with which viruses deliver genes to cells, without the safety concerns that arise from disease-related viruses. The therapies are safe, efficient, stable and effective. Avigen owns, co-owns or holds licenses to 25 issued U.S. patents and 34 pending patent applications. In recent news, the firm announced a collaboration with Sangamo Biosciences to evaluate potential therapies for chronic pain, based on Sangamo's zinc finger DNA binding protein transcription factors and Avigen's gene delivery system. Avigen employees receive health care, eye care and disability benefits, as well as generous stock options. More than a third of its workers hold advanced degrees.
BRANDS/DIVISIONS/AFFILIATES: AAV Vectors
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John Monohan, CEO Kenneth G. Chahine, COO John Monohan, Pres. Thomas J. Paulson, VP-Finance/CFO Alan McClelland, VP- Research and Dev. Frederick Johnson, VP-Oper. Kenneth G. Chahine, VP-Bus. Dev. Kenneth G. Chahine, VP-Intellectual Property Elliot G. Grossbard, VP-Clinical Affairs Janice Castillo, VP-Regulatory Affairs
Phone: 510-748-7150 Fax: 510-748-7155 Toll-Free: Address: 1301 Harbor Bay Pkwy., Alameda, CA 94502 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 29 ( 9 months) 2002 Profits: $-21,221 ( 9 months) Stock Ticker: AVGN 2001 Sales: $1,000 2001 Profits: $-11,300 Employees: 143 2000 Sales: $ 58 2000 Profits: $-15,000 Fiscal Year Ends: 6/30 1999 Sales: $ 185 1999 Profits: $-9,600 1998 Sales: $ 1998 Profits: $-8,900
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $315,000 Stock Purch. Plan: Second Exec. Salary: $220,080 ADVANTAGE: Unique biotech strategy/Proprietary gene delivery technology/25 patents.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $200,000 Bonus: $100,000
Northeast:
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
AXONYX INC
www.axonyx.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 104 Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Central Nervous System Degeneration
Axonyx, Inc. is a biopharmaceutical company engaged in the discovery, acquisition and development of proprietary pharmaceutical compounds and new technologies useful for the diagnosis and treatment of Alzheimer’s Disease and other memory disorders. The company has a comprehensive portfolio of five technologies focused solely on the central nervous system. The firm is preparing a Phase III clinical trial for Phenserine, its lead drug candidate for the treatment of Alzheimer’s Disease. Tolserine and Phenethylnorcymserine are also being developed to treat Alzheimer’s Disease. Axonyx has signed a license agreement with Applied Research Systems, a subsidiary of Serono International, under which it granted exclusive sublicense to its patent rights regarding the Amyloid Inhibitory Peptide and the Prion Inhibitory Peptide technology. The company also has a research agreement with Thomas Jefferson University, under which Axonyx agreed to fund a gilatide research program. Gilatide, a potential pharmaceutical peptide, is designed to enhance memory and cognition. Recently, Axonyx extended its agreement with the U.S. Army Medical Research Institute of Chemical Defense. The U.S. Army will continue to study Axonyx’s AchE and BchE compounds for testing against chemical warfare agents. Axonyx also entered into a three-year consulting and research agreement with the Laboratory of Molecular Neurobiology at the University of Melbourne.
BRANDS/DIVISIONS/AFFILIATES: Phenserine Tolserine Phenethylnorcymserine Prion Inhibitory Peptide Amyloid Inhibitory Peptide
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Marvin S. Hausman, CEO Gosse B. Bruinsma, COO Marvin S. Hausman, Pres. Michael R. Espey, Corp. Sec. Michael R. Espey, General Counsel Gosse B. Bruinsma, Treas. Robert G. Burford, VP-Product Dev. Gosse B. Bruinsma, Pres.-Axonyx Europe Albert D. Angel, Chmn.
Phone: 212-688-4770 Fax: 212-688-4843 Toll-Free: Address: 825 Third Ave., 40th Fl., New York, NY 10022 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $-5,000 ( months) Stock Ticker: AXYX 2001 Sales: $ 2001 Profits: $-8,144 Employees: 7 2000 Sales: $1,605 2000 Profits: $-4,870 Fiscal Year Ends: 12/31 1999 Sales: $ 146 1999 Profits: $-5,000 1998 Sales: $ 1998 Profits: $- 700
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $225,000 Stock Purch. Plan: Y Second Exec. Salary: $175,000 ADVANTAGE: Focus on neurological disorders such as Alzheimer's.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $ Bonus: $
Northeast: Y
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
BARR LABORATORIES INC
www.barrlabs.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 32 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 30
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Breast Cancer Pharmaceuticals
Barr Laboratories, Inc. is an established pharmaceutical company engaged in the development, manufacture and marketing of generic and proprietary prescription pharmaceuticals. The company currently markets more than 80 generic and five proprietary products, representing various dosage strengths and product forms of 32 chemical entities. The firm’s product line is concentrated primarily on six core therapeutic categories: oncology, female healthcare, cardiovascular, anti-infectives, pain management and psychotherapeutics. Barr’s business strategy has three core components, including the development and marketing of generic pharmaceuticals that have one or more barriers to entry, developing the generic version and then challenging patents protecting select brand pharmaceuticals where the company believes that such patents are either invalid, unenforceable or not infringed by the company's product. The third business focus is centered on the development and introduction of proprietary pharmaceuticals. The company's largest selling product, Tamoxifen Citrate (Tamoxifen), the generic equivalent of Nolvadex, is used to treat advanced breast cancer, as well as impede the recurrence of tumors following surgery. Recently, Barr completed a merger with Duramed Pharmaceuticals, Inc. which will operate under the Barr Laboratories name. In addition, the company has received F.D.A. approval for many of its generic medicines which include: Flutamide capsules, a generic form of Eulexin that treats metastatic carcinoma of the prostrate; Fluoxetine Hydrochloride, a generic form of Eli Lilly's Prozac, an anti-depressant; Norethindrone Acetate, the generic equivalent to Aygestin which is utilized in women's healthcare; Nortel which substitutes Ortho-McNeil's Modicon and Ortho-Novum tablets; and Trexal, an antimetabolite used to treat certain neoplastic diseases. Barr has also challenged Aventis' Allegra patent in the hopes that it may market its generic Fexofenadine HCL version.
BRANDS/DIVISIONS/AFFILIATES: Tamoxifen Meperidine Fexofenadine HCL Trexal Nortel Norethindrone Acetate Fluoxetine Hydrochloride Flutamide
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Bruce L. Downey , CEO Paul M. Bisaro, COO Paul M. Bisaro, Pres. William T. McKee, VP/CFO Timothy P. Catlett, VP-Sales and Mktg. Catherine F. Higgins, VP-Human Resources Salah Ahmed, VP-Research and Dev. Suzanne Donaghy, VP/CIO Ann S. Boyle, VP/Controller Michael J. Bogda, VP- Engineering Michael J. Bogda, VP-Mfg. William T. McKee, Corp. Sec. Martin Zeiger, General Counsel Mary E. Petit, Sr. VP-Operations Martin Zeiger, Sr. VP- Strategic Bus. Dev. Jake Hansen, VP-Govt. Affairs William T. McKee, Treas. Carole S. Ben-Maimon, Pres./COO-Barr Research, Inc. Christine Mundkur, VP-Quality and Regulatory Counsel Robert G. Bell, VP- Proprietary Product Dev.
Phone: 845-362-1100 Fax: 845-362-2774 Toll-Free: 800-227-7522 Address: 2 Quaker Rd., Pomona, NY 10970-0519 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,189,000 (12 months) 2002 Profits: $212,200 (12 months) Stock Ticker: BRL 2001 Sales: $509,700 2001 Profits: $62,500 Employees: 685 2000 Sales: $482,278 2000 Profits: $42,342 Fiscal Year Ends: 6/30 1999 Sales: $444,033 1999 Profits: $49,250 1998 Sales: $377,304 1998 Profits: $32,720
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Aggressive generic drug strategy.
OTHER THOUGHTS:
Top Exec. Salary: $646,154 Second Exec. Salary: $323,077
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 5 Hot Spot for Advancement for Women/Minorities: Y
West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $400,000 Bonus: $200,000
Northeast: Y
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
BAUSCH & LOMB INC
www.bausch.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales: 2 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Y
TYPES OF BUSINESS:
Profits: 9
Computers: Hardware: Software: Arrays: Database Management:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Supplies-Eye Care Generic and Prescription Pharmaceuticals Vision Care Surgical Products
Bausch and Lomb Inc. is a world leader in the development, manufacture and marketing of health care products for the eye. Bausch and Lomb operates in three segments: vision care, pharmaceuticals and surgical products. The company’s vision care division includes contact lenses, lens care products and the vision accessories business. Vision care products are marketed to licensed eye care professionals, health products retailers, independent pharmacies, drug stores, food stores and mass merchandisers by the company's sales force and distributors. The pharmaceutical division manufactures and sells generic and proprietary prescription pharmaceuticals with a strategic emphasis in the ophthalmic field and over-the-counter ophthalmic medications. Finally, the surgical sector manufactures and sells products and equipment for cataract, refractive and retinal surgery. Some of Bausch and Lomb’s significant consumer and eye care professional recognition products include ReNu, ReNu MultiPlus, Sensitive Eyes, Medalist, Boston, Optima FW, SofLens, PureVision and Opcon. Bausch and Lomb sold its Charles River Laboratories, its sunglass division (including the Ray Ban brand) and the Miracle-Ear hearing aid business. In an effort to increase its international business, the company acquired Woehlk Contact Lens GmbH, a seller of soft and rigid gas permeable contact lenses and distributor of contact lens solutions. Bausch and Lomb recently bought French eye medicine company Groupe Chauvin in a bid to become a top European eye care company. The firm also announced plans to develop the Envision TD drug delivery system, a tiny implant that will continually release therapeutic levels of medicine directly inside the eye for up to three years. The system is currently undergoing clinical trials for the treatment of posterior uveitis and diabetic macular edema in the U.S., Europe and Japan. Bausch and Lomb offers employment around the world, with positions ranging from customer service to research and development. It offers comprehensive benefits.
BRANDS/DIVISIONS/AFFILIATES: Arnette Optic Illusions, Inc. Orbtek Woehlk Contact Lens GmbH ReNu Polymer Technology Corp. Bausch & Lomb Vision Care Groupe Chauvin Envision TD
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Ronald L. Zarrella, CEO C. E. Sassano, COO C. E. Sassano, Pres. Stephen C. McCluski, CFO Ian J. Watkins, VP-Human Resources Gary M. Aron, Sr. VP-Research and Dev. Marie L. Smith, CIO Jurij Z. Kushner, Controller Gary M. Aron, Sr. VP-Eng. Jean F. Geisel, Sec. Robert B. Stiles, General Counsel Angela J. Panzarella, VP-Strategy Barbara M. Kelley, VP-Corp. Comm. Barbara M. Kelley, VP-Investor Rel. Alan H. Resnick, VP-Treas. Alan H. Farnsworth, Sr. VP/Pres., Europe, Middle East and Africa Geoffrey F. Idle, VP/Pres., Bausch and Lomb, Japan
Phone: 585-338-6000 Fax: 585-338-6007 Toll-Free: 800-344-8815 Address: 1 Bausch & Lomb Pl., Rochester, NY 14604-2701 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,339,300 ( 9 months) 2002 Profits: $40,000 ( 9 months) Stock Ticker: BOL 2001 Sales: $1,711,900 2001 Profits: $21,500 Employees: 11,600 2000 Sales: $1,772,400 2000 Profits: $83,400 Fiscal Year Ends: 12/31 1999 Sales: $1,764,300 1999 Profits: $444,800 1998 Sales: $1,604,500 1998 Profits: $25,200
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Y Profit Sharing: Top Exec. Salary: $790,865 Stock Purch. Plan: Second Exec. Salary: $376,800 ADVANTAGE: Strategic positioning in eye care products/Increasing international market share.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 4 Hot Spot for Advancement for Women/Minorities: Y
West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $ Bonus: $
Northeast: Y
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
BAXTER INTERNATIONAL INC
www.baxter.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales: 1 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Y
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Y
TYPES OF BUSINESS:
Profits: 1
Computers: Hardware: Software: Arrays: Database Management:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Supplies-Intravenous and Renal Dialysis Systems Tissue Heart Valves Valve-Repair Products Cardiac-Monitoring Products Kidney Failure Products Intravenous Products Biotech Investments and Products
Baxter International, Inc. develops, manufactures and distributes its products in 28 countries and sells them in over 100 countries. The company operates in three segments: medication delivery, which provides a range of intravenous solutions and specialty products that are used in combination for fluid replenishment, nutrition therapy, pain management, antibiotic therapy and chemotherapy; BioScience, which develops biopharmaceuticals, biosurgery products, vaccines and blood collection, processing and storage products and technologies; and renal, which develops products and provides services to treat end-stage kidney disease. The medication delivery segment recently grew with the acquisition of ASTA Medica Oncology, a German-based manufacturer of chemotherapy drugs. The BioScience division is known as a leading producer of both plasma-based and recombinant clotting factors for hemophilia, as well as biopharmaceuticals used to treat immune deficiencies, cancer and other disorders. It recently received European licensure for Ceprotin, a new protein C concentrate used to treat congenital protein C deficiency. Baxter has been growing its presence in renal care by addressing the needs of kidney-disease patients from initial diagnosis through dialysis and organ replacement. It recently acquired the assets and exclusive rights to a proprietary recombinant drug for the treatment of anemia. In addition, Baxter purchased Fusion Medical Technologies, Inc., a company that develops and commercializes proprietary products used to control bleeding during surgery. Of the company's officials and managers, 13.6% are minorities, and 24.2% of the employees in the entire work force are minorities. In recent years, 30% of the participants in the company's financial development program have been minorities. The company offers employees a relaxed work environment with business casual dress.
BRANDS/DIVISIONS/AFFILIATES: Immuno International AG Research Medical, Inc. Baxter World Trade Corporation Baxter Healthcare Corporation Cook Pharmaceutical Solutions ASTA Medica Oncology Ceprotin Fusion Medical Technologies, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Harry M. Jansen Kraemer, Jr., CEO Brian P. Anderson, CFO Karen J. May, Corp. VP-Human Resources Norbert G. Riedel, Chief Scientific Officer J. Michael Gatling, Corp. VP-Global Mfg. Oper. Jan Stern Reed, Corp. Sec. Thomas J. Sabatino, Jr., General Counsel Timothy B. Anderson, Sr. VP-Corp. Strategy & Dev. Neville J. Jeharajah, Corp. VP-Investor Rel. Steven J. Meyer, Treas. Eric A. Beard, Pres., Europe Carlos del Salto, Sr. VP-Intercontinental/Pres., Latin America David F. Drohan, Pres., Medication Delivery Thomas H. Glanzmann, Pres., BioScience
Phone: 847-948-2000 Fax: 847-948-3948 Toll-Free: 800-422-9837 Address: 1 Baxter Pkwy., Deerfield, IL 60015-4633 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $6,074,000 ( 9 months) 2002 Profits: $769,000 ( 9 months) Stock Ticker: BAX 2001 Sales: $7,663,000 2001 Profits: $612,000 Employees: 48,000 2000 Sales: $6,896,000 2000 Profits: $740,000 Fiscal Year Ends: 12/31 1999 Sales: $6,380,000 1999 Profits: $797,000 1998 Sales: $5,706,000 1998 Profits: $315,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $880,000 Stock Purch. Plan: Y Second Exec. Salary: $600,000 ADVANTAGE: A leader in manufacturing heart valves/Worldwide marketing.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $528,000 Bonus: $252,000
Northeast: Y
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
BENTLEY PHARMACEUTICALS INC www.bentleypharm.com Industry Group Code: 325412 Ranks within this company's industry group: Sales: 84 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 51
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Diversified Drug Delivery Technologies
Bentley Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on advanced drug delivery technologies and pharmaceutical products. The company has U.S. and international patent and other proprietary rights to technologies that enhance or facilitate the absorption of drugs across membranes of the skin, mouth, nose, vagina and eye. Bentley is developing products incorporating these technologies and seeks to form alliances with major biotechnology companies to facilitate the development and commercialization of its products. Currently, the company has strategic alliances with Pfizer, Inc., Auxilium A2, Inc. and Teva Pharmaceutical Industries. The firm has a significant commercial presence in Spain, where it manufactures and markets more than 100 pharmaceutical products. The company's product line consists of generic and branded products within four primary areas: cardiovascular, gastrointestinal, infectious and neurological diseases. Bentley's CPE-215 technology enhances the absorption of drugs across skin membranes and can be incorporated into a variety of formats and products, including creams, ointments, gels, solutions, lotions, sprays or patches. The technology has a record of safety in humans as a food additive and fragrance. Bentley has a number of products in various stages of development, including a topical testosterone gel for the treatment of hypogonadism; an improved acetaminophen for pain relief; an antifungal nail lacquer; an androgenic steroid therapy for chronic fatigue syndrome; and intranasal insulin for diabetes. The company's branded products include Belmazol, sold by others as Prilosec; Senioral, sold by others as Denoral; and Enalapril Belmac, sold by others as Vasotec. In recent news, the firm received approval to market Paroxetine, the generic equivalent of Paxil, in Spain. Bentley also recently extended its research and development relationship with Pfizer, giving Pfizer access to the company's drug delivery platform.
BRANDS/DIVISIONS/AFFILIATES: Belmac Corp. Laboratorios Belmac Laboratorios Davur Belmazol Mio Relax Enalapril Belmac Senioral Codeisan
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James R. Murphy, CEO James R. Murphy, Pres. Michael D. Price, VP/CFO Robert M. Stote, Sr. VP/Chief Science Officer Robert J. Gyurik, VP-Pharmaceutical Dev. Michael D. Price, Corp. Sec. Jordan A. Hovrath, VP/General Counsel Michael D. Price, Treas. James R. Murphy, Chmn.
Phone: 603-964-8006 Fax: 603-964-6889 Toll-Free: Address: 65 Lafayette Rd., 3rd Fl., North Hampton, NH 038622403 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $28,200 ( 9 months) 2002 Profits: $ 945 ( 9 months) Stock Ticker: BNT 2001 Sales: $26,400 2001 Profits: $1,400 Employees: 265 2000 Sales: $18,617 2000 Profits: $- 745 Fiscal Year Ends: 12/31 1999 Sales: $20,200 1999 Profits: $-1,100 1998 Sales: $15,200 1998 Profits: $-2,900
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Has a large international market.
OTHER THOUGHTS:
Top Exec. Salary: $390,000 Second Exec. Salary: $304,500
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $100,000 Bonus: $
Northeast: Y
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
BIGMAR INC
www.bgmr.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Infusion Solutions Generic Drugs
Bigmar, Inc. manufactures generic pharmaceutical oncology products and intravenous infusion solutions through its Swiss subsidiaries and markets these products in Europe, the United States and other countries, primarily through pharmaceutical distributors. Currently, the company has distribution rights for more than 20 generic oncology products. Bioren, one of Bigmar’s three subsidiaries, is engaged in manufacturing and marketing various pharmaceutical products in Switzerland. Its products include 22 types of intravenous infusion solutions (IV Solutions) and other related products. Bioren's strategy is to expand its IV Solutions product line and its market penetration. Bigmar Pharmaceuticals, another subsidiary, manufactures and markets oncology products, such as calcium leucovorin, methotrexate and cisplatin. These products are marketed in the United States, Italy, Germany, Switzerland, Brazil, Greece and Spain. Recently, Bioren and PLM Langeskov entered into an agreement that grants Bioren the exclusive rights to distribute its IV Solutions throughout Switzerland and Liechtenstein in PLM's collapsible containers.
BRANDS/DIVISIONS/AFFILIATES: Bioren Bigmar Therapeutics Bigmar Pharmaceuticals IV Solutions
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. John G. Tramontana, CEO Bernard Kramer, COO Cynthia R. May, Pres. Phillippe J.H. Rohrer, CFO Massimo Pedrani, Exec. VP-Research and Dev. Cynthia R. May, Corp. Sec. Phillippe J.H. Rohrer, Treas. John G. Tramontana, Chmn.
Phone: 740-966-5800 Fax: 740-966-5801 Toll-Free: Address: 9711 Sportsman Club Rd., Johnstown, OH 43031-9141 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $ ( months) Stock Ticker: BGMR.PK 2001 Sales: $ 2001 Profits: $ Employees: 2000 Sales: $7,651 2000 Profits: $-4,900 Fiscal Year Ends: 12/31 1999 Sales: $7,700 1999 Profits: $-6,300 1998 Sales: $6,400 1998 Profits: $-7,200
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Focus on generic products/International marketing.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
West:
Southwest:
Midwest: Y
Bonus: $ Bonus: $
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Northeast:
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
BIO RAD LABORATORIES INC
www.bio-rad.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales: 5 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Y Y Y
TYPES OF BUSINESS:
Profits: 3
Computers: Hardware: Software: Arrays: Database Management:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Equipment-Life Sciences Research Clinical Diagnostics Analytical Instruments Proprietary Equipment Sales and Service Laboratory Services
Bio-Rad Laboratories manufactures and supplies the life science research, health care, analytical chemistry and other markets with a broad range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The company operates in two industry segments: life science and clinical diagnostics. The life science segment focuses on specific segments of the life science market, including laboratory devices, biomaterials, imaging products and microscopy systems. Bio-Rad primarily uses electrophoresis, image analysis and microplate readers, chromatography, gene transfer and sample preparation and amplification as its primary technological applications . Bio-Rad supplies its services to universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers and biotechnology researchers. Its clinical diagnostics industry encompasses a broad array of technologies incorporated into a variety of tests used to detect, identify and quantify substances in blood or other bodily fluids and tissues. The test results are used as aids for medical diagnosis, detection, evaluation, monitoring and treatment of diseases and other medical conditions. Bio-Rad recently acquired Quantase, Ltd. of Perth, Scotland, a company specializing in newborn screening diagnostic products. It also announced a distribution agreement with Immucor which will transfer all of Immucor’s commercial activities in France to Bio-Rad. Bio-Rad stresses the overall organization of its employees into small entrepreneurial teams in order to spur innovation. The firm offers its employees tuition reimbursement and dental and vision insurance.
BRANDS/DIVISIONS/AFFILIATES: Chiron Diagnostics Corp. Pasteur Sanofi Diagnostics Bio-Metrics Properties, Ltd. Blood Virus Diagnostics, Inc. Polaron Instruments Quantase, Ltd.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. David Schwartz , CEO James J. Bennett, COO David Schwartz , Pres. Richard Anderson, VP-Human Resources James R. Stark, Controller Sanford S. Wadler, Sec. Sanford S. Wadler, General Counsel Ronald Hutton, Treas. Norman Schwartz, VP/Group Mgr. John Goetz, VP/Group Mgr.
Phone: 510-724-7000 Fax: 510-741-5817 Toll-Free: 800-224-6723 Address: 1000 Alfred Nobel Dr., Hercules , CA 94547 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 6 months. 2002 Sales: $424,842 ( 6 months) 2002 Profits: $35,005 ( 6 months) Stock Ticker: BIO 2001 Sales: $817,500 2001 Profits: $44,200 Employees: 4,300 2000 Sales: $725,884 2000 Profits: $31,100 Fiscal Year Ends: 12/31 1999 Sales: $555,399 1999 Profits: $11,721 1998 Sales: $447,863 1998 Profits: $24,302
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Y Stock Purch. Plan: Y ADVANTAGE: Diverse group of customers.
OTHER THOUGHTS:
Top Exec. Salary: $528,835 Second Exec. Salary: $494,000
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
West: Y
Southwest: Y
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $271,882 Bonus: $266,482
Northeast: Y
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
BIO TECHNOLOGY GENERAL CORP
www.btgc.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 49 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 184
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Weight Loss Endocrine and Metabolic Disorders Products Cardio/Pulmonary Diseases Products Ophthalmic and Skin Disorders Products
Bio Technology General (BTG) is engaged in the research, development, manufacture and marketing of biopharmaceutical products. Through a com bination of internal research and development, acquisitions, collaborative relationships and licensing arrangements, BTG has developed a portfolio of therapeutic products, including nine products that have received regulatory approval for sale. Additionally, the firm has four products in registration or clinical trials and several products in preclinical development. BTG's approved products include Oxandrin for the treatment of weight loss, used primarily for AIDS patients; Bio-Tropin, which treats growth hormone deficiency in children; BIOLON, used as protection of the corneal endothelium during ophthalmic implant surgery; Delatestryl, a treatment for hypogonadism and delayed puberty; Bio-Hep-B, the first recombinant hepatitis B vaccine; and Silkis, a vitamin D derivative utilized in the treatment of psoriasis and many other drugs. BTG recently acquired Myelos Corp., a privately held biopharmaceutical company focused on the development of novel therapeutics to treat diseases of the nervous system. The acquisition has added the drug Prosaptide, a new compound for the treatment of neuropathic pain associated with diabetic peripheral neuropathy, to the company’s lineup.
BRANDS/DIVISIONS/AFFILIATES: Oxadrin Bio-Tropin Delatestryl BIOLON Arthease BioLon Bio-Hep-B Myelos Corp.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Sim Fass, CEO Yehuda Sternlicht, CFO Donald A. Fishbein, VP-Mktg. Norman Barton, Chief Medical Officer Ronald J. Simko, VP-Mfg. Robert M. Shaw, Corp. Sec. Robert M. Shaw, General Counsel Leah Berkovits, VP-Admin. Lawrence B. Brown, VP-Bus. Dev. Leah Berkovits, VP-Corp. Comm. John Bond, Treas. Sim Fass, Pres., BTG, Ltd. Dov Kanner, Gen. Mgr, BTG, Ltd. Ernest L. Kelly, Sr. VP-Quality Assurance Thomas Eckhardt, VP-Regulatory Affairs
Phone: 732-632-8800 Fax: 732-632-8844 Toll-Free: Address: 70 Wood Ave. S., Iselin, NJ 08830 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $71,900 ( 9 months) 2002 Profits: $8,900 ( 9 months) Stock Ticker: BTGC 2001 Sales: $102,000 2001 Profits: $-30,300 Employees: 378 2000 Sales: $84,900 2000 Profits: $7,700 Fiscal Year Ends: 12/31 1999 Sales: $85,300 1999 Profits: $13,900 1998 Sales: $76,900 1998 Profits: $17,700
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $419,583 Stock Purch. Plan: Y Second Exec. Salary: $243,750 ADVANTAGE: Innovative products for niche diseases.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $160,000 Bonus: $75,000
Northeast: Y
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
BIOANALYTICAL SYSTEMS INC
www.bioanalytical.com
Industry Group Code: 541710 Ranks within this company's industry group: Sales: 22 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Y Y Y
TYPES OF BUSINESS:
Profits: 10
Computers: Hardware: Software: Arrays: Database Management:
Specialty: Specialty Services: Consulting: Blood Collection:
Y
GROWTH PLANS/SPECIAL FEATURES:
Contract Research Services Instruments-Liquid Chromotography Bioanalytical Separation Instrumentation Chemical Analyzers Diagnostic Kits In Vivo Sampling Devices Support Screening Drug Evaluation
Bioanalytical Systems, Inc. is a contract research organization (CRO) providing research and development resources to many of the leading pharmaceutical, medical device and biotechnology companies in the world. The company concentrates on services and tools to improve the speed and efficiency of preclinical development. It has played a significant role in understanding the underlying causes of central nervous system disorders, diabetes, osteoporosis and other diseases. The company offers an efficient, variable-cost alternative to its clients' internal product development, compliance and quality control programs. Bioanalytical Systems’ services and products combine basic research with diagnostic and therapeutic experience. The firm is capable of supporting the analytical needs of researchers and clinicians, from small molecule drugs and hormones through large biomolecules such as proteins. The analytical services provided include support screening and pharmacological testing, toxicology and safety testing, formulation development, laboratory testing, regulatory and compliance consulting and quality control testing. In addition to these services, Bioanalytical Systems designs, manufactures and markets a broad range of products that collect, separate, detect and quantify chemicals in biological samples. These tools and the Vetronics line of veterinary physiological monitors are used to track complex chemical, physiological and behavioral effects in laboratory animal models. The company’s principal clients include scientists engaged in drug metabolism studies, pharmacokinetics and basic neuroscience research at pharmaceutical research organizations. Recently, Bioanalytical Systems and RenaSci Consultancy, Ltd. of Nottingham, U.K. announced the formation of a strategic alliance for drug discovery and development. In other news, the company signed a definitive agreement to acquire PharmaKinetics Laboratories, Inc. in Baltimore, Maryland. The compay also has plans to acquire LC Resources, Inc., a private company based in Walnut Creek, California.
BRANDS/DIVISIONS/AFFILIATES: BAS Analytics, Ltd. BAS Technicol, Ltd. Bioanalytical Systems, Ltd. LC Resources, Inc. Vetronics PharmaKinetics Laboratories
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Peter T. Kissinger, CEO Peter T. Kissinger, Pres. Douglas P. Wieten, VP-Finance/CFO Candice B. Kissinger, Sr. VP-Mktg. Lina L. Reeves-Kerner, VP-Human Resources Michelle L. Carson, Controller Donnie A. Evans, VP-Eng. Candice B. Kissinger, Corp. Sec. Michael P. Silvon, VP-Bus. Dev. Douglas P. Wieten, Treas. Craig S. Bruntlett, Sr. VP-Int'l Sales Stephen Geary, VP-U.S. Sales and Mktg. Ronald E. Shoup, Pres., BAS Analytics Peter T. Kissinger, Chmn.
Phone: 765-463-4527 Fax: 765-497-1102 Toll-Free: Address: 2701 Kent Ave., West Lafayette, IN 47906 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $26,500 (12 months) 2002 Profits: $1,100 (12 months) Stock Ticker: BASI 2001 Sales: $25,300 2001 Profits: $1,800 Employees: 260 2000 Sales: $19,200 2000 Profits: $-1,400 Fiscal Year Ends: 9/30 1999 Sales: $19,900 1999 Profits: $ 600 1998 Sales: $18,200 1998 Profits: $ 400
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $108,000 Stock Purch. Plan: Second Exec. Salary: $88,800 ADVANTAGE: State-of-the-art research services/Innovative research products.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
West:
Southwest:
Midwest: Y
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $18,000 Bonus: $16,000
Northeast: Y
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
BIOCOMPATIBLES INTERNATIONAL PLC www.biocompatibles.com Industry Group Code: 339113 Ranks within this company's industry group: Sales: 11 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Y
TYPES OF BUSINESS:
Profits: 28
Computers: Hardware: Software: Arrays: Database Management:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Supplies-Phosphorycholine Coatings Site and Lesion-Specific Stents Ureteric Stents and Catheters
Biocompatibles is an international biomaterials firm that focuses on the development and commercial marketing of its phosphorylcholine (PC) technology, a chemical group found in membranes of living cells. When devices are coated with the firm's PC materials, they can significantly reduce the incidence of adverse interactions with blood, tears, urine and other body fluids. Biocompatibles’ two divisions, eye care and cardiovascular, are commercializing contact lenses and coronary stents, among other products. The company’s eye care division focuses on the application of Biocompatibles’ PC technology to contact lenses and eye care products, refractive surgical devices, ophthalmic surgical devices and the management of ocular diseases. Among the division’s products are Proclear Compatibles and Proclear Tailor-Made Toric. Biocompatibles’ contact lenses are the only ones approved by the FDA for easing discomfort for symptoms related to dryness. Recently, Cooper Companies, Inc. purchased the eye care division of Biocompatibles. The cardiovascular stent business and associated drug delivery programs were sold to its marketing partner, Abbott Laboratories. The cardiovascular division of Biocompatibles’ business produces and markets the BiodivYs io Stent. Biocompatibles licences PC technology to the Italian medical device company Sorin-Dideco for use on its cardiopulmonary bypass systems. Recently, the company began new product developments of PC gel systems for the treatment of tumors, the filling of aneurysms and the bulking of tissue to compensate for loss of shape or elasticity.
BRANDS/DIVISIONS/AFFILIATES: BiodivYsio Stents Proclear Biocompatibles Cardiovascular Ireland Biocompatibles Eyecare, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Crispin Simon, CEO Geoffrey Pierson, Dir.-Group Human Resources Fiona Evans, Sec. Mike Driver, Dir.-Group Dev. Richard Needham, Chmn.
Phone: +44-1252-732-732 Fax: +44-1252-732-777 Toll-Free: Address: Frensham House, Farnham Business Park, Weydon Ln., Farnham , Surrey GU9 8QL UK
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $32,423 ( 9 months) 2002 Profits: $17,882 ( 9 months) Stock Ticker: BCTBF.PK 2001 Sales: $100,200 2001 Profits: $-28,600 Employees: 1,173 2000 Sales: $82,200 2000 Profits: $-29,900 Fiscal Year Ends: 12/31 1999 Sales: $36,400 1999 Profits: $-31,000 1998 Sales: $26,900 1998 Profits: $-72,500
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Innovative technology relating to fluids in the human body.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
West:
Southwest:
Midwest:
Bonus: $ Bonus: $
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Northeast:
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
BIOCRYST PHARMACEUTICALS
www.biocryst.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 124 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 88
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Immunological, Infectious and Inflammatory Disease
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on the development of pharmaceuticals for the treatment of infectious, inflammatory and cardiovascular diseases and disorders. The company has several products under development. Its PNP inhibitor, known as BCX-1777, is in Phase I/II trials. BCX1777 is in development at M.D. Anderson Cancer Center for patients with T-cell leukemia and T-cell lymphomas. The company is developing tissue factor/factor VIIa inhibitors and cardiovascular inhibitors for the treatment of cardiovascular and acute coronary events. Hepatitis C inhibitors and viral inhibitors are also in developmental stages. The company uses strategic alliances early in the drug identification process, through the aggressive inlicensing of drug targets, and in late-stage clinical development with large pharmaceutical or biotechnology companies that have expertise in its therapeutic areas of focus. BioCryst currently has collaborations with leading academic organizations including the University of Alabama at Birmingham, Emory University and St. Jude's Children Research Hospital, as well as commercial collaborations with 3-Dimensional Pharmaceuticals, Inc. and Sunol Molecular Corporation. In recent news, BioCryst announced that patient enrollment is complete in the first Phase III trial of once-a-day orally administered peramivir (RWJ-270201), its influenza neuraminidase inhibitor.
BRANDS/DIVISIONS/AFFILIATES: BCX-1777 RWJ-270201
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Charles E. Bugg, CEO J. Claude Bennett, COO J. Claude Bennett, Pres. Michael A. Darwin, CFO Michael A. Darwin, Corp. Sec. John R. Uhrin, VP- Corp. Dev. Michael A. Darwin, Treas. Yarlagadda S. Babu, VP-Drug Discovery Tami Warren, Dir.-Clinical Dev. Charles E. Bugg, Chmn.
Phone: 205-444-4600 Fax: 205-444-4640 Toll-Free: Address: 2190 Parkway Lake Dr., Birmingham , AL 35244 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for months. 2002 Sales: $ ( months) 2002 Profits: $-14,200 ( months) Stock Ticker: BCRX 2001 Sales: $7,700 2001 Profits: $-5,000 Employees: 77 2000 Sales: $7,700 2000 Profits: $-11,600 Fiscal Year Ends: 12/31 1999 Sales: $5,300 1999 Profits: $-5,300 1998 Sales: $7,600 1998 Profits: $-4,800
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $381,576 Stock Purch. Plan: Y Second Exec. Salary: $291,707 ADVANTAGE: Proprietary drug for the prevention of influenza.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
West:
Southwest:
Midwest:
Southeast: Y
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $ Bonus: $15,000
Northeast:
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
BIOGEN INC
www.biogen.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 22 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Y
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 14
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Multiple Sclerosis Genetic Engineering
Biogen, Inc. is a biopharmaceutical company that develops, manufactures and markets drugs for human health care. The company currently derives its revenues from worldwide sales of AVONEX, for the treatment of relapsing forms of multiple sclerosis, and from sales by Biogen’s licensees of a number of products, including alpha interferon and hepatitis B vaccines and diagnostic products. In addition, Biogen has a significant number of ongoing research programs and a pipeline of development stage products, the furthest along of which, AMEVIVE, is currently being considered for approval by the FDA and regulatory authorities in the European Union and Canada for the treatment of moderate to severe psoriasis. Biogen focuses its research on biological systems and processes where its scientific expertise in molecular biology, cell biology, immunology and protein chemistry can lead to a greater understanding of disease processes and, as a result, to the creation of new pharmaceuticals. The company recently launched PsoriasisSupport.com, a website that will provide content and community support for people with psoriasis. Biogen’s partners include Schering-Plough, SmithKline Beecham, Merck and Abbott Laboratories. Employee benefits at Biogen include maternity leave and tuition reimbursement.
BRANDS/DIVISIONS/AFFILIATES: AVONEX AMEVIVE PsoriasisSupport.com Biogen Japan, Ltd.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. James C. Mullen, CEO James C. Mullen, Pres. Peter N. Kellogg, CFO Frank A. Burke, Jr., VP-Human Resources Burt Adelman, Exec. VP-Research and Dev. Patrick J. Purcell, CIO Thomas J. Bucknum, General Counsel Kees Been, Sr. VP-Bus. Dev. Sylvie L. Gregoire, Exec. VP-Tech. Oper. Hans Peter Hasler, Exec. VP-Commercial Oper. Nadine Cohen, Sr. VP-Regulatory Affairs Toshio Nakata, Pres., Biogen Japan, Ltd.
Phone: 617-679-2000 Fax: 617-679-2617 Toll-Free: Address: 14 Cambridge Center, Cambridge, MA 02142-1481 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $845,934 ( 9 months) 2002 Profits: $157,724 ( 9 months) Stock Ticker: BGEN 2001 Sales: $1,043,400 2001 Profits: $272,700 Employees: 1,992 2000 Sales: $926,452 2000 Profits: $333,577 Fiscal Year Ends: 12/31 1999 Sales: $794,435 1999 Profits: $220,450 1998 Sales: $557,587 1998 Profits: $138,697
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $1,024,324 Bonus: $993,000 Stock Purch. Plan: Y Second Exec. Salary: $914,513 Bonus: $218,800 ADVANTAGE: Marketer of AVONEX, a treatment for relapsing forms of multiple sclerosis/Expertise in molecular biology.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Northeast: Y
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
BIOMARIN PHARMACEUTICAL
www.biomarinpharm.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 106 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 218
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Mucopolysaccharidosis -I Carbohydrate Enzyme Therapies
BioMarin Pharmaceutical, Inc. is a developer of carbohydrate enzyme therapies for debilitating, lifethreatening, chronic genetic disorders and other diseases and conditions. Its lead drug product, Aldurazyme, is being developed for the treatment of mucopolysaccharidosis -I, or MPS-I. MPS-I is a lifethreatening genetic disorder caused by the lack of a sufficient quantity of the enzyme (alpha)-L-iduronidase. Patients with MPS-I have multiple debilitating symptoms resulting from the buildup of carbohydrate residues in all tissues in the body. These symptoms include delayed physical and mental growth, enlarged liver and spleen, skeletal and joint deformities, airway obstruction, heart disease, reduced endurance and pulmonary function and impaired hearing and vision. BioMarin has a joint venture with Genzyme for the worldwide development and commercialization of Aldurazyme. The company recently completed regulatory filings seeking approval to market Aldurazyme in the U.S. and Europe. Neutralase is also being developed for reversal of anticoagulation by heparin in patients undergoing coronary artery bypass graft (CABG), surgery and angioplasty. Other products that BioMarin is developing include Aryplase for the treatment of MPS VI and Vibrilase for the treatment of acute burn injuries. In recent news, BioMarin completed the acquisition of Glyko Biomedical, Ltd., a Canadian company.
BRANDS/DIVISIONS/AFFILIATES: Aldurazyme Glyko Biomedical Genzyme Neutralase Aryplase Vibrilase
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Fredric D. Price, CEO John C. Klock, Pres. Louis Drapeau, CFO/VP-Finance Christopher M. Starr, Sr. VP-Scientific Oper. Kim R. Tsuchimoto, VP/Controller John L. Jost, VP-Mfg. and Process Dev. Louis Drapeau, Corp. Sec. Jeffrey I. Landau, VP-Admin. Emil D. Kakkis, Sr. VP-Bus. Oper. Robert A. Baffi, VP-Quality Assurance and Control Brian K. Brandley, VP-Pharmacology and Toxicology Robert A. Heft, VP-Product Dev. and Program Mgmt. Stuart J. Swiedler, VP-Clinical Affairs Fredric D. Price, Chmn.
Phone: 415-884-6700 Fax: 415-382-7427 Toll-Free: Address: 371 Bel Marin Keys Blvd., Ste. 210, Novato, CA 94949 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $8,621 ( 9 months) 2002 Profits: $-32,684 ( 9 months) Stock Ticker: BMRN 2001 Sales: $11,700 2001 Profits: $-67,600 Employees: 216 2000 Sales: $12,326 2000 Profits: $-37,364 Fiscal Year Ends: 12/31 1999 Sales: $7,000 1999 Profits: $-28,100 1998 Sales: $1,200 1998 Profits: $-12,300
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Joint venture with Genzyme.
OTHER THOUGHTS:
Top Exec. Salary: $408,269 Second Exec. Salary: $250,000
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $278,500 Bonus: $
Northeast:
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
BIOMIRA INC
www.biomira.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 147 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Y
TYPES OF BUSINESS:
Profits: 168
Computers: Hardware: Software: Arrays: Database Management:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Cancer Diagnostics
Biomira, Inc. focuses its biotechnology expertise on the development of cancer therapeutics. The firm’s proprietary immunotherapy and organic chemistry knowledge has resulted in the development of the Theratope vaccine, a drug currently in Phase III trials for metastatic breast cancer involving 1,030 breast cancer patients in 10 countries across the globe. The drug’s trial is the largest of its kind. Theratope is also being tested in a Phase II trial for the treatment in colorectal cancer. BLP25 Liposomal vaccine is being designed to generate a cellular immune response to the tumor-associated antigen mucin MUC1. It is being developed for metastatic cell lung cancer and potential prostate cancer treatment. Biomira has formed a strategic alliance with Merck KgaA, a German chemical-pharmaceutical company. Biomira and EMD Pharmaceuticals, Inc., Merck’s U.S. affiliate, will jointly market Theratope and BLP25 vaccines in the U.S., while Merck will have sole development and marketing rights for Biomira’s vaccines in the rest of the world. In recent news, Biomira completed enrollment of patients in its Phase IIb clinical trial for BLP25. There are now 168 patients from Canada and the United Kingdom enrolled in the trial.
BRANDS/DIVISIONS/AFFILIATES: Theratope BLP25 Merck KgaA
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. T. Alexander McPherson, CEO Mark D. Young, COO T. Alexander McPherson, Pres. Edward A. Taylor, CFO/VP-Finance Robert D. Aubrey , VP-Mktg. Paul Bokenfohr, Human Resources B. Michael Longnecker, Sr. VP-Research and Dev. Guy Ely, VP-Clinical and Regulatory Affairs Edward A. Taylor, Corp. Sec. Edward A. Taylor, VP-Admin. Robert D. Aubrey , VP-Bus. Dev. Thomas J. Facklam, VP-Tech. Oper. and Quality Mircea Popescu, VP/Mgr.-Biomira U.S.A. Eric E. Baker, Chmn.
Phone: 780-450-3761 Fax: 780-463-0871 Toll-Free: 877-234-0444 Address: 2011 94th St., Edmonton, Alberta T6N 1H1 Canada
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $4,028 ( 9 months) 2002 Profits: $-22,809 ( 9 months) Stock Ticker: BIOM 2001 Sales: $4,600 2001 Profits: $-24,300 Employees: 162 2000 Sales: $3,000 2000 Profits: $-29,300 Fiscal Year Ends: 12/31 1999 Sales: $3,100 1999 Profits: $-20,200 1998 Sales: $3,900 1998 Profits: $-14,700
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Novel vaccines that trigger the immune system to identify and fight cancer cells.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $ Bonus: $
Northeast: Y
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
BIONX IMPLANTS INC
www.bionximplants.com
Industry Group Code: 339113 Ranks within this company's industry group: Sales: 24 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Y
TYPES OF BUSINESS:
Profits: 17
Computers: Hardware: Software: Arrays: Database Management:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Equipment- Polymer Implants
Bionx Implants is a leading manufacturer of self-enforced, resorbable polymer implants, including screws, pins and stents. The company’s polymer implants are used in orthopedic trauma, sports medicine, dentistry, maxillofacial surgery and urology. Bionx’s resorbable pins can be used in open surgical procedures and percutaneous and endoscopic techniques. Bionx’s Meniscus Arrow was the first resorbable, arthroscopically implanted fixation device designed for use in the repair of longitudinal, vertical tears of the medial and lateral meniscus. The firm recently announced the release of BioCuff, a bioresorbable screw and spiked washer implant used to fixate torn rotator cuff tissue back to bone. In addition to the release of BioCuff, the company introduced the Wedge, a bioresorbable interference fit implant used to attach a graft using cruciate ligament reconstruction, including bone-patella, tendonbone or soft tissue grafts. Bionx, having signed a collaboration agreement with Toray Medical Co., Ltd., has introduced its products to the Japanese market. Toray has exclusive distribution rights to the Bionx resorbable stent products for urology applications in Japan. In exchange for exclusive Japanese distribution rights, Toray makes investments to achieve market clearance for the Bionx stent products in Japan, and is required to meet market penetration and minimum purchase requirements.
BRANDS/DIVISIONS/AFFILIATES: Meniscus Arrow BioSorb Smart Pin Smart Tack Smart Screw Bankart Tack Wedge, The BioCuff
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Gerard S. Carlozzi, CEO Gerard S. Carlozzi, Pres. Drew Karazin, VP-Finance/CFO Ira Benson, VP-Mktg. & Sales Pertti Tormala, Exec. VP-Research and Dev. Pertti Viitanen, VP-Mfg. Drew Karazin, VP-Admin. James Hogan, Pres.-Stenting Div. Michael Matz, VP-Sales, Craniofacial Div.
Phone: 215-643-6177 Fax: 215-653-0984 Toll-Free: 800-349-3801 Address: 1777 Sentry Parkway W., Gwynedd Hall, Ste. 400, Blue Bell, PA 19422 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $13,628 ( 9 months) 2002 Profits: $-2,668 ( 9 months) Stock Ticker: BINX 2001 Sales: $18,900 2001 Profits: $-2,500 Employees: 108 2000 Sales: $18,232 2000 Profits: $-4,609 Fiscal Year Ends: 12/31 1999 Sales: $21,068 1999 Profits: $-12,463 1998 Sales: $21,100 1998 Profits: $1,261
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Expansion into Japanese market.
OTHER THOUGHTS:
Top Exec. Salary: $ Second Exec. Salary: $
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 2 Hot Spot for Advancement for Women/Minorities: Y
West:
Southwest:
Midwest:
Bonus: $ Bonus: $
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Northeast: Y
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
BIOPURE CORPORATION
www.biopure.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 157 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 205
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Oxygen Therapeutics Veterinary Drugs
Biopure develops, manufactures and markets oxygen therapeutics, including Hemopure, for human use, and Oxyglobin, for veterinary use. The company is developing Hemopure as an alternative to red blood cell transfusions, as well as for use in the treatment of other critical care conditions. During 2001, Biopure received approval to sell Hemopure for human use in South Africa and launched animal-based Oxyglobin in Europe. The firm also began construction for a new $110-million manufacturing plant for the production of Hemopure. The average Hemopure molecule is less than 1/1000th the size of a red blood cell. Once infused into a patient, these molecules disperse throughout the plasma space and are in continuous contact with the blood vessel wall, turning plasma into an oxygen-delivering substance. Plasma containing Hemopure flows everywhere blood flows and can also bypass partial blockages or pass through constricted vessels that impede the normal passage of red blood cells. As an alternative to red blood cell transfusion, Hemopure's advantages include immediate onset of action, more efficient oxygen release, long shelf life, universal compatibility, low viscosity and room temperature storage. Studies show that the product could also be used for applications including trauma treatment, ischemic conditions including heart attack and stroke and malignant hypoxic tumors. Oxyglobin, the firm's other product, is used for the treatment of anemia in dogs and is marketed and sold to veterinary hospitals and small animal veterinary practices in the U.S. and Europe. In recent news, Biopure's marketing application for Hemopure as a treatment for anemia in patients undergoing orthopedic surgery was accepted by the FDA for review. The company also received a grant from the U.S. Army to develop the drug for military trauma applications. Biopure employees receive benefits including medical, dental and life insurance, tuition reimbursement, transportation assistance and access to a credit union.
BRANDS/DIVISIONS/AFFILIATES: Hemopure Oxyglobin Oxygen Bridge
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Thomas A. Moore, CEO Thomas A. Moore, Pres. Francis H. Murphy, CFO William A. Eudailey, VP-Mktg. and Sales Carolyn R. Fuchs, VP-Human Resources Carl W. Rausch, Chief Tech. Officer Virginia T. Rentko, VP-Veterinary Medicine Jane Kober, Sr. VP/Corp. Sec. Jane Kober, General Counsel Barry L. Scott, VP-Int'l Bus. Dev. Geoffrey J. Filbey, VP-Eng. Howard P. Richman, VP-Regulatory Affairs and Compliance Maria S. Gawryl, Sr. VP-Research and Dev. Alain C. Massot, VP-Int'l Mktg. and Sales
Phone: 617-234-6500 Fax: 617-234-6505 Toll-Free: 877-879-2787 Address: 11 Hurley St., Cambridge, MA 02141 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $1,916 ( 9 months) 2002 Profits: $-35,012 ( 9 months) Stock Ticker: BPUR 2001 Sales: $3,500 2001 Profits: $-49,400 Employees: 211 2000 Sales: $3,100 2000 Profits: $-29,282 Fiscal Year Ends: 10/31 1999 Sales: $2,900 1999 Profits: $-35,500 1998 Sales: $1,100 1998 Profits: $-30,000
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $324,170 Bonus: $ Stock Purch. Plan: Second Exec. Salary: $309,332 Bonus: $ ADVANTAGE: Unique therapies for anemia and shock/Product may be used as an alternative to red blood cell transfusions.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 5 Hot Spot for Advancement for Women/Minorities: Y
West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Northeast: Y
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
BIORA AB
www.biora.se
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 112 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 75
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Oral Disease Wound Treatments Bone Treatments
Biora AB focuses its efforts on developing new, proprietary products for the dental market and on expanding the indications for its Emdogain product. Biora AB has treated over 200,000 patients with Em dogain, which is marketed in 25 countries throughout Europe, North and South America, Asia and Africa. Emdogain is a topically applied adjunt to periodontal surgery that leaves a protein matrix on the roots of teeth in order to facilitate a foundation for periodontal tissues. The company’s dedication to continued product development has produced Emdogain Gel, a version of the product that is prepackaged in a syringe. The pre-packaged nature of this product provides greater ease of use than others of its kind and reduces inchair time for the dental patient. Further research and development efforts concerning Emdogain are ongoing, including studies of the drug’s mechanism of action, recession defects, treatment of avulsed teeth, endodonics, impacted wisdom teeth, wound healing, local bone formation and dry mouth. Studies have shown that Emdogain has the ability to lead to periodontal regeneration. Another product, PrefGel, is a root surface gel that promotes the cleaning of the tooth root surface during surgery without damaging the surrounding tissues. The company’s two largest subsidiaries are located in the United States and Germany. Subsidiary BioEx was formed to develop enamel matrix protein-based products for indications outside the oral cavity. BioEx is currently involved in a project for stimulating bone formation and a patent application for the inhibition of certain cancer cells. Biora has several research collaborations with universities in the U.S., Europe, Japan and Australia.
BRANDS/DIVISIONS/AFFILIATES: Emdogain BioEx Emdogain Gel PrefGel
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Donna Janson, CEO Donna Janson, Pres. Svante Lundell, CFO Christer Tingnell, Dir.-Mktg. Stina Gestrelius, Dir.-Research and Dev. Kerstin Palsson, Group Controller Lars Heijl, Dir.-Medical Tommie Johansson, Dir.-Corp. Comm. Tommie Johansson, Dir.-Investor Rel. Stina Gestrelius, Dir.-Regulatory Affairs Per Wahlstrom, Chmn.
Phone: +46-40-32-13-33 Fax: +46-40-32-13-55 Toll-Free: Address: Medeon Science Park, Malmo, SE-205, 12 Sweden
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 3 months. 2002 Sales: $3,900 ( 3 months) 2002 Profits: $- 100 ( 3 months) Stock Ticker: BIORY 2001 Sales: $10,500 2001 Pr ofits: $-2,400 Employees: 79 2000 Sales: $8,200 2000 Profits: $-6,100 Fiscal Year Ends: 12/31 1999 Sales: $6,800 1999 Profits: $-7,300 1998 Sales: $4,600 1998 Profits: $-5,300
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $ Stock Purch. Plan: Second Exec. Salary: $ ADVANTAGE: Focus on unique drugs for dental patients.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
West:
Southwest:
Midwest:
Bonus: $ Bonus: $
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Northeast:
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
BIORELIANCE CORP
www.bioreliance.com
Industry Group Code: 621511 Ranks within this company's industry group: Sales: 4 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Y Y Y
TYPES OF BUSINESS:
Profits: 4
Computers: Hardware: Software: Arrays: Database Management:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Research-Nonclinical Product Testing Contract Drug Manufacturing
BioReliance Corporation is a leading contract service organization that provides testing, development and manufacturing services for biologics and for other biomedical products. Its clients include biotechnology and pharmaceutical companies worldwide. BioReliance provides its services throughout the product cycle, starting from early preclinical development through licensed production. Through its testing and development business, the firm evaluates products to ensure that they are free of disease-causing agents and do not cause adverse effects; characterizes products' chemical structures; develops formulations for long-term stability; and validates purification processes under regulatory guidelines. In its manufacturing business, BioReliance develops unique production processes and manufactures biologics on behalf of clients both for use in clinical trials and for the worldwide commercial market. BioReliance's testing services include assessments of the cell banks used to manufacture biologics, validation of purification processes for clearance of adventitious agents such as viruses and testing of in-process and final products. Recently, BioReliance entered into a laboratory agreement with MedImmune, Inc., in which it will perform a range of tests for MedImmune’s developed products. In other news, the company entered into a multi-year manufacturing agreement with Celltech Group, one of Europe’s largest biotechnology companies. Under this agreement, BioReliance will manufacture and supply clinical-grade, antibody fragment-based drugs to Celltech. BioReliance provides its employees with health benefits, tuition reimbursement and bonuses.
BRANDS/DIVISIONS/AFFILIATES:
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Capers W. McDonald, CEO Capers W. McDonald, Pres. John L. Coker, VP-Finance/CFO Ronald R. Baker, VP-Mktg. and Sales John J. Gilly, VP-U.S. Mfg. John L. Coker, Corp. Sec. John L. Coker, VP-Admin. John L. Coker, Treas. Raymond F. Cosgrove, VP-European Testing and Dev. David Jacobson-Kram, VP-Toxicology and Laboratory Animal Health
Phone: 301-738-1000 Fax: 301-738-1036 Toll-Free: Address: 14920 Broschart Rd., Rockville, MD 20850 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $61,340 ( 9 months) 2002 Profits: $8,077 ( 9 months) Stock Ticker: BREL 2001 Sales: $69,700 2001 Profits: $5,900 Employees: 556 2000 Sales: $55,900 2000 Profits: $1,200 Fiscal Year Ends: 12/31 1999 Sales: $47,200 1999 Profits: $-1,000 1998 Sales: $49,800 1998 Profits: $3,700
SALARIES/BENEFITS: Pension Plan: Y Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Experts in biology manufacturing.
OTHER THOUGHTS:
Top Exec. Salary: $381,253 Second Exec. Salary: $213,473
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $173,750 Bonus: $94,825
Northeast: Y
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
BIOSITE INC
www.biosite.com
Industry Group Code: 325413 Ranks within this company's industry group: Sales: 3 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Y
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Y Y
TYPES OF BUSINESS:
Profits: 2
Computers: Hardware: Software: Arrays: Database Management:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Diagnostics Protein Microarray s Drug Abuse Tests Food-Born Bacteria Tests Heart Disease Diagnostics
Biosite, Inc. is a research-based diagnostics company dedicated to the discovery and development of novel protein-based tests that improve physicians' ability to diagnose diseases. The firm combines separate yet integrated discovery and diagnostics businesses to access proteomics research, identify proteins with high diagnostics value, develop and commercialize products and educate the medical community on new approaches to diagnosis. Biosite is a leading provider of rapid immunoassays, or antibody-based diagnostic tests, sold primarily for use in hospitals worldwide. The company's products include the Triage Drugs of Abuse Panel, the Triage Cardiac Panel and the Triage BNP Test. The Triage Drugs of Abuse Panel is a small, self-contained, qualitative test capable of detecting a broad spectrum of commonly overdosed prescription and illicit drugs in urine within approximately 10 minutes. The product is used in nearly 50% of U.S. acute care hospitals. In 2002, the FDA approved the Triage TOX Drug Screen, a secondgeneration drug test capable of simultaneously screening up to eight classes of commonly abused drugs. The Triage Cardiac System aids in the detection of acute myocardial infarction, otherwise known as heart attack. The system is in the early stages of market penetration and produced nearly $18 million in net sales in 2001. The Triage BNP Test is the first and only blood test currently approved in the U.S. for the diagnosis of congestive heart failure. The firm's Biosite Discovery business is dedicated to the identification of new protein markers of acute diseases that lack effective diagnostic tests. In addition, Biosite maintains collaborative agreements with a number of partners, including Amgen, Inc., Medarex, Inc. and Corixa Corp. Recently, the company entered into a multiyear agreement with MedImmune, under which Biosite will use its Omniclonal phage display technology to generate antibodies to drug targets provided by MedImmune.
BRANDS/DIVISIONS/AFFILIATES: Triage Drugs of Abuse Panel Triage Meter Biosite Discovery Trans-Phage Technology Medarex, Inc. Triage BNP Test Triage TOX Drug Screen Omniclonal Phage Display Technology
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Kim D. Blickenstaff, CEO Kim D. Blickenstaff, Pres. Christopher J. Twomey, VP-Finance/CFO James E. Douglas, VP-Mktg. and Sales Laura Weatherford, Human Resources Kenneth F. Buechler, VP-Research and Dev. Thomas M. Watlington, Sr. VP-Commercial Oper. Christopher R. Hibberd, VP-Strategic Planning and Bus. Dev. Nadine Padilla, VP-Corp. and Investor Rel. Peter Witerzens, VP-Oper. Gunars E. Valkirs, VP-Discovery Gary A. King, VP-Worldwide Mktg.
Phone: 858-455-4808 Fax: 858-455-4815 Toll-Free: Address: 11030 Roselle St., San Diego, CA 92121 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $72,529 ( 9 months) 2002 Profits: $8,426 ( 9 months) Stock Ticker: BSTE 2001 Sales: $65,600 2001 Profits: $6,700 Employees: 351 2000 Sales: $55,000 2000 Profits: $6,163 Fiscal Year Ends: 12/31 1999 Sales: $43,700 1999 Profits: $1,100 1998 Sales: $37,100 1998 Profits: $-1,100
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $311,250 Bonus: $100,567 Stock Purch. Plan: Second Exec. Salary: $246,000 Bonus: $176,581 ADVANTAGE: Biosite's Triage brand rapid diagnostic tests are used in nearly 50% of U.S. hospitals and in approximately 40 international markets
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 3 Hot Spot for Advancement for Women/Minorities: Y
West: Y
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Northeast:
International:
Plunkett Research, Ltd.
www,plunkettresearch.com
BIOSOURCE INTERNATIONAL INC
www.biosource.com
Industry Group Code: 325413 Ranks within this company's industry group: Sales: 6 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Y Y
TYPES OF BUSINESS:
Profits: 7
Computers: Hardware: Software: Arrays: Database Management:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Supplies-Enzyme-Linked Immunosorbent Assay Test Kits (ELISA) Clinical Diagnostics Immunology Molecular Biology
BioSource International, Inc. develops, manufactures and distributes products used worldwide in disease-related biomedical research and clinical diagnostics. Its products enable scientists and biom edical researchers to better understand the biochemistry, immunology and cell biology of the human body, as well as disease processes. It offers over 3,200 products that are grouped into the following product lines: assays, antibodies bioactive proteins and peptides, oligonucleotides, serum, buffers and media. BioSource intends to increase its organic growth rate through focused research and development and sales and marketing investments in cell biology markets with high growth potential. The firm recently launched the industry’s first p38 MAPK ELISA assay. The protein p38 MAPK is important in drug discovery research focused on mitogen activated protein kinases. Companies are studying p38 MAPK modifiers as drug candidates in a wide variety of diseases including several types of cancer, Parkinson’s Disease, diabetes and cardiovascular disease. BioSource’s new p38 MAPK ELISA kit is directly targeted at applications for these areas of research.
BRANDS/DIVISIONS/AFFILIATES: Keystone Laboratories BioSource Europe, S.A. Quality Controlled Biochemical Biofluids p38 MAPK ELISA
CONTACTS: Note: Officers with more than one job ti tle may be intentionally listed here more than once. Leonard Hendrickson, CEO Leonard Hendrickson, Pres. David S. Thrower, VP-Global Sales and Mktg. Cirilo Cabridilla, Jr., VP-Molecular Biology Kevin J. Reagan, VP-Immunology Jozef Vangenechten, Gen. Mgr., BioSource Europe, S.A.
Phone: 805-987-0086 Fax: 805-383-5386 Toll-Free: 800-242-0607 Address: 542 Flynn Rd., Camarillo, CA 93012 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $30,175 ( 9 months) 2002 Profits: $-1,097 ( 9 months) Stock Ticker: BIOI 2001 Sales: $35,200 2001 Profits: $ 700 Employees: 257 2000 Sales: $32,210 2000 Profits: $- 166 Fiscal Year Ends: 12/31 1999 Sales: $29,257 1999 Profits: $3,577 1998 Sales: $21,859 1998 Profits: $-5,136
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Focus on molecular biology.
OTHER THOUGHTS:
Top Exec. Salary: $ Second Exec. Salary: $
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
West: Y
Southwest:
Midwest:
Bonus: $ Bonus: $
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Northeast: Y
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
BIOSPECIFICS TECHNOLOGIES CORP www.biospecifics.com Industry Group Code: 325412 Ranks within this company's industry group: Sales: 140 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 65
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Skin Wound Therapies Tissue Remodeling Therapies
BioSpecifics Technologies Corporation is a pharmaceutical company focused on health-related disorders, including wound healing and tissue remodeling. The company produces and licenses a fermentationderived enzyme named Collagenase ABC that has been approved by the FDA for debriding chronic dermal ulcers and severely burned areas. Additionally, the firm researches and develops products derived from the enzyme for potential pharmaceutical use. The company acquires the majority of its revenue through a license agreement with Abbott Laboratories for the sale of powdered Collagenase and Collagenase Santyl Ointment. BioSpecifics Technologies is currently developing injectable Collagenase ABC. Clinical trials are underway for the treatment of Dupuytren’s disease, Peyronie’s disease, frozen shoulder and lipolysis using the injectable form of collagenase. The company also has a joint research project with Bausch & Lomb for the treatment of glaucoma. The company extended marketing rights to Smith & Nephew, Inc. to market Collagenase Santyl Ointment in the United States. BioSpecifics is also in collaboration with University Hospital and Medical Center at Stony Brook for a clinical study using the injectable form of Collagenase.
BRANDS/DIVISIONS/AFFILIATES: Collagenase ABC Biospecifics Pharma GmbH Collagenase Santyl Ointment
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Edwin H. Wegman, Pres. Albert Horcher, Principal Financial Officer Albert Horcher, Chief Acc. Officer Albert Horcher, Corp. Sec. Albert Horcher, Treas. Thomas L. Wegman, Exec. VP Rainer Friedel, Managing Dir., Biospecifics Pharma GmbH Edwin H. Wegman, Chmn.
Phone: 516-593-7000 Fax: 516-593-7039 Toll-Free: Address: 35 Wilbur St., Lynbrook, NY 11563 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $8,200 (12 months) 2002 Profits: $- 300 (12 months) Stock Ticker: BSTC 2001 Sales: $5,500 2001 Profits: $-1,468 Employees: 44 2000 Sales: $6,600 2000 Profits: $ 200 Fiscal Year Ends: 1/31 1999 Sales: $7,100 1999 Profits: $1,200 1998 Sales: $5,800 1998 Profits: $ 800
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $412,961 Stock Purch. Plan: Second Exec. Salary: $205,895 ADVANTAGE: License agreement with Abbott Laboratories.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $ Bonus: $
Northeast: Y
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
BIOSPHERE MEDICAL INC
www.biospheremed.com
Industry Group Code: 325414 Ranks within this company's industry group: Sales: 6 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 6
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Bioengineered Microspheres Tissue Engineering Technology
Biosphere Medical pioneers the use of its proprietary bioengineered acrylic beads, known as microspheres, for medical applications using embolotherapy techniques, as well as to develop potential applications in several nonembolotherapy applications. The firm believes its microsphere platform enables the rapid development of a new micro-interventional market, which will expand the capability of catheter-based interventional technologies and permit clinicians to treat medical conditions in a more effective and minimally invasive manner. Embolotherapy is a minimally invasive procedure in which embolic materials, such as microspheres, are delivered through a catheter into the blood vessels to inhibit blood flow to tumors or vascular defects or to control blood loss presurgically. The company's initial product, Embosphere microspheres, is targeted for the treatment of hypervascularized tumors and arteriovenous malformations. Microspheres have a number of advantages over currently available embolic materials, including ease of use and more controlled delivery. Nonembolotherapy applications of Biosphere's products include tissue bulking, repair and regeneration. The company, through subsidiary BSMD Ventures, Inc., is exploring and developing its products for these uses and for the treatment of such conditions as stress urinary incontinence and gastroesophageal reflux disease. In 2000, Biosphere established Biosphere Medical Japan, Inc., to develop and commercialize its Embosphere and HepaSphere SAP products in the Far East.
BRANDS/DIVISIONS/AFFILIATES: Biosphere Medical Japan, Inc. Embosphere HepaSphere SAP BSMD Ventures, Inc.
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Paul A. Looney, CEO Paul A. Looney, Pres. Robert M. Palladino, VP/CFO Tom M. Keenan, VP- Int'l Sales and Mktg. Jonathan R. McGrath, VP-Worldwide Research and Dev. Peter Sutcliffe, VP-Mfg. Robert T. Phelps, VP-Sales, Mktg. and Bus. Dev.
Phone: 781-681-7900 Fax: 781-792-2745 Toll-Free: 800-394-0295 Address: 1050 Hingham St., Rockland, MA 02370 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $9,106 ( 9 months) 2002 Profits: $-5,624 ( 9 months) Stock Ticker: BSMD 2001 Sales: $9,000 2001 Profits: $-10,300 Employees: 87 2000 Sales: $3,961 2000 Profits: $-8,447 Fiscal Year Ends: 12/31 1999 Sales: $2,300 1999 Profits: $-4,500 1998 Sales: $ 202 1998 Profits: $-1,800
SALARIES/BENEFITS: Pension Plan: Savings Plan: Y
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $220,577 Stock Purch. Plan: Second Exec. Salary: $210,000 ADVANTAGE: Expertise in embolotherapy/Ability to create therapies that restrict blood flow.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: Hot Spot for Advancement for Women/Minorities:
West:
Southwest:
Midwest:
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Bonus: $45,000 Bonus: $
Northeast: Y
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
BIOTECH HOLDINGS LTD
www.biotechltd.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 185 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 72
Computers: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Diabetes Health Care Products Personal Care Products
Biotech Holdings, Ltd. is engaged in the research, development, manufacture and marketing of various pharmaceutical, personal care and health care products, including topical creams, lotions, sunscreen, skin care products, Vitamin E and bath products. The company’s proprietary product is Diab II, a treatment for type II diabetes designed to increase insulin utilization by the body. As part of a new class of drugs labeled insulin sensitizers, Diab II is designed to control high blood sugar levels in individuals with diabetes. Diab II is currently marketed in China and is licensed for sale in Argentina, Chile, Peru and Venezuela, among other international areas. Biotech announced its plan to introduce the product into Brazil to increase its presence in the Latin market. The company has opened a new facility in Canada, where it manufactures and markets its Diab II product. Recently, Biotech Holdings announced the introduction of two new lines of products, Larisse skin care brand and Feelgood progesterone cream, for sales direct to consumers through the Internet across North America.
BRANDS/DIVISIONS/AFFILIATES: Diab II Larisse Feelgood
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Robert B. Rieveley, CEO Robert B. Rieveley, Pres. Lorne D. Brown, CFO Ping Sun, VP- Research and Dev. Gale V. Belding, Exec. VP Robert B. Rieveley, Chmn.
Phone: 604-736-3351 Fax: 604-736-3806 Toll-Free: 888-216-1111 Address: W. Broadway Ave., Ste. 400-1501, Vancouver, BC V6J 4Z6 Canada
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 12 months. 2002 Sales: $1,006 (12 months) 2002 Profits: $-2,140 (12 months) Stock Ticker: BIOHF.OB 2001 Sales: $1,163 2001 Profits: $-1,938 Employees: 2000 Sales: $ 834 2000 Profits: $-2,400 Fiscal Year Ends: 3/31 1999 Sales: $1,733 1999 Profits: $-2,258 1998 Sales: $ 889 1998 Profits: $-2,200
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Stock Purch. Plan: ADVANTAGE: Novel treatment for type II diabetes.
OTHER THOUGHTS:
Top Exec. Salary: $ Second Exec. Salary: $
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
West:
Southwest:
Midwest:
Bonus: $ Bonus: $
Southeast:
Note: Financial information, benefits and other data can change quickly and may vary from those stated here.
Copyright©2003 Plunkett Research, Ltd., All Rights Reserved
Northeast:
International: Y
Plunkett Research, Ltd.
www,plunkettresearch.com
BIOTIME INC
www.biotimeinc.com
Industry Group Code: 325412 Ranks within this company's industry group: Sales: 216 Drugs: Drugs: Contract Manufacturing: Drug Delivery Systems: Nutriceuticals:
Y
Other: AgriBio: Genomics: Proteomics: Tissue Replacement: Cell Transplantation:
Clinical: Trials: Labs: Equipment/Supplies: Research & Dev. Svcs.: Assays/Diagnostics:
Profits: 83
Computer s: Hardware: Software: Arrays: Database Management:
TYPES OF BUSINESS:
Specialty: Specialty Services: Consulting: Blood Collection:
GROWTH PLANS/SPECIAL FEATURES:
Drugs-Blood Replacement Solutions Organ Preservation Solutions
BioTime, Inc. is a development-stage company engaged in the research and development of synthetic solutions that can be used as blood plasma expanders, blood replacement solutions during hypothermic surgery and organ preservation solutions. The firm is also developing a specially formulated hypothermic blood substitute solution to be used for the replacement of very large volumes of patients' blood during cardiac surgery, neurosurgery and other surgeries that involve lowering body temperature to hypothermic levels. Hextend, the company's first product, is a physiologically balanced blood plasma volume expander for the treatment of hypovolemia, a condition associated with blood loss during surgery. Hextend maintains circulatory system fluid volume and keeps vital organs perfused during surgery. The product is sold in the U.S. and Canada through Abbot Laboratories. BioTime is developing two other blood volume replacement products, PentaLyte and HetaCool. The company has completed Phase I clinical trials of PentaLyte and plans to test the product for the treatment of hypovolemia. HetaCool is a modified formulation of Hextend. Other potential uses of BioTime's products include use during anti-cancer therapies.
BRANDS/DIVISIONS/AFFILIATES: Hextend HetaCool PentaLyte
CONTACTS: Note: Officers with more than one job title may be intentionally listed here more than once. Paul Segall, CEO Ronald S. Barkin, COO Stephen A. Seinberg, CFO Hal Sternberg, VP-Research Judith Segall, VP-Tech. Harold Waitz, VP-Eng. Judith Segall, Corp. Sec. Stephen A. Seinberg, Treas. Harold Waitz, VP-Regulatory Affairs
Phone: 510-845-9353 Fax: 510-845-7914 Toll-Free: Address: 935 Pardee St., Berkeley, CA 94710 US
FINANCIALS:
Sales and profits are in thousands of dollars—add 000 to get the full amount. Yr. 2002 note: Fiscal 2002 results were not available for all companies at press time. For this company, yr. 2002 is for 9 months. 2002 Sales: $ 203 ( 9 months) 2002 Profits: $-2,068 ( 9 months) Stock Ticker: BTX 2001 Sales: $ 200 2001 Profits: $-3,700 Employees: 12 2000 Sales: $ 100 2000 Profits: $-4,900 Fiscal Year Ends: 12/31 1999 Sales: $1,000 1999 Profits: $-5,500 1998 Sales: $ 300 1998 Profits: $-2,100
SALARIES/BENEFITS: Pension Plan: Savings Plan:
COMPETITIVE
ESOP Stock Plan: Profit Sharing: Top Exec. Salary: $163,000 Bonus: $ Stock Purch. Plan: Second Exec. Salary: $125,083 Bonus: $ ADVANTAGE: Received FDA approval for Hextend/Unique solutions for the treatment of blood loss and for use in blood replacement during surgeries.
OTHER THOUGHTS:
LOCATIONS: ("Y" = Yes)
Apparent Women Officers or Directors: 1 Hot Spot for Advancement for Women/Minorities:
West: